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Abstract 
The identification of protein kinase CK1 isoform δ as an important determinant in development 
and progression of severe pathogenic disorders such as Alzheimer’s disease, amyotrophic lateral 
sclerosis, familial advanced sleep phase syndrome, and cancer has dramatically increased 
interest in small molecule inhibitors for both therapeutic approaches and basic research. 
Consequently, selective CK1δ inhibitors have been pursued with increasing interest over the 
past decade. However, the existence of further five evolutionary conserved human CK1 isoforms 
that possess similar, different, or even opposite physiological and pathophysiological 
implications renders the design of suitable candidates enormously complicated. Especially 
highly related CK1 isoforms δ and ε remain difficult to discriminate and have therefore often 
been reported as redundant, rather by means of missing evidence. 
The present study reports on in silico design, synthesis, and biological evaluation of novel and 
optimized 4,5-diaryl-imidazoles as potent dual-specific ATP-competitive inhibitors of CK1 
isoforms δ and ε as well as p38α mitogen-activated protein kinase. In fact, most promising 
candidate 191 is among the most effective CK1 inhibitors published to date with an IC50 value in 
the low single-digit nanomolar range and good selectivity in a panel of 321 protein kinases. 
Although its physicochemical properties require further optimization, acceptable efficacy in 
different human cancer cell lines has been observed. Consequently, 191 holds the potential to 
serve as an important biological tool for pharmacological evaluation of CK1-dependent activity 
such as in stem cell applications. 
Apart from 191, molecular modeling-aided approaches led to structurally divergent but highly 
potent inhibitors that have been designed in order to enhance specificity. Among the most 
promising candidates, 224 represented a creative-empirically generated molecule while 266 
has been obtained by hybrid synthesis utilizing fragments from known compounds that 
exhibited suitable properties. Although significant impact on specificity has unfortunately not 
been examined, co-crystallization of 191, 224, and 266 with CK1δ and p38α revealed valuable 
structure-activity relationship insights that will surely prove beneficial for future attempts. 
  
 
  
Kurzzusammenfassung 
Die Identifikation der Protein Kinase CK1 Isoform δ als einer der bestimmenden Faktoren in 
Entwicklung und Progression schwerwiegender pathogener Störungen wie der Alzheimer-
Erkrankung, der amyotrophen Lateralsklerose, des familiären vorverlagerten Schlafphasen 
Syndroms und Krebs hat die Kinase zu einem attraktiven Target sowohl für therapeutische 
Aspekte, als auch für Grundlagenforschung gemacht. Es ist daher kaum verwunderlich, dass die 
Bestrebungen hinsichtlich selektiver niedermolekularer CK1δ Inhibitoren innerhalb der 
vergangenen Dekade kontinuierlich zugenommen haben. Allerdings ist die Entwicklung 
derartiger Hemmstoffe durch die Existenz weiterer fünf evolutionär konservierter humaner CK1 
Isoformen mit zum Teil ähnlicher, unterschiedlicher, oder sogar gegensätzlicher physiologischer 
und pathophysiologischer Bedeutung erheblich erschwert. Insbesondere die hochkonservierten 
Isoformen δ und ε sind bis heute durch kleine Moleküle nicht erfolgreich unterscheidbar und 
wurden daher in verschiedenen Zusammenhängen als redundant klassifiziert, ohne dass jedoch 
ausreichend Evidenz für diese Annahme geliefert werden konnte. 
Die vorliegende Arbeit beschreibt das in silico basierte Design, die Synthese und die biologische 
Charakterisierung neuer und optimierter 4,5-Diaryl-imidazole als potente und dual-spezifische 
ATP-kompetitive Inhibitoren der CK1 Isoformen δ und ε sowie der p38α Mitogen-aktivierten 
Protein Kinase. Tatsächlich handelt es sich bei der vielversprechendsten Verbindung 191 um 
einen der potentesten CK1 Hemmstoffe die bis heute publiziert werden konnten. Der Inhibitor 
weist eine halbmaximale Hemmkonzentration im niedrigen einstelligen nanomolaren Bereich 
auf, zeigt gute Selektivität über 321 Protein Kinasen und ist biologisch aktiv in verschiedenen 
humanen Tumorzelllinien, obwohl seine physikochemischen Eigenschaften sicherlich noch wei-
terer Optimierung bedürfen. 191 besitzt somit das Potential als biologisches Tool in der fort-
schreitenden Untersuchung der pharmakologischen Bedeutung der CK1 entscheidend Beitrag zu 
leisten, gerade im Hinblick auf die zunehmende Anwendung Stammzell-basierter Testsysteme. 
Abgesehen von 191 konnten mit Hilfe computergestützter Verfahren (Molecular Modelling) 
weitere strukturell unterschiedliche und hochpotente Inhibitoren mit dem Ziel einer Erhöhung 
der Spezifität entwickelt werden, von denen insbesondere zwei herausstachen: während 224 
ein kreativ-empirisch designtes Molekül darstellt, wurde 266 durch Fragment-basierte Hybrid-
Synthese dargestellt, wobei auf Teilstrukturen bekannter Verbindungen mit entsprechend 
gewünschten Eigenschaften zurückgegriffen wurde. Obgleich letztendlich keine signifikante 
Steigerung der Selektivität erzielt werden konnte, wurden durch Ko-Kristallisation von 191, 
224 und 266 mit der CK1δ und der p38α interessante Aspekte der Struktur-Wirkungsbeziehung 
aufgedeckt, die sich fraglos für zukünftige Bestrebungen als hilfreich erweisen werden. 
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1 Introduction 
1.1 Protein Phosphorylation and Protein Kinases 
Reversible phosphorylation is one of the most important post-translational modifications of 
proteins and corresponds to the transfer of a phosphate group onto specific amino acid hydroxyl 
moieties by covalent attachment. Enzymes that catalyze phosphate transfer reactions are re-
ferred to as kinases and phosphatases. Protein kinases (PK) mediate γ-phosphate transfer from 
their cofactors adenosine or guanidine triphosphate (ATP, GTP) to serine and threonine 
(Ser/Thr-specific kinases) or tyrosine residues (Tyr-specific kinases). Several so-called dual-
specific kinases have been reported to phosphorylate all three residues1–4. In contrast, cleavage 
of amino acid phosphate esters is catalyzed by protein phosphatases1–4. 
Phosphorylation of target proteins modifies protein function, stability, and localization either by 
induction of conformational rearrangement or activation and inactivation of protein interaction 
sites4. Consequently, reversible phosphorylation displays a crucial mechanism in most signal 
transduction cascades in eukaryotic cells, including e.g. metabolism, survival and apoptosis, 
transcription, proliferation, and differentiation1,5. Due to their physiological relevance, most PK 
act as members in highly regulated signaling networks of kinases and other effectors. Mutation 
and deregulation are closely related to numerous pathophysiological events and diseases such 
as tumorigenesis, inflammation, central nervous system (CNS) disorders, pain, cardiovascular 
diseases, and complications of diabetes and osteoporosis6. PK have therefore become one of the 
most intensively pursued targets in pharmacological research over the last decades6,7. 
518 PK are encoded in the human genome, nearly 2 % of all genes, which account for phos-
phorylation of at least 30 % of the human proteome4,5. According to sequence analysis, the hu-
man kinome is subdivided into seven distinct groups, though the focus of the current disserta-
tion has been set to CK1 superfamily (Figure 1). 
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Figure 1 | The human kinome .  Human kinases are subdivided into seven distinct groups: 
AGC = containing PKA, PKG, PKC families; CAMK  = calcium/calmodulin-dependent protein kinase; 
CK1 = formerly known as casein kinase 1; CMGC  = containing Cdk,  MAPK, GSK3, CLK families;  
STE = homologs of yeast sterile 7 , ster i le 11,  steri le 20 kinases;  TK = tyrosine kinases; 
TKL = tyrosine kinase-like. Obviously, CK1 and CK2 (black arrow) family members are non -related.  
The phylogenetic tree is taken from MA N NI N G  et al .5 .  The dendrogram (right) is  made in accordance 
to the same publication.  
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1.2 Protein Kinase CK1δ 
In 1969 two distinct liver enzymes were amongst the first PK described in literature, referred to 
as casein kinases 1 and 2 with respect to their ability to phosphorylate casein in vitro. Several 
years later, in the early 1970s, the casein kinase “pseudo family” was supplemented by a third 
member, the Golgi casein kinase (G-CK) which is in fact the only one of these phosphorylating 
casein in vivo. Considering this confusing situation, it was decided in 1994 to rename the pseudo 
casein kinases in accordance to their acronyms to protein kinases CK1 and CK28. It is further 
noteworthy that the enzymes formerly known as casein kinases represent phylogenetically non-
related proteins which primarily share their ability to phosphorylate casein in vitro. While CK1 
and CK2 represent distinct families, G-CK has recently been identified as a member of the 
atypical Fam20C (family with sequence similarity 20C) protein kinase family5,8. 
Since then, six distinct genes encoding human CK1 isoforms α, γ1, γ2, γ3, δ, and ε have been 
identified. These isoforms, together with their closest relatives tau tubulin kinases 1 (TTBK1) 
and 2 (TTBK2) and vaccinia-related kinases 1-3 (VRK1-3), represent one of the seven groups 
(CK1) of the human kinome (Figure 1). Another isoform from the bovine brain (CK1β) as well as 
diverse splice variants (transcription variants, TV) add to the diversity of this family5,9–11. 
The CK1 family members represent evolutionary highly conserved monomeric Ser/Thr-specific 
protein kinases with sequence homology referred to the catalytic domain of at least 51 % 
amongst CK1 isoforms and less than 21 % towards other members of the Ser/Thr kinase super-
family11. Significant differences between CK1 isoforms are length and primary structure of the 
non-catalytic but regulatory carboxyl-terminal domains leading to molecular weights ranging 
from 37 kDa (CK1α) to 51 kDa (CK1γ3)12. The highest consensus within the CK1 family display 
isoforms δ and ε with more than 98 % sequence identity of their catalytic domains and at least 
40 % of their C-termini9,11,13. 
CK1-mediated phosphorylation is generally second messenger independent and exclusively 
relies on ATP as a co-substrate12. Early studies also suggested CK1 isoforms to be dual-specific 
kinases, but it still remains undefined which isoforms are actually able to additionally 
phosphorylate tyrosine residues or whether they are able to do so at all11,12. 
In detail, two transcription variants (TV1, TV2) have been identified for the CK1 isoform δ gene 
CSNK1D that has been mapped to chromosome 17q2514,15. Although these variants include iden-
tical small N-terminal regions (eight amino acids) and kinase domains (286 amino acids), they 
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exclusively differ in the length of their C-termini, leading to transcripts of 415 (TV1) and 409 
(TV2) amino acids with molecular weights of 47.2 kDa and 46.7 kDa, respectively (Figure 2)9. 
 
Figure 2 | Sequence alignment of human CK1δ transcription variants and CK1ε .  The conserved 
N-terminal domain consists of amino acids 1 -8, followed by the kinase domain (286 amino acids) . 
Identical residues within the kinase domain are highlighted in green, different residues in yellow. 
The non-conserved C-terminal domains of CK1δ TV1/TV2 and CK1ε exhibit highly variable 
sequences. The alignment was generated by Cl ustal Omega 1 6  using transcript sequences for CK1δ 
TV1 (Gene Bank AAH03558.1), CK1δ TV2 (Gene Bank ABM64211.1), and CK1ε (Gene Bank 
ABM64212.1). For abbreviations DFG, KHD , SIN, NLS cp. chapter 1.2 .   
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1.2.1 CK1δ Kinase Domain Structure 
Crystal structures of CK1δ show the typical bilobal organization common to all protein kinases 
(Figure 3): the smaller N-terminal and the larger C-terminal domains (lobes) are connected by a 
linker loop, the so-called hinge region. This linker is included in a CK1-specific sequence motifa 
and contains the highly conserved Gly86 which is suggested to be crucial for domain flexibility. 
The nucleotide-binding site is positioned adjacent to the hinge within the cleft between both 
lobes11,17,18. 
The N-lobe primarily consists of five antiparallel β-sheets (β1ab, β2, β3, β4, and β5), one helical 
structure (αA) between strands three (β3) and four (β4), and the conserved glycine-rich P-loop, 
bridging strands one and two. The P-loop forms the ceiling of the ATP-binding region18. 
Four prominent antiparallel α-helices (αC, αE, αH, αI) set up the framework of the C-lobe, 
complemented by an approximately vertical helix (αF), three smaller helices (αB, αD, αG), four 
small β-sheets (β6-β9), and the T-loop (L-9D), L-EF, and L-HI. Two phosphate moiety-binding 
sites (W1, W2) have been identified within this lobe (Figure 3). Both sites are located easily 
accessible on the protein surface within hydrogen bonding distance to residues Arg178, Gly215, 
Lys224 (W1) and Arg157, Lys154 (W2), respectively17,18. 
The highly flexible loop L-EF adjacent to W1 contains a putative nuclear localization signal 
(NLSb) sequence at the junction to αF which is conserved in CK1 isoforms δ and ε. Another motifc 
within this loop is reportedly unique to the CK1 family17,19. Further optional phosphorylation 
sites are situated in close proximity to the regulatory T-loop. Especially Thr161 and Thr174 are 
likely targets for reversible phosphorylation as being exposed on the surface17,18. 
In CK1δ the T-loop is the equivalent of the so-called activation-loop (A-loop) in other protein 
kinases where it is located between the conserved DFGd and APE (Ala, Pro, Glu) motifs.18 
Interestingly, all CK1 family members lack the APE consensus sequence19. The appropriate 
triplet in CK1δ, though without equivalent functionality, is SINe within a CK1-specific sequence 
motif ranging from the end of the T-loop over αD and into αE17. Conformational rearrangement 
of the T-loop regulates substrate access to the active site2. An additional important motif 
included in the T-loop is a conserved kinesin homology domain (KHDf) that is usually part of the 
head regions of microtubule motor proteins18,20. 
                                                             
a Leu84, Leu85, Gly86, Pro87, Ser88, Leu89, Glu90, Asp91, Leu92, Phe93 (hinge motif) 
b Thr220, Lys221, Arg222, Gln223, Lys224, Tyr225 (NLS) 
c Ser210, Leu211, Pro212, Trp213, Gln214, Gly215, Leu216, Lys217, Ala218 (CK1 L-EF family motif) 
d Asp194, Phe195, Gly151 (DFG) 
e Ser181-Ile-Asn183 (SIN) within CK1-specific Thr184, His, Leu, Gly, Ile, Glu, Gln, Ser, Arg, Arg, Asp, Asp, Leu, Glu197 
f His164, Ile165, Pro166, Tyr167, Arg168 (KHD) 
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Upon crystallization, homodimerization of CK1δ has been observed and a dimerization domain 
can be suggested including various amino acids of strands β1, β2, β3, and β7 as well as loops 
L-12 and L-78, helix αB, and the hinge (chapter 1.2.3, Figure 8). Whether homodimers are of 
any importance for in vivo settings still has to be investigated9,17,21. 
 
Figure 3 | Structural presentation of the CK1δ kinase domain .  The N- (red) and C-terminal lobe 
(blue) are connected by the hinge region (yellow). The nucleotide binding site (not occupied) lies 
within the cleft between t he domains. Indicated by arrows are the kinesin homology domain (KHD) 
and the nuclear localizati on signal (NLS). The significance of the DFG (Asp,  Phe, Gly) motif  for 
CK1δ has not been determined yet.  The nomenclature is adapted from XU  et  al .1 8  and LO N G E NE CK E R  
et al .1 7 .  The figure refers to CK1δ crystallization by HUA N G  et al .  (PDB code 4HGT) 2 2 .  
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In the absence of ATP CK1δ remains in a “closed conformation”. Consequently, a slight rotation 
of the N-lobe is necessary to gain access to the catalytic cleft for nucleotide binding17. According 
to the pharmacophore model by TRAXLER and FURET the ATP-pocket of protein kinases ought to 
be subdivided into three distinct regions which mediate ATP-binding (Figure 4): first, the pre-
dominantly hydrophobic adenine-binding region (AB), supporting two hydrogen bonds 
(H-bonds) between hinge residues and the adenine moiety; second, the hydrophilic sugar pocket 
(SP) and third, the solvent-exposed and less conserved phosphate-binding region (PB). Adjacent 
to these, two non-conserved hydrophobic regions offer potential for the design of selective ATP-
competitive inhibitors: the hydrophobic pocket I (HPI, selectivity pocket) and the solvent-
exposed hydrophobic region II (HRII, affinity pocket). HPI is lined by the gatekeeper residue 
(Met82 in CK1δ) which allows or prohibits access to this cavity. Especially HPI is occupied by 
many potent kinase inhibitors9,23. 
 
Figure 4 | ATP-binding mode in CK1δ .  The representation is in accordance with crystallization 
results of CKi1 and magnesium-ATP complex (PDB code 1CSN) and the pharmacophore model by 
TRAXLER and FURET. For clarity, w ater molecules are left out 1 7 , 1 8 , 2 3 .  
Crystallization of yeast CK1-homolog CKi1 with ATP and magnesium by XU et al. revealed the 
exact nucleotide-binding mode for CK1 that is in line with the pharmacophore model18. In detail, 
two H-bonds are formed with hinge residues: Asp86 (Glu83 in CK1δ) accepts an H-bond donated 
by the adenine amino group while Leu88 (Leu85 in CK1δ) forms the second bond towards the 
adenine N1 atom. N7 interacts with CKi1 via water-mediated H-bonds with αA side chains of 
Glu55 (Glu52 in CK1δ) and Tyr59 (Glu56 in CK1δ, Figure 5 A). The ribose hydroxyl moieties 
form one direct bond towards L-67 Asp135 (Asp132 in CK1δ) and water-mediated contacts 
8 | I n t r o d u c t i o n  
 
 
towards L-5B Ser91 (Ser88 in CK1δ) and αB Asp94 (Asp 91 in CK1δ, Figure 5 B). P-loop 
residues Ser22, Gly24 (Ser19 and Gly21 in CK1δ), strand three (β3) Lys41 (Lys38 in CK1δ), and 
L-67 Lys133 (Lys130 in CK1δ) participate in stabilizing the ATP triphosphate moiety. One 
magnesium ion is complexed by the ATP α- and γ-phosphates and coordinated by L-67 Asn136 
(Asn133 in CK1δ, Figure 5 C)18. 
 
Figure 5 | Detailed ATP-binding mode in CKi1 .  Direct and water -mediated contacts between CKi1 
and ATP adenine (A), ribose (B), and magnesium -phosphate moiety (C). Interactions were modeled 
according to XU et al .  (PDP code 1CSN) 1 8 .  
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1.2.2 Substrate Recognition and Substrates of CK1δ 
Like all CK1 family members, CK1δ is a phosphate-directed Ser/Thr-specific protein kinase, 
preferentially catalyzing conversion of previously phosphorylated or acidic peptides. The 
canonical CK1 consensus sequence motif has been described as Ser(P)/Thr(P)-X-X-Ser/Thr with 
X being any amino acid and the phosphorylatable residue (Ser/Thr) located C-terminal of a 
phosphoserine Ser(P) or phosphothreonine Thr(P). The phosphorylated Ser(P)/Thr(P) can also 
be replaced by negatively charged acidic residues changing the motif to Aspn/Glun-X-X-Ser/Thr 
with n ideally being three or four. Asp residues are thereby slightly more effective than Glu, but 
both are significantly less favored compared to phospho-primed substrates19,24–27. Apart from 
these, noncanonical consensus sequences have been identified e.g. in β-catenin in which the 
phosphorylatable Ser45 is implemented in a so-called SLS motifg followed downstream by acidic 
residues28. Furthermore, linking the sulfated lipids sulfatide and cholesterol-3-sulfate (SCS) to 
target proteins has been reported to affect CK1 isoform-specific phosphorylation: while 
sulfatide-mediated stimulation caused only a slight increase in phosphorylation of the potent 
Aspn/Glun-X-X-Ser/Thr motif in myelin basic protein (MBP) by CK1δ, it highly excites 
CK1δ/γ-catalyzed phosphate transfer to Ras homolog family member A (RhoA). Therefore, 
phosphorylation of basic proteins may effectively be increased by SCS, as a consensus motifh for 
CK1α/δ/ε-mediated phosphorylation has been identified e.g. within SCS-binding proteins MBP 
and tau. Binding of SCS within this sequence, however, is suggested to be accomplished by the 
first three residues, presumably Lys, Gly, Arg29. Apart from this, substrate specificity of CK1 
isoforms seems not to be achieved by preferring different target sequences30. 
The phosphate moiety-binding site W1 appears to be the major site for substrate organization 
with regard to the phosphate transfer. W1 was originally detected in crystallographic analysis as 
a sulfate- and tungstate-binding site, where the particular ion is coordinated via H-bonds by 
Arg178 (T-loop), Gly215 (L-EF) and Lys224 (αF)17,18. According to these observations molecular 
modeling brilliantly visualizes the preference of CK1 isoforms for previously phosphorylated 
substrates (Figure 6): the phosphate moiety of an in silico generated peptidei, in accordance 
with the canonical consensus motif, is coordinated by the same residues as the sulfate/tungstate 
ion whereupon the phospho-acceptor hydroxyl group of the peptide target Ser is directed within 
H-bonding range of the ATP γ-phosphate. In dependency on the substrate, the highly flexible 
L-EF is able to adapt variable conformations and is likely to mediate different interactions. 
                                                             
g Ser45-Leu-Ser-X2-5-Glun/Aspn (SLS consensus motif) 
h Lys/Arg-X-Lys/Arg-X-X-Ser/Thr (SCS-binding protein consensus motif) 
i Ser(P), Ala, Ala, Ser (in silico peptide sequence) 
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Consequently, it has been designated as the substrate-binding loop17,18. Unprimed acidic 
substrates might act in a similar way as there are several basic residues within the T-loop 
(Arg178), L-EF (Lys217, Lys221, Arg222) and αF (Lys224) accessible for potential electrostatic 
interactions towards the acidic cluster of peptides28. 
 
Figure 6 |  Postulated substrate-binding mode at CK1δ phosphate -binding moiety W1 .  An in 
silico  peptide (yellow) consisting of Ser(P) -Ala-Ala-Ser is coordinated by Arg178 (T-loop, green in 
A), Gly215 (L-EF, red in A) and Lys224 (αF, blue in A). The phosphorylatable Ser hydroxyl group is 
placed in H-bonding range towards ATP (maroon) γ -phosphate. A surface model (B) visualizes the 
close fitting of  Mg2 +-ATP and substrate to the catalytic cleft of CK1δ. Modeling was performed 
based on MA RI N  et al .2 8  (PDB code 1CSN 1 8 ,  4HGT2 2) utilizing Schrödinger software ( chapter 7.1).  
In addition to the phosphate-binding moiety W1 adjacent to the ATP-binding pocket several 
sites within the N- and C-terminal domain participate in substrate interaction31. CK1δ docking 
motifs have been identified in different proteins such as the Phe-X-X-X-Phe motif in nuclear 
factor of activated T-cells 1 (NFAT1) and period 2 (PER2) or the Ser-Gln-Ile-Pro motif in 
microtubule plus-end-binding protein 1 (EB1)32,33. As these motifs are not necessarily localized 
in proximity to the respective phosphorylation sites, it is suggested that their function refers to 
proper positioning and stabilization of kinase domain and substrate34. 
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In the absence of docking motifs, the C-terminus has been observed to act in a similar manner: 
autophosphorylation and phosphorylation by other kinases within this region prevents 
substrate-binding as the C-terminal tail subsequently functions as a pseudo-substrate blocking 
access to the binding site35. 
Despite the fact that several substrates are in vitro targets of different CK1 family members, the 
isoforms possess strong in vivo substrate specificity. This specificity is presumably ascribed to 
non-conserved residues within the kinase domains as observed for the specific interaction 
between CK1δ/ε and PER35 as well as isoform-specific phosphorylation of p53 by CK1 isoforms 
δ, ε, and α, but not CK1γ1-336. 
In general, more than 150 substrates have been identified for CK1 family members to date. 
Although it is often difficult to assign distinct CK1 isoforms to particular substrates, more than 
80 proteins have been ascribed to in vitro or in vivo phosphorylation by CK1δ in literature. An 
admittedly incomplete summarization of these proven CK1δ substrates is given in Table 1. In 
addition, it is likely that in cases of inhibition or knockdown several highly related isoforms like 
δ and ε are able to take over several substrates from each other in form of an escape mechanism. 
Table 1 | Specified in vitro  and in vivo  CK1δ substrates of different species .  The list is  
admittedly incomplete due to the fact that many CK1 substrates  have not been assigned to distinct 
isoforms. The classification of substrates in this table is based on their major function and in 
association with chapter 1.2.4 .  Several substrates could appear in more than the assigned group.  
Putative function Substrates 
  
Key regulatory stress-associated 
factors 
p5337, murine double minute 2 homolog (MDM2)38, hypoxia-inducible factor 1α 
(HIF-1α)39 
  
DNA-/RNA-associated proteins 
and transcription (factors) 
Topoisomerase IIα (TOP2A)40, DNA methyltransferase 1 (Dnmt1)41, ubiquitin-
like, with PHD and RING finger domains (UHRF1)42, heterogeneous nuclear ribo-
nucleoprotein A1 (hnRNP A1)43, putative RNA helicase43, forkhead box G1 
(FoxG1)44, nuclear factor of activated T-cells 1 (NFAT1)31,32, yeast sterol  
regulatory element-binding protein homolog (Sre1N)45, chromatin-associated 
protein swi6 (Swi6)46 
  
Ribosome-associated proteins Ribosomal proteins L4 (RPL4), L8 (RPL8), L13 (RPL13)43, nucleolar protein 56 
(Nop56)43, LTV147,48, ENP1, Bystin (BYSL)47, eukaryotic initiation factor 6 (eIF6), 
Tif6p49 
  
Mitotic and meiotic control Wee150, Rec8 meiotic recombination protein (Rec8)51, endogenous meiotic  
inhibitor 2 (Emi2)52 
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Cytoskeleton- and scaffolding-
associated functioning 
α/β-tubulin53, γ-tubulin9,53,54, microtubule-associated proteins 1A (MAP1A)31 and 
4 (MAP4)53, tau29,53,55, end-binding 1 (EB1)33, stathmin53, Ran-binding protein 
microtubule-organization center (RanBPM)56, Ras homolog family members A 
and B (RhoA, RhoB)29,57, keratin 1743, connexin-43 (Cx43)58, desmoglein 243,  
annexin II/lipocortin II43, Sid459, protein kinase C-potentiated myosin  
phosphatase inhibitor of 17 kDa (CPI-17)60 
  
Vesicular trafficking and Golgi-
associated functioning 
Snapin61, protein kinase D2 (PKD2)62, ADP-ribosylation factor GTPase-activating 
protein (ARF GAP1)63 
  
Neurodegeneration-associated 
proteins 
β-secretase (BACE1)64, presenilin-2 (PS-2)65, cyclin-dependent kinase 5 (Cdk5)66, 
α-synuclein67, parkin68, myelin basic protein (MBP)29, cyclic AMP response ele-
ment-binding protein (CREB)69, TAR DNA-binding protein of 43 kDa (TDP-43)70 
  
Circadian rhythm-associated 
functioning 
Period 1-3 (PER1-3)71–74, brain and muscle Arnt-like protein 1 (BMAL1)9,75,  
cryptochromes 1 (CRY1) and 2 (CRY2)9,75, proliferator-activated receptor γ  
co-activator 1α (PGC-1α)76, frequency (FRQ)77, white collar-1 (WC-1)78 
  
Cancer development-associated 
functioning 
Bid9,79, β-catenin80, axin15, dishevelled (Dvl)15, adenomatous polyposis coli 
(APC)81, dapper1a (Dpr1a)82, full-length cubitus interruptus (Ci-155)83, yes-
associated protein (YAP)84, sprouty2 (SPRY2)85, fat86, neural precursor cell  
expressed developmentally down-regulated protein 4 (NEDD4)87, metastasis 
suppressor 1 (MTSS1)88, nucleoside diphosphate kinase A (nm23-H1)89,  
deoxycytidine kinase (dCK)90 
  
Viral proteins Simian virus 40 large T-antigen (SV40 T-Ag)91, human herpes virus (HHV) E3 
ubiquitin ligase (ICP0)92, human cytomegalovirus phosphoprotein (ppUL44)93 
  
Various receptor- and second 
messenger-related proteins 
Estrogen receptor α (ERα)94, amplified in breast cancer 1 (AIB1)94, adiponectin95, 
transmembrane tumor necrosis factor α (mTNFα)96, dopamine- and cAMP-
regulated neuronal phosphoprotein (DARPP-32)97,98 
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1.2.3 Regulation of CK1δ Activity 
Given its ubiquitous expression and the large number of substrates, a tight regulation of 
constitutively active and second messenger independent CK1δ seems mandatory, even though 
CK1 family members were thought for many years to be lacking any regulatory mechanisms99. Of 
course, upstream protein kinases and phosphatases are indirectly regulating CK1δ-mediated 
phosphorylation of certain substrates by adding or removing phosphate moieties and hence 
creating or eliminating consensus phosphorylation motifs. Cyclic AMP-dependent protein 
kinase A (PKA) has e.g. been reported to prime substrates for subsequent phosphorylation by 
CK1δ78. Besides this indirect regulation, direct mechanisms have been identified to affect CK1δ 
activity: regulation of CK1δ expression, subcellular localization, protein-protein interactions, and 
post-translational modification. 
Regulation of CK1δ Expression 
CK1δ appears ubiquitously expressed, but expression levels vary in adjustment to its respective 
physiological function in different tissues, organs, and cell types100. Consequently, expression 
levels rely to some extend on cellular circumstances and can be adapted in stress response, e.g. 
upon stimulation by viral transformation101 or DNA-damaging effectors like topoisomerase 
inhibitors etoposide and camptothecin or γ-irradiation37,53. Appropriate observations exhibited 
increased levels of CK1δ mRNA and protein as reaction to induction of p53 in vivo37. Gastrin62, 
adiponectin95, and presumably insulin102 have been linked to elevated CK1δ expression levels as 
well. 
Subcellular Localization and Protein-Protein Interactions 
At protein level CK1δ is distributed between nucleus and cytoplasm and it is even covalently 
attached or stably associated to (plasma) membranes, cytoskeleton proteins, receptors, and 
diverse nuclear and cytosolic factors11,100. This spatial sequestration appears both permanent 
and temporary: permanent, as mammalian CK1δ is predominantly cytosolic, especially enriched 
at the Golgi apparatus and the endoplasmic reticulum (ER); and temporary, as it colocalizes with 
the centrosome in interphase and spindle poles in mitosis103. While nucleocytoplasmic shuttling 
is often explained by the NLS, gastrin has also been reported to enhance nuclear accumulation of 
CK1δ, potentially by activating the cholecystokinin 2 receptor (CCK2R)62. The majority of spatial 
and temporal subcellular organization, however, is reportedly achieved by scaffold proteins that 
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mediate sequestration and anchorage of CK1δ to organelles and membranes or assembly of 
functional complexes (Figure 7)9,104. Anchorage of CK1δ to organelles and membranes is e.g. 
mediated by the A-kinase anchoring protein 450 (AKAP450) which recruits CK1δ and CK1ε in an 
isoform-specific manner and tethers them to centrosome and Golgi apparatus without affecting 
substrate interaction105. Although AKAP450 is necessary for Golgi targeting of both isoforms and 
localization of isoform ε at the centrosome, the latter does not apply to isoform δ. CK1δ 
possesses a centrosomal localization signal (CLS) comprising several residues between positions 
278 and 364 within its C-terminus106. DEAD-box RNA-helicase 3 (DDX3) is recruited to CK1δ/ε 
upon Wnt-activation and stimulates phosphorylation of dishevelled (Dvl) by acting as an 
allosteric activator of CK1107. Other scaffold proteins like EB1 direct proper positioning of 
complexes33 or isoform-specifically inhibit CK1δ activity such as dysbindin paralog CK1-binding 
protein (CK1BP) in human brain108. In other cases complex formation is required for 
translocation to the nucleus (Figure 7)13. 
Although scaffolding proteins interact with CK1δ and CK1ε kinase domains, as shown by the use 
of C-terminal truncation mutants, and although they are often phosphorylated during the 
process (e.g. DDX3, EB1, CK1BP, CRY, PER), they are not necessarily CK1 substrates 
(e.g. AKAP450)33,105,108. Consequently, scaffold proteins represent important regulatory 
mechanisms by dynamically recruiting (and sometimes inhibiting) specific isoforms upon need 
and selectively creating and channeling access to certain substrates. In addition, they provide 
another level of regulation as they are tightly regulated themselves104,105. 
 
Figure 7 | Scaffold protein-mediated subcellular spatial organization .  AKAP450 anchors 
CK1δ/ε to membranes and organelles ,  DDX3 binds CK1δ/ε and promotes Dvl phosphorylation, CRY -
PER-CK1δ/ε complexes translocate to the nucleus, CK1BP binds and inhibits CK1δ. Phosphoryl a-
tion is represented by yellow stars. The figure is adapted from GO OD  et al .1 0 4 .  
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Additionally, crystallographic studies of CK1δ revealed the formation of homodimers which is 
suggested to provide another negative regulatory mechanism in vivo as intermolecular 
interaction of the dimerization domains accounts for exclusion of ATP from the catalytic cleft 
(Figure 8)21. 
 
Figure 8 | Homodimerization of CK1δ .  Monomers 1 (purple) and 2 (green) form dimers via  
interaction of their dimerization domains  (A). The dimerization domain  (yellow) includes various 
amino acid residues of strands β1, β2, β3 ,  and β7 as well as loops L -12 and L-78, helix αB, and the 
hinge region (B, PDB code 4HGT 2 2) .  
 
Post-translational Modification 
Reversible phosphorylation represents the major mechanism in post-translational modification 
of CK1δ, either by intramolecular autophosphorylation or phosphorylation by other protein 
kinases. Studies using CK1δ truncation mutants identified six potential autophosphorylation 
sites within an inhibitory C-terminal domain (Figure 9 B), although not all of them seem to 
influence kinase activity. Autophosphorylation of Ser318, Thr323, Thr329, Ser331, and Thr337, 
but not Ser328 generates sequence motifs summarized as Ser(P)/Thr(P)-X-X-Y that might act as 
pseudosubstrates and inhibit kinase activity, with Y being any amino acid except Ser/Thr109. 
Besides autophosphorylation, cAMP-dependent protein kinase (PKA), protein kinase C α (PKCα), 
checkpoint kinase 1 (Chk1), cyclin E-activated cyclin-dependent kinase 2 (Cdk2/E), and p35-
activated cyclin-dependent kinase 5 (Cdk5/p35), as well as protein kinase B (Akt) and CDC-like 
kinase 2 (CLK2) have been identified to participate in regulatory phosphorylation within the 
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C-terminal region of CK1δ110–113. Site-directed phosphorylation by all of these kinases led to 
decreased CK1δ kinase activity. Among these, PKA has to be considered as the main cellular 
kinase targeting predominantly Ser370 in vitro and in vivo110. Colocalization of PKA and CK1δ is 
achieved by AKAP450-mediated anchorage to the centrosome (Figure 9 C)110. Interestingly, 
Ser370 which has not been defined as an autophosphorylation site is also a target for PKCα, 
Chk1, Akt, and CLK2. PKCα and Chk1, however, additionally phosphorylate residues which 
certainly do represent autophosphorylation sites110–112. Dephosphorylation by various Ser/Thr-
specific protein phosphatases and cleavage of the C-terminus are mechanisms to overcome 
inhibitory phosphorylation within the C-terminal region. While multiple phosphatases are 
believed to be capable of activating CK1δ, only the catalytic subunit of protein phosphatase 1 
(PP1C) has been characterized in this context109. PP1C has also been outlined as an AKAP 
substrate, though not AKAP450, suggesting a colocalization of CK1δ, PP1C, and PKA (Figure 
9 C)114. Interestingly, inhibitor-2 of PP1C is phosphorylated by CK1, CK2, and glycogen synthase 
kinase 3 (GSK-3) leading to activation of PP1C, even though the exact CK1 isoform has not been 
defined (Figure 9 A)115. 
Although not a proper post-translational modification, heparin has been reported to activate 
only full length CK1δ in vitro, presumably by interaction with the partially positively charged 
C-terminus which was prohibited by preincubation of CK1δ with PP1C or C-terminal truncation. 
Heparin is unlikely to represent a physiological regulator of CK1δ, but interaction of regulatory 
compounds with the C-terminus imitating dephosphorylation can be deemed possible (Figure 
9 A)19,116. 
Apart from phosphorylation events, CK1δ levels are controlled by the anaphase-promoting 
complex/cyclosome (APC/CCdh1) during cell cycle exit in the developing cerebellum. APC/C 
activator protein cadherin 1 (Cdh1) isoform-specifically targets CK1δ for ubiquitination by the 
ubiquitin E3-ligase complex APC/C and subsequent degradation (Figure 9 A)117. 
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Figure 9 | Post-translational regulation of CK1δ .  Mechanisms of post-translational regulation 
(A): inactivation by C-terminal autophosphorylation (1) or phosphorylation by other kinases (4) 
and subsequent activation by phosphatases (1, 4 vice versa), C-term truncation (2, 5) or 
interaction with activator molecules (3).  Truncation is also imaginable without previous 
phosphorylation (6).  CK1δ is marked for degradation by ubiquitination (7). Brackets indicate 
insufficient evidence. Phosphorylation sites within the CK1δ TV1 C -terminal domain (B, adapted 
from KNI PPSC HIL D  et al .9). Colocalization of CK1δ, PKA, and PP1 C  is mediated by AKAPs (C) 1 0 9 – 1 1 7 .  
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1.2.4 Physiological and Pathophysiological Relevance of CK1δ 
CK1δ-mediated regulatory activity is associated with numerous physiological and pathophysio-
logical processes. Many of these represent responding to situations of cellular stress: in Saccha-
romyces cerevisiae yeast CK1δ homologue Hrr25 is directly involved in DNA repair mecha-
nisms11–13 and human CK1δ is upregulated through its connection to p53 in an autoregulatory 
feedback loop9,37. Upon DNA damage-activated p53 binds to a p53 response element within 
CSNK1D and initiates transcription. Tumor suppressor p53 is phosphorylated by CK1δ (and 
CK1ε) at several sites in order to preserve genomic integrity by inducing either cell cycle arrest 
or apoptosis. CK1δ/ε-mediated phosphorylation at Ser15 and Thr18 stabilizes and activates p53 
by diminishing interaction with its inhibitory counterpart mouse double minute 2 homolog 
(MDM2). Interestingly, MDM2 is targeted by CK1δ as well and phosphorylation can either lead to 
enhanced binding of MDM2 to p53 with subsequent degradation of p53 in unstressed cells or 
prepare MDM2 for ubiquitination and proteolysis9,38. CK1δ is also suggested to negatively regu-
late p53 by forming complexes with MDM2 under non-stress conditions118. Under hypoxic condi-
tions activation of p53 is initiated by transcriptional activator hypoxia-inducible factor 1α 
(HIF-1α) which promotes cell survival under these circumstances and is negatively regulated by 
CK1δ9,12. In addition, CK1δ influences cellular processes such as DNA transcription and methyla-
tion40–42,70, translation (ribosomal assembly and biogenesis)43,47–49, mitosis and meiosis50–52, and 
signal transduction94–96. CK1δ-mediated regulation and disorder in cytoskeleton-associated pro-
cesses, circadian rhythm, and development of cancer are discussed in detail below. CK1δ further 
phosphorylates various viral proteins, thereby playing a role in parasites infection91–93. Patho-
genic phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) has been associated with 
upregulated CK1δ activity in amyotrophic lateral sclerosis (ALS)119. Naturally, complete cove-
rage of physiological or pathophysiological CK1δ-mediated processes is not given and research 
continuously increases the understanding of the roles of CK1δ in health and disease. 
Cytoskeleton-associated Functions and Alzheimer’s Disease 
Protein kinase CK1δ activity has repeatedly been highlighted to be essential for accurate cell 
cycle progression, cytokinesis, and vesicular trafficking53,54,120. In interphase cells CK1δ 
associates with membrane structures of the trans Golgi network (TGN) where it presumably 
holds regulatory tasks in the budding of clathrin-coated vesicles. Furthermore, a general role in 
vesicular trafficking has been suggested: CK1δ interacts with and phosphorylates the soluble 
SNAREj-associated protein snapin53,61. Supporting observations proved yeast CK1δ homologue 
                                                             
j N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) 
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Hrr25 involvement in vesicle budding from the endoplasmic reticulum121. Besides TGN 
membranes CK1δ localizes with microtubules and centrosomes suggesting participation in 
microtubule-mediated transport processes, as CK1δ kinase domain is known to contain a 
KHD20,53. During mitosis CK1δ shows enhanced affinity for tubulins in response to genotoxic 
stress exposure. It is therefore increasingly recruited to mitotic spindles and centrosomes, likely 
in the meaning of a mitotic checkpoint signal to assure ordered rearrangement of the 
microtubule network and chromosome segragation53,54. Phosphorylation of α- and β-tubulins by 
CK1δ directly modulates microtubule dynamics, while CK1δ-mediated phosphorylation of 
microtubule-associated proteins 1A (MAP1A)31, 4 (MAP4)53, γ-tubulin9,53,54, and tau29,53,55, as well 
as stathmin and the Ran-binding protein in the microtubule organization center (RanBPM)56, 
influences microtubule assembly, disassembly, and stability53. Consequently, inhibition of CK1δ 
leads to p53-dependent cell cycle arrest or apoptosis, depending on the cell line in question54,120. 
Retardation of cytokinesis also occurs upon CK1δ-mediated phosphorylation and subsequent 
ubiquitination and degradation of Sid459. 
Centrosomal functions of CK1δ include neurite outgrowth and ciliogenesis. While neuritogenesis 
requires Wnt3a-dependent and centrosomal CK1δ-mediated Dvl phosphorylation106, formation 
of primary cilia presumably comprises regulation of microtubule networks and ciliary 
distribution of effector proteins. In addition, ciliogenesis also relies on AKAP450-mediated 
microtubule nucleation at the Golgi, Golgi organization, and vesicular trafficking. Therefore, 
direct interaction of CK1δ and the anchoring protein has been reported to be crucial for 
coordination of AKAP450-dependent Golgi positioning122. In contrast, CK1δ might also play a 
role in Wnt5a-induced primary cilia disassembly by contributing to Dvl2 phosphorylation, 
although its participation remains somewhat uncertain and CK1ε has been shown to be the 
predominant centrosomal kinase in this case123. 
During T-cell activation CK1δ manages centrosome translocation to the immunological synapse 
by increasing microtubule growth speed and stabilization via binding and phosphorylation of 
EB133. By the way, EB1 has also been found to serve in ciliogenesis, though direct association 
with CK1δ has not been reported in this context124. 
Apart from physiological events, microtubule-associated phosphorylation by CK1δ is closely 
connected with neurodegenerative disorders and especially with the pathogenesis of 
Alzheimer’s disease (AD). AD is characterized by the appearance of neurofibrillary tangles of 
accumulated tau protein and senile neuritic plaques, eventually causing neurons to die. CK1δ is 
upregulated more than 30-fold in AD brain, leading to pathological hyperphosphorylation of tau 
and subsequent microtubule destabilization and tau fibrillization55,125,126. Furthermore, CK1δ 
acts as a priming kinase for GSK-3β-mediated tau phosphorylation and activates cyclin-
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dependent kinase 5 (Cdk5), another kinase participating in phosphorylation of tau66,127. 
Sequential cleavage of the amyloid-β precursor protein (βAPP) by proteases β-secretase and 
presenilin-dependent γ-secretase yields the neurotoxic peptide amyloid-β that is the main 
component of senile plaques. Both proteases are to a certain degree CK1δ-regulated as 
β-secretase and presenilin-2 represent known targets64,65. Amyloid-β in turn has been reported 
to stimulate CK1 activity, suggesting a vicious circle that might explain the progressive character 
of the disease128. 
Besides its AD participation CK1δ phosphorylates α-synuclein and parkin, both key determi-
nants in the pathogenesis of Parkinson’s disease67,68. 
CK1δ in Circadian Rhythm and its Connection to FASPS 
Numerous physiological processes are subject to time of day-dependent regulation. Besides 
external effectors such as light, temperature, and food biochemical activity within every cell is 
regulated by an autonomous circadian clock. This intracellular timer consists of transcriptional 
activators and repressors that reciprocally regulate their own expression in an oscillating 
system129: heterodimers of brain and muscle ARNT-like protein (BMAL1) or neuronal PAS 
domain protein 2 (NPAS2) and CLOCK initiate transcription of Period (PER1-3), Cryptochrome 
(CRY1/2), and REV-ERBα genes. Furthermore, cytoplasmic PER levels are controlled by 
reversible CK1δ/ε-mediated phosphorylation, followed by degradation. Proteasomal digestion is 
avoided by the formation of CRY-PER complexes that bind CK1δ/ε and translocate to the nucleus 
where they repress transcription of BMAL1-CLOCK target genes9,129,130. 
About 10 % of all genes are under control of this circadian autoregulatory feedback loop. Among 
them are of course regulators of the cell cycle such as Wee1, encoding a tyrosine kinase that 
inhibits mitotic entry and is degraded in the course of CK1δ-mediated phosphorylation50,129. 
PGC-1α is activated upon nutritional signals and coordinates circadian metabolic processes by 
cross-activation of circadian (BMAL1, REV-ERBα) and metabolic gene expression76,131. CK1δ-
mediated phosphorylation represses transcriptional activity of PGC-1α and initiates its 
degradation76. Additionally, circadian proteins are important regulators responding to oxidative 
stress. BMAL1, for instance, is a regulator of p53-induced cell cycle arrest upon DNA-damage 
and PER proteins possess tumor suppressor capacity9,132–135. 
CK1 isoforms δ and ε are central effectors in the regulation of circadian proteins. Stability and 
subcellular localization of PER proteins are regulated by the interplay of reversible 
phosphorylation and dephosphorylation by CK1δ/ε and PP1, leading to alteration of the length 
of circadian cycles73,136. Interestingly, even though CK1δ and CK1ε have often been considered 
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redundant in this context, CK1δ might possess a predominant position because absence of CK1δ 
- but not CK1ε - has been reported to significantly lengthen circadian periods in mice74. This 
observation is supported by investigations from zebrafish that prove CK1δ to be crucial for 
circadian timing, whereas CK1ε is only of minor importance137. Another modulator of period 
length that is differently affected by CK1δ and CK1ε is enhancer box (E-box) repressor 
prohibitin 2 (PHB2). Although the exact mechanism remains uncertain, knockdown of CK1δ 
decreases PHB2 mRNA and conversely, knockdown of CK1ε has been reported to increase PHB2 
protein level138. BMAL1, CRY1, and CRY2 are phosphorylated by CK1δ and CK1ε in a redundant 
manner. But while BMAL1, PER1, and PER2 are subject to direct phosphorylation, CRY proteins 
and PER3 are dependent on PER1 or PER2 acting as scaffold proteins. Consequently, PER-CRY 
complexes bind CK1δ/ε and translocate CRY-mediated to the nucleus75,139. 
Taken together, it is not surprising that alterations such as mutation and misregulation within 
this network are closely associated with sleeping disorders and even tumorigenesis, as well as 
cardiovascular and metabolic disorders76,129. The most prominent among sleeping disorders is 
probably familial advanced sleep phase syndrome (FASPS) which is characterized by early 
evening onset of sleep, early morning awakening, and a shortened circadian period. FASPS is 
caused by mutation either within the CK1-binding domain of human PER2 or the catalytic 
domain of CSNK1δ (T44A mutation), the latter expressing proteins with decreased catalytic 
activity140. In addition, circadian rhythm disruptions are generally connected to bipolar subjects 
and have been discussed as starting point for pharmacological intervention in this context141. 
CK1δ-associated Functions in the Development of Cancer 
Tumorigenesis is generally related to pathological changes due to mutation or misregulation in 
various signaling pathways with the result of independently proliferating and often highly 
resistant cancer cells. Especially participation of CK1δ in pathways referring to cell proliferation, 
genomic integrity, and the regulation of key modulator proteins in stress situations such as p53, 
MDM2, and β-catenin support the oncogenic importance of this protein kinase. Consequently, 
mutation of either CK1δ itself or phosphorylation sites of CK1δ-targeted substrates contributes 
to cancerogenesis. For instance, a gain-of-function mutation within the autoregulatory 
C-terminal domain of CK1δ (R324H), though without affecting autophosphorylation, has been 
identified in an adenomatous colorectal polyp142. Furthermore, different mutations affecting 
ATP-binding affinity in different tumor entities lead to either elevated or reduced catalytic 
activity with variable influence on tumor growth and oncogenic potential143,144. CK1δ mutations 
identified in various tumors are summarized in Table 2. 
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Table 2 | CK1δ mutants in different tumor entities .  The structural domain comprising the point 
mutation(s) is given in parentheses. P66T, R69K refers to a double muta nt.  
Mutation Consequence Tumor entity 
R324H (autoregulatory C-term)  Gain of function  Adenomatous colorectal polyp142 
T67S (ATP-bind. domain)  Increased catalytic activity Colorectal cancer143 
I68N (ATP-bind. domain)  Decreased catalytic activity Colorectal cancer143 
P66T, R69K (ATP-bind. domain)  Decreased catalytic activity Colorectal cancer143 
S97C (ATP-bind. domain)  Decreased ATP-bind. affinity Breast cancer, ductal carcinoma144 
 
Alterations in the expression of CK1δ have been described for various human tumors (Table 3) 
whereas the effect of up- or downregulation strongly depends on the tissue-based cellular back-
ground and tumor entity. Interestingly, while decreased expression of CK1δ is associated with 
prolonged survival of patients with colorectal cancer, the same applies to elevated expression 
levels in several forms of breast cancer, leukemia, and glioma145,146. In many cases it is worth 
mentioning that it remains unknown whether the alteration in CK1δ levels represent cause or 
consequence of oncogenic events145. 
Table 3 | CK1δ misregulation in different tumor entities .  Increase and/or decrease primarily 
refer to CK1δ  mRNA, although this is  predominantly in accordance with up -/downregulation on 
protein level . In cases of  altered expression  the reference did not specify levels compared to 
healthy tissue. Reduced immunostaining  has not been specified as well .  
Misregulation Tumor entity 
Increased expression Chorioncarcinomas120 
Increased expression High-grade pancreatic ductal adenocarcinomas147 
Decreased expression Lymphoid neoplasms148 
Increased expression Breast tumors149 
Altered expression Colorectal cancer146 
Reduced immunostaining Ductal carcinomas in situ, invasive breast carcinomas13 
Increased expression 
Tumors of bladder, brain, kidney, lung, melanoma, ovarian, pancreatic, prostate, 
and hematopoietic system145 
 
In addition to p53-related participation in apoptotic pathways CK1δ-mediated phosphorylation 
of Bid prevents cleavage by caspase 8 and therefore inhibits Fas-mediated apoptosis79. The anti-
apoptotic potential is of particular importance because resistance to apoptosis is crucial for var-
ious human tumors. Consequently, inhibition of CK1δ/ε has been reported to reduce pancreatic 
tumor growth effectively and to enhance the amount of dead cancer cells by re-sensitization for 
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Fas-induced apoptosis147. Besides, this provides evidence that CK1δ/ε are jointly responsible for 
aberrant proliferation147. The Wingless/Int-1 (Wnt) and β-catenin, Hedgehog (Hh), and Hippo 
signaling pathways are further CK1δ-dependent cascades contributing to tissue development, 
growth, and homeostasis. Mutations in regulatory mediators as well as aberrant activation of 
these pathways are frequently associated with the development of various human cancers9,150. 
In Wnt/β-catenin signaling CK1 isoforms synergistically perform positive and negative 
regulatory functions. Without pathway activation cytoplasmic β-catenin is regulated by 
β-catenin destruction complexes consisting of Axin, adenomatous polyposis coli (APC), GSK-3β, 
and CK1 isoforms α, δ, and ε. Axin acts as a scaffold and directly binds the components of the 
complex. CK1δ and GSK-3β, presumably supported by CK1ε, phosphorylate APC in order to 
increase binding affinity of APC towards β-catenin and thus promote β-catenin recruitment to 
the complex. Bound β-catenin is phosphorylated by CK1α, thereby primed for GSK-3β-mediated 
phosphorylation and subsequent ubiquitination (β-Trcp E3 ligase) and proteasomal 
degradation. Upon pathway stimulation, binding of Wnt ligand to transmembrane receptors 
Frizzled and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) is followed by 
binding of dishevelled (Dvl) to Frizzled and consecutive phosphorylation (CK1γ1) and activation 
of LRP5/6. Subsequent recruitment of the destruction complex implies inhibition of GSK-3β. 
Axin and Dvl phosphorylation by CK1δ/ε, catalyzed by Wnt-activated DDX3, promotes GSK-3β 
inhibition and induces conformational changes and destruction complex dissociation. Finally, 
β-catenin degradation is prevented, and accumulated β-catenin translocates to the nucleus 
where it binds T-cell factor/lymphoid enhancer factor (TCF/LEF) and initiates transcription of 
target genes. Additionally, CK1δ-mediated phosphorylation of dapper 1a (Dpr1a) disrupts the 
inhibitory interaction of Dpr1a and Dvl and therefore activates Wnt signaling9,15,151. 
The role of CK1δ in both Hh and Hippo signaling is of negative regulatory nature: consecutive 
phosphorylation of full-length cubitus interruptus (Ci-155), the Drosophila melanogaster homo-
log of human glioma-associated oncogene transcription factors 2 and 3, by CK1δ and GSK-3 trig-
gers proteolysis and inhibits Hh target gene transcription. In the Hippo pathway, phosphoryla-
tion of transcriptional co-activator Yes-associated protein (YAP) by large tumor suppressor ki-
nase (LATS) primes for CK1δ-mediated phosphorylation and subsequent ubiquitination (β-Trcp 
E3 ligase) and degradation. So in this case, too, target gene transcription is prohibited9. 
Finally, the involvement of CK1δ-dependent phosphorylation in regulation of tumor suppressors 
sprouty 2 (SPRY2)85 and Fat (Drosophila melanogaster homolog of human FAT)86, as well as me-
tastasis suppressors MTSS1 (metastasis suppressor 1)88 and nucleoside diphosphate kinase A 
(nm23-H1)89, confirms the oncogenic potential of CK1δ and underlines the protein kinase as an 
interesting drug target for cancer treatment. 
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1.3 Kinase Inhibitors 
The eminent position of phosphorylation events in cellular signaling and the high prevalence of 
kinase-associated mutation and dysregulation in development and progression of serious 
diseases have already made protein kinases the most pursued drug targets in pharmaceutical 
research of the twenty-first century7. Since kinase research has predominantly been 
concentrated on cancer treatment, now inflammation, central nervous system disorders, and 
cardiovascular or diabetic complications are getting into the center of attention as well7,152. 
Currently, more than 20 small molecule kinase inhibitors (smKI) in clinical trials and plenty 
more potential modulators at the preclinical stage are tested for these indications152. 
Back in the early 1980s, isoquinoline sulfonamide derivatives were characterized as the first 
generation of smKI that blocked kinase activity in an ATP-competitive manner. Pharmaceutical 
research virtually kicked off with the identification of Streptomyces staurosporeus-isolated 
bisindolyl maleimide staurosporine as the first nanomolar, but still highly non-selective kinase 
inhibitor in 1986153.Although non-selective and of relatively low potency, fasudil hydrochloride 
progressed to clinical trials for the treatment of cerebral vasospasm and became the first 
approved (Japan) smKI in 1995153. Discouragement soon took possession of research 
communities as selective inhibition of protein kinases was regarded impossible due to the highly 
conserved ATP-binding site. Fortunately this was proved wrong in 1991 when Streptomyces 
hygroscopius agent rapamycin was shown to selectively prevent activity of mammalian target of 
rapamycin (mTOR)7,153,154. 
The breakthrough of smKI in clinical use came 2001 with the FDA-approval of imatinib 
(Gleevec®). ATP-competitive tyrosine-kinase inhibitor imatinib effectively inhibits Bcr-Abl 
(breakpoint cluster region-Abelson tyrosine kinase) fusion protein and represented a milestone 
in targeted cancer therapy7. In the course of this achievement additional eight kinase inhibitors 
entered clinical use until 2009 and the remarkable number of further 19 smKI has been 
established in therapy since 2011. Intense efforts have afforded more than one million 
publications, 5000 crystal structures, and multiple inhibition assays targeting more than 
four-fifth of the human kinome, leading to the FDA-approval of 28 low-molecular kinase 
inhibitors and three rapalogs to date (status January 2016, Table 4)7,152. 
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Table 4 | FDA-approved small molecule kinase inhibitors  as of January 2016 .  FDA-approval 
refers only to the first date of authorization. More than three targets for a single inhibitor are 
referred to as multiple .  Ser/Thr kinase (1) , tyrosine kinase (2), lipid kinase (3) smKI, rapalogs 
(4)6 , 7 , 1 5 2 , 1 5 5 – 1 5 8 .  For explanation of  types I to V cp. chapter 1.3.1 .  Abbreviations: INN, international 
nonproprietary name; ALL , acute lymphoblastic leukemia ; AMD, age-related macula degeneration; 
B-RafV 6 0 0 ,  B-Raf V600 mutant; CLL, chronic lymphocytic le ukemia; CML, chronic myelogenous 
leukemia; CRC, colorectal cancer; FL, follicular lymphoma; GIST, gastrointestinal stromal tumors;  
HCC, hepatocellular cancer; IPF,  idiopathic pulmonary fibrosis;  MCL, mantle cell lymphoma; MTC, 
medullary thyroid cancer;  NSCL, non-small  cell lung carcinoma; PC, pancreatic cancer;  RCC, renal 
cell carcinoma; SEGA, subependymal giant cell astrocytoma ; SLL, small lymphocytic leukemia ; STS, 
soft-tissue sarcoma; TC, thyroid carcinoma ; TP, transplantation .  
 INN Trade name Type Targets Indications FDA approval 
1 
Dabrafenib Tafinlar® I B-RafV600 melanoma 2013 
Palbociclib Ibrane® I Cdk breast cancer 2015 
Trametinib Mekinist® III MEK melanoma 2013 
Vemurafenib Zelboraf® I B-RafV600 melanoma 2011 
2 
Afatinib Gilotrif® V EGFR, Her2 NSCLC 2013 
Axitinib Inlyta® I multiple RCC 2012 
Bosutinib Bosulif® I Bcr-Abl, Src CML 2012 
Cabozantinib Cometriq® II multiple MTC 2012 
Ceritinib Zykadia® I ALK NSCLC 2014 
Crizotinib Xalkori® I ALK, ROS1, MET NSCLC 2011 
Dasatinib Sprycel® I multiple CML, ALL 2006 
Erlotinib Tarceva® I EGFR NSCLC, PC 2004 
Gefitinib Iressa® I EGFR NSCLC 2003 
Ibrutinib Imbruvica® V BTK MCL, CLL 2013 
Imatinib Gleevec® II multiple CML, GIST, ALL 2001 
Lapatinib Tykerb® I, II EGFR, Her2 breast cancer 2007 
Lenvatinib Lenvima® I, II multiple TC 2015 
Nilotinib Tasigna® II multiple CML 2007 
Nintedanib Ofev® II VEGFR, PDGFR, FGFR IPF 2014 
Pazopanib Votrient® I multiple RCC, STS 2009 
Ponatinib Iclusig® II multiple CML, ALL 2012 
Regorafenib Stivarga® II multiple CRC, GIST 2012 
Ruxolitinib Jakafi® I JAK myelofibrosis 2011 
Sorafenib Nexavar® II multiple RCC, HCC, TC 2005 
Sunitinib Sutent® I multiple RCC, GIST 2006 
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2 
Tofacitinib Xeljanz® I JAK rheumatoid arthritis 2012 
Vandetanib Caprelsa® I multiple MTC 2011 
3 Idelalisib Zydelig® II PI3K CLL, FL, SLL 2014 
4 
Everolimus Zortress® IV mTOR TP, SEGA, RCC 2009 
Sirolimus Rapamune® IV mTOR TP, AMD 1999 
Temsirolimus Torisel® IV mTOR RCC 2007 
 
1.3.1 Different Types of Small Molecule Kinase Inhibitors 
Most kinase inhibitors, including 23 of the currently approved 28 compounds, are inhibitors of 
tyrosine kinases. Further four of them are inhibitors of Ser/Thr-specific kinases and idelalisib 
(Zydelig®) is the only one targeting a lipid kinase7,152. Considering binding mechanisms and 
structural features, smKI are subdivided into six subgroups: ATP-competitive inhibitors (Types 
I, II, I ½), allosteric inhibitors (Type III, IV), and covalent inhibitors (Type V)156,159. Several sub-
stances possess characteristics of more than one of these binding modes7. 
Type I inhibitors displace ATP from the active state of PK whereas the activation-loop resides 
in the so-called DFG-in conformation. Type I pharmacophores usually consist of heterocyclic 
systems occupying the adenine-binding region and form H-bonds with hinge residues. As this 
region is highly conserved within the kinome, additional side chains occupy the less conserved 
hydrophobic regions I and II, adjacent to the ATP-binding site156. Especially the non-conserved 
gatekeeper residue which regulates access to hydrophobic pocket I is a central determinant for 
the development of selective kinase inhibitors154. 
Type II inhibitors stabilize the inactive conformation of kinases. Emanating from the active 
state (DFG-in) the Asp residue of the DFG motif is rotated by 180° (DFG-out) and the active site 
is blocked for ATP154. Type II inhibition has therefore been called indirectly ATP-competitive159. 
Rearrangement of the activation-loop towards the inactive state permits access to another 
hydrophobic pocket (deep pocket) which is less conserved and provides additional prospects for 
kinase-specific inhibition156. 
Type II inhibitors have commonly been assumed to have an intrinsic selectivity advantage over 
type I binders, though binding mode analysis were unable to provide evidence for this thesis158. 
It has further been observed that, while many kinases are sensitive to type II inhibition, others 
appear to be incapable of adapting the inactive DFG-out conformation. In general, DFG-in/out 
rearrangement is especially common for tyrosine kinases158. Significant differences between 
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inhibitor binding modes I and II are based on their binding kinetics: while rapid association and 
dissociation is common for type I, type II exhibits slow binding kinetics and prolonged residence 
time157. In addition to type I and II binders, several inhibitors have been identified to induce 
conformations that are intermediate between active and inactive state158. 
Type I ½ inhibitors are recently identified intermediates of types I and II. They occupy 
domains between hydrophobic pocket I and deep pocket and thereby interrupt the hydrophobic 
spine (regulatory spine) which is essential for kinase activity159,160. The hydrophobic spine is a 
highly conserved regulatory motif which consists of four not contiguous amino acid residues 
that originate from different parts of the kinase. One of these residues is the conserved DFG 
phenylalanine (Figure 10). Type I ½ inhibitors are suggested to bind both DFG-in and DFG-out 
conformation159. 
 
Figure 10 | Interruption of the hydrophobic spine by type I ½ inhibitors on the example of 
dibenzosuberone derivative 1 in p38α mitogen -activated protein kinase .  Binding of the 
inhibitor (green) interrupts the hydrophobic spine (red). H -bonds (black dashed lines) are formed 
towards hinge and αC-helix. Hydrophobic interaction (yellow dashed line)  accommodates DFG 
Phe169. Dibenzosuberone derivative 1  refers to (S)-N-(5-((7-(2,3-dihydroxypropoxy)-5-oxo-10,11-
dihydro-5H-dibenzo[a ,d][7]annulen-2-yl)amino)-2-f luorophenyl)benzamide (1) by F ISCHE R  et al .  
The figure was modeled in accordance to the same publication (PDB code 3UVQ) 1 6 1 .  
Although the majority of reported smKI inhibit target kinases in an ATP-competitive, often 
type I-dependent manner, and although several highly selective probes have been achieved, the 
evolutionary conservation of the ATP-binding site favors off-target effects7. ATP-competitive 
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inhibitors also require particular high affinity and good bioavailability to compete with 
nucleotides in vivo (2-10 mM)153,159. Intense efforts are therefore invested in the development of 
ATP non-competitive approaches: 
Allosteric inhibitors bind outside the ATP-binding site and induce conformational changes that 
negatively modulate kinase activity. The allosteric site can either be adjacent to (Type III) or 
remote from the ATP-binding pocket (Type IV)7. These binding sites are often unique to single 
kinases and type III and IV binders thereby tend to the highest degrees of selectivity known for 
smKI so far156. Especially the substrate-binding site is assumed to exhibit enormous potential as 
an allosteric site153,154. At the moment, trametinib (Mekinist®) is the only type III inhibitor in the 
market and, except of rapamycin derivatives, not a single type IV binder has been approved to 
date154. 
Covalent inhibitors (Type V) irreversibly bind to the active site of target kinases. Electrophilic 
moieties of the inhibitor react with nucleophilic cysteine residues in a MICHAEL addition and are 
therefore covalently attached to the ATP-binding pocket7,156. This type of inhibition is suggested 
to achieve increased specificity and potency, but concerns have been raised about possible 
toxicity7,156. With afatinib (Gilotrif®, 2 Figure 11) and ibrutinib (Imbruvica®) two covalent 
inhibitors have already entered clinical use in 20137,152. 
 
Figure 11 | Binding mode of irreversible type V inhibitor afatinib .  Afatinib (2) displays a type I 
binding mode: the quinazoline core occupies the adenine -binding region and forms an H -bond 
towards a hinge residue. The halogen-substituted phenyl moiety extends into HPI .  But unlike type I  
inhibition, the enone moiety reacts with a n ucleophilic cysteine residue in a M ICHA EL  addition and 
covalently attaches the l igand to the active site of epidermal growth factor receptor (EGFR) 7 .  
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1.3.2 Limitations and Challenges of Small Molecule Kinase Inhibitors 
Despite tremendous achievements in kinase-concerning drug discovery over the past years, 
several challenges and limitations remain to be solved. The majority of current smKI were 
identified by high throughput screening or based on previously approved therapeutics using 
fragment-based approaches such as analogue synthesis, isosteric replacement, or compound 
hybridization. Consequently, many smKI possess structural similarity and concentrate on a small 
subset of the human kinome. Among the currently available kinase inhibitors all but two have 
been developed for cancer treatment7,156. In fact, only 10-15 % of the human kinome are covered 
by approved inhibitors155. Given the fact that most of the approved smKI are type I, accompanied 
by several type II and I ½, and only one type III, but not a single type IV binder, suitable assay 
and model systems are required to identify allosteric sites and inactive conformations2,154. Even 
in the case of type I inhibition, high throughput screening-based approaches are becoming less 
effective, due to the restricted availability of scaffolds from compound libraries. Innovative 
structures and screening methods will soon become urgently needed7. 
Therapeutic application is often limited by rapidly evolving resistances and severe side effects7. 
Point mutations within the Bcr-Abl kinase domain, for instance, make cancer cells resistant to 
imatinib treatment7. Especially mutation of the gatekeeper residue is a common event in drug 
resistance mechanisms7,154. Apart from second line kinase inhibitors which inhibit already 
resistant PK, irreversible type V inhibitors are assumed beneficial in this context. Multitarget 
kinase inhibitors that block multiple signaling cascades and combined application of different 
smKI are also suggested to prevent resistance development as tumors are known to dynamically 
adapt to the disturbance by single (target) inhibitors6,7,162. Additionally, tumors represent 
heterogeneous masses consisting of different cancer cell populations that can be traced back to 
different aberrant signaling pathways. Thus, specific inhibition might not be capable of 
effectively stemming tumor growth and even select for drug resistant cells6,163. On the contrary, 
ZHANG et al. have postulated that “it is forbiddingly dangerous to welcome promiscuous 
compounds […] without a rational strategy to control their specificity and therapeutic index”164. 
In summarization, the above emphasizes the increasing importance of personalized medicine 
and genetic profiling6. Controlling the balance between selectivity and beneficial effects of pro-
miscuous drugs seems inevitable for reasonable clinical use of small molecule kinase inhibi-
tors164,165. Furthermore, unexpected toxicity and poor solubility or bioavailability often abrogate 
therapeutic use during preclinical and clinical stages156,162. 
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1.3.3 CK1δ Inhibitors 
The involvement of CK1δ in the pathogenesis of severe disorders such as Alzheimer’s disease, 
amyotrophic lateral sclerosis, FASPS, and cancer has dramatically increased interest in small 
molecule inhibitors for therapeutic application9,119,166. Unfortunately, the design of suitable 
compounds proves highly complicated due to the existence of several CK1 isoforms that possess 
similar, different, or even opposite physiological and pathophysiological implications166. 
Especially the highly conserved CK1 isoforms δ and ε remain difficult to discriminate and have 
therefore often been reported as redundant, rather by means of missing evidence. Consequently, 
only a relatively small subset of CK1δ inhibitors has been reported so far and not a single 
representative reached clinical stages166. Most of these small molecules, if not all of them, 
represent ATP-competitive type I inhibitors9, although it has to be noted that it remains 
unknown whether the kinase is even able to adopt an inactive DFG-out conformation. 
Regrettably, the comparison of these compounds proves difficult because their half maximal 
inhibitory concentrations (IC50) have been determined at different ATP concentrations and, in 
some cases, have not been assigned to distinct isoforms. Allosteric inhibitors (type III) have not 
been reported so far and covalent inhibition seems unlikely due to the absence of addressable 
cysteine residues in the active site of CK1δ. Nevertheless, several of the published small 
molecule inhibitors display high potency and good CK1-specificity. A selection of the most 
promising or interesting molecules has been classified in this work due to mainly structural and 
developmental aspects into first generation inhibitors, pyridinyl-imidazoles and-isoxazoles, 
benzimidazoles and -thiazoles, purines and pyrazolo-pyrimidines or –pyridines, and amino-
anthraquinones. 
First Generation CK1δ Inhibitors 
Isoquinoline sulfonamide derivative CKI-7 (3) became the first ever reported CK1 inhibitor in 
1989, although non-selective and unable to discriminate between CK1 isoforms or to cross cell 
membranes167,168. The first compound exhibiting selectivity among isoforms followed in 2000. 
IC261 (4) inhibited CK1 isoform δ and ε with increased potency (IC50 = 1 µM) compared to 
isoform α (IC50 = 10 µM). Interestingly, IC261 shows slight deviation from the type I inhibition 
concept as it stabilizes the kinase in a state midway between apo and cofactor-bound 
structure166,169. The cell-permeable indoline compound proved valuable in several 
pharmacological studies despite the fact that IC261 itself is a potent inhibitor of tubulin 
polymerization166,170. During the following decade, naturally derived compounds have been 
identified by high throughput screening. Thujopsis dolabrata (-)-matairenisol (5) and anticancer 
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alkaloid lamellarin 3 (6), isolated from marine invertebrates, inhibit CK1 isoforms in a 
presumably ATP-competitive manner, but with low selectivity concerning the complete 
kinome171,172. 
Table 5 | First generation CK1δ inhibitors1 6 7 – 1 6 9 , 1 7 1 – 1 7 3 .  
# Structure IC50 (µM) ATP (µM) 
3 
 
6 (CK1)173 100 
    
4 
 
1.0 (CK1δ/ε)169 
2.5 (CK1δ/ε)173 
10 
100 
    
5 
 
10 (CK1)171 10 
    
6 
 
0.41 (CK1δ/ε)172 15 
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Pyridinyl-imidazoles and -isoxazoles (Teardropbinder) 
The 4,5-diaryl-imidazole core of these compounds originally derives from inhibitors of p38 
mitogen-activated protein kinases (MAPK) which have been referred to as “teardropbinders” 
due to their three-dimensional structure159. Selectivity over p38 MAPK isoforms is therefore a 
common problem for these substances. For instance, p38 MAPK inhibitor SB-202190 (7) non-
specifically blocks CK1δ with moderate potency (IC50 = 0.6 µM) and most likely without 
significant isoform-selectivity174. In 2004 D4476 (8) was identified to prevent CK1 activity 
nearly an order of magnitude more potent (IC50 = 0.3 µM) than IC261 in a rather CK1-specific 
manner in vitro. In a panel of 30 additional kinases only p38α and phosphoinositide-dependent 
kinase 1 (PDK1) were inhibited, but although it is suggested to favor CK1δ/ε, discrimination 
among isoforms has not been reported173. Potent and rather CK1-selective inhibition was 
achieved with the development of pan-CK1δ/ε inhibitor PF-670462 (9) by Pfizer Global 
Research and Development (CK1δ IC50 = 0.013 µM, CK1ε IC50 = 0.080 µM, Figure 12 A). Besides 
CK1δ/ε it was active against several kinases including p38, GSK3β, PKA, and PKC175. In vivo 
studies revealed beneficial use in the treatment of bipolar disorder, addictive behavior, and 
aberrant circadian behavior9. Promising compounds have also been reported in 2009 by PEIFER 
et al.: 3,4-diaryl-isoxazole 10 proved a potent dual inhibitor for CK1δ and p38α MAPK (CK1δ 
IC50 = 0.047 µM, p38α IC50 = 2.52 µM). Interestingly, changing the scaffold towards 4,5-diaryl-
imidazole 11 significantly increased potency and generated limited isoform-selectivity for CK1δ 
over CK1ε (CK1δ IC50 = 0.005 µM, CK1ε IC50 = 0.073 µM, p38α IC50 = 0.019 µM). Oxidation of the 
thioether afforded sulfoxide 12 with even enhanced isoform-selectivity (CK1δ IC50 = 0.011 µM, 
CK1ε IC50 = 0.447 µM, p38α IC50 = 0.041 µM). Due to the acrylamide moiety, which could 
potentially function as a MICHAEL acceptor, covalent binding might be suggested, but is unlikely 
as neither CK1δ nor CK1ε possess suitable cysteine residues, and consequently, ATP-competitive 
inhibition has been demonstrated176. Unfortunately, the same moiety accounts for reduced 
stability and thereby limited usability in vivo148,176. 
Table 6 | Pyridinyl-imidazole and -isoxazole CK1δ inhibitors 1 7 3 – 1 7 6 .  
# Structure IC50 (µM) ATP (µM) 
7 
 
0.6 (CK1δ)174 50 
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8 
 
0.3 (CK1δ)173 100 
    
9 
 
0.013 (CK1δ)175 
0.080 (CK1ε)175 
10 
    
10 
 
0.47 (CK1δ)176  
2.52 (p38α)176 
100 
    
11 
 
0.005 (CK1δ)176 
0.073 (CK1ε)176 
0.019 (p38α)176 
100 
    
12 
 
0.011 (CK1δ)176 
0.447 (CK1ε)176 
0.041 (p38α)176 
100 
 
Benzimidazoles and Benzothiazoles (Linearbinder) 
In contrast to teardrop-like structures, benzimidazole and benzothiazole derivatives exhibit 
linear pharmacophores (linearbinder)159. Already in 1990 halogenobenzimidazole nucleoside 
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5,6-dibromo-1-(β-D-ribofuranosyl)benzimidazole (13) was shown to be slightly active on non-
related CK1 and CK2177, followed by the more potent but still highly unselective 
4,5,6,7-tetrabromo-2-mercaptobenzimidazole (14) in 2003178 and the first substituted 
benzothiazole (TG003, 15) in 2004179,180. Several years later the first benzimidazole-based 
linearbinders had been developed as highly potent and selective CK1δ inhibitors in vitro. The 
most promising 16 even exhibited increased affinity towards isoform δ compared to ε (CK1δ 
IC50 = 0.040 µM, CK1ε IC50 = 0.199 µM, Figure 12 B). Selectivity profiling over 442 kinases 
revealed additional inhibition of only CK1α, CDC-like kinases 1 (CLK1) and 4 (CLK4), dual 
specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and 1B (DYRK1B), and 
phosphatidylinositol 5-phosphate 4-kinase type-2γ (PIP5K2C)181. Further optimization led to 
closely related and even more potent benzimidazole 17 with increased isoform-specificity 
(CK1δ IC50 = 0.02 µM, CK1ε IC50 = 0.21 µM), favorable physiochemical properties, and excellent 
selectivity: in a panel of 442 protein kinases additional inhibitory activity was limited to CK1α 
and wild-type and mutant forms of Fms-like tyrosine kinase 3 (FLT-3)182. Interestingly, parallel 
development of benzimidazole 18 by another research group and subsequent optimization 
towards pyrrolopyridinone 19 and derivatives achieved highly potent and selective inhibitors 
for CK1γ which were only slightly active on the δ isoform. Consequently, the binding mode of 
this pyrrolopyridinone does not exhibit the typical linearbinder-character in CK1δ crystal 
structures22,183. 
 
Figure 12 | Crystal structures of inhibitors 9 and 16 in CK1δ .  Comparison of teardropbinder  9  
(A, PDB code 3UZP) 1 8 4  and linearbinder 16  (B, PDB code 4TWC) 1 8 1  in CK1δ.  
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In addition, synthesis of compounds including benzothiazole cores instead of benzimidazoles 
has produced a batch of potent and cell permeable inhibitors for CK1δ (20, IC50 = 0.01 µM), 
although IC50 values of CK1ε inhibition are missing and selectivity profiles seem less favorable. 
Several kinases from a panel of 290 kinases were also inhibited including CK1 isoforms α, γ2, 
and ε, CLK1 and CLK4, DYRK1A and DYRK1B, FLT1, myosin light chain kinase 3 (MCLK3), and 
platelet-derived growth factor receptor (PDGFR)119. 
Table 7 | Benzimidazole and benzothiazole CK1δ inhibitors 2 2 , 1 1 9 , 1 7 7 – 1 8 3 .  Abbreviation: n.d. ,  not 
defined. 
# Structure IC50 (µM) ATP (µM) 
13 
 
n.d.177 n.d. 
    
14 
 
2.2 (CK1)178 20 
    
15 
 
0.4 (CK1δ)180 
0.55 (CK1ε)180 
n.d. 
    
16 
 
0.040 (CK1δ)181 
0.199 (CK1ε)181 
10 
    
17 
 
0.02 (CK1δ)182 
0.21 (CK1ε)182 
10 
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18 
 
0.018 (CK1γ)183 
2.32 (CK1δ)183 
9.18 (CK1α)183 
n.d. 
    
19 
 
0.005 (CK1γ)22 
0.040 (CK1δ)22 
0.251 (CK1α)22 
32 
8 
11 
    
20 
 
0.01 (CK1δ)119 10 
Purines and Pyrazolo-pyrimidines or -pyridines 
In 2008 roscovitine derivative (R)-DRF053 (21) was shown to be a potent dual inhibitor of CK1 
(IC50 = 0.014 µM) and Cdk family kinases (Cdk1/cyclin B IC50 = 0.220 µM, Cdk5/p25 
IC50 = 0.080 µM) in vitro, but without discrimination of isoforms185. Five years later structurally 
similar trisubstituted purine compound SR-2890 (22) and its derivatives were reported to ex-
hibit excellent potency (CK1δ IC50 = 0.004 µM), striking activity in human cancer cell lines, and 
acceptable selectivity, hitting six off-targets out of 442 kinases. Among them there were CK1ε 
and FLT3 wild-type and mutant kinases186. 
The first pyrazolo-pyrimidine-based CK1 inhibitor PF-4800567 (23) has been published in 2009 
by Pfizer Global Research and Development. PF-4800567 is a highly potent and selective inhibi-
tor for CK1 isoform ε (CK1ε IC50 = 0.032 µM) with less activity on isoform δ (CK1δ 
IC50 = 0.711 µM). In a panel of 50 additional kinases only EGFR showed significant inhibition and 
in vivo studies revealed alteration of the circadian clock period175. In 2012 a novel pyrazolo-
pyrimidine lead structure 24 for CK1-specific inhibition187 was postulated, although in need of 
further optimization. This was followed in 2013 by the discovery of pyrazolo-pyridine 
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MRT00033659 (25) as a dual, though neither potent nor selective, inhibitor of CK1δ 
(IC50 = 0.8935 µM) and Chk1188. 
Table 8 | Purine and pyrazolo-pyrimidine or –pyridine CK1δ inhibitors 1 8 5 – 1 8 8 .  
# Structure IC50 (µM) ATP (µM) 
21 
 
0.014 (CK1)185 
0.220 (Cdk1/B)185 
0.080 (Cdk5/p25)185 
15 
    
22 
 
0.004 (CK1δ)186 10 
    
23 
 
0.711 (CK1δ)175 
0.032 (CK1ε)175 
10 
    
24 
 
0.078 (CK1)187 n.d. 
    
25 
 
0.8935 (CK1δ)188 20 
 
38 | I n t r o d u c t i o n  
 
 
Amino-anthraquinones 
Structure-based virtual screening by COZZA et al. in 2008 identified 5,8-diaminoanthraquinone 
(26) from a group of known CK2 inhibitors to be active against CK1δ as well. Although of weak 
potency and rather unselective it provides a completely novel lead structure for structure-based 
drug design regarding inhibition of CK1δ189. 
Table 9 | Amino-anthraquinone CK1δ inhibitor 26 1 8 9 .  
# Structure IC50 (µM) ATP (µM) 
26 
 
0.3 (CK1δ)189 n.d. 
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2 Aim of the Present Study 
The importance of protein kinase CK1 in development and progression of serious diseases has 
dramatically increased interest in isoform-specific inhibition as discussed in chapters 1.2.4 and 
1.3.3. In this context, especially highly conserved CK1 isoforms δ and ε are suggested to possess 
enormous potential. Although several δ and ε subgroup-specific inhibitors have been reported 
so far, actually only very few of them display at least tendencies for isoform-selective activity. 
Consequently, structure-activity relationship (SAR) data is rare and suitable mechanisms for the 
rational design of δ and ε discriminating probes with high selectivity are still to be developed. 
Starting point of this dissertation was the previously by PEIFER et al. designed diaryl-imidazole 
inhibitor 12176. Its excellent potency in the low nanomolar range and its tendency for isoform 
δ-specific inhibition marked it as a lead structure for further investigation. Unfortunately, direct 
usage of 12 was prohibited by instability based on a MICHAEL acceptor present in the molecule. 
The inevitable optimization procedure followed a well-established workflow for structure-based 
drug development in medicinal chemistry: in silico lead structure optimization was followed by 
hit synthesis and biological evaluation. The objectives were therefore summarized as: 
(1) Design and synthesis of chemically stable, potent, specific, and ideally isoform-selective 
(≥ 100-fold) CK1δ inhibitors starting from 12 
(2) Establishment of SAR by successive comparison of in silico and in vitro generated results 
and identification of selectivity-determinants for CK1δ-specific inhibition 
(3) Verification of modeling results (proof of concept) by co-crystallization of potent and sta-
ble compounds in CK1δ and structurally related kinases (CK1ε, p38α) 
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3 Molecular Modeling Strategies 
Molecular modelingk provides a powerful tool for structure-based drug design in medicinal 
chemistry. More than 100,000 three-dimensional protein structures have been solved to date 
that allow tightly focused studies of structure-activity relationships (SAR). Therefore, the 
integration of experimental in vitro or in vivo methods with in silico generated results is well-
established in protein research190,191. Despite the immense benefit we have to accept that 
molecular modeling is also a highly limited technique. The multitude of essential parameters 
such as enthalpic and entropic effects, flexibility, and hydration states of proteins and ligands, as 
well as the cooperative interplay of hydrophilic and hydrophobic interactions, require an 
extensive knowledge of the medicinal chemist that often goes beyond software-mediated 
calculation191,192. Every in silico generated model requires reasonable questioning and a definite 
awareness of the difference between model and reality, as summarized by BISSANTZ et al.: 
“Finally, as the level of confidence in structure-based design has increased, it is important to 
emphasize that any modeled binding mode remains a model until it is experimentally 
validated.”191 
3.1 In Silico Lead Structure Optimization 
Starting point for the in silico optimization of lead structure 12 was the definition of its central 
pharmacophore. Therefore, the binding mode of 12 was postulated based on molecular 
modeling (Figure 13), receiving nearly identical results as published by PEIFER et al.176. Two 
H-bonds are formed between hinge residue Leu85 and the 2-aminopyridine moiety (hinge-
binder). Core catalytic residues Lys38 and Asp149144,184 coordinate a structural water moleculel 
within the catalytic cleft which donates an H-bond towards an imidazole nitrogen of 12. The 
gatekeeper residue Met82 is rotated by 180° towards Pro66 (cp. Figure 15)144,184 relative to the 
CK1δ apo structure (PDB code 3UYS) and permits access to the selectivity pocket (HPI) which is 
occupied by the 4-fluorophenyl moiety. Pro66 is of essential importance for selectivity as only 
few kinases possess equivalent residues that allow the observed gatekeeper rotation144. The 
cinnamic acid side chain of 12 extends into the solvent-exposed hydrophobic region (HRII). In 
addition, lead 12 includes one chiral center at the oxidized sulfur atom at the imidazole 
2-position. Consequently, both enantiomers have been considered, but docking analysis did not 
reveal any significant differences. In literature the racemate is reported with one exception193. 
                                                             
k For detailed information on modeling performance and computational software cp. experimental chapter 7.1 
l Ideally coordinated water molecule within the active site, please refer chapter 3.1.4 
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Figure 13 | Postulated binding mode of lead structure 12 in CK1δ .  The 2D interaction diagram 
(B) was generated in accordance to the modeling results (A, PDB code 3UZP).  
The assumed binding mode of 12 was compared to published binding modes of structurally 
similar inhibitors that had been crystallized with CK1δ or related kinases (Table 10). Among 
them there were pan-CK1δ/ε inhibitors PF-670462 (9)184 and PF-5006739 (27)194, several 
CK1δ-targeting 3,4-diaryl-pyrazoles (28-31)165 as well as seven p38α MAPK inhibitors: 
pyridinyl-imidazoles SB203580 (32) and SB220025 (33), pyrimidinyl-imidazoles SB216995 
(34) and SB218655 (35)195, and pyridinyl-pyrazolon 36196. 
Table 10 | Schematic binding modes of related diaryl-heterocyclic inhibitors crystallized 
with CK1δ or p38α .  H-bonds formed between inhibitor and hinge residues are indicated by 
arrows1 6 5 , 1 9 4 – 1 9 6 .  
# Structure Protein kinase PDB code 
9 
 
CK1δ 3UYS, 3UZP184 
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27 
 
CK1δ 4TN6194 
    
28 
 
CK1δ 4KBC165 
    
29 
 
CK1δ 4KB8165 
    
30 
 
CK1δ 4KBA165 
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31 
 
CK1δ 4KBK165 
    
32 
 
p38α 1A9U195 
    
33 
 
p38α 1BL6195 
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34 
 
p38α 1BMK195 
    
35 
 
p38α 1BL7195 
    
36 
 
p38α 1YWR196 
 
Evaluation of these crystallographic studies revealed crucial structural requirements for optimal 
inhibition of CK1δ and p38α. Consequently, characterization of core interactions led to the 
definition of a central pharmacophore for in silico optimization (Figure 14): the 4-fluorophenyl 
moiety is shared by every considered inhibitor and has been reported ideal for occupation of HPI 
concerning selectivity over most other kinases. A vicinal pyridin-4-yl or pyrimidin-4-yl moiety 
accepts an H-bond from the hinge region and is a main determinant for potency165,184,195–201. An 
amino group in 2-position of this heterocycle has also proved beneficial: the positive mesomeric 
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effect (+M) increases the electron density at the pyridine ring and thereby the acceptor strength 
of the ring nitrogen. The amino moiety itself forms a second H-bond towards the hinge 
region184,191,195–197,201. Both the fluorophenyl and the pyridine moiety are connected by 
five-membered heterocycles bearing an unsubstituted nitrogen atom for 
H-bonding184,194,195,197,198,200,201. It seems that five-membered rings are the optimal choice in this 
position as they dictate an ideal angle for the positioning of the aryl moieties within the ATP-
pocket. Further influence on binding kinetics can be exerted by targeting the remaining less 
conserved domains of the active site. Several studies have already examined the consequences of 
different substituents at the five-membered heterocycle addressing the CK1δ and p38α sugar- 
and phosphate-binding regions. Although the importance for activity and selectivity remains 
uncertain, these sites represent the major positions for modifying physicochemical 
properties165,176,184,194,194,197–204. Albeit less understood, targeting the solvent-exposed and rather 
vast hydrophobic front region of the catalytic cleft (HRII) is reportedly beneficial in gaining both 
potency and specificity and will be the main topic of this dissertation176,195–197,200,201. Addressing 
HRII by hydrophobic substituents replaces the suboptimal hydration (hydrophobic effect) and 
might be suggested to account for large gains in binding free energy (ΔG). In addition, sterically 
demanding groups shield the hydrophobic surface and the deeper cavities of the ATP-binding 
pocket from surrounding water. 
It is further noteworthy that the initial toxicity problem of pyridinyl-imidazoles regarding 
cytochrome P450 (CYP450) inhibition has been shown to be positively influenced by different 
substitution pattern at the imidazole and the pyridine ring197. 
 
Figure 14 | Central pharmacophore for in si lico lead structure optimization .  The central 
pharmacophore has been defined with X and Y being carbon, nitrogen, oxygen, or sulfur  (n = 0-3). 
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Subsequent molecular modeling studies were performed to predict the influence of consecutive 
variation of the defined moieties and to identify promising candidates for synthesis and 
biological evaluation. The main focus has consequently been put on possible gains of potency 
and selectivity for CK1δ, mediated by different side chains at positions R4 to R7 addressing the 
hydrophobic region II and thereby diminishing interactions towards CK1ε and p38α. 
In general, docking algorithms imply two mating operations: first, the prediction of possible 
binding modes for the ligand in question; and second, the calculation (scoring) of the binding 
free energy (ΔG)192. As relying on ΔG is certainly the most appropriate technique in practice191, in 
silico modeling results were compared based on their predicted Glide scores which 
approximately reflect ΔG. It has further to be kept in mind that credibility of molecular modeling 
decreases with increasing flexibility of the protein structure in question. Especially modeling 
studies regarding the highly flexible and solvent-exposed hydrophobic region II require in vitro 
and ideally crystallographic proof of concept. 
In CK1δ excellent results were easily afforded by the fast Glide Docking procedure. 
Unfortunately, molecular docking of 12 in CK1ε and p38α is not suitable to explain its activity in 
these kinases: rational docking modes have only been received by the computational costly and 
time-consuming Induced Fit Docking (IFD), though without appropriate scoring. Regarding the 
limited available computational resources, the Induced Fit Docking protocol is generally 
inaccessible for compound screening205. Even Glide Docking approaches based on IFD-mediated 
protein preparation did not yield suitable scoring for CK1ε and p38α. Screening of these kinases 
was therefore not purposeful in the context of this dissertation. 
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3.1.1 Influence of different Substituents in the Selectivity Pocket 
The fluorinated aryl moiety is a main determinant for selectivity regarding a large subset of 
other kinases. Consequently, the addressed hydrophobic back pocket (HPI) present in both CK1 
and p38 has often been termed the “selectivity pocket”. In CK1 isoforms δ and ε the pocket 
mainly consists of residues Met80, Val81, and Met82, while in p38 it is Thr, Val, and Leu, 
respectively. Despite these differences in primary sequence, hydrophobic environment and size 
of the sites are quite similar165,197. The main difference, however, is located at the entrance of the 
pocket. In p38 MAPK the relatively small gatekeeper residue Thr readily provides access to HPI, 
while in CK1δ/ε 180° rotation of the larger gatekeeper Met82 is required. Subsequently, the 
4-fluorophenyl moiety penetrates deeply into the cavity forming strong hydrophobic 
interactions with residues Met80 and Met82 (Figure 15)184. 
 
Figure 15 |  Positioning of the 4 -fluorophenyl moiety of 12 within the selectivity pocket  of 
CK1δ .  The halogenated aryl moiety penetrates deeply into the pocket forming hydrophobic 
interactions (violet) with Met80 and Met82. Met82 is rotated towards Pro66 (PDB code 3UZP) 1 8 4 .  
Although several studies have already reported the optimal fitting of the 4-fluorophenyl moiety 
within the selectivity pocket, this has only been experimentally evaluated for p38α197,206. On 
account of this, modeling studies have been performed to investigate the influence of different 
para and meta substituents for R1 (Figure 15) in CK1δ. Hydrophobic substituents were selected 
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in accordance to experimental results published for p38α considering the observations of 
CRAIG207. 
The in silico results revealed the assumed behavior based on the experimental data of p38α 
(Table 11). Different small substituents (H, F, Cl, CH3) are tolerated in para- and meta-position 
but without any significant gain in ΔG. Optimal binding within hydrophobic cavities has empiri-
cally been defined upon 55 % occupation of the pockets volume by the ligand191 which is approx-
imately achieved only with this set of substituents. Except for the tolyl group, para-substitution 
seems to be slightly favored. Sterically more demanding groups or larger halogen substituents 
(Br, I, meta-CF3, OCH3) are also accepted, preferentially in meta-position, but affect the overall 
positioning of the ligand in the active site: a weaker penetration depth of the aryl moiety leads to 
weakening or disruption of several hydrophobic and hydrophilic interactions by alteration of 
donor-acceptor distances and decreased inhibition potency has to be suggested. Bulky function-
alities (isopropyl, cyclohexyl, para-CF3) are not tolerated and did not provide rational binding 
modes of these derivatives. 
Table 11 | In silico  influence of different substituents for R 1  and R2  in CK1δ .  Lead structure 12  
is deposited in grey.  
 # R1 R2 Glide score 
 
37 CH3 H -14.0 
38 F F -14.0 
39 CH3 H -13.8 
40 Cl H -13.8 
12 F H -13.7 
41 H H -13.7 
42 H F -13.5 
43 I I -13.2 
44 H Cl -13.0 
45 Br H -12.6 
46 I H -12.6 
47 H OCH3 -12.1 
48 H Br -12.0 
49 H CF3 -11.6 
50 OCH3 H -11.2 
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3.1.2 Addressing the Phosphate- and Ribose-binding Regions 
Substitution of the imidazole core in order to target the phosphate- and ribose-binding domains 
of CK1δ and p38α has already been studied intensely by several groups176,194,197–204. Herein, the 
main benefit in p38 MAPK inhibition is the modification of physicochemical properties197 while 
few CK1δ inhibitors additionally exhibited slightly enhanced selectivity over other kinases, 
though not CK1ε204. Especially the 2-thioether functionality has been highlighted by several 
publications for its high potency and its ability to effectively reduce CYP inhibition176,197,203. The 
sulfanyl group is further predestined to act as a linker for moieties that address the hydrophilic 
domains of the active site202. Bulky residues at the sulfanyl, however, can be assumed to 
decrease activity197. Interestingly, synthetic easily accessible sulfoxides such as 12 which are 
expected as the main metabolites have been postulated to increase CK1 isoform-selectivity 
(Table 6)176,200. Substitution at the 1- and 3-position of the imidazole has also been examined for 
p38α and less intensely for CK1δ inhibitors. The nitrogen atom directed towards the back side of 
the pocket participates in H-bonding and does not tolerate substitution197. In contrast, the 
nitrogen positioned towards the solvent-exposed entrance of the cleft has repeatedly been 
screened carrying different predominantly hydrophilic moieties. Unfortunately, the effect of this 
substitution remains less clear and has been discussed controversely176,194,197,198,200–202,204. Albeit 
a beneficial gain of selectivity for CK1δ is generally conceivable, moieties in this position can be 
suggested to cause steric hindrance within the inhibitor if bulky side chains are existent in 
2-position of the pyridine198. In silico optimization studies have therefore been limited to the 
2-position of the imidazole in this dissertation. 
The aim was to evaluate the benefit of hydrophilic substituents that might be linked to the 
exocyclic sulfur atom at the imidazole 2-position of 12, thereby replacing the methyl group. 
Flexible aliphatic n-alcoholic moieties with increasing length were screened in a first attempt. In 
a second step, chiral centers were introduced into these substituents and additional hydroxyl 
groups were added to address specific amino acids for H-bonding. The use of chiral residues in 
this context was expected to influence selectivity in vitro and in vivo due to the less-conserved 
character of the addressed domains. In order to promote the introduction of chirality even 
further, moiety screening included several chiral iminosaccharides from a compound list 
provided by the Ferrier Research Institute (Victoria University of Wellington, New Zealand). 
These molecules were connected (in silico) to the imidazole 2-position via a nitrogen instead of a 
sulfur linker as this seemed the most promising method for potential synthetic approaches. 
Synthetic realization of this concept, however, has been the topic of the master thesis of SCHMIDT 
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in 2015 who functionalized diaryl-oxazoles with iminosaccharides (Figure 16)208. A selection of 
top hits from several in silico screenings is given in Table 12. 
Table 12 | In silico  screening top hits with different hydrophilic moieties for R 3  in CK1δ .  
 # R3 Glide score 
 
51 
 
-16.5 
52 
 
-16.5 
53 
 
-15.9 
54 
 
-15.4 
55 
 
-15.4 
56 
 
-15.2 
57 
 
-15.2 
58 
 
-15.1 
59 
 
-15.1 
60 
 
-14.8 
61 
 
-14.1 
12 
 
-13.7 
62 
 
-13.5 
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Modeling exhibits the expected excellent results with high gains in ΔG. Hydroxyl groups of 
primary aliphatic alcohol substituents interact either with residue Asp132 or Ser17. Additional 
hydroxyl and amine groups of polyvalent alcohols and iminosaccharides also permit H-bonds 
with residues Ile15, Asp91, and Asn133. It is noteworthy that these residues have 
predominantly been suggested to participate in substrate recognition and ATP-binding. 
Nevertheless, the enhanced calculated Glide scores could be misleading as additional H-bond 
donors do not necessarily increase ΔG. In fact, the formation of additive H-bonds requires 
replacement of potentially coordinated water molecules from the addressed regions 
(cp. chapter 3.1.4). Regrettably, this is not completely represented in docking and might 
overcompensate the enthalpic gains. The calculated binding mode of top hit 51 in CK1δ is 
exemplified in Figure 16. 
 
Figure 16 | Postulated binding mode of 51 in CK1δ .  Hydroxyl moieties of the iminosaccharide 
(yellow) form H-bonds with residues Ser17 and Asp132. Interactions between other parts of  the 
ligand and the kinase are not shown (PDB code 3UZP).  
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Despite these results, the enormous gain in ΔG does not seem to account for in vitro studies as 
suggested from initial evaluation by SCHMIDT208. Only compound 64 out of three iminosaccha-
ride-substituted ligands 64-66 exhibited a significant but rather weak increase in activity com-
pared to the unsubstituted analog 63 in kinase assays (Figure 17). Further biological data con-
cerning inhibition of CK1 isoforms δ, ε, and α did not reveal any significant isoform-specificity. In 
cell assays a complete lack of activity was observed208. According to the results of SCHMIDT, unfa-
vorable hydration of ligand (and protein) is most likely to compensate the potential gain in ΔG 
upon H-bond formation by high desolvation penalties. The complete loss of inhibitory activity in 
cells might be due to inability of plasma membrane penetration or rapid intracellular metaboli-
zation. In this context it has to be noted that hydroxyl moieties provide additional sites for deri-
vatization and inactivation of compounds in vitro and in vivo197. 
 
Figure 17 | In vitro  biological evaluation of diaryl -oxazoles by SCH M ID T .  Iminosaccharide-
substituted compounds 64 ,  65 ,  66  derived from unsubstituted compound 63  ( left). Residual activ i-
ty of CK1δ at 10 µ M  inhibitor is shown in relation to control  (DMSO). Each bar shows the mean 
value of n = 3 experiments ± standard deviation  (right , modified from SCH MI D T2 0 8). 
Even though no increase in potency and selectivity might be achieved, hydrophilic substituents 
have in general been used to beneficially modify physicochemical properties such as solubility 
and oral bioavailability, but this was not the focus of the present dissertation. The weak overall 
activity of these compounds is most likely provoked by the fluorine substituent at ortho-position 
of the pyridine. The strong negative inductive effect could weaken the pyridine H-bond acceptor 
which is the main determinant for potency of this inhibitor class. 
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3.1.3 Alternatives for the Imidazole (Core Hopping) 
Although the majority of teardrop-like CK1δ inhibitors published to date consist of variably sub-
stituted diaryl-imidazoles, alternatives have been reported. Among them were the less potent 
oxazoles208 and isoxazoles176, but also several highly active pyrazoles165. An in silico core hopping 
has been performed to identify promising alternatives in order to improve potency and selectivi-
ty regarding CK1δ. Imidazoles are further less favorable regarding potential CYP inhibition197. 
The substitution pattern of the lead structure was retained while the core imidazole was con-
secutively replaced by heterocyclic scaffolds from the Glide fragment library (Schrödinger®, 
cp. chapter 7.1.3 and Table 13). It is therefore not surprising that predominantly five-
membered heterocycles were received, although without significant gains in ΔG compared to the 
lead structure. Strikingly, an H-bond acceptor positioned towards the structural water is con-
served among the top hits and its absence consequently leads to reduced predicted affinity 
(i.e. less negative scores). Apart from this, prediction is less simple as multiple parameters de-
termine the quality of H-bond acceptation in an additive but non-linear fashion. In general, aro-
matic nitrogen acceptors are slightly favored to aromatic oxygens and electron-donating effec-
tors (positive mesomeric and inductive effects) increase acceptor strength while electron-
withdrawing (negative mesomeric and inductive effects) ones lead to weakened H-bonds191,199. 
Consequently, pyrazole scaffold 67 shows slightly improved values (i.e. more negative scores) 
for ΔG when compared to lead 12, presumably caused by the electronic effect of the vicinal 
nitrogens. In contrast, isoxazole 68 which accepts the H-bond via the nitrogen atom exhibits 
reduced predicted affinity values, suggesting weakened H-bonding due to the vicinal negative 
inductive effect. Interestingly, oxazole 69 and imidazole 12 depict nearly equivalent values. On 
the other hand, even oxygen H-bond acceptors such as furan 70 unexpectedly show ΔG values 
similar to imidazole and their acceptor strength seems to be further increased through 
additional ring nitrogens (oxazole 71, isoxazole 72). A selection of suitable five-membered 
heterocyclic scaffolds from in silico screenings is given in Table 13. 
Furthermore, the fitting of four- and six-membered heterocycles has also been investigated. 
While pyridine derivative 73 is well tolerated with scores similar to lead structure 12, four-
membered azete 74 exhibits a significant loss in ΔG. This effect is most likely due to the angles 
between the vicinal aryl moieties and the core heterocycle (Figure 18). Five- and six-membered 
aromatic scaffolds generally dictate similar angles, though in dependency of substitution and the 
existence of heteroatoms. The slight decrease of the pyridine scaffold might be caused by less 
penetration depth into the selectivity pocket (Figure 18). In contrast, four-membered aromatic 
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systems generate taller angles, forcing the vicinal aryl moieties further apart and leading to 
suboptimal fitting (cp. Figure 18). The postulated binding mode of the azete (in silico) derivative 
e.g. shows only a single H-bond towards the hinge instead of the initial bidentate binding. 
Table 13 | In silico  core hopping results for the imidazole  of lead 12 in CK1δ .  H-bond accep-
tors are indicated by arrows.  
 # C Glide score 
 
67 
 
-14.2 
71 
 
-14.1 
69 
 
-13.9 
12 
 
-13.7 
72 
 
-13.7 
70 
 
-13.6 
73 
 
-13.5 
68 
 
-13.3 
74 
 
-12.0 
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Figure 18 | Postulated binding modes of 12, 73, and 74 in CK1δ .  Smaller aromatic systems dic-
tate increased angles leading to less optimal  fitting of the azete scaffold 74  (violet) compared to 
imidazole 12  (green) and pyridine 73  (black) scaffolds. The indicated distances refer to the 3D 
structure and thus the angle of torsion.  All data refer to energetically minimized structures.  
Taken together, the in silico core hopping suggests no significant increase in potency for CK1δ by 
the use of alternatives for the lead imidazole. Nevertheless, the replacement would surely be 
tolerated regarding pharmacological or physicochemical (or synthetic) reasons. 
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3.1.4 Structural Water 
In the apo state of kinases when neither inhibitor nor cofactor is bound, the active site is flooded 
with water. Consequently, every binding event requires water displacement and should there-
fore be entropically favorable. Although binding sites are characterized by highly disordered 
water that is readily replaceable in practice, several water molecules are buried more deeply 
and interact with the protein environment through multiple H-bonds. Some of these can even be 
considered part of the binding site and a displacement has to be assumed as energetically disfa-
vorable. These water molecules are ideally coordinated by not less than three H-bonds with pro-
tein side chains and are referred to as structural water. Replacement of non-ideally coordinated 
water might be possible and depends on the local geometry191. 
In human CK1δ one specific water molecule is conserved over all crystal structuresm published 
in the Protein Data Bank (PDB). Although not ideally coordinated, it is deeply buried in the 
phosphate-binding region within H-bonding distance to Lys38 and Asp149. Another bond is 
formed towards ATP-competitive ligands whenever possible. In order to evaluate the possibility 
of replacement, several substituents at the 4-fluorophenyl moiety and the imidazole core were 
screened in silico. The best hits from this screening are depicted in Table 14 and Figure 19. In 
derivative 75, a hydroxymethyl substituent in 2-position of the 4-fluorophenyl moiety exhibits 
significant gain in ΔG. Interestingly, the hydroxyl group interacts neither with Lys38 nor with 
Asp149. Instead, an H-bond is accepted from Tyr56 (Figure 19 B). Displacement of the water 
molecule might also be achieved by substituents at the imidazole nitrogen. A hydroxyethyl moie-
ty in 76 only interacts with Lys38 (Figure 19 C) while a chiral hydroxycyclopropyl moiety in 77 
adopts the exact H-bonds from the water molecule (Figure 19 D). Both structures show energy 
values equivalent to the lead compound. The missing gain in ΔG as compared to the 4-fluoro-2-
(hydroxymethyl)phenyl moiety is most likely due to steric hindrance within the ligand. 
Table 14 |  Screening hits for the replacement of the structural water .  Glide scores are given 
beyond 75 ,  76 ,  77 ,  and lead 12 .  R = (E)-4-(2-(3-(2,4-dimethoxyphenyl)acrylamido)pyridin -4-yl .  
12 75 76 77 
    
                                                             
m Human CK1δ PDB codes: 3UYS, 3UYT, 3UZP, 4TW9, 4TN6, 4TWC, 4KB8, 4KBA, 4KBC, 4KBK, 4HGT, 4HNF 
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These results assume that replacement of the conserved water molecule within the CK1δ active 
site might be possible, although the in vitro and in vivo benefit has to be determined experimen-
tally. Even if no gain in potency can be achieved, this approach might prove valuable in gaining 
selectivity. An equivalent water molecule cannot be detected in CK1ε crystal structuresn and the 
analogue position in the p38α active site is occupied by residue Lys53. 
 
Figure 19 |  Replacement of a conserved water molecule in CK1δ .  One conserved water molecule 
in the CK1δ active site interacts with  Lys38, Asp149, and the ligand 12  (A) . It might be replaceable 
by a hydroxymethyl group in 2-position of the 4-fluorophenyl moiety in 75  (B)  and a hydroxyethyl 
group in 76  (C) or a chiral hydroxycyclopropyl group in 77  (D) at the imidazole nitrogen. The 
(E)-3-(2,4-dimethoxyphenyl)acrylamide side  chains (cp. lead structure 12) in 2-position of the 
pyridine are not displayed. Glide scores are given beyond the structures.  
                                                             
n Human CK1ε PDB codes: 4HNI, 4HOK 
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3.1.5 Addressing the Solvent-exposed Hydrophobic Region II 
The evolutionary less-conserved and solvent-exposed HRII does not participate in cofactor-
binding and has therefore been associated with gains in both potency and selectivity regarding 
ATP-competitive small molecule kinase inhibitors197. Presumably hydrophobic residues form a 
lipophilic groove in the front region of the catalytic cleft, restricted by an agglomeration of acid 
and hydrophilic residues at the rim. Although CK1 isoforms δ and ε share the same residueso in 
this region, they slightly differ in their three-dimensional organization. The correspondent 
domain in p38α MAPK is formed by different residuesp leading to significant distinction in its 
geometry (Figure 20). 
 
Figure 20 | Positioning of 12 in the hydrophobic region II of CK1δ, CK1ε, and p38α .  The lipo-
philic groove (yellow) is restricted by acid and hydrophilic residues at the rim of the region (red) .  
Modeling refers to PDB codes 3UZP, 4HNI, and 1BMK. 
CK1δ and CK1ε provide spacious and mainly planar hydrophobic front regions. Especially 
isoform δ allows optimal fitting with high flexibility. Consequently, the displayed binding mode 
of lead structure 12 in CK1δ shows an entirely planar conformation of the (E)-3-(2,4-
dimethoxyphenyl)-N-(pyridin-2-yl)acrylamide moiety. In CK1ε and p38α torsion about two 
dihedrals along the acrylamid chain leads to either syn- or anticlinal conformation. Energetically, 
these conformers can be assumed slightly less favored, thereby providing a possible explanation 
for the rather weak preference for CK1δ over the other two kinases.  
                                                             
o Human CK1δ/ε HRII residues: Ile15, Leu25, Leu84, Leu85, Gly86, Pro87, Ser88, Leu92, Phe95, Leu135, Leu138  
p Human p38α HRII residues: Val30, Ala40, Leu108, Met109, Gly110, Ala111, Leu167 
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In p38α the hydrophobic region II is significantly less spacious and shows an overall non-planar 
folding. The overhang of the larger N-terminus generates a relatively flat channel which is 
occupied by the dimethoxyphenyl moiety and confines rotational flexibility (Figure 20). In 
addition, the hinge is “dislocated forwards” (Figure 21) enforcing the above mentioned rotation 
of the side chain. In contrast, protein structure alignment of CK1δ and CK1ε depicts only minimal 
shifts in the hinge region which do not seem suitable to justify the torsion within the acrylamide 
moiety. Furthermore, an accommodation of the 2,4-dimethoxyphenyl moiety by the flexible L-78 
loop has been reported for CK1δ176 (and therefore presumably CK1ε) whereas the equivalent 
loop in p38α is significantly smaller and differently orientated. 
The (E)-conformation of the acrylamide, however, is conserved in all three binding modes 
(Figure 21). This is not surprising as the (Z)-conformer is associated with losses in ΔG in any of 
these kinases and has to be assumed less bioactive. 
 
Figure 21 | Protein structure alignment of CK1δ, CK1ε, and p38α .  The hinge of p38α (red) is 
displaced in relation to CK1δ (green) and CK1ε (yellow ,  left).  Different conformation of  ligands 
(12)  taken from the protein structure alignment (right) , though the (E)-conformation (grey box) is  
preserved. Modeling refers to PDB codes 3UZP, 4HNI, and 1BMK. 
Taken together, the solvent-exposed front region seems potentially suited for the improvement 
of both potency and selectivity regarding CK1δ. Lipophilic side chains most likely enhance 
affinity through multiple VAN DER WAALS interactions. Methoxyphenyl moieties might be ideal in 
this context as they can additionally interact with adjacent water molecules and thereby shield 
the hydrophobic region from the surrounding polar environment200. As this is the main issue of 
the present dissertation, multiple in silico studies have been performed to evaluate suitable 
candidate compounds for subsequent synthetic realization. These were subdivided into six 
distinct series regarding the type of substituent at the ortho-pyridine position of 
4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-amine (78, Figure 22). 
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Figure 22 |  Schematic representation of series 1 to 6 deriving from 78 .  Residues (R) are de-
fined in the following chap ters.  
Primary and Secondary Amino Substituents (Series 1) 
The predicted planar conformation of the lead structure side chain is enabled by the 
sp2 hybridization of the acrylamide carbon atoms. Therefore, the carbonyl functionality and the 
π-bond were abolished from the structure to gain complete sp3 hybridization within the linker, 
leading to significantly enhanced flexibility for derivative 79 (Figure 23). In addition, increased 
chemical and oxidative stability were expected as the MICHAEL acceptor has been regarded 
responsible for instability of lead structure 12. In general, enhanced rotational freedom is 
associated with the confinement of translational and rotational degrees of freedom and thereby 
negatively influences the entropic contribution to the energetic binding profile of inhibitors209. 
Increased flexibility can also be assumed to initiate a loss of selectivity as flexible moieties and 
flexible kinase residues easily adapt to each other159. It has further been suggested that deletion 
of the carbonyl group is accompanied by decreased activity as the negative inductive effect of 
the carbonyl polarizes the N-H-bond of 12 whereas the positive inductive effect of an alkyl chain 
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might weaken the H-bond donor. The carbonyl group might further be beneficial for positioning 
the N-H in the correct angle. 
As expected, modeling results for 79 exhibit high degrees of flexibility within hydrophobic re-
gion II, whereas the conformation of the diaryl-imidazole scaffold is highly conserved in all ra-
tional in silico binding modes (Figure 23). Consequently, additional off-target effects have to be 
assumed as the folding of the solvent-exposed front region is less determining for specificity in 
the case of highly flexible side chains. Modeling also indicates reduced potency of 79 for CK1δ in 
relation to 12. These screening results were anticipated and will have to be evaluated in vitro. 
 
Figure 23 |  Postulated binding modes of 79 in CK1δ .  Alignment of several possible binding 
modes i l lustrates the high flexibility of  the  N-3-(2,4-dimethoxyphenyl)propyl side chain within the 
hydrophobic region II (left). In contrast, the diaryl - imidazole scaffold is highly conserved in all 
binding modes (right) . Modeling refers to PDB code 3UZP.  
Although removing both the carbonyl group (sp2) and the π-bond (sp2) of 12 is most likely to 
afford overall less potent and selective inhibitors it is thought to represent an important proof of 
concept. Furthermore, the length of the linker side chain and the influence of different di- and 
trimethoxy substitution pattern at the final phenyl moiety should be investigated. It has to be 
noted that in all series the focus has been put on different methoxyphenyl moieties as explained 
previously (chapter 3.1.5)200. Mono-methoxy substitution has not been considered as it has 
been reported to be most favorable for p38α inhibition, whereas di- and trimethoxy substituents 
impair fitting in this kinase200. The linker was thereby varied from zero to three carbon atoms. 
Unfortunately, no preferences have been observed in silico regarding substitution or linker 
length. Multiple combinations show similar scoring without revealing any distinct trends, which 
is most likely due to the planar and spacious folding of this CK1δ region. The overall scoring is, 
as expected, significantly increased (i.e. loss of ΔG) as compared to lead structure 12 (Table 15). 
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Short or non-existent linker chains combined with unfavorable substitution in the ortho-
positions cause intramolecular steric hindrance and are least favored. 
Another approach was to investigate if additional H-bonds might be formed with hydrophilic 
side chains at the rim of the hydrophobic region (Figure 20, red surface). Therefore the terminal 
aryl moiety was exchanged for a dimethylamino group which might be positively charged under 
physiological conditions. In fact, an H-Bond towards Asp91 can be observed in silico with cyclic 
and aliphatic linkers containing three or four carbon atoms in a row (Figure 24), though with-
out any significant improvement in ΔG as compared to more lipophilic moieties. This H-bond 
should therefore be considered rather weak. The influence of this interaction in vitro, however, 
has to be examined experimentally. 
 
Figure 24 | In silico  binding mode of 80 and 81 addressing Asp91 .  Positively charged dimethy l-
amino side chains linked to the 2 -aminopyridine through aliphatic (A) or cyclic (B) linkers 
(cp. Table 15) .  Asp91 is positioned at the rim of CK1δ hydrophobic region II (PDB code 3UZP).  
Besides primary amines several less flexible secondary amines were screened, expecting strong 
losses in activity as they prevent formation of the second H-bond with the hinge. Alternatives for 
the final dimethoxyphenyl moiety have also been computationally examined. An overview over 
several in silico screened compounds is given in Table 15. For clarity, only those which have 
been selected for syntheses from these screenings have been included (cp. syntheses 
chapter 4.2). Apart from the mentioned intentions they have been selected upon commercial 
availability or synthetic feasibility. 
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Table 15 | In silico  screened compounds of series 1  that have been selected for synthese s .  
Series 1 refers to primary and secondary amine substituents.  As these compounds exhibit consi d-
erable losses in ΔG anyway, they are sorted by structure instead of Glide score .  
 # R4 / R5 Glide score 
 
82 
 
-11.8 
83 
 
-10.9 
84 
 
-11.2 
85 
 
-12.0 
86 
 
-11.7 
87 
 
-12.7 
88 
 
-11.6 
 
89 H -8.4 
90 CH3 -8.4 
91 
 
-10.7 
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Propionic Acid Substituents (Series 2) 
The second series was mainly motivated by two distinct intentions: first, to provide evidence for 
the importance of acyl moieties at the 2-aminopyridine position regarding potency for CK1δ. The 
hypothesis was that the carbonyl function might strengthen the adjacent H-bond donor and 
support positioning of the N-H group in the correct angle (cp. series 1). Second, to avoid an 
α,β-unsaturated carbonyl moiety (MICHAEL acceptor) such as in 12 that is considered responsi-
ble for specificity and instability, but not for potency. Propionic acid (sp3) instead of cinnamic 
acid (sp2) side chains were assumed to account for highly active and chemically stable inhibitors. 
If so, these compounds might further be used for crystallographic evaluation in CK1δ, CK1ε, and 
p38α as a decrease in selectivity has to be suggested in the absence of the π-bond. The carbonyl 
group only partially restricts flexibility compared to the first series. Previous studies also high-
lighted the influence of acyl moieties in the exact position for metabolic stability200. 
As discussed for series 1, different substitution pattern for double and triple methoxy-
substituted 3-phenylpropionic acid moieties were screened in silico (Table 16). Modeling sug-
gests trimethoxy substitution to be slightly favored over dimethoxy derivatives - with the excep-
tion of the 3,4-dimethoxy pattern which exhibits superior gains in ΔG. Interestingly, derivative 
102, lacking the π-bond of the lead structure, shows identical scoring compared to 12. Although 
losses in selectivity are most likely, all compounds can be considered highly potent regarding the 
in silico results. Synthetic realization, however, concentrated on commercially available 
3-phenylpropionic acids from this series (cp. syntheses chapter 4.3) in order to generate highly 
stable and active inhibitors as biological tools for further in vitro evaluation. 
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Table 16 | In silico  screened compounds of series 2 .  Series 2 refers to di - and trimethoxy-
substituted 3-phenylpropionic acid side chains at the 2-aminopyridine.  
 # R6 Glide score 
 
92 2,3,6-Trimethoxyphenyl -14.6 
93 3,4-Dimethoxyphenyl -14.6 
94 2,3,4-Trimethoxyphenyl -14.5 
95 3,4,5-Trimethoxyphenyl -14.4 
96 2,3,5-Trimethoxyphenyl -14.3 
97 2,4,5-Trimethoxyphenyl -14.3 
98 2,4,6-Trimethoxyphenyl -14.3 
99 2,3-Dimethoxyphenyl -14.1 
100 2,6-Dimethoxyphenyl -13.9 
101 3,5-Dimethoxyphenyl -13.8 
102 2,4-Dimethoxyphenyl -13.7 
103 2,5-Dimethoxyphenyl -13.6 
 
Carbamide Substituents (Series 3) 
The slightly different position of the hinge region in CK1 isoforms δ and ε on the one hand and 
p38α on the other has been taken into account in the third series. The idea was to generate addi-
tional rigidity in this domain to gain selectivity for CK1δ (and presumably CK1ε) over other ki-
nases, especially p38α. Substitution with isocyanates at the 2-aminopyridine affords carbamide 
derivatives. These carbamides might be able to form a third H-bond towards hinge residue 
Leu85 and restrict rotational freedom of the side chain by waiving sp3 hybridized carbon atoms. 
The idea of an additional H-bond towards the hinge has been confirmed by molecular modeling. 
Docking studies with stereotype carbamide compound 104 (Figure 25) exhibit an excellent gain 
in ΔG (Glide score = -17.2), presumably caused by the intended tridentate hinge-binder. It has to 
be noted, though, that carbamides are known to possess unfavorable physicochemical proper-
ties, especially regarding solubility. Thereby the in silico observed advantages might be (over) 
compensated in vitro which has to be evaluated experimentally. In fact, several approved small 
molecule kinase inhibitors such as sorafenib, regorafenib, and lenvatinib possess carbamide 
functionalities7. Differently substituted 3-phenylcarbamides were synthesized (cp. syntheses 
chapter 4.4) and biologically tested. The selection of isocyanates was carried out based on 
commercial availability. 
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Figure 25 | Postulated binding mode of carbamide derivative 10 4 in CK1δ .  The 2D interaction 
diagram (B) was formulated in accordance to the modeling results (A, PDB code 3UZP).  
Conservation of the (E)-configured π-Bond (Series 4 and 5) 
The suspected advantages and disadvantages of the (E)-configured π-bond of lead 12 have 
already been discussed: increased isoform-selectivity over CK1ε but also chemical instability 
(MICHAEL acceptor potential) and the existence of a less bioactive (Z)-isomer. In addition, the 
reactivity of the α,β-unsaturated carbonyl compound is enhanced through the vicinal phenyl 
moiety. Consequently, the idea was to minimize MICHAEL acceptor reactivity while conserving an 
(E)-like geometry either by using five-membered heterocycles (series 4) or alkyne moieties 
(series 5). The additional rigidification caused by altered hybridization, sp2 in heterocyclic 
systems and sp in alkynes, was also assumed to positively affect selectivity over different kinases 
as this is a well-established mechanism in this context159. In addition, an entropy-driven 
contribution to the binding free energy can be assumed as rigidification of ligands is associated 
with beneficial modification of degrees of freedom upon binding to the active site209. Especially 
heterocyclic scaffolds (series 4) have been considered beneficial (Table 17): first, aromatic 
systems including an N-H group in β-position of the carbonyl function might enable a third 
H-bond towards hinge Leu85 as discussed for carbamide derivatives (cp. series 3); second, 
additional contribution to kinase specificity was suggested as bulky substituents at the 
2-aminopyridine have been reported to decrease inhibitory activity for p38α198. Although less 
bulky, the linear geometry of alkynes (sp hybridization) was supposed to have an analogue effect 
due to the slightly different position of the hinge in p38α (cp. chapter 3.1.5). 
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Molecular modeling studies using 4–(2,4-dimethoxyphenyl)-1H-pyrrol-2-carboxylic acid (stere-
otype series 4 compound 105) and 3-(2,4-dimethoxyphenyl)propiolic acid (stereotype series 5 
compound 106) as side chains at the 2-aminopyridine of 78 confirmed this hypothesis, although 
fitting of 105 and 106 in p38α still has to be assumed (Figure 26). 
Subsequently, several five-membered heterocycles were screened in silico for their binding in 
CK1δ in order to identify suitable candidates for syntheses (Table 17). These studies indicate 
the fourth series to be more effective than the fifth. Heteroaromatic scaffolds containing an N-H 
group show the highest gain in ΔG (Glide scores ≤ -16.6) as they are suggested to act as 
tridentate hinge-binders. Among the remaining heterocyclic systems the calculated activity 
explicitly depends on the included heteroatoms in accordance to the HASB concept. In general, 
nitrogen accounts for higher gains in ΔG than sulfur, while oxygen is least active (cp. 109-112, 
Table 17). The preference for additional aromatic moieties over alkyne side chains is most likely 
due to multiple VAN DER WAALS interactions and entropic (hydrophobic) effects within the 
hydrophobic region II. The scoring of the alkyne derivative 106 (Glide score = -13.7) matches 
that of lead structure 12 (Glide score = -13.7). 
 
Figure 26 | Postulated binding mo des of 105 and 106 in CK1δ .  Three H-bonds are formed 
between compound 105  (series 4) and hinge Leu85 (arrow) while compound 106  (series 5)  
represents a bidentate hinge-binder. HRII  residues are indicated with their V A N D ER WA ALS  radii by 
yellow spheres (PDB code 3UZP).  
In summary, both series represent interesting approaches that can be assumed to beneficially 
affect selectivity for CK1δ over other kinases. Especially the heteroaromatic side chains 
(series 4) might further provide enhanced potency, though this has to be evaluated in vitro. 
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Table 17 | In silico  screened compounds of series 4 and 5 .  These series refer to acyl side chains 
that were designed to  mimic the (E)-configured π -bond of the lead structure bearing either five-
membered heterocycles (series 4) or an alkyne  moiety (series 5).  R = 2,4-dimethoxyphenyl.  
  R7 Glide score 
 
107 
 
-16.8 
105 
 
-16.7 
108 
 
-16.6 
109 
 
-14.6 
110 
 
-14.6 
111 
 
-14.3 
112 
 
-14.1 
106 
 
-13.7 
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Hybrid Inhibitors (Series 6) 
Another approach was to adapt side chains from known kinase inhibitors with suitable proper-
ties and to attach them to 2-aminopyridinyl-imidazole 78. Recent studies identified a class of 
nanomolar Porcupine (Porcn) inhibitors to be moderate inhibitors of CK1 isoform δ without 
showing inhibitory activity on the ε isoform and p38α at an inhibitor concentration of 1.0 µM 
(unpublished data by KUHL and KNIPPSCHILD). Porcn is a membrane-associated O-acyltransferase 
family member that catalyzes Wnt palmitoylation and thereby initiates Wnt activity. The com-
pounds have therefore been initially designated as inhibitors of Wnt production (IWP)210. 
Molecular docking studies postulated a binding mode for these IWP with the dihydro-
thieno[3,2-d]pyrimidin-4-one side chain interacting with the hydrophobic region II of CK1δ. This 
binding mode is in accordance with the hypothesis of HRII being a main determinant for 
selectivity. The idea was to examine whether this effect can be grafted onto diaryl-imidazole 
inhibitors by hybridization. Although in silico evaluation of the generated hybrid inhibitors (115, 
116) deriving from IWP-2 (113) and IWP-4 (114, Figure 28Figure 27)210 exhibited slight 
losses in ΔG compared to lead structure 12, the in vitro effect on kinase specificity is worth to be 
investigated experimentally. 
 
Figure 27 | Hybrid inhibitors 115 and 116 deriving from Porcn inhibitors 113 and 114 .  The 
postulated binding mode of 115  in CK1δ is depicted (right)  (PDB code 3UZP). 
The second class of hybrids concentrated on the 4-((4-methylpiperazin-1-yl)methyl)benzamide 
moiety of multiple tyrosine kinase inhibitor imatinib (117, Figure 28)7,211. The aromatic feature 
of the side chain was assumed to form multiple VAN DER WAALS interactions with the 
hydrophobic region II while the 4-methylpiperazine which will be positively charged under 
physiological conditions might donate an H-bond towards Asp91 (cp. series 1). Interestingly, 
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modeling suggested significant enthalpic gains (Glide score = -14.7) for hybrid inhibitor 118, 
though no additional H-bond formation could be observed in silico. Regarding the development 
of imatinib itself, the moiety was introduced to enhance water solubility as well as oral 
bioavailability211. 
 
Figure 28 | Hybrid inhibitor 118 deriving from imatinib .  The postulated binding mode in CK1δ 
is depicted (right) (PDB code 3UZP) . 
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4 Chemistry 
In order to synthesize differently amino-substituted 2-aminopyridinyl-imidazoles for SAR 
studies, a straightforward four-step synthesis towards 2-fluoro-4-(5-(4-fluorophenyl)-2-
(methylthio)-1H-imidazole-4-yl)pyridine (119) has been established (Figure 29). Nucleophilic 
aromatic substitution (SNAr) afforded alkyl amino-substituted diaryl-imidazoles (series 1), or 
the unsubstituted 2-aminopyridine derivative (120, building block). Coupling of 120 with 
activated carboxylic acids and isocyanates provided the respective amides (series 2, 4-6) and 
carbamides (series 3). Subsequent sulfoxidation towards sulfoxides was performed with several 
selected compounds. Both sulfides and sulfoxides have been biologically evaluated. 
 
Figure 29 | Synthetic route towards inhibitors of series 1 -6 .  Syntheses are given as an overview 
and will be discussed in detail in the following chapters (4.1  to 4.8) .  
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4.1 Synthesis of Building Block 120 
The syntheses of key intermediate 119 and building block 120 have already been described in 
literature and were mainly adapted from THOMPSON et al.212 and LAUFER et al.203. In general, the 
five-step synthetic route depicted in Figure 29 has been followed (procedure A). An alternative 
procedure has been performed starting from 2-amino-4-methylpyridine (126, procedure B) as 
nucleophilic aromatic substitution (SNAr) towards 120 is critical and requires harsh reaction 
conditions (step 5, Figure 29). Low overall yields of this alternative protocol, however, led to 
acquisition of a high pressure reactor to cope with SNAr of 119 as large quantities of building 
block 120 were required. 
4.1.1 Procedure A 
Ethanone 123 is easily accessible by the protocol of THOMPSON et al.203,212 from 2-fluoro-4-
methylpyridine (121) and ethyl 4-fluorobenzoate (122) in a CLAISEN-similar condensation. The 
CH-acidic methyl group in ortho-position to the picoline nitrogen is readily deprotonated by 
strong bases. Mesomeric stabilization involving the ring nitrogen is mandatory for reasonable 
progression of this step. The respective carbanion attacks the benzoate carbonyl group and re-
places the ethanolate in a nucleophilic SN2t substitution. The reaction was performed at temper-
atures between 0 °C and 25 °C (room temperature, rt) using sodium bis(trimethylsilyl)amide 
(NaHMDS) in anhydrous tetrahydrofuran (THF) under protective gas atmosphere (nitrogen) to 
afford 123 in quantitative yields. 
The equivalent 2-bromo-4-methylpyridine (127) was reacted analogously, though the appropri-
ate ethanone 128 was obtained in significantly reduced yields (Figure 30). 
 
Figure 30 | Synthesis of ethanone  derivatives 123 and 128 .  121 ,  123:  R = F; 127 ,  128:  R = Br. 
a)  NaHMDS, anhyd. THF, 2  h 0 °C then 1 h rt .  Yield: quant. (123), 51 % (128).  
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The respective α-oximinoketones 124 and 129 were synthesized through nitrosation from the 
ethanones by exposure to nitrous acid at room temperature in excellent yields (Figure 31)203. 
1H NMR data indicated predominant formation of the favored regioisomer of at least 95 %. 
 
Figure 31 |  Synthesis of  α-oximinoketones 124 and 129 .  123 ,  124:  R = F; 128 ,  129:  R = Br. 
a) Glacial acetic acid, NaNO 2 ,  1h 0 °C then 3.5 h rt . Yield: 95 % (124) , 92 % (129).  
Reduction of hydroxime 124 by catalytic hydrogenation using palladium on activated charcoal 
(Pd/C) afforded α-ketoamine 125203. Acidic conditions were required for this synthesis to 
prevent reduction towards the amino alcohol. As 2-halogenopyridines are reportedly sensitive 
to primary alcohols regarding acid-catalyzed SNAr reactions, the sterically more demanding 
2-propanol was saturated with hydrogen chloride gas and used as solvent. Formation of the 
respective 2-isopropanoxy pyridine, however, would require heating under reflux213. The 
desired 2-aminoethanone hydrogen chloride was prepared under atmospheric pressure of 
hydrogen gas and intense stirring in good yields. 
Despite using even more gentle reaction conditions as compared to literature203, 
2-bromopyridinyl α-ketoamine has not been maintained. Instead, hydrogenolytic cleavage 
afforded ortho-unsubstituted pyridine 130 (Figure 32). 
 
Figure 32 | Reduction of hydroximes 124, 128 towards α-aminoketones 125, 130 .  124 ,  125:  
R1  = R2  = F; 129 ,  130:  R1  = Br, R2  = H. a) H2 ,  Pd/C, 1 atm, HCl-saturated 2-propanol, 12 h rt .  Yield:  
82 % (125) , 69 % (130) .  
Cyclization of α-ketoamine 125 using methyl thiocyanate in anhydrous N,N-dimethylformamide 
(DMF) gave key intermediate 2-methylthio-4,5-diaryl imidazole 119 in one step following a 
protocol based on an advanced MARCKWALD synthesis by ASINGER203,214. Conveniently, progress of 
the reaction was tracked visually: the initially light orange mixture turned an intensive bright 
orange upon heating to reflux under nitrogen. Completion of the reaction was indicated by 
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fading of the color. 1H NMR spectroscopy indicated formation only of the favored imidazole 
tautomer (i.e. at least 95 %) which was obtained in good yields (Figure 33). 
 
Figure 33 |  Ring closure of α-ketoamine 125 towards key intermediate 119 .  a) Methyl thiocya-
nate, DMF, 45 min reflux the n 45 min rt .  
In a final step, building block 120 was accessible through a TSCHITSCHIBABIN reaction in 
concentrated ammonia at 180 °C under pressure (Figure 34)193. The electron deficient pyridine 
moiety is activated for SNAr in ortho-position by the positive mesomeric effect of the ring 
nitrogen. The strong electronegative character of the fluorine atom in this exact position further 
enhances reactivity. Consequently, the respective amide attacks the pyridine C2 and substitutes 
the fluorine in an addition-elimination mechanism. 
 
Figure 34 | Synthesis of building block 120 by S NAr .  a) Conc. aq. NH3 ,  20-30 bar, 18 h 180 °C.  
Interestingly, literature protocols typically involved copper(I) iodide-mediated catalysis193 
which led in our hands to partial cleavage of the thioether: although the by-product has not been 
isolated, mass spectrometry analysis indicated formation of the imidazole-2-thione. In fact, ca-
talysis is not required under these conditions and abandoning copper(I) iodide from the reaction 
even enhanced yields in relation to literature. 
An alternative method reported by PEIFER et al.176 for an analogous 3,4-diaryl-isoxazole has been 
approached as well. The procedure involved the reaction of 2-fluoropyridine derivatives with 
sodium azide to afford the appropriate tetrazoles and subsequent reduction towards 
2-aminopyridines. This technique, however, could not be adapted for the imidazole-containing 
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compound 119 and several approaches gave only unconverted starting material (Figure 35). 
This is interesting as the reaction proceeds well with analogous scaffolds including isoxazoles176 
or thiazoles215 in place of the imidazole. It is most likely that the electron-donating effect of the 
imidazole reduces activation of the pyridine and thereby prevents formation of the 
MEISENHEIMER-like complex by SNAr. 
 
Figure 35 | Alternative potential procedure for the preparation of 120 from 119 via tetrazolo 
derivative 131 .  a) NaN3 ,  DMSO, 3 h 140 °C.  
4.1.2 Procedure B 
Procedure B was performed to investigate whether building block 120 could be synthesized 
starting from 2-amino-4-methylpyridine (126). Protection of 126 was performed using di-tert-
butyl dicarbonate (Boc2O) in tert-butanol affording carbamate 132202. The Boc-protecting group 
has been selected because it is stable under basic conditions and readily cleaved upon treatment 
with acid which is beneficial for the following steps. Introduction of a second Boc group to 13 
was achieved through STEGLICH-like esterification in THF adding 4-(dimethylamino)pyridine 
(4-DMAP) as a nucleophilic catalyst leading to compound 133216. Interestingly, when 126 and 
Boc anhydride were reacted in THF, quantitative conversion towards 1,3-bis(4-methylpyridin-2-
yl)carbamide (134) has been observed. The respective ethanone 135 was afforded from 133 
following THOMPSON’S protocol as described for procedure A203,212 in dramatically reduced yields. 
One of the Boc groups was cleaved in the process. It was further possible to synthesize 135 
directly from mono-protected 132, though with an increasing number of non-identified 
by-products and only when the reaction temperature was lowered to -78 °C. Nitrosation203 gave 
α-oximinoketone 136 in approximately quantitative rates with less than 5 % of the 
non-preferred regioisomer (1H NMR). Subsequent reduction203 produced α-aminoketone 137 as 
a mixture of 2-aminopyrdinyl hydrogen chloride and the respective carbamate (mass 
spectrometry only). Finally, 120 was obtained by ring closure based on ASINGER (Figure 
36)203,214. 
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Figure 36 | Synthetic procedure B towards building block 120 .  137:  R  = NH3 +Cl - ,  NHBoc. 
a) Boc2O, tert-butanol, 12 h rt . b) Boc2O, 4-DMAP, THF, 24 h rt. c) 122 ,  NaHMDS, THF, 2 h 0 °C then 
1 h rt. d) NaHMDS, 122 ,  1 h -78 °C to rt then 2 h rt. e) Glacial acetic acid, NaNO 2 ,  1h 0 °C then 3.5 h 
rt . f) H2 ,  Pd/C, 1 atm, HCl-saturated 2-propanol, 12 h rt .  g) Methyl thiocyanate, DMF, 45 min reflux 
then 45 min rt.  
4.1.3 Synthesis of 2-unsubstituted 4,5-Diaryl-imidazole 
In order to enable possible functionalization at the imidazole 2-position by nucleophilic 
substituents, a synthetic pathway towards 2-unsubstituted diaryl-imidazoles has been 
established (Figure 37). Oxidation of 1-(4-fluorophenyl)-2-(2-fluoropyridin-4-yl)ethan-1-one 
(123) was achieved in accordance to THAHER et al.217,218 by selenium dioxide and gave 
1,2-diketone 138. Ring closure, however, was performed following a different protocol to avoid 
the use of formaldehyde. In fact, an elegant microwave-assisted method has been published by 
BRATULESCU219: the 1,2-diketone was reacted with ammonium acetate and methenamine 
(hexamethylenetetramine) as an in situ source of formaldehyde in the absence of solvent. 
Instead, a catalytic amount of glacial acetic acid was added to generate a thick paste-like 
medium. In this medium the polar solvent absorbs microwave radiation and creates catalytic 
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centers (hot spots) which initiate rapid cyclization and provide 4,5-disubstitued imidazole 139 
in good yields. 
 
Figure 37 | Synthesis of 2-unsubstituted 4,5-diary-imidazole 139 .  a) SeO2 ,  glacial acetic acid, 
1.5 h 95 °C. b) CH3 COONH4 ,  methenamine, glacial acetic acid (cat.) ,  4 min 117 °C (microwave).  
It has to be noted that this synthetic approach has not been followed any further as the analog 
functionalization in 4,5-diaryl-oxazole and –thiazole inhibitors of CK1δ has become content to 
the master thesis of SCHMIDT208 and SCHEHR215, as well as SCHEHR’S dissertation (current labor). 
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4.2 Syntheses of Series 1: Pyridine-2-amines and -piperazines 
In general, two different synthetic routes have been established to synthesize 4-(5-(4-
fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-amines. First, different aromatic and 
aliphatic primary and secondary amino substituents have been introduced at the pyridine 
2-position of 119 by SNAr (chapter 4.2.1). And second, by reacting aliphatic alkyl halides with 
2-aminopyridines in an SN2 mechanism (chapter 4.2.2): 
4.2.1 SNAr Reaction of 2-Fluoropyridines with Amines 
The activation of 2-fluoropyridine 119 for SNAr reactions has already been discussed (4.1.1). 
Different aromatic and aliphatic primary amines and piperazines are well-tolerated as nitrogen 
nucleophiles in this position following the procedure by LAUFER et al. (Figure 38)197,203. The 
nucleophilic substitutions could be performed in the absence of solvent (green chemistry). 
Instead, 2-fluoropyridine derivative 119 was dissolved or suspended in an excess of the 
respective amine and heated to 160 °C in a glass screw cap. These syntheses were performed by 
KUHL during her bachelor thesis220 in 2013. In general, primary amines gave better yields than 
the applied piperazines. The appropriate amines and piperazines applied as starting material 
are summarized in Table 18. 
 
Figure 38 | Synthesis of pyridin-2-amine derivatives .  Moieties (R) are given in Table 18 .  
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Table 18 | Amines applied for S NAr reaction towards pyrdin-2-amines .  (Series 1).  
Amine or Piperazine # Product Yield (%) 
    
140 
 
148 54 
    
141 
 
149 52 
    
142 
 
150 90 
    
143 
 
151 73 
    
144 
 
152 35 
    
145 
 
153 17 
    
146 
 
154 23 
    
147 
 
155 50 
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4.2.2 SN2 Reaction of Alkyl Halides with 2-Aminopyridines 
The idea was to incorporate primary alkyl halides such as 1-(3-bromopropyl)-2,4-dimethoxy-
benzene (156) and 2-aminopyridines in an SN2 reaction to provide the appropriate 
N-alkylpyridine-2-amines. As 156 was commercially not available it has been prepared from 
2,4-dimethoxycinnamic acid (157) in three steps: 
Reduction of 2,4-dimethoxycinnamic acid (157) towards the appropriate propionic acid 158 
and alcohol 159, respectively, was generally based on a procedure by LAL et al.221, though the 
first step was adapted for microwave (Figure 39): 3-(2,4-dimethoxyphenyl)propionic acid 
(158) was obtained in a Pd/C-catalyzed reaction of 157 with cyclohexene acting as the 
reduction equivalent. The propionic acid was subsequently treated with lithium aluminum 
hydride under protecting gas atmosphere to give 3-(2,4-dimethoxyphenyl)propan-1-ol (159). 
Both reductive steps showed almost quantitative conversion. 
 
Figure 39 | Reduction of  2,4-dimethoxycinnamic acid ( 157) .  a) Pd/C, cyclohexene, methanol, 
3 min (microwave). b) LiAlH4 ,  THF, 1 h rt .  
Subsequent transformation of primary alcohol 159 into the desired alkyl bromide 156 was 
achieved by APPEL reaction with triphenylphosphine (PPh3) and N-bromosuccinimide (NBS) 
instead of the usually applied carbon tetrabromide (Figure 40)222. 
 
Figure 40 | Conversion of primary alcohol 159 into alkyl bromide 156  by APPE L  reaction .  
a) NBS, PPh3 ,  dichloromethane (DCM), 2 h rt .  
In the following approaches, benzyl bromide has been used as an analog of 156 to determine 
suitable reaction conditions. The aim was to react the alkyl bromides in an SN2 mechanism with 
building block 120 or Boc-protected building block 160. Yields, however, were unsatisfying and 
an unacceptable amount of by-products was observed, among them e.g. a dibenzyl derivative 
(mass spectrometry data). As the 2-aminopyridine moiety of the building block is a poor 
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nucleophile in general and the protecting group of 160 has not been cleaved, substitution at the 
imidazole 1-nitrogen can be assumed, though the products have not been isolated. Hence, 
benzylation of Boc-protected 2-amino-4-methylpyridine (132) was tested: in the absence of the 
imidazole heterocycle, the SN2t reaction readily afforded the benzyl carbamate 161 in good 
yields and high purity. Subsequently, de-novo synthesis starting from 161 gave the desired 
N-benzyl-4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-amine (162). The 
procedure involved the already discussed steps of CLAISEN-like condensation towards the 
respective ethanone 163, nitrosation, reduction, and cyclization (cp. chapter 4.1)203,214 in 
excellent overall yields. Analogue synthesis applying 1-(3-bromopropyl)-2,4-dimethoxybenzene 
(156) afforded primary amine 164q. 
 
Figure 41 | De-novo  synthesis of N-alkylated 4,5-diaryl-imidazoles .  161-163 ,  165 ,  166:  
R = benzyl;  164 ,  167-170 :  R = 3-(2,4-dimethoxyphenyl)propyl. a) NaH, benzyl bromide or 156 ,  
DMF, 20 min 0 °C then 2 h 0 °C to rt . Yield: 87 % (161), 94 % (167).  b) 122 ,  NaHMDS, THF, 2 h 0 °C 
then 1 h rt .  Yield: 93 % (163) , 48 % (168). c) Glacial acetic acid, NaNO 2 ,  1h 0 °C then 3.5 h rt .  
Yield: 96 % (165), quant.  (169). d) H2 ,  Pd/C, 1 atm, HCl-saturated 2-propanol, 12 h rt. Yield: 96  % 
(166),  99 % (170) . e) Methyl thiocyanate,  DMF, 45 min reflux then 45 min rt.  Yield: 60 % (162) ,  
38 % (164) .  
It is further noteworthy that 167 can also be synthesized from 3-(2,4-dimethoxyphenyl)-N-(4-
methylpyridin-2-yl)propanamide (171) by LiAH4-mediated reduction of the carbonyl affording 
172 and subsequent Boc-protection. In order to provide 171, propionic acid 158 was activated 
by (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and reacted 
with 2-amino-4-methylpyridine (126) in an amide coupling (for mechanism cp. chapter 4.3). 
                                                             
q 164 = N-(3-(2,4-dimethoxyphenyl)propyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-amine 
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4.3 Syntheses of Series 2: Amide Coupling 
Differently substituted 3-phenylpropionic acids were to be reacted with building block 120 in 
amide couplings. In order to determine the ideal coupling reagent, 2-amino-4-methylpyridine 
(126) as an analog of 120 was coupled with commercially available 3-(2,5-dimethoxy-
phenyl)propionic acid (173) using either CDIr, PyBOP, HATUs, DCCt, EDCIu plus 
1-hydroxybenzotriazole (HOBt), or T3Pv plus HOBt (Table 19). Equivalent reaction conditions 
were chosen if possible and the actual coupling was performed in all approaches for 12 h at 
110 °C. The elevated temperature is necessary as 2-aminopyridine derivatives represent poor 
nucleophiles and more gentle conditions led to significantly decreased yields. 
Table 19 | Determination of different amide coupling reagents .  
Coupling reagent Yield (%) Product 
CDI 72 
 
PyBOP 78 
HATU 75 
DCC n.d.* 
EDCI, HOBt 55 
T3P, HOBt 0 
* The overall yield was ~84 % but the pure product could not be isolated due to a single by-product. 
Comparable yields and good purity were obtained by the use of CDI, PyBOP, and HATU while 
EDCI/HOBt gave lower amounts of the desired product. DCC exhibited formation of a single by-
product which prevented isolation of pure 174. No conversion of starting material has been 
observed upon use of the T3P/HOBt system. 
Amide synthesis using CDI (175) is a standard procedure223 which does not necessarily need an 
additional base as imidazole is generated in situ (Figure 42): in a first step the propionic acid 
(173) is deprotonated by one of the imidazole moieties. Nucleophilic attack of the carboxylate at 
the CDI carbonyl is followed by rapid formation of an acyl carboxy-imidazole and an imidazole 
which react together to afford the activated acylimidazole. The activated species and amine 126 
are subsequently converted into the desired amide 174 in a SN reaction. In practice, the 
acylimidazole step was reacted for at least 1 h before the amine was added. 
                                                             
r CDI = N,N’-carbonyldiimidazole 
s HATU = 1-(bis(dimethylamino)methylene)-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate 
t DCC = N,N’-dicyclohexylcarbodiimide 
u EDCI = 1-ethyl-3-(3-dimethylaminoproyl)carbodiimide 
v T3P = 1-propylphosphonic acid cyclic anhydride 
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Figure 42 | Mechanism of CDI-mediated amide coupling .  R = 3-(2,5-dimethoxyphenyl)propyl.  
Coupling reagents based on phosphonium or aminium/uronium salts of 1H-benzotriazoles 
HOAtw (176) and HOBt (177) operate by similar mechanisms. HATU (178, Figure 43) has 
initially been reported as the HOAt uronium salt (O-isomer), though X-ray analysis identified the 
less reactive aminium form (N-isomer) to be the favored isomer. Activation is initiated by 
formation of oxy-7-azabenzotriazole (OAt) active esters (179) which react with the amine 
component. In general these active esters are known to repress racemization. Unfortunately, 
direct reaction of the amine with the coupling reagent itself leads to stable guanidinium 
derivatives in a side-reaction223,224. Phosphonium salt reagents such as PyBOP (180, Figure 43) 
act analogously through the respective oxybenzotriazole (OBt) active esters (181) without 
formation of the disadvantageous by-product. Active ester 181 has exemplarily been isolated 
and analyzed. Both HOAt and HOBt derivatives require deprotonation of the carboxylic acid by 
an alternative base in a first step which is usually realized by addition of HÜNIG’S base 
(N,N-diisopropylethylamine, DIPEA). The reactions are driven by formation of 
thermodynamically stable phosphine oxide (182) and tetramethylcarbamide (183), respectively 
(Figure 44). PyBOP223–225 has been developed as the non-toxic alternative of its precursor BOPx. 
 
Figure 43 | Coupling reagents HATU (178) and PyBOP (180 ) .  At least for HATU, O- and 
N-isomers have been reported.  
                                                             
w HOAt = 1-hydroxy-7-azabenzotriazole 
x BOP = (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
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Figure 44 |  Mechanism of HATU- and PyBOP-mediated amide coupling .  R = 3-(2,5-dimethoxy-
phenyl)propyl; NR’ 2  = pyrrolidin-1-yl. 179:  Z = N; 181  Z = C.  
DCC (184)-mediated STEGLICH-amidation also provided the desired product in similar amounts. 
In general, carbodiimides were the first coupling reagents described in literature, though they 
have lost much of their importance in peptide coupling due to the number of possible by-
products. In order to reduce side-reactions, the addition of HOBt has proved beneficial by 
initially converting the intermediate O-acylcarbamide 185 into the active ester 181. An 
alternative base is not necessary as DCC itself deprotonates the carboxylic acid. In the case of 
STEGLICH-esterification the reaction depends on 4-DMAP-mediated catalysis224,226. Regarding the 
current amidation, application of the catalyst did not reveal any effect on yield, but has been 
associated with the reduction of by-products. Nevertheless, the product has not been obtained 
purely: the compellent carbamide by-product 186 which has been indicated by mass 
spectrometry could not be separated from amide 174 (Figure 45). 
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Figure 45 | Mechanism of DCC-mediated amide coupling .  R = 3-(2,5-dimethoxyphenyl)propyl.  
In contrast to reactions mediated by DCC, carbodiimide reagent EDCI generates carbamide by-
products which can readily be separated from the product. The decreased yield in this work, 
however, led to the refusal of both DCC and EDCI for further amidations. Consequently, amide 
coupling reactions have been performed using CDI or PyBOP for their easy handling, high yields, 
good purity, and cost-effectiveness. 
In accordance, 3-(2,4-dimethoxyphenyl)- (158), 3-(2,5-dimethoxyphenyl)- (173), 3-(2,3-
dimethoxyphenyl)- (187), 3-(3,4-dimethoxyphenyl)- (188), and 3-(3,4,5-trimethoxyphenyl)-
propionic acid (189) have been coupled CDI-mediated with building block 120 to obtain the 
respective amides 190-194 (Figure 46). The decreased yields in relation to the appropriate 
dummy reaction presumably depend on the more demanding purification. 
 
Figure 46 | Amide coupling of 3 -(di-/tri-methoxyphenyl)propionic acids and 120 .  158 ,  190:  
2,4-dimethoxyphenyl; 173 ,  191 :  2,5-dimethoxyphenyl; 187 ,  192:  2,3-dimethoxyphenyl; 188 ,  193:  
3,4-dimethoxyphenyl; 189 ,  194 :  3,4,5-trimethoxyphenyl.  a) CDI, 120 °C, DMF, rt then 12 h 110 °C.  
Yield: 27 % (190) , 39 % (191) , 63 % (192), 57 % (193), 49 % (194).  
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4.4 Syntheses of Series 3: Carbamide Derivatives 
Heterocumulenes such as isocyanates represent chemically highly active molecules which readi-
ly react with different nucleophiles. Accordingly, isocyanates 195-203 (Table 20) have been 
converted with building block 120 into the respective carbamides 204-212 in a WÖHLER-like 
synthesis227. Addition of HÜNIG’S base led to increased yields. Mechanistically, the nucleophilic 
attack of the amine at the sp-hybridized isocyanate carbon atom leading to formation of the trig-
onal-planar (sp2) transitional state depicts the rate-determining step (Figure 47)228. Unfortu-
nately, the resulting carbamide derivatives were hardly soluble in most standard solvents and 
purification was tedious. 207 and 211 have therefore not been isolated in adequate purity. 
 
Figure 47 | Mechanism of carbamide derivative synthesis .  For isocyanate R 1  cp. Table 20 .  
Beside amines, isocyanates react with different nucleophiles as characterized for 195: in the 
presence of water the isocyanate is converted into the respective carbamic acid 213 which is 
instable and decomposes into carbon dioxide and the appropriate amine 214. The amine further 
reacts with another isocyanate molecule to the dimer carbamide 215 (Figure 48) that can be 
isolated. 
 
Figure 48 | Formation of dimer carbamide by-product 215 from isocyanate 195 in the 
presence of water .  R = 2,4-dimethoxyphenyl.  
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The reactions have therefore been performed in anhydrous DMF under protective gas atmos-
phere. Addition of molecular sieve to the reaction mixture has also proved beneficial229. 
Table 20 | Isocyanates applied for synthesis of carbamide derivatives .  (Series 3).  
Isocyanate # Product Yield (%) 
195 
 
204 21 
196 
 
205 15 
197 
 
206 26 
198 
 
207 n.d.* 
199 
 
208 28 
200 
 
209 34 
201 
 
210 26 
202 
 
211 n.d.* 
203 
 
212 41 
* Product has been identified by mass spectrometry, but has not been isolated in adequate purity. 
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4.5 Syntheses of Series 4: Five-membered Heterocycles 
As discussed in chapter 3.1.5 several side chains conserving the originally present 
(E)-configuration within different five-membered heterocycles (Figure 49) should be coupled in 
the pyridine ortho-position of building block 120. None of these heterocyclic acids were com-
mercially available and therefore a selection ought to be prepared in parallel synthesis. Among 
them were pyrroles, thiazoles, imidazoles, and triazoles. 
 
Figure 49 | Schematic representation of acid side chains of series 4 .  A,  B, D refer to carbon, 
nitrogen, or sulfur .  
4.5.1 Synthesis of 4-(dimethoxyphenyl)pyrrole-carboxamides 
Synthesis of 4-(2,4-dimethoxyphenyl)pyrrol-2-carboxylic acid (216) has been realized in three 
steps starting from ethyl 4-bromo-1H-pyrrole-2-carboxylate (217, Figure 50)230. First, the pyr-
role nitrogen was protected using Boc anhydride. The obtained carbamate (218) was subse-
quently converted in a SUZUKI cross-coupling using organoboronic acid to afford ethyl 
4-(2,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylate (219). Simple ester hydrolysis in diluted 
alkali gave pyrrolic acid 216. Finally, the respective carboxamide 220 was obtained by amide 
coupling of 216 and building block 120. Reaction conditions for successful amide couplings 
were first evaluated in a dummy synthesis of N-(4-methylpyridin-2-yl)-1H-pyrrol-2-
carboxamide (221) using 1H-pyrrole-2-carboxylic acid and 2-amino-4-methylpyridine (126). 
Unfortunately, 220 was subject to slow oxidation under atmospheric conditions maybe towards 
a pyrrole N-oxide (not isolated) as alkylation of the pyrrole nitrogen with methyl iodide or 
benzyl bromide forestalled this side reaction. The alkyl groups have also been introduced 
successfully on the step of carboxylate 219 and acid 216, though with decreasing yields. 
N-Methylated 4-(2,5-dimethoxyphenyl)pyrrolic acid (222) and the appropriate carboxamide 
223 have been synthesized in accordance to this procedure. Active ester 224 of 
3-(2,4-dimethoxy)-1-methyl-1H-pyrrole-2-carboxylic acid (225) has been isolated and analyzed 
exemplarily. 
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Figure 50 | Synthesis of carboxamides 220, 223, 231 of Series 4 .  220 :  R = H,  
2,4 dimethoxyphenyl; 227 ,  225 ,  231:  R = CH3 ,  2,4-dimethoxyphenyl;  228 ,  230:  R = Bn,  
2,4 dimethoxyphenyl; 223 ,  224 ,  230:  R = CH3 ,  2,5-dimethoxyphenyl. a) Boc2 O, 4-DMAP, ACN, 1  h rt.  
b) 2,4-dimethoxyphenyl boronic acid, Pd(PPh 3)4 ,  aq. Na2CO3 ,  DMF, 4 h reflux then 12 h rt.  Yield:  
67 % (227) , 71 % (229). c) aq.  NaOH, THF/methanol,  5  h 50 °C then 12 h rt .  Yield: 63 % (230) ,  
quant.  (222) , quant. (225) d) PyBOP, DIPEA, DMF, 30  min rt , then 120 ,  12 h 110 °C. Yield: 13 % 
(220),  20 % (223),  24 % (231).  e) NaH, DMF, 20 min 0 °C, then CH3 I,  15 min 0 °C then 2.5 h rt .  
Yield: 52 % (225) . f) NaH, DMF, 20 min 0 °C,  then CH3 I or BnBr, 15 min 0 °C then 2.5  h rt.  Yield:  
65 % (228) , 86 % (227) .  
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With respect to the rather low yields, efforts were undertaken to enhance nucleophilicity of the 
2-aminopyridine moiety by deprotonation of the amino group. Therefore, amine 120 has been 
stirred with sodium hydride in DMF at room temperature before active ester 224 was added. 
Interestingly, by analyzing the product 1H NMR data suggested the side chain to be mainly 
attached to the imidazole nitrogen assuming this to be the predominant position for 
deprotonation. It has to be mentioned, though, that the respective NMR data suffered from poor 
resolution and did not allow complete analysis. Nevertheless, the imidazole and amide NH are 
herein only slightly visible whereas they normally produce clear and distinct signals. 
 
Figure 51 |  Reaction of building block 120 and active ester 224 in the presence of base .  
a) NaH, DMF, 30 min rt , then 224 ,  72 h rt.  
Based on these observations we decided an intermediate protection of the imidazole: 120 was 
to be deprotonated at the imidazole NH at -78 °C by one equivalent of n-butyllithium (nBuLi) and 
temporarily protected as the collaborating carbamic acid 233. Therefore, carbon dioxide was 
bubbled through the reaction mixture at -40 °C. Subsequently, careful addition of tert-
butyllithium (tBuLi) at -78 °C in order to deprotonate the amino group was followed by addition 
of active ester 224. The reaction was allowed to reach room temp. over a period of approx. 12 h. 
Unfortunately, this approach also failed and the starting material was regained unconverted. 
 
Figure 52 | Aimed reaction procedure towards 231 via intermediate protection of the 
imidazole nitrogen .  R = 4-(2,4-dimethoxyphenyl)-1-methyl-1H-pyrrole-2-yl.  a)  nBuLi, THF, 35 min 
-78 °C, then CO2 ,  1.5 h -40 °C. b) tBuLi , 30 min -78 °C,  then 224 ,  -78 °C to rt over 12 h, 12 h rt .  
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4.5.2 Synthesis of Thiazole-containing Side Chains 
Synthesis of 4-(2,4-dimethoxyphenyl)thiazole-2-carboxylic acid (234) has been performed in 
three steps: first, bromination of 2,4-dimethoxycetophenone (235) in ω-position or 
FRIEDEL-CRAFTS acylation of 1,3-dimethoxybenzene (236); second, cyclization of the appropriate 
2,4-dimethoxyphenacyl halides 237 and 238 in accordance to HANTZSCH thiazole synthesis; and 
third, ester hydrolysis of thiazole-2-carboxylate 239. 
4.5.2.1 ω-Bromination of Acetophenones 
The acid-catalyzed ω-halogenation of acetophenone is a standard procedure231: enolization is 
followed by electrophilic attack of the bromine molecule at the nucleophilic enole carbon. An 
acidic milieu is inevitable as basic catalysis is known to provide triple ω-halogenated deriva-
tives. Although the reaction worked satisfactory for the conversion of acetophenone (240) into 
phenacyl bromide (241), it failed when 2,4-dimethoxyacetophenone (235) was applied as start-
ing material. As expected, the positive mesomeric effect of the methoxy groups activates the ar-
omatic compound for electrophilic substitution in the ortho- and para-positions. Consequently, 
3-bromo-2,4-dimethoxyphenacyl bromide (242) was obtained instead (Figure 53). 
 
Figure 53 | Acid-catalyzed ω-bromination of acetophenones with bromine .  235:  R = H;  
237:  R = Br.  
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This problem was handled following the protocol by KING et al.232: copper(II) bromide selectively 
brominates the ω-position of activated acetophenones in ethyl acetate. In fact, nearly 
quantitative conversion was obtained upon addition of two equivalents of CuBr2. The 
appropriate mechanism is most likely characterized by a radical reaction involving simultaneous 
one-electron transfers within the copper-bound enolate complex whereas copper(II) is reduced 
to copper(I) (Figure 54)233. 
 
Figure 54 | Selective radical ω-bromination of 2,4-dimethoxyacetophenone with Copper(II) 
bromide .  R = 2,4-dimethoxyphenyl.  
4.5.2.2 FRIEDEL-CRAFTS Acylation of 1,3-Dimethoxybenzene 
The SEAr reaction was performed in accordance to standard literature231 using 
1,3-dimethoxybenzene (236) and chloroacetyl chloride (243). Addition of a LEWIS acid catalyst 
is inevitable for the formation of acylium ions which attack the aromatic compound in an 
electrophilic manner. The procedure readily afforded 2,4-dimethoxyphenacyl chloride (238) in 
equivalent yields as reported in literature (Figure 55). 
 
Figure 55 | FR IE DE L -CRA FT S  acylation of 1,3-dimethoxybenzene .  a) AlCl3 ,  3 h 0 °C.  
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4.5.2.3 Cyclization of Phenacyl Halides by HANTZSCH Synthesis 
The cyclization of phenacyl halides 237 and 238 was achieved with thioamide 244 by HANTZSCH 
thiazole synthesis following a protocol for microwave radiation234. Mechanistically, the reaction 
comprises two steps in accordance to the HSAB concept235: substitution of the halogen atom by 
the thiol tautomer of 244 in an addition-elimination (SN2t) mechanism and formation of an 
imine by intramolecular exo-trig cyclization (Figure 56). In accordance to the BALDWIN rules235 it 
is most likely that these two steps do not occur in a definite order: initial formation of the imine 
might be followed by intramolecular exo-tet cyclization as well. The mechanism provides rapid 
access to thiazole derivative 239 in good yields and purity. 
 
Figure 56 | Cyclization mechanism of phenacyl halides and thioamide 244 by HAN TZS C H  
synthesis .  R1  = ethyl carboxylate; R 2  = 2,4-dimethoxyphenyl; X = Br, Cl .  
4.5.2.4 Ester Hydrolysis of Ethyl Thiazole-2-carboxylate 239 
Several systematic approaches have been tried out for ester hydrolysis of 239 in diluted alkali to 
gain carboxylic acid 234. These involved different solvents and bases, temperatures, and 
variation of reaction time. Unfortunately, formation of the carboxylic acid has in all cases been 
followed by rapid and quantitative decarboxylation towards 4-(2,4-dimethoxyphenyl)thiazole 
(245). The desired product has therefore only been obtained as an unstable intermediate which 
could not be isolated. 
 
Figure 57 | Ester hydrolysis and subsequent decarboxylation of ethyl thiazole -2-carboxylate  
239 .  R = 2,4-dimethoxyphenyl. a) Aq. NaOH, THF/methanol, 48  h rt .  
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4.5.3 Synthesis of Imidazole-containing Side Chains 
Preparation of ethyl 4-(2,4-dimethoxyphenyl)-1H-imidazole-2-carboxylate (246) was achieved 
from α-ketoamine 247. Cyclization of 247 with thioamide 244 was followed by ester hydrolysis 
in order to obtain carboxylic acid 248. 
4.5.3.1 Synthesis of α-Ketoamine 247 
2-Amino-1-(2,4-dimethoxyphenyl)ethan-1-one (247) was readily synthesized by two different 
procedures. In order to prevent intermolecular dimerization of the α-ketoamine it was 
synthesized as the more stable hydrogen chloride. 
Based on the protocol by SUZUKI et al.229,236 activation of 2,4-dimethoxybenzoic acid (249) by use 
of CDI and subsequent conversion of the reactive species with strong bases and methyl 
isocyanate gave oxazole 250 in moderate yields. Decarboxylation of the methyl carboxylate with 
release of carbon dioxide and methanol, and cleavage of the oxazole scaffold under harsh 
reaction conditions gave the appropriate phenacyl ammonium chloride 247. The reaction 
conditions include a strong acidic milieu and reflux temperature (Figure 58). 
 
Figure 58 | Synthesis of α-ketoamine 247 in two steps via an oxazole intermediate .  a) CDI, 
methyl isocyanate, NaHMDS, THF, 12  h rt. b) Conc. HCl/methanol (1:1), 4  h ref lux.  
Due to the only moderate yields of oxazole 250 another synthetic procedure towards the 
α-ketoamine was established: 2,4-dimethoxyphenacyl bromide (237) was transformed quantita-
tively into the appropriate α-ketoamine 247 hydrogen chloride via DELÉPINE reaction237. The 
reaction implies acid-based hydrolysis of quaternary hexamethylenetetramine salt 251 to afford 
primary amines (Figure 59). The intermediate has not been isolated. 
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Figure 59 |  DE LÉ P I NE  synthesis of α -ketoamine 247 .  a) Methenamine,  chloroform, 4  h rt.  b)  Conc. 
HCl/methanol, 3  h reflux.  
4.5.3.2 Cyclization of Phenacyl Ammonium Chloride 247 
The cyclization step of α-ketoamine 247 towards ethyl imidazole-2-carboxylate 246 was again 
performed with thioamide 244238. In contrast to the discussed thiazole synthesis by HANTZSCH 
(chapter 4.5.2.3), the thiol group herein acts as a leaving group instead of a nucleophile. The 
product 246 was obtained in moderate yields upon heating to reflux in an acetate-buffered sys-
tem. A HANTZSCH-similar reaction mechanism can be assumed involving two SN2t reactions, one 
of them an exo-trig cyclization towards a 4,5-dihydro-1H-imidazole (Figure 60). Consequently, 
methylation of the sulfur atom with MEERWEIN’S salt trimethyloxonium tetrafluoroborate239 
(252) increased yields from 35 % to 78 % and reduced the number of by-products: alkylation 
prevented the tautomeric equilibrium and led to enhanced nucleophilicity of the nitrogen and an 
improved leaving group. Thereby, the thiazole group acts first as a nucleophile attacking a me-
thyl group of the alkylation reagent followed by its function as a leaving group during the ring 
formation step. The methylated intermediate 253 has not been isolated. 
 
Figure 60 | Cyclization mechanism of α -ketoamine 247 with thioamide 244 .  R1  = ethyl 
carboxylate; R 2  = 2,4-dimethoxyphenyl.  
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4.5.3.3 Ester Hydrolysis of Ethyl Imidazole-2-carboxylate 246 
Regrettably, all approaches to prepare carboxylic acid 248 by hydrolysis of ethyl ester 246 
exhibited the same problem as discussed for the respective thiazole-2-carboxylic acid 234 
(Figure 61): rapid decarboxylation towards the 2-unsubstitued imidazole derivative 254. 
Although the decarboxylation did not seem to occur quantitatively as observed in the case of the 
thiazole derivative, it was in this case neither possible to isolate the desired product 248 nor the 
by-product 254. 
 
Figure 61 | Ester hydrolysis and subsequent decarboxylation of ethyl imidazole -2-
carboxylate 246 .  R = 2,4-dimethoxyphenyl. a) Aq. NaOH, THF/methanol, 48 h rt.  
4.5.4 Synthesis of Triazole-containing Side Chains 
The idea was to synthesize ethyl 3-(2,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-carboxylate 
(255) in an analog approach by cyclization of 2,4-dimethoxybenzohydrazide (256) and 
thioamide 244. Hydrazide 256 was prepared from 2,4-dimethoxybenzoic acid (249) and 
hydrazine hydrate via the methyl carboxylate in quantitative yields (Figure 62)240. 
Cyclization241 of the hydrazide and thioamide 244, however, could not be performed satisfacto-
ry. Although the desired triazole has been identified in the reaction mixture by mass spectrome-
try, conversion was minimal and isolation of a pure product failed completely. Regarding these 
data, the main product might be the decarboxylated triazole, though this could not be isolated 
either. Based on the observations from thiazole- and imidazole-2-carboxylates regarding decar-
boxylation, this approach has not been pursued any further. 
 
Figure 62 | Synthesis o f 2,4-dimethoxybenzohydrzide 256 .  a) Conc. H2SO4 ,  methanol, 4  h ref lux, 
then N2 H4 ,  30 min rt to reflux. b) 244 ,  optional [(CH3 )2O]BF4 ,  optional DMF or NMP,   h 180 °C.  
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4.6 Syntheses of Series 5: Propiolic Acid 
Synthesis of 3-(2,4-dimethoxyphenyl)propiolic acid (257) was realized in three steps242: prepa-
ration of the appropriate methyl propiolate 258 in two steps by the COREY-FUCHS procedure was 
followed by ester hydrolysis. 
4.6.1.1 COREY-FUCHS Synthesis of Methyl Propiolate 258 
The first step of the COREY-FUCHS reaction is a WITTIG-like one-carbon homologation of 
2,4-dimethoxybenzaldehyde (259) towards the respective 1,1-dibromoalkene 260 in acceptable 
yields (41 %)242. The reactive ylide species is generated in situ from tetrabromomethane (261) 
and triphenylphosphine (262, Figure 63). Subsequently, the ylide carbanion approaches the 
appropriate 2,4-dimethoxybenzaldehyde (151) carbonyl group in a nucleophilic attack generat-
ing a four-membered oxaphosphetane intermediate by [2+2]-cycloaddition. The immense affini-
ty of phosphor and oxygen, however, accounts for instability of the oxaphosphetane which irre-
versibly decomposes into 260 and triphenylphosphine oxide228,235. 
In the second step, treatment with nBuLi at -78 °C initially initiates a bromine/lithium exchange 
at the sterically more hindered position. The α-lithiated bromoalkene anionotropically 
[1,2]-rearranges via the carbenoid by selective movement of the aryl moiety to the alkyne 
α-position in accordance to the FRITSCH-BUTTENBERG-WIECHELL rearrangement. The appropriate 
alkyne is promptly deprotonated by another equivalent of nBuLi. Subsequent addition of methyl 
chloroformate (263) led to propiolate 258 in good yields (87 %) through SN2t reaction of 
lithium acetylide and the electrophile228. 
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Figure 63 | Reaction mechanism of the CORE Y-FU CH S  synthesis of methyl propiolate 258 .  
R = 2,4-dimethoxyphenyl.  
4.6.1.2 Ester Hydrolysis of Methyl Propiolate 258 
Hydrolysis of methyl propiolate 258 was achieved under mild reaction conditions using lithium 
hydroxide at room temperature. Lithium hydroxide is a mild base which has been reported to 
allow safe hydrolysis of less stable compounds243 and has therefore been chosen to afford 257. 
 
Figure 64 | Ester hydrolysis of methyl propiolate 258 .  a) LiOH∙H2O, THF/methanol/water 
(4:1:1), 12 h rt.  
4.6.1.3 Coupling of Propiolic Acid 257 and Building Block 120 
The coupling of 2,4-dimethoxyphenylpropiolic acid (257) and building block 120 has been 
approached through different procedures regarding reaction temperature and coupling 
reagents. As the propiolic acid was assumed to be less stable, the reaction was first performed 
with DCC under 4-DMAP-catalysis at -20 °C and room temperature. QIAN at al. had reported to 
use this protocol for the coupling of phenylpropiolic acid and aniline226. The 2-aminopyridine 
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nucleophile of building block 120, however, is less reactive as pyridine represents an electron 
deficient aromatic scaffold which did not react under these conditions. Further approaches have 
been performed using PyBOP, CDI, HATU, and the activated propioloyl chloride at consecutively 
elevated temperatures. The appropriate propioloyl chloride has been prepared from 257 and 
oxalyl chloride in dichloromethane (DCM) with catalytic amounts of DMF. Conversion to the 
desired carboxamide 264 has been observed between 80 °C and 110 °C by mass spectrometry 
from the reaction mixture. Unfortunately, formation of 264 has always been accompanied by a 
multitude of by-products and was indicated by a shift of color towards intense red. It has not 
been evaluated, though, whether the color indicates successful conversion or degradation. The 
product could not be isolated. 
 
Figure 65 | Coupling of propiolic acid 257  and building block 120 failed in different 
approaches .  At least purif ication could not be performed successfully.  
The consequent idea was to react building block 120 with phosgene (or better its less critical 
analogs diphosgene and triphosgene, respectively) in order to synthesize the appropriate 
carbamic chloride 265. This might be converted with 1,1-dibromoalkene 260 to the desired 
carboxamide 264. The reaction, however, has not been performed to date. 
 
Figure 66 | Retrosynthetic contemplation of propiolic carboxamide 264 .  
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4.7 Syntheses of Series 6: Hybrid Inhibitors 
As discussed in chapter 3.1.5, side chains were adapted from reported Porcn inhibitors IWP-2 
(113) and IWP-4 (114), as well as from approved Bcr-Abl inhibitor imatinib (117). The 
imatinib-hybrid, however, has not been received. All side chains were synthesized in accordance 
to literature procedures210,244. 
4.7.1 Synthesis of IWP-Hybrids 266 and 267 
Preparation of the dihydrothieno[3,2-d]pyrimidin-4-one side chains has been performed in two 
steps following the protocol by BARALDI et al.210,245 from acrylonitrile (268) and methyl 
thioglycolate (269, Figure 67): the MICHAEL adduct 270 reacts in the presence of 
1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU) in methanol through intramolecular exo-dig THORPE-
ZIEGLER-like cyclization to afford methyl 3-amino-4,5-dihydrothiophene-2-carboxylate (271) in 
moderate yields (45 %). 
 
Figure 67 | Reaction mechanism of consecutive M IC HAE L -like addition and THO RPE -Z IE GLE R-like 
cyclization to afford 271 .  
Thienopyrimidines 272 and 273 were obtained by ring closure of enamino ester 271 and 
phenyl isothiocyanates 274 and 275 via thiocarbamide intermediates and intramolecular 
exo-trig cyclization (Figure 68)210,245. Although thin layer chromatography (TLC) and high 
performance liquid chromatography (HPLC) control showed high turnover of starting material 
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into the desired products, purification was tedious and caused rather low yields of 28 % (272) 
and 14 % (273), respectively. 
 
Figure 68 |  Cyclization mechanism of 271 and phenyl isothiocyanates towards thienopyri m-
idines .  274 ,  272:  R = H; 275 ,  273:  R = OCH3 .  
These side chains were attached to building block 120 via a 2-chloroacetyl chloride linker 
(Figure 69)210. An evaluation of suitable reaction conditions was performed starting from 
2-amino-4-methylpyridine (126): SN2t reaction with the linker gave 2-chloro-N-(4-
methylpyridin-2-yl)acetamide (276) which was coupled with aniline in a first attempt, and with 
thienopyrimidine 272 in a second to give 277y and 278z, respectively (Figure 69). 
                                                             
y 277 = N-(-methylpyridin-2-yl)-2-(phenylamino)acetamide 
z 278 = N-(4-methylpyridin-2-yl)-2-((4-oxo-3-phenyl-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)acetamide 
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Figure 69 | Synthesis of hybrid inhibitors 266, 267 .  266:  R = H; 267:  R = OCH3 .  a) Chloroacetyl  
chloride, Et3N, DCM, 12 h rt .  b) Aniline, Et3N, DMF, 2 h 80 °C. c) 272  or 273 ,  Et3N, DMF, 2 h 80 °C. 
Yield: 59 % (266) , 76 % (267) .  
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4.7.2 Synthesis of Imatinib-Hybrid 280 
4-((Methylpiperazin-1-yl)methyl) benzoic acid (281) was synthesized from 4-(bromo-
methyl)benzoic acid (282) and N-methylpiperazine following the procedure by MACDONALD et 
al.244. Thereby, formation of the by-product 1,4-bis(4-carboxybenzyl)-1-methylpiperazin-1-ium 
chloride (283) has been observed, but could largely be oppressed by adding the piperazine 
component in one portion (Figure 71). 
Unfortunately, amide coupling approaches of 281 and building block 120 initially failed. Besides 
the moderate nucleophilicity of the 2-amino-pyridine moiety of 120, the ampholytic character of 
281 has to be regarded responsible: in solution the equilibrium is shifted by an intramolecular 
protonation towards the carboxylate (Figure 70) with reduced carbonyl reactivity which is 
rather insensitive for activation and amide coupling. 
 
Figure 70 | Ampholytic character of 281 in pH neutral solution .  
Even adaptation of the reaction for microwave synthesis in accordance to the protocol by 
JOHANNES229 did not initiate product formation. Finally, HATU-mediated conversion into the 
desired amide has been observed by mass spectrometry from the reaction mixture upon an 
exchange of solvent from DMF towards NMP, though in rather low percentage (approx. 11 %, 
HPLC). Regrettably, the product could not be isolated and 280 has not been obtained purely. 
 
Figure 71 | Synthesis of hybrid inhibitor 280 .  a) N-Methylpiperazine, n-butanol, 2  h rt.  283  has 
been isolated as a by-product. b) 120 ,  HATU, DIPEA, NMP, 30  min rt then 30 min 90 °C (100 W). 
280  has not been isolated purely.  
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4.8 Sulfoxidation of Selected Compounds 
Sulfoxides are most likely to represent the main metabolites (cp. chapter 3.1.2). Therefore, 
oxidation of several sulfide compounds has been performed in accordance to PEIFER et al. using 
Oxone® (potassium peroxymonosulfateaa, 284) as the oxidant176. Oxidation by Oxone® 
combines a catalyst-free and environmental friendly (green) procedure with synthetic 
advantages such as high yield and purity, high sensitivity, and easy handling246,247. Although the 
inclination towards overoxidation is less pronounced than for other reagents, the reaction 
conditions need to be accurately controlled: Oxone® also oxidizes sulfides to the respective 
sulfones consuming two equivalents of oxidant (Figure 72), though the reaction can be 
quenched on the sulfoxide level. Consequently, strict monitoring of the reaction progress is 
inevitable. Nevertheless, the sulfone is obtained as a by-product in low percentage. 
 
Figure 72 | Postulated reaction mechanism of sulfide oxidation using Oxone® .  
Several selected compounds from different series have been oxidized following the mentioned 
protocol with Oxone® in a mixture of THF and water at 0 °C and room temperature. The 
reaction time typically ranged from 30 min to 2 h, dependent on the amount of sulfide. Hybrid 
inhibitors (series 6) have not been included as oxidation of the thienopyrimidine sulfur atom has 
to be expected. The selected compounds, products, and appropriate yields are given in Table 21. 
Low yields are rather due to critical purification than uncomplete conversion. 
                                                             
aa Oxone® = triple salt (2 KHSO5∙KHSO4∙K2SO4)246 
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Table 21 | Sulfoxidation of selected compounds .  R = 4-fluorophenyl.  Products are assigned to 
the appropriate series 1 , 2,  3,  and 4.  Test compound 160  does not belong to any series.  
Start .  = starting material.  
 # Start. # Product Product structure Yield (%) 
     
 160 285 
 
75 
     
1 
162 82 
 
47 
    
149 84 
 
82 
    
150 85 
 
39 
     
2 
190 102 
 
93 
    
191 103 
 
26 
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3 
204 104 
 
22 
    
206 286 
 
61 
    
208 287 
 
72 
    
209 288 
 
75 
    
210 289 
 
73 
    
212 290 
 
70 
    
4 231 291 
 
88 
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4.9 Photochemical π6a-Electrocyclization of Diaryl-imidazoles 
The caging concept of active compounds using photo-cleavable protecting groups is well-
established in our working group. Consequently, the potential suitability of 4,5-diaryl-imidazoles 
was evaluated by ultraviolet (UV) irradiation of 162 in THF with a wavelength of 365 nm 
(Figure 73). Thereby it has been found that the concept is not applicable for this class of inhibi-
tors: interestingly, 162 underwent a π6a-electrocyclization reaction towards the appropriate 
tetracyclic planar system 292. In fact, conversion was higher than 24 %, but purification signifi-
cantly lowered yields. Similar reactions have been reported for structurally related compounds 
leading to Janus kinase (JAK) inhibitors212, though 292 has not been biologically tested. 
 
Figure 73 | Photochemical π6a-electrocyclization of 162 .  a) THF, 2 min 365 nm (5.4 W).  
Mechanistically, the π6a-electrocyclization follows the orbital-symmetry-based WOODWARD-
HOFFMANN rules for pericyclic reactions (Figure 74)235. The conjugated system involved in the 
photochemical cyclization comprises six π-electrons (π6). In accordance to the rules the reaction 
is permitted as the sum of the participating (4q + 2)-components is uneven. By antarafacial (a) 
rotation of the terminal orbitals about 90° a new molecule orbital and thereby the respective 
σ-bond is formed. 
 
Figure 74 | WOO DWA R D-HO FF MA N N-based photochemical π6a -electrocyclization mechanism of 
162 .  
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The photochemically-induced conrotatory reaction (antarafacial rotation) inevitably affords the 
trans-product with respect to the hydrogens in question (Figure 75). In the presence of 
atmospheric oxygen or other oxidants, however, the dihydro-intermediate 293 oxidatively 
strives for an aromatic system leading to 292. Intermediate 293 has not been isolated. 
 
Figure 75 | Reaction mechanism of π6a-electrocyclization towards 292 .  Dihydro-intermediate 
293  is initially oxidized in the presence of atmospheric oxygen.  
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5 Results and Discussion 
The identification of CK1δ as an important determinant in the progression of various severe 
diseases has made it an attractive target for both therapeutic approaches and ongoing 
research9,119,166. Consequently, isoform-specific CK1 inhibitors are pursued with increasing 
interest. In the scope of this dissertation, 38 newly designed and synthesized CK1δ inhibitors 
arranged in five series (1, 2, 3, 4, 6) have been implemented in biological characterization. All 
compounds are based on lead structure 12 and its non-sulfoxidized derivative 11, originally 
deriving from p38α MAPK inhibitors, and were classified as ATP-competitive type I binders176. 
Biological evaluation has been performed in collaboration with the group of PROF. DR. UWE 
KNIPPSCHILD (Department of General and Visceral Surgery, Ulm University Hospital, Germany) by 
MARC KRÜGER248 and CHIARA IANES249, or results were acquired commercially from ProQinase 
GmbH (Freiburg, Germany). The newly synthesized small molecule inhibitors were initially 
screened in kinase assays on CK1δ and CK1ε, complemented by screenings against CK1α, CK1γ3, 
and p38α for several compounds. Their activity in cell culture has been evaluated using different 
human cancer cell lines. The most promising compound 191 has additionally been screened 
over a panel of 321 protein kinases by ProQinase GmbH in order to identify potential off-targets. 
It has further been co-crystallized by the group of PROF. DR. DANIEL RAUH (Institute of Chemical 
Biology, Dortmund University of Technology, Germany) with p38α which should be considered 
the main off-target of the current teardrop-like inhibitor class. Moreover, crystallization of 224 
and 266 in CK1δ and CK1ε has also been performed by the group of PROF. DR. ULRICH BAUMANN 
(Department for Chemistry, University of Cologne, Germany). 
5.1 Characterization of Series 1 
Kinase Assays 
The compounds of series 1 are lacking the carbonyl group and the π-bond of 11 and 12 leading 
to complete sp2 hybridization of the side chain linker atoms. Structurally, these molecules 
resemble early ATP-competitive p38α MAPK inhibitors developed by LAUFER et al.197,202,213. In 
order to investigate their biological activity they were assayed at 10 µM in the presence of 
100 µM ATP against CK1 isoforms δ, ε, α, and γ3 as well as p38α. The measurement thereby 
referred to the normalized residual phosphorylation activity of the respective kinase using 
GST-p53 fragment (aa 1-64), α-casein, or GST-CK1δ fragment (aa 305-375) as substrates248,249. 
The results of these initial screens are shown in Figure 76. 
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Figure 76 | Inhibition of CK1 isoform and p38α kinase activity by inhibitors of series 1 at a 
concentration of 10 µM .  Compounds 148-155 ,  84 ,  85  have been biologically  evaluated in kinase 
assays against CK1δ, CK1ε,  CK1α, CK1γ3 ,  and p38α. Compounds 162 ,  82 ,  164  have only been tested 
against CK1δ and CK1ε.  GST-p53 fragment (aa 1-64) (CK1δ, ε , α) , α -casein (CK1γ3), or GST-CK1δ 
fragment (aa 305-375) (p38α) have been used as substrate .  The inhibitors were screened in tripl i-
cate measurement in the presence of 100 µM  ATP. Residual activities were  normalized to DMSO. 
Error bars indicate the standard error of the mean (SEM) 2 4 8 , 2 4 9 .  
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As expected, the initial screenings identified compounds of series 1 as dual-specific inhibitors of 
CK1δ and p38α. Although CK1 isoforms α and γ3 were only slightly affected, the inhibitors did 
not significantly discriminate between CK1δ and CK1ε. At an assay concentration of 10 µM the 
most efficient inhibition of CK1δ has been observed for compound 150, reducing the residual 
kinase activity of CK1δ and CK1ε to approximately 9 % and 16 %, respectively, followed by 
compounds 151 (10 % and 12 %), 162 (13 % and 36 %), and 164 (14 % and 39 %). Among all 
compounds of series 1, 162 and 164 also exhibited the strongest isoform-preferring potential as 
inhibition of CK1ε was approximately threefold less pronounced in comparison to CK1δ. Conse-
quently, half maximal inhibitory concentration (IC50) values have been determined for 150, 151, 
and 164 in order to validate their isoform-specificity (Figure 77). Compound 162 has not been 
considered as it had already been characterized by LAUFER et al. as a p38α inhibitor with moder-
ate potency (IC50 = 139 nM)197. 
 
Figure 77 | IC5 0  determination of series 1 compounds 150, 151, and 164 .  IC 5 0  values have been 
determined using CK1δ or CK1ε and α -casein as substrate. Error bars indicate the SEM 2 4 8 , 2 4 9 .  
IC50 determination of these compounds exhibited both moderate potency and isoform-specificity 
regarding CK1δ and CK1ε. While 150, 151, and 164 showed half maximal inhibition of CK1δ at 
644 nM, 344 nM, and 386 nM, respectively, CK1ε activity was approximately five-fold less effec-
tive inhibited by 150 (IC50 = 3323 nM) and 151 (IC50 = 1753 nM), and even 17-fold by 164 
(IC50 = 6731 nM), highlighting especially the latter for further optimization. With respect to their 
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IC50 values 151 and 164 are comparable with the well-known inhibitor D4476 (8, CK1δ 
IC50 = 0.3 µM)173. 
Although molecular modeling-based affinity prediction within HRII of CK1δ is rather error-
prone due to the flexibility of the domain, 150, 151, and 164 were among the best hits from 
computational screenings with nearly equivalent scoring (cp. Table 22). Modeling even predict-
ed 151 to be the most potent inhibitor of series 1, though the order of 150 and 164 has been 
inverted. Nevertheless, these results provide a first proof of concept for the applicability of the 
computational model as in silico and in vitro approaches generated comparable results. 
Table 22 | IC5 0  values and Glide scores of compounds 150, 151, and 164 2 4 8 , 2 4 9 .  
# Structure Glide Score (CK1δ) IC50 (nM) 
150 
 
-14.2 
644 (CK1δ) 
3323 (CK1ε) 
n.d. (p38α) 
151 
 
-14.7 
344 (CK1δ) 
1753 (CK1ε) 
n.d. (p38α) 
164 
 
-13.7 
386 (CK1δ) 
6731 (CK1ε) 
n.d. (p38α) 
 
Structurally, these results point towards side chains including aryl moieties, presumably 
methoxy-substituted phenyls, which are attached to the pyridine-2-amine of 120 by an n-ethyl 
or n-propyl linker. Interestingly, compound 164 which is the most promising inhibitor of series 
1 regarding its isoform-preferring potential, represents the “sp3 derivative” of non-oxidized lead 
structure 11 considering the carbon atoms of the side chain linker. Consequently, this structural 
element can be assumed to be an important determinant for isoform-specificity. Sulfoxidation of 
compounds 149, 150, and 162 leading to 84, 85, and 82 significantly reduced efficacy for CK1δ 
while the effect on CK1ε seemed to be less pronounced. However, the efficacy for p38α has 
apparently not been affected by sulfoxidation (cp. Figure 76). 
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Cellular Assays 
Intending to provide evidence for beneficial physicochemical parameters, the efficacy of several 
compounds has been evaluated in cellular assays using different human cancer cell lines. The 
increasing molecular weight and the often lipophilic character of kinase inhibitors is readily 
accompanied by a loss of cell permeability and solubility, leading to poor efficacy in cellular 
systems. 
In order to determine their effect on cell viability compounds of series 1 have been implemented 
in colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays at a 
concentration of 20 µM, 10 µM (162, 82), or 25 µM (164) using the CK1-dependent human colo-
rectal adenocarcinoma epithelial cell line HT-29248,249. 
 
Figure 78 | Cell viability of HT -29 cells after treatment with series 1 compounds  at concen-
trations of 10 µM ,  20 µM ,  or 25 µM .  The inhibitors were screened in triplicate measurement. Cell 
viability was normalized to mock . Error bars indicate the SEM 2 4 8 , 2 4 9 .  
The initial screens indicated compounds 151 and 148 to be the most promising candidates of 
series 1 in HT-29 cells. At 20 µM they significantly reduced viability to approximately 22 % and 
31 %, respectively. 164, however, has also been observed to be active in cells, though not potent, 
leading to cell viability of approximately 61 % at 25 µM. In general, the overall efficacy of the 
tested compounds in the cellular system was rather low but significant with the exception of 
compound 82 that did not seem to affect cell viability at 10 µM. The results of these screens are 
shown in Figure 78. 
In addition, the half maximal effective concentration (EC50) has been determined for 151 to vali-
date the inhibitory effect on HT-29 cells (Figure 79)248. The inhibitor exhibited an EC50 value in 
the high single-digit micromolar range (EC50 = 9.3 µM) revealing the necessity of further optimi-
zation in order to enhance cell penetration and to gain applicability as a biological tool. 
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Figure 79 | EC5 0  determination of compound 151 in HT-29 cells .  Error bars indicate the SEM 2 4 8 .  
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5.2 Characterization of Series 2 
Kinase Assays: IC50 Determination 
Series 2 compounds were conceptually derived from lead structure 12 and its non-sulfoxidized 
derivative 11 by deletion of the potentially reactive π-bond (MICHAEL acceptor). Furthermore, 
190 and derivatives (series 2) were hypothetically obtained by introduction of a carbonyl 
function at the α-methylene group of secondary amine 164. Consequently, the design of series 2 
should be considered an optimization of series 1 compounds. In addition, structure-activity 
relationship data were gained by consecutively varying the methoxy substitution pattern of the 
terminal phenyl moiety. Their biological activity has been evaluated in kinase assays against 
CK1δ and CK1ε at 10 µM in the presence of 10 µM ATP. 190, 191, and 103 have additionally been 
assayed against CK1α. The assays have been performed using α-casein as substrate248,249. 
The compounds exhibited excellent inhibition of CK1δ reducing the residual activity below 5 % 
in all cases (Figure 80). In addition, all compounds effectively inhibited CK1ε, although less 
potently. Especially sulfoxidation of 191 leading to 103 seemed to increase isoform-specificity 
regarding CK1δ and CK1ε. Interestingly, sulfoxide 103 also exhibited enhanced potency for 
CK1α compared to non-oxidized 191. Both 190 and 191 were significantly less active against 
CK1α.  
In order to validate their inhibitory potential of CK1 isoforms δ and ε IC50 values have been 
determined for all compounds (Figure 81). The assayed inhibitors of series 2 exhibited IC50 
values in the low nanomolar range for CK1δ indicating high affinity and potency with the most 
promising compound being 191 (CK1δ IC50 = 4 nM, CK1ε IC50 = 25 nM). Regarding inhibition of 
CK1ε, isoform-specificity was rather low as 192 possessed the highest isoform-discriminating 
effect with IC50 values of 20 nM (CK1δ) and 233 nM (CK1ε), respectively. Unfortunately, the 
promising discrimination by 103 observed in the initial screens could not be confirmed. 
As 191 was the most active compound IC50 values have commercially been obtained for CK1δ 
and p38α from ProQinase GmbH revealing a ten-fold preference for CK1δ (CK1δ IC50 = 1 nM, 
p38α IC50 = 10 nM). The IC50 value for CK1δ, however, is an extrapolated result as it was outside 
the concentration range, though it was at least < 3 nM in their assays. These results also 
identified the limits of the present computational model as the in silico generated Glide scores 
did not adequately correlate with the biological data. Apparently, the utilized molecular 
modeling approaches were not suitable to predict the influence of sulfoxidation and varying 
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methoxy substitution patterns in HRII. The in vitro determined IC50 values and in silico received 
Glide scores are summarized in Table 23. 
 
Figure 80 | Inhibition of CK1 isoform kinase activi ty by inhibitors of series 2 at a concentra-
tion of 10 µM .  Compounds 190-194 ,  102 ,  103  have been biologically evaluated in kinase assays 
against CK1δ and CK1ε. Compounds 190 ,  191 ,  103  have additionally been tested against CK1α. 
α-Casein has been used as substrate . The inhibitors were screened in triplicate measurement in the 
presence of  10 µM  ATP. Residual activities were  normalized to DMSO. Error bars indicate 
SEM2 4 8 , 2 4 9 .  
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Figure 81 | IC5 0  determination of series 2 compounds 190 -194, 102, and 103 .  IC5 0  values have 
been determined using CK1δ or CK1ε and α -casein as substrate . Error bars indicate the SEM 2 4 8 , 2 4 9 .  
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Table 23 | IC5 0  values and Glide scores of series 2 compounds 2 4 8 , 2 4 9 .  
# Structure Glide Score (CK1δ) IC50 (nM) 
190 
 
-13.8 
20 (CK1δ) 
129 (CK1ε) 
n.d. (p38α) 
 
102 
 
-14.7 
93 (CK1δ) 
499 (CK1ε) 
n.d. (p38α) 
 
191 
 
-13.6 
4 (CK1δ) 
25 (CK1ε) 
< 3 (CK1δ)PQ 
10 (p38α)PQ 
 
103 
 
-14.2 
87 (CK1δ) 
573 (CK1ε) 
n.d. (p38α) 
 
192 
 
-13.7 
20 (CK1δ) 
233 (CK1ε) 
n.d. (p38α) 
 
193 
 
-14.3 
14 (CK1δ) 
91 (CK1ε) 
n.d. (p38α) 
 
194 
 
-13.6 
27 (CK1δ) 
204 (CK1ε) 
n.d. (p38α) 
 
PQ IC50 value has been determined by ProQinase GmbH. 
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Regarding SAR methoxyphenyl-substituted propionic acid side chains proved beneficial in order 
to gain potency. Thereby, differently dimethoxyphenyl-substituted derivatives exhibited similar 
IC50 values in the low double-digit nanomolar range with the exception of 2,5-dimethoxyphenyl-
possessing 191 which showed significantly enhanced activity. In principle, dimethoxyphenyl 
substitution was slightly favored over one appropriate trimethoxy substitution pattern (194). 
All compounds of series 2 represented potent inhibitors of CK1δ, though only slightly 
discriminating the ε isoform. 191 reaches the inhibitory potential of lead compound 12 (CK1δ 
IC50 = 11 nM, CK1ε IC50 = 447 nM) and its non-oxidized derivative 11 (CK1δ IC50 = 5 nM, CK1ε 
IC50 = 73 nM)176 and is therefore among the most potent CK1δ inhibitors published to date. As 
expected, removal of the potential MICHAEL acceptor of 12 led to chemical stability of the 
inhibitors. Introduction of the carbonyl group starting from compounds 150 (CK1δ 
IC50 = 644 nM, CK1ε IC50 = 3323 nM) and 164 (CK1δ IC50 = 386 nM, CK1ε IC50 = 6731 nM) towards 
193 (CK1δ IC50 = 14 nM, CK1ε IC50 = 91 nM) and 190 (CK1δ IC50 = 20 nM, CK1ε IC50 = 129 nM) led 
to increased potency for CK1δ by 157- and 20-fold, respectively. CK1ε was inhibited 37- and 
52-fold more potently. Considering this enormous increase of potency upon introduction of the 
carbonyl function as well as the reported benefit on metabolic stability200, the appropriate amide 
group should be considered mandatory for further approaches. Interestingly, sulfoxidation of 
190 and 191 which favored CK1δ by approximately seven- and six-fold did not significantly 
affect isoform-specificity (102: five-fold, 103: seven-fold). This was unexpected as oxidation of 
11 (fifteen-fold) towards lead 12 strongly increased the CK1δ-preference to approximately 
41-fold indicating the π-bond of 12 to be a potential determinant for selectivity but not potency. 
Kinase Assays: Selectivity Profiling 
In order to investigate 191 regarding kinase selectivity the inhibitor has been screened over a 
panel of 320 wild-type protein kinases and B-Raf V600E by ProQinase GmbH. The assays 
revealed good specificity for CK1δ hitting only five additional kinases (residual kinase 
activity ≤ 50 %) apart from CK1 isoforms δ, ε, and α at a concentration of 100 nM (Figure 82). 
Among them was unsurprisingly p38α, but also highly related c-Jun N-terminal kinases 2 and 3 
(JNK2, JNK3), lymphocyte-specific protein tyrosine kinase (LCK), and Receptor-interacting 
serine/threonine-protein kinase 2 (RIPK2). Potent inhibition with residual activities below 
20 %, however, has only been observed for CK1δ (residual activity = 3 %) and CK1ε (residual 
activity = 7 %). JNK3 (residual activity = 37 %) and RIPK2 (residual activity = 45 %) were 
inhibited less potently while CK1α (residual activity = 26 %), p38α (residual activity = 22 %), 
JNK2 (residual activity = 21 %), and LCK (residual activity = 26 %) exhibited reduced residual 
kinase activities between 20 % and 30 %. The inhibited enzymes were predominantly Ser/Thr-
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specific kinases deriving from three distinct superfamilies (CK1, CMGC, TKL) with the exception 
of LCK (TK) which selectively phosphorylates tyrosine residues. Fortunately, CK1γ3 showed 
only weak inhibition (residual activity = 73 %) while isoforms γ1 (residual activity = 100 %) and 
γ2 (residual activity = 91 %) nearly remained unaffected. Residual kinase activities of the 
complete screening are given in Supplementary Table 1. Regarding the determined IC50 value 
of 4 nM, 191 represents a highly specific inhibitor of CK1δ and CK1ε with an overall selectivity 
(residual activity < 50 %) score of 0.027. 
 
Figure 82 | Schematic representation of the selectivity profile of 191  at a concentration of 
100 nM .  The inhibitor has been screened over a panel of 320 wild -type protein kinases and B -Raf  
V600E by ProQinase GmbH. The phylogenetic tree is taken from MA N NI N G  et al .5 .  
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Cellular Assays 
The efficacy of series 2 inhibitors in cellular assays was initially evaluated at 10 µM using the 
CK1-dependent human pancreatic adenocarcinoma cell lines Colo357 and Panc89 (Figure 
83)248,249.  
 
Figure 83 | Cell viability of Colo357 and Panc89 cells after treatme nt with series 2 com-
pounds at a concentration of 10 µM .  The inhibitors were screened in triplicate measurement. Cell 
viability was normalized to mock. Error bars indicate the SEM 2 4 8 , 2 4 9 .  
The assays identified 191, 192, 193, and 194 as rather potent inhibitors of cell viability in both 
cell lines, while 190 as well as sulfoxides 102 and 103 did not reveal significant efficacy in 
Colo357 cells. In Panc89 cells, however, weak but significant inhibition by 190 and 102 was 
observed while the effect mediated by 103 was comparable to 191-194 indicating cell line- or 
tumor entity-dependent inhibition. Furthermore, the 2,4-dimethoxyphenyl substitution pattern 
of 190 and 102 seems to negatively influence cellular efficacy. In order to further examine this 
effect, 190 was screened over the tumor cell lines Colo357, Panc-1, and MiaPaca-2 at 15 µM249. 
The results of these screens are shown in Figure 84. 
 
Figure 84 |  Cell viability of Colo357, Panc -1, and MiaPaca-2 cells after treatment with 190 at 
a concentration of 15 µM .  The inhibitor was screened in quadruplicate measurement. Cell viabi l-
ity was normalized to mock. Error bars indicate the SEM 2 4 8 , 2 4 9 .  
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Interestingly, cell viability was reduced to similar extents in Colo357 and Panc-1 cells while the 
MiaPaca-2 cell line showed enhanced sensitivity for the inhibitor. 
As 191 was the most promising probe of series 2 its efficacy has been validated by EC50 deter-
mination in CK1-dependent Colo357 and Panc89 cells (Figure 85). MTT assays revealed EC50 
values in the low single-digit micromolar range (Colo357 EC50 = 3.5 µM, Panc89 EC50 = 1.5 µM) 
indicating significant improvement in efficacy starting from series 1. The different EC50 values 
also promote the thesis of cell line specific inhibition. 
 
Figure 85 | EC5 0  determination of compound 191 in Colo357 and Panc89 cells .  Error bars indi-
cate the SEM2 4 8 .  
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X-ray Crystallography 
The biological evaluation identified chemically stable compound 191 as a potent and specific 
inhibitor of CK1δ, CK1ε, and p38α. Consequently, the exact binding mode in these kinases ought 
to be examined by X-ray crystallography in cooperation with PROF. DR. DANIEL RAUH and PROF. DR. 
ULRICH BAUMANN. Unfortunately, co-crystallization of 191 with CK1δ and CK1ε has not been 
successful to date. Nevertheless, the binding pose in p38α has been revealed (Figure 86). 
 
Figure 86 | Binding mode of 191 in p38α MAPK .  Binding mode revealed by X-ray crystallography 
(A) in comparison to the in s ilico  model (B). The DFG Phe169 occupies different conformations:  
DFG-out (A), DFG-in (B) . The propionic acid side chain has not been completely resolved by X-ray 
analysis (A).  Modeling (B) refers to PDB code 1BMK 1 9 5 .  π-π-stacking is indicated by a violet dashed 
line. X-ray analysis has been performed by the group of PROF .  DR .  DA NI E L RAUH .  
X-ray crystallographic analysis and molecular modeling revealed highly similar binding poses 
for 191 in p38α MAPK. The 4-fluorophenyl moiety penetrates into HPI lined by the gatekeeper 
Thr106. The 2-aminopyridine acts as a bidentate hinge-binder forming two H-bonds with 
Met109. Lys53 donates another H-bond accepted by the imidazole nitrogen of 191. The 
propionic acid side chain is situated in HRII which is significantly less spacious compared to 
CK1δ and CK1ε. Therefore, the side chain has not completely been resolved by X-ray analysis 
indicating high flexibility of the moiety in this domain. The major difference between in silico 
model and crystallographic data referred to the conformation of the DFG motif at the junction of 
the activation-loop (A-loop). Molecular modeling of p38α has been performed based on a crystal 
structure including the structurally similar teardrop-like inhibitor 34 (PDB code 1BMK)195. 
Binding of 34 to p38α obviously retained the DFG-in conformation of the kinase (type I 
inhibition). Co-crystallization of p38α and 191, however, revealed that the inhibitor initiates 
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rotation of the Phe169 residue out of its hydrophobic deep pocket (DFG-out). The DFG-out-like 
conformation is stabilized by π-π-stacking interaction between Phe169 and the imidazole ring of 
191 gaining additional binding affinity. Consequently, the obtained DFG-out-like crystal 
structure has been aligned to a published DFG-out conformation of p38α (Figure 87). 
 
Figure 87 | Protein alignment of the obtained crystal structure of 191 in p38α with published 
DFG-in and DFG-out conformations of the kinase .  Rotation of Phe169 from the active DFG -in 
(turquoise, PDB code 1BMK) 1 9 5  towards the DFG-out conformation (yellow, PDB code 1WBT) 2 5 0  
permits access to the deep pocket. The obtained crystal structure (violet) exhibits a  conformation 
halfway between DFG-in and DFG-out. Fitting of 191  (green) into the DFG-out state of the kinase 
might be forestalled by steric clashes (bad contacts, red da shed lines).  
The alignment revealed that 191 actually stabilizes a conformation halfway between active 
DFG-in and inactive DFG-out state of the kinase (DFG-half-out). Rotation of Phe169, however, 
seemed sufficient in order to permit access to the deep pocket, although this cavity is not 
addressed by the inhibitor. X-ray analysis thereby provided strong evidence that 191 might 
rather be a type I ½-like inhibitor of p38α, whereas it is in fact likely that the ligand is able to 
bind both DFG-in and DFG-half-out conformation. Regarding the DFG-out state steric clashes 
between inhibitor and Phe169 can be assumed to forestall fitting. The shift between active and 
inactive conformation could further explain the non-correlating results from p38α-based Glide 
scoring and in vitro obtained data. 
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5.3 Characterization of Series 3 
Kinase Assays 
The crystallographic data gained by co-crystallization of 191 and p38α supported the thesis 
assuming beneficial effects on selectivity by rigidification side chains addressing HRII. Conse-
quently, the sp2-hybridized planar carbamide linker of series 3 compounds was suggested to 
forestall adjustment to the restricted HRII of p38α while the equivalent domain in CK1δ is more 
spacious and planar. The carbamide group might further enable a third H-bond towards hinge 
residue Leu85 (CK1δ) leading to strengthened ligand-receptor binding. It has to be noted, 
though, that the effect of additional H-bonds is often not reliably predictable and requires in 
vitro evaluation191. Therefore, compounds 204-206, 208-210, 212, 104, and 286-290 have 
been screened at 10 µM against CK1δ and CK1ε in the presence of 10 µM ATP. 204, 104, 206, 
286, 209, 210, and 212 have additionally been tested against CK1α (Figure 88)248,249. 
The initial screenings showed effective reduction of CK1δ residual kinase activity only slightly 
less potent than compounds of series 2. In addition, especially 104 but also 204, 209, and 210 
exhibited promising isoform-specificity over CK1ε. CK1α was overall less potently inhibited. 
Subsequent IC50 determination has been performed to validate the effect of promising 
compounds 204, 104, 205, 206, 209, and 210 on CK1 isoforms δ and ε (Figure 89)248,249. IC50 
values stretching across the low double-digit to the low triple-digit nanomolar range identified 
the appropriate carbamides as rather potent or moderate inhibitors that slightly prefer CK1 
isoform δ. Interestingly, dimethoxyphenyl-substituted carbamides 204 (CK1δ IC50 = 19 nM, CK1ε 
IC50 = 227 nM) and 205 (CK1δ IC50 = 31 nM, CK1ε IC50 = 186 nM) represented the most promising 
derivatives of series 3 indicating again the dimethoxy substitution pattern to be positively suited 
to fit in HRII of CK1δ. In addition, 204 exhibited the strongest isoform-specificity by twelve-fold 
among this series. As observed before, sulfoxidation significantly reduced potency without 
positive gains in selectivity in most cases. In fact, only 289 (CK1δ IC50 = 88 nM, CK1ε 
IC50 = 623 nM) showed enhanced properties compared to its non-oxidized derivative 210 (CK1δ 
IC50 = 169 nM, CK1ε IC50 = 498 nM) while conversion of 204 towards the appropriate sulfoxide 
104 (CK1δ IC50 = 153 nM, CK1ε IC50 = 910 nM) was accompanied by losses of both potency and 
specificity. The naphthyl-substituted carbamide 290 (CK1δ IC50 = 48 nM, CK1ε IC50 = 182 nM) 
displayed another promising scaffold that was rather potent despite sulfoxidation. 
Unfortunately, an IC50 value for its non-oxidized derivative 212 has not been determined. 
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Figure 88 | Inhibition of CK1 isoform kinase activity by inhibitors of series 3 at a 
concentration of 10 µM .  Compounds 204-206 ,  208-210 ,  212 ,  104 ,  and 286-290  have been 
biologically evaluated in kinase assays against CK1δ and CK1ε. Compounds 204 ,  104 ,  206 ,  286 ,  
209 ,  210 ,  and 212  have additionally been tested against CK1α. α -Casein has been used as 
substrate . The inhibitors were screened in triplicate measurement in the presence of 10  µM  ATP. 
Residual activities were  normalized to DMSO. Error bars indicate the SEM 2 4 8 , 2 4 9 .  
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Figure 89 | IC5 0  determination of series 3 compounds 204, 205, 208-210, 104, and 287-290 .  
IC5 0  values have been determined using CK1δ or CK1ε and α -casein as substrate . Error bars 
indicate the SEM 2 4 8 , 2 4 9 .  
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The enormous predicted affinities indicated by Glide scores ranging from -17.1 for compound 
104 to -12.5 for compound 208 (Table 24), however, have not been confirmed as 191 (Glide 
score = -13.6) was still the most effective inhibitor characterized so far. It might be possible, 
though, that physicochemical parameters such as limited solubility of the carbamides restrained 
their theoretical potency. Regarding the effect of rigidification on inhibition of p38α, 204 has 
been submitted to ProQinase GmbH for further IC50 determination. The assays showed values in 
the low double-digit nanomolar range for CK1δ (IC50 = 10 nM) and p38α (IC50 = 28 nM) assuming 
carbamides to be inept to initiate selectivity in this context. Nevertheless, especially 204 proved 
promising in order to discriminate CK1 isoforms and might therefore be worth optimizing. 
Table 24 | IC5 0  values and Glide scores of series 3 compounds 2 4 8 , 2 4 9 .  
# Structure Glide Score (CK1δ) IC50 (nM) 
204 
 
-16.6 
19 (CK1δ) 
227 (CK1ε) 
10 (CK1δ)PQ 
28 (p38α)PQ 
104 
 
-17.1 
153 (CK1δ) 
910 (CK1ε) 
n.d. (p38α) 
205 
 
-17.0 
31 (CK1δ) 
186 (CK1ε) 
n.d. (p38α) 
208 
 
-12.5 
47 (CK1δ) 
272 (CK1ε) 
n.d. (p38α) 
287 
 
-15.8 
160 (CK1δ) 
804 (CK1ε) 
n.d. (p38α) 
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209 
 
-15.7 
35 (CK1δ) 
203 (CK1ε) 
n.d. (p38α) 
288 
 
-15.7 
115 (CK1δ) 
764 (CK1ε) 
n.d. (p38α) 
210 
 
-14.8 
169 (CK1δ) 
498 (CK1ε) 
n.d. (p38α) 
289 
 
-14.3 
88 (CK1δ) 
623 (CK1ε) 
n.d. (p38α) 
290 
 
-15.6 
48 (CK1δ) 
182 (CK1ε) 
n.d. (p38α) 
PQ IC50 value has been determined by ProQinase GmbH. 
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Cellular Assays 
The inhibitors of series 3 were screened in cellular assays at a concentration of 10 µM using the 
discussed human pancreatic adenocarcinoma cell lines Colo357 and Panc89 in order to evaluate 
their cellular efficacy (Figure 90)248,249. 
 
Figure 90 | Cell viability of Colo357 and Panc89 cells after treatment with series 3 co m-
pounds at a concentration of 10 µM .  The inhibitors were screened in triplicate or quadruplicate 
measurement. Cell viability was normalized to mock.  Error bars indicate the SEM 2 4 8 , 2 4 9 .  
The majority of series 3 derivatives reduced cell viability rather weakly, indicating poor cell 
penetration which is presumably due to their unfavorable physicochemical properties such as 
solubility. Nevertheless, especially compounds 206 and 104, followed by 205 and 204, 
exhibited promising effects as they reduced metabolic activity at best (206) below 20 % in both 
cell lines. Fortunately, these results excellently fit with the previous findings as all four of them 
represent methoxyphenyl-substituted carbamides. In general, Panc89 cells seemed more 
sensitive to treatment with small molecule kinase inhibitors than Colo357 cells. 
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5.4 Characterization of Series 4 
Kinase Assays 
The intention of series 4 compounds was to enhance selectivity by rigidification of side chains 
and conservation the (E)-configured π-bond of lead structure 12 within 4-(dimethoxyphenyl)-
substituted pyrroles. Especially p38α was assumed to be less potently inhibited by compounds 
232, 291, and 224 as bulky side chains have been reported to negatively affect fitting into the 
p38α ATP-pocket198. The inclusion of the discussed π-bond of 12 in heterocyclic scaffolds was 
further meant to reduce reactivity of the potential MICHAEL acceptor while conserving the bond 
itself as well as the resulting sp2 hybridization. Chemical stability, however, has not been gained 
unless the pyrrole nitrogen was methylated (cp. chapter 4.5.1). Unfortunately, N-alkylation 
forestalled the idea of a tridentate hinge-binder. Consequently, molecular modeling estimated 
addition of the methyl group by a predicted loss of binding free energy: while the Glide score of 
non-methylated 105, for instance, is -16.7 it is modified for methylated 291 leading to -13.6. The 
modeled poses of 105 and 291 in CK1δ are shown in Figure 91. 
 
Figure 91 | Postulated binding modes of 105 (A) and 291 (B) in CK1δ .  (PDB code 3UZP) . 
According to molecular modeling methylation of the pyrrole nitrogen of 105 leading to 291 
forces the heterocycle to rotate by approximately 180°, thereby affecting the overall orientation 
within HRII. Consequently, 291 does only represent a bidentate hinge-binder. Although 
enthalpic losses can theoretically be assumed in relation to non-methylated 105, they might not 
necessarily be translated into decreased in vitro efficacy as previous results indicated the 
entropic effect to be the determining factor regarding affinity for HRII. Considering the 
calculated Glide scores which are in the range of series 2 compounds, potent inhibition can still 
be suggested. Therefore, derivatives 232, 291, and 224 have been assayed at 10 µM against 
CK1δ and CK1ε in order to evaluate their biological activity (Figure 92)249. 
132 | R e s u l t s  a n d  D i s c u s s i o n  
 
 
 
Figure 92 | Inhibition of CK1 isoform kinase activity by inhibitors of series 4  at a concentra-
tion of 10 µM .  Compounds 232, 291, and 224  have been biologically evaluated in kinase assays 
against CK1δ and CK1ε. α -Casein has been used as substrate. The inhibitors were screened in tri p-
licate measurement in the presence of 10  µM  ATP. Residual activities were  normalized to DMSO. 
Error bars indicate the SEM 2 4 9 .  
In fact, the initial screens identified 232, 291, and 224 as potent inhibitors that reduced residual 
CK1δ activity below 1 % at a concentration of 10 µM, though without significant discrimination 
of CK1ε. Subsequently, IC50 values have been determined to validate the observed effects 
(Figure 93)249. 
 
Figure 93 | IC5 0  determination of series 4  compounds 232, 291, and 224 .  IC 5 0  values have been 
determined using CK1δ or CK1ε and α -casein as substrate. Error bars indicate the SEM 2 4 9 .  
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Fortunately, IC50 determination confirmed the assumption of series 4 derivatives being rather 
potent inhibitors of CK1δ comparable to series 2. 232 (CK1δ IC50 = 9 nM, CK1ε IC50 = 45 nM) and 
224 (CK1δ IC50 = 8 nM, CK1ε IC50 = 81 nM) exhibited IC50 values in the single-digit nanomolar 
range while sulfoxidation of 232 seemed to reduce potency by three- to four-fold leading to still 
highly effective 224 (CK1δ IC50 = 32 nM, CK1ε IC50 = 181 nM). Significant discrimination of CK1 
isoforms δ and ε, however, has not been observed as 224 was the most specific inhibitor in this 
context favoring CK1δ by approximately ten-fold. In order to further validate specificity CK1δ 
and p38α IC50 values have been determined for 224 by ProQinase GmbH. Regrettably, the 
expected positive gains in specificity have been disproved as 224 exhibited potent dual-specific 
inhibition. The assays showed half maximally reduced CK1δ activity after treatment with < 3 nM 
inhibitor, corresponding to an extrapolated IC50 value of 1 nM, which is only by approximately 
three- to ten-fold more effective than the determined inhibition of p38α (IC50 = 10 nM). IC50 
values are summarized in Table 25. 
Table 25 | IC5 0  values and Glide scores of series 4 compounds2 4 9 .  
# Structure Glide Score (CK1δ) IC50 (nM) 
232 
 
-14.4 
9 (CK1δ) 
45 (CK1ε) 
n.d. (p38α) 
291 
 
-13.6 
32 (CK1δ) 
181 (CK1ε) 
n.d. (p38α) 
224 
 
-14.2 
8 (CK1δ) 
81 (CK1ε) 
< 3 (CK1δ)PQ 
10 (p38α)PQ 
PQ IC50 value has been determined by ProQinase GmbH. 
Structurally, the 4-(2,5-dimethoxyphenyl)-substituted pyrrole 224 seems to be slightly favored 
over the 2,4-dimethoxyphenyl substitution pattern of 232 in the context of specificity, although 
both CK1ε and p38α have also been potently inhibited. Sulfoxidation accounted for a loss of 
potency without significantly increased specificity. Nevertheless, sulfoxide 291 still represented 
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a highly potent inhibitor of CK1δ. Considering the overall high affinity which is in the range of 
series 2 derivatives, molecular modeling-based prediction has insofar been confirmed. 
Cellular Assays 
In order to evaluate efficacy on the cellular level 232, 291, and 224 have been applied to MTT 
assays in a concentration of 15 µM using the different human cancer cell lines Colo357, Panc-1, 
and MiaPaca-2 (Figure 94)249. Interestingly, Colo357 cells repeatedly exhibited enhanced 
resistance to treatment with small molecule CK1δ inhibitors while Panc-1 and MiaPaca-2 cells 
were significantly more sensitive. The overall efficacy was rather low but definite with the 
strongest effect in MiaPaca-2 cells, reducing cell viability to approximately 50 %. In general, the 
inhibitors did not reveal any structural preferences leading to similar inhibition of metabolic 
activity of Panc-1 and MiaPaca-2 cell lines. In Colo357 cells, however, 224 seemed slightly 
favored over 291 while 232 did not seem to express any effect at all. Considering the limited 
cellular efficacy despite IC50 values in the low nanomolar range it is most likely that the high 
molecular weight and the lipophilic character of these inhibitors accounted for poor solubility in 
cell medium and poor cell penetration. 
 
Figure 94 | Cell viability of Colo357, Panc -1, and MiaPaca-2 cells after treatment with series 
4 compounds at a concentration of 15 µM .  The inhibitors were screened in triplicate or quadr u-
plicate measurement. Cell viability was normalized to mock. Error bars indicate the SEM 2 4 9 .  
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X-ray Crystallography 
In order to validate the predicted binding mode crystal structures of CK1δ in complex with 224 
have been achieved by the group of PROF. DR. ULRICH BAUMANN (Figure 95). 
 
Figure 95 | Binding mode of 224 in CK1δ .  The binding mode revealed by X -ray crystallography is 
presented as ribbon (A) and surface (B) diagram. The in s ilico  predicted mode (C) shows different 
orientation of  the pyrrole  moiety.  X-ray analysis has been performed by the group of P RO F .  DR .  
ULRICH  BAU M A N N .  
Crystallographic analysis revealed the actual binding pose of 224 in CK1δ to be rather well 
predicted by the used in silico model, although the pyrrole moiety is rotated counterclockwise by 
approximately 90°. Consequently, the pyrrole and the dimethoxyphenyl ring are orientated 
vertically to each other rather than being situated in the same plane. Despite rotation of the 
pyrrole linker, however, positioning of the dimethoxyphenyl moiety has been predicted quite 
accurately. Furthermore, the geometry of the diaryl-imidazole pharmacophore has been 
calculated exactly including the bidentate hinge-binder and the penetration of the 
4-fluorophenyl moiety into HPI. The buried water molecule, however, has not been resolved, 
thereby providing evidence that it might actually not be referred to as a structural water. 
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5.5 Characterization of Series 6 
Kinase Assays 
Porcn inhibitors 113 and 114 have recently been found to weakly inhibit CK1δ in kinase assays 
without affecting CK1ε (unpublished data by KUHL and KNIPPSCHILD). Therefore, hybrid 
inhibitors 266 and 267 were designed to resume this specificity to a certain degree. In addition, 
the bulky and non-flexible dihydro-thieno[3,2-d]pyrimidin-4-one moiety was expected to 
positively influence the overall selectivity regarding p38α198. Potency, however, was assumed 
comparable to series 2 and 4 derivatives (191 Glide score = -13.6, 224 Glide score = -14.2) 
according to molecular modeling approaches that revealed Glide scores in an equivalent range 
(266 Glide score = -13.5, 267 Glide score = -14.2). The cellular efficacy, on the contrary, might 
suffer from poor physicochemical properties regarding solubility and cell penetration, for 
instance. Nevertheless, the synthesis of hybrid inhibitors and their biological characterization 
were believed beneficial in order to evaluate the possibility of HRII-mediated selectivity for 
CK1δ in combination with the affinity-gaining teardrop scaffold 120. Consequently, 266 and 
267 have been examined in initial screens against CK1 isoforms δ and ε (Figure 96)249. 
 
Figure 96 | Inhibition of CK1 isoform kinase ac tivity by inhibitors of series 6  at a concentra-
tion of 10 µM .  Compounds 266 and 267  have been biologically evaluated in kinase assays against 
CK1δ and CK1ε. α-Casein has been used as substrate. The inhibitors were screened in triplicate 
measurement in the presence of 10  µM  ATP. Residual activities were normalized to DMSO. Error 
bars indicate the SEM2 4 9 .  
The kinase assays confirmed the expected potent inhibition of CK1δ as both derivatives reduced 
the residual kinase activity below 1 % at a concentration of 10 µM. The obtained results 
R e s u l t s  a n d  D i s c u s s i o n  | 137 
 
 
regarding isoform-specificity, though, were deflating because 266 and 267 effectively blocked 
CK1ε activity as well. Validation of these findings was maintained by IC50 determination for CK1 
isoforms δ and ε (Figure 97)249 as well as CK1δ and p38α (ProQinase GmbH, only 266). 
 
Figure 97 | IC5 0  determination of series 6 compounds 266 and 267 .  IC5 0  values have been de-
termined using CK1δ or CK1ε and α -casein as substrate. Error bars indicate the SEM 2 4 9 .  
IC50 values in the low nanomolar range identified 266 and 267 as potent dual-specific inhibitors 
of CK1δ and p38α without selective discrimination of CK1 isoforms δ and ε (Table 26). 266 
proved to be the more specific inhibitor favoring CK1δ by approximately nine-fold over CK1ε 
and up to 18-fold over p38α (ProQinase: CK1δ IC50 < 3 nM, corresponding to an interpolated 
IC50 = 2 nM, p38α IC50 = 36 nM). 
Although the in silico prediction of affinity towards CK1δ has been confirmed, the expected 
effects regarding kinase- or even isoform-specificity were declined. Taken together, the 
practicability of conceptual substitution of building block 120 has to be reviewed, at least 
regarding selective inhibition of CK1δ. 
Table 26 | IC5 0  values and Glide scores of series 4 compounds 2 4 9 .  
# Structure Glide Score (CK1δ) IC50 (nM) 
266 
 
-13.5 
27 (CK1δ) 
237 (CK1ε) 
< 3 (CK1δ)PQ 
36 (p38α)PQ 
267 
 
-14.2 
29 (CK1δ) 
151 (CK1ε) 
n.d. (p38α) 
PQ IC50 value has been determined by ProQinase GmbH. 
138 | R e s u l t s  a n d  D i s c u s s i o n  
 
 
Cellular Assays 
The cellular efficacy of 266 and 267 has subsequently been evaluated using the human 
pancreatic carcinoma cell lines Colo357, Panc-1, and MiaPaca-2249. As expected, both compounds 
are only slightly active in Panc-1 and MiaPaca-2 cells and did not significantly reduce cell 
viability of the Colo357 cell line which has been observed rather resistant in previous 
experiments. In Panc-1 and MiaPaca-2 cells, however, metabolic activity has been inhibited by 
approximately 20 % with compound 266 being slightly more effective than 267. The high 
molecular weight of the inhibitors most likely accounted for unfavorable physicochemical 
properties which are suitable to explain the low efficacy on the cellular level regarding solubility 
and cell penetration. 
 
Figure 98 | Cell viabili ty of Colo357, Panc -1, and MiaPaca-2 cells after treatment with series 
6 compounds at a concentration of 15 µM .  The inhibitors were screened in triplicate or quadr u-
plicate measurement. Cell viability was normalized to mock.  Error bars indicate the SEM 2 4 9 .
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X-ray Crystallography 
Crystallization of CK1δ in complex with 266 was performed by the group of PROF. DR. ULRICH 
BAUMANN revealing two slightly different binding poses of the ligand in the kinase (Figure 99). 
 
Figure 99 | Binding mode of 266 in CK1δ .  X-ray crystallization revealed two poses for 266  in 
CK1δ HRII  (A, B) , opposed by the in s il ico  predicted geometries  (C) . The 2D ligand interaction 
diagram refers to crystallization  (D). X-ray analysis has been performed by the group of PRO F .  DR .  
ULRICH  BAU M A N N .  
While the fitting of the diaryl-imidazole pharmacophore including the bidentate hinge-binder as 
well as the 4-fluorophenyl moiety within HPI is conserved in both crystals, two different 
conformations of 266 in HRII have been observed which are characterized by a 180° flip of the 
dihydrothieno[3,2-d]pyrimidin-4-one moiety. This flexibility is enabled by the 2-mercapto-
acetamide linker and is most likely to be responsible for the unintended fitting into p38α despite 
the rigid and non-flexible thienopyrimidine. Interestingly, both binding poses have similarly 
been predicted in silico, thereby highlighting the quality of the established model. Another 
astonishing peculiarity that has not been observed previously is the presence of a different 
imidazole tautomer: both in silico studies and crystal structures indicate the imidazole NH group 
pointing towards the back of the ATP-pocket. Consequently, the water-mediated H-bond 
towards Lys38 and Asp149 is prohibited suggesting the bulky side chain to initiate a slightly 
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different positioning of the ligand in the ATP-binding cleft compared to previously discussed 
compounds. Considering the potent inhibition by 266, however, an increased entropic 
contribution based on the large hydrophobic thienopyrimidine moiety can be assumed which 
partially overcompensated the loss of the discussed H-bond. The buried structural water 
molecule has repeatedly not been resolved. 
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6 Conclusions 
6.1 Design and Synthesis of Potent and Selective CK1δ Inhibitors 
In the framework of the current dissertation, CK1δ inhibitors have been designed, synthesized, 
and biologically evaluated. From a total of 38 tested compounds, 37 have not been reported in 
literature and therefore represent novel and optimized small molecule kinase inhibitors, 
originally deriving from lead structure 12 and its non-oxidized derivative 11176. Compound 162, 
however, has already been characterized as a moderate early-stage p38α teardrop-like 
inhibitor197, although its effect on CK1 isoforms had not been examined. 
The synthesized compounds exclusively depict ATP-competitive, presumably type I-like 
inhibitors of CK1δ, although a type I ½-similar mechanism has been proven for the interaction of 
191 and p38α by crystallographic analysis as discussed in chapter 5.2. In this context it is 
noteworthy that equivalent DFG-in and DFG-out conformations have not been observed and are 
most likely non-relevant for CK1. The inhibitors have been classified in five distinct series based 
on structural and conceptual features. 
Among them, several compounds exhibited excellent inhibition in the single-digit nanomolar 
range with 191 being the most effective ligand expressing an IC50 value of 4 nM in standardized 
kinase assays by our collaboration partner248. ProQinase GmbH even extrapolated the IC50 value 
of the compound to be approximately 1 nM. Followed by 224 and 232 with IC50 values of 8 nM 
(ProQinase: extrapolated IC50 = 1 nM) and 9 nM, respectively, these compounds are readily 
among the most potent CK1δ inhibitors reported to date. Actually, 191 might in fact represent 
the most effective agent regarding inhibition of CK1δ in kinase assay systems. 266 is another 
promising ligand whose IC50 value has been extrapolated by ProQinase GmbH to be 2 nM, alt-
hough kinase assays in the hands of our collaboration partner249 identified half maximal inhibi-
tion at a concentration of 27 nM, which is still highly active. Further nine compounds from the 
total set have been found to possess IC50 values in the low double-digit nanomolar range 
(< 50 nM). The complete set of tested compounds with their appropriate IC50 values is listed in 
Supplementary Table 2. 
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Figure 100 | Potent CK1δ inhibitors 191, 224, 232, and 266 .  The most potent compounds of the 
current work inhibit CK1δ with IC 5 0  values in low nanomolar range.  
Furthermore, 191 exhibited good selectivity hitting only five additional kinases (residual 
activity ≤ 50 %) apart from CK1 isoforms δ, ε, and α from a panel of 321 protein kinases as 
discussed in chapter 5.2. Mitogen-activated protein kinase p38α which is the defined main off-
target of the current teardrop-like inhibitor class was effectively blocked ten-fold less potently 
compared to CK1δ with an IC50 value of 10 nM (ProQinase, in relation to CK1δ IC50 = 1 nM). 
Therefore, 191 has to be considered a potent dual-specific inhibitor of these kinases. Regarding 
isoform-specificity, however, profiling showed potent inhibition only of isoforms δ and ε, the 
latter approximately six-fold less effective with an IC50 value of 25 nM (in relation to CK1δ 
IC50 = 4 nM). CK1α residual activity was reduced to approximately 26 % while relevant inhibition 
of isoforms γ1-3 has not been observed in the same screening (ProQinase). Consequently, 191 
should be referred to as a potent and specific inhibitor of CK1 isoforms δ and ε. In fact, none of 
the designed novel inhibitors achieved the intended isoform-selectivity of at least 100-fold, the 
most specific compound in this context being weakly potent 164 which favored CK1δ by 
approximately 17-fold. Among the set of potent inhibitors, 192 (CK1δ IC50 = 20 nM, CK1ε 
IC50 = 233 nM) and 204 (CK1δ IC50 = 19 nM, CK1ε IC50 = 227 nM) exhibited the most promising 
preference by twelve-fold, followed by ten-fold preference of 224 (CK1δ IC50 = 8 nM, CK1ε 
IC50 = 81 nM). Discrimination of p38α was most pronounced by 266 by approximately 18-fold, 
although it has to be noted that IC50 values regarding p38α have only been determined for four 
compounds. 
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Figure 101 | CK1δ-preferring inhibitors 164, 192, and 204 .  The depicted compounds favor 
isoform δ over ε. 224  as well as p38α partially discriminating 266  are shown in  Figure 100 .  
The potent inhibition observed in kinase assays, however, has not been necessarily translated 
into high efficacy on cellular level. In fact, the majority of tested inhibitors requires optimization 
of physicochemical properties. Amine-based compounds (series 1, chapter 5.1) were rather 
ineffective, even at elevated concentrations of 20 µM or 25 µM, although it is not known whether 
this due to poor cell penetration or metabolic instability200. 151 represented an exception being 
weakly active in HT-29 cells with an EC50 of 9.3 µM. In order to gain applicability in cell culture, 
propionic acid amides (series 2, chapter 5.2) exhibited a significant overall improvement 
identifying 191 to be the most active inhibitor with EC50 values in Colo357 and Panc89 cells of 
3.5 µM and 1.5 µM, respectively. Carbamides (series 3, chapter 5.3) suffered from poor solubility 
leading to non-relevant efficacy in Colo357 and Panc89 cells in most cases. 104, 204, 205, and 
206, however, revealed moderate effects on cell viability. Therefore, improvement of water-
solubility of these compounds might prove extremely beneficial as this is likely to be their major 
limiting factor regarding cellular efficacy. 224, 232, 291 (series 4, chapter 5.4), 266, and 267 
(series 5, chapter 5.5) possess molecular weights > 500 g ∙ mol-1, thereby violating LIPINSKI’S 
rule of five251. They can therefore be assumed unfavorable regarding solubility and absorption. 
Consequently, both series reduced metabolic activity of Colo357, Panc-1, and MiaPaca-2 cells 
rather weakly. Considering the number of possible H-bond donors and acceptors virtually all 
series are in accordance with LIPINSKI’S concept. The octanol-water distribution coefficients, 
however, have not been determined and should be assumed to represent another violation of 
the rule of five for most of the newly designed inhibitors. 
Nevertheless, several compounds depict potent inhibitors of CK1δ in kinase assays. Especially 
191 is a specific inhibitor for CK1 isoforms δ and ε with good selectivity regarding 321 protein 
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kinases that is among the most potent agents for CK1δ reported to date. Therefore we provide a 
suitable biological tool with promising properties which is also moderately active in cells and 
should further be optimized regarding its physicochemical properties. 
6.2 Structure-Activity Relationship of CK1δ Inhibitors 
Structurally, building block 120 represents the central pharmacophore of the newly designed 
and synthesized inhibitors as discussed in chapter 3.1. The 4-fluorophenyl moiety ideally fits 
into HPI of CK1 isoforms δ and ε as proven by X-ray crystallography (Figure 102), but also p38α 
and is mainly responsible for selectivity over most other kinases. Regarding the aspect of 
potency the bidentate hinge-binding 2-aminopyridine moiety has to be considered the major 
determinant. The imidazole ring which is predominantly situated in the adenine-binding region 
of the ATP-pocket bears an unsubstituted nitrogen atom that is another important H-bond 
acceptor165,176,184,194–204. Addressing the solvent-exposed HRII by the use of varying side chains is 
expected to enhance both potency and selectivity176,195–197,200,201. Especially bulky side chains 
have been considered as these are thought to reduce affinity for the highly similar p38α 
mitogen-activated protein kinase198. 
 
Figure 102 | Binding poses of 191, 224, and 266 in CK1δ or  p38α .  224  (A) and 266  (B) have 
been co-crystallized with CK1δ while p38α has been crystallized in complex with 191 .  
The current biological evaluation verified the use of sterically demanding and mainly lipophilic 
moieties to be highly beneficial in order to gain affinity for CK1 isoforms δ and ε. Large gains in 
binding free energy can be achieved by exploiting the hydrophobic effect whereupon lipophilic 
substituents enable replacement of the suboptimal hydration state of HRII. The release of water 
molecules from hydrophobic environments thereby increases entropy and thus directly depends 
on the size of the appropriate moiety191,209. 
In addition, sterically demanding side chains shield the hydrophobic surface and the deeper 
cavities of the catalytic cleft from surrounding water. Methoxyphenyl-substituted scaffolds 
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proved highly beneficial in this context. In fact, from a set of sixteen designed and tested 
inhibitors that possess IC50 values < 50 nM eleven include methoxyphenyl-substituted moieties 
situated in HRII. Therefore, different substitution pattern have been compared within the scope 
of series 2 revealing dimethoxyphenyl substitution to be slightly more effective than the 
appropriate trimethoxyphenyl-bearing 194 (IC50 = 27 nM). Furthermore, 2,5-dimethoxyphenyl 
derivative 191 (IC50 = 4 nM) showed enhanced potency in relation to the respective 2,3-, 2,4-, 
and 3,4-substituted compounds 192 (IC50 = 20 nM), 190 (IC50 = 20 nM), and 193 (IC50 = 14 nM, 
Figure 103). The 2,3-substitution, however, might be favorable regarding isoform-
discrimination as this effect was slightly enhanced for 192. The preference for the 
2,5-dimethoxyphenyl substitution pattern was also reflected by 224 (IC50 = 8 nM) and 232 
(IC50 = 9 nM, series 4), though the effect was rather weak in this case. Unfortunately, these in 
vitro results did not correlate with in silico predicted data assuming that the current model is not 
capable of an accurate prediction concerning the regio- and stereo-chemical impact of different 
methoxy substitution pattern. 
 
Figure 103 | Differently methoxy -substituted series 2 compounds 191, 192, 193, and 194 .  The 
di- and trimethoxy substitution pattern  have been compared wit h regard to inhibition of CK1δ.  
There is no doubt, though, that these observations can hardly be generalized as substitution has 
always to be considered in the context of the complete side chain: series 3 derivatives 204 
(IC50 = 19 nM) and 205 (IC50 = 31 nM), for instance, exhibited inverted results. Regarding the 
relatively short and non-flexible side chain carbamide linker of these compounds to the longer 
equivalent structures of series 2 and 4 it might be suggested that the 2,5-substitution pattern is 
favored with an increasing linker length (Figure 104). Basically, the longer side chains of 191 
and 224 proved superior compared to the shorter moiety of 205. 
146 | C o n c l u s i o n s  
 
 
 
Figure 104 | Lengths of side chains might select for different dimethoxy substitution pat tern .  
The measured distances refer to appropriate energetically minimized 3D  structures.  
Referring to kinase screening results of series 3 compounds the dimethoxyphenyl substitution of 
205 seemed to outmatch the substitution pattern including a single methoxy group of 206. As 
discussed in chapter 3.1.5 mono-methoxy substitution was mainly left unconsidered as it has 
been reported to be most favorable for inhibition of p38α, whereas di- and trimethoxy substitu-
ents might forestall suitable fitting in this kinase200. 
Nevertheless, the hypothesis of bulky moieties prohibiting effective inhibition of p38α198 could 
not be fully confirmed as even the steric highly demanding ligands 224 and 266 potently 
inhibited the mitogen-activated protein kinase with IC50 values of 10 nM and 36 nM (ProQinase) 
which is only up to maximal ten- and 18-fold less active than their respective efficacy against 
CK1δ. Previous modeling-based investigations further postulated an accommodation of inhibitor 
side chains within CK1δ HRII by residues of the L-78 loop that is not present in p38α176. 
However, this thesis has not been reassured by crystallization for the present ligands. 
In general, structural comparison of series 1 to 4 reveals increasing planarity and size of the 
respective side chains. Starting from amine 164 (CK1δ IC50 = 386 nM, CK1ε IC50 = 6731 nM) 
introduction of the carbonyl function led to amide 190 (CK1δ IC50 = 20 nM, CK1ε IC50 = 129 nM) 
which was accompanied by a 19-fold increase of potency, although selectivity seemed to be 
significantly decreased. The weak inhibitory activity of 164 regarding inhibition of CK1ε in 
relation to CK1δ, however, is structurally not comprehensible as the sp3 hybridization-based 
enhanced flexibility was predicted to improve adaptivity to HRII of both CK1δ and CK1ε. Based 
on these observations as well as the reported beneficial effects on metabolic stability200 the 
carbonyl group has been accepted as mandatory for the following approaches. As discussed in 
chapter 3.1.5 it was hypothesized that the negative inductive effect of the carbonyl group 
strengthens the adjacent H-bond donor while the planar conformation of the sp2 hybridized 
amide function might be beneficial for positioning the N-H group in the correct angle. 
Structurally, substitution of the side chain α-methylene group by a nitrogen and shortening of 
the linker by deletion of the β-methylene led to planar carbamide derivative 204 (series 3, CK1δ 
IC50 = 19 nM, CK1ε IC50 = 227 nM) assuming less flexibility by an additional H-bond towards 
hinge residue Leu85. Biological analyzation of this effect, however, did not reveal significantly 
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increased potency providing an IC50 value of 19 nM for CK1δ which is nearly identical to 190. 
Unfortunately, co-crystallization of CK1δ in complex with carbamide derivatives has not been 
achieved and it has therefore not been possible to evaluate, though, whether the discussed 
H-bond was existent. The discrepancy between the in silico predicted gain of binding free 
energy, reflected by Glide scores of -13.8 for 190 and -16.6 for 204, and the in vitro data might 
consequently be due to energetic and steric prohibition of the tridentate hinge-binder or 
forestalled by low solubility of the carbamides. Isoform-selectivity, on the other hand, was 
increased for 204 by approximately two-fold compared to 190. However, 2,5-dimethoxyphenyl-
substituted carbamide 205 (CK1δ IC50 = 31 nM, CK1ε IC50 = 186 nM) did not improve isoform-
specificity compared to appropriate propionic acid amide 191 (CK1δ IC50 = 4 nM, CK1ε 
IC50 = 28 nM) but exhibited in fact even significantly reduced potency. These results thereby 
further supported the thesis of an intrinsically tied interplay of substitution pattern and linker 
length as previously discussed. The expected effect regarding selectivity by enhanced 
rigidification of carbamide derivatives over p38α, however, has been disproved as 204 (CK1δ 
IC50 = 10 nM, p38α IC50 = 28 nM) is in fact even less specific than 191 (CK1δ IC50 = 1 nM, p38α 
IC50 = 10 nM), although the different substitution pattern is likely to contribute to these results. 
Subsequent substitution of the carbamide linker by the N-methylated pyrrolic acid scaffold of 
series 4 led to bulkier ligands with enhanced linker length which has already been discussed. 
While 232 and 224 exhibited an increase of potency for CK1δ with IC50 values of 9 nM (CK1ε 
IC50 = 45 nM) and 8 nM (CK1ε IC50 = 81 nM) they did not enhance isoform-specificity either. 
Considering selectivity over p38α which has been determined by ProQinase GmbH for 224 
(CK1δ IC50 = 1 nM, p38α IC50 = 10 nM) revealed that CK1δ was preferred by about ten-fold. 
Thereby, properties of 224 proved comparable to 191 while the latter still showed highest 
efficacy and should be assumed favorable regarding activity in cell culture. 
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Figure 105 | Comparison of series 1 to 4 based on compounds 164, 190, 204, and 232 .  Potency 
and isoform-specificity were either increased ( +), decreased (-), or unaffected.  
Hybrid inhibitors 266 and 267 of series 6 were derived from known Porcn inhibitors and 
therefore structurally non-dependent on previous series. They exhibited good potency for CK1δ 
with IC50 values of 27 nM and 29 nM, though only moderate isoform-specificity favoring isoform 
δ by approximately nine-fold. Consequently, the approach to graft the astonishing selectivity of 
113 and 114 onto pharmacophore 120 by hybrid synthesis failed in this context but proved 
beneficial otherwise: 266 showed the most effective discrimination of p38α by about 18-fold 
(ProQinase: CK1δ IC50 = 2 nM, p38α IC50 = 36 nM), although it was still a potent dual-specific 
inhibitor. Crystallographic analysis identified the flexible 2-mercaptoacetic acid linker to enable 
different binding poses and also has to be assumed responsible for fitting into off-target kinases 
such as p38α. 
Taken together, the in vitro and crystallization results provide proof of concept for the estab-
lished computational model of CK1δ which enabled prediction of binding poses rather correctly. 
Nevertheless, its limits were also identified as molecular modeling has neither been able to cal-
culate the influence of different (methoxy) substitution pattern within highly flexible domain 
HRII, nor the impact of sulfoxidation. 
Consequently, these results raise the question whether the current approach is suitable to 
achieve selectivity for CK1δ over highly similar CK1ε and other structurally related kinases as 
the most specific inhibitors were 164 (discriminating CK1ε by approx. 17-fold) and 266 
(discriminating p38α by approx. 18-fold). In fact, pharmacophore 120 itself should be assumed 
rather effective regarding inhibition of CK1 isoforms δ and ε as well as p38α, considering the 
excellent fitting into their active sites which has been proven by X-ray crystallography. It seems 
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furthermore most likely that the highly flexible and solvent-exposed HRII is capable of adapting 
to various different side chains (induced fit). Crystallization also confirmed the respective 
domain of p38α to be significantly restricted in size and planarity compared to CK1δ and CK1ε. 
Therefore, decreased enthalpic gains can be suggested for p38α to arise from hydrophobic 
protein-ligand interaction within HRII: the discussed side chains are virtually “too large” to fully 
interfere with this region and consequently reach into the solvent space. Nevertheless, p38α was 
potently inhibited with IC50 values in the low nanomolar range, thereby indicating enthalpic 
compensation elsewhere which could be hypothesized to rely on the adenine-binding region: 
first, the H-bond which is accepted by the imidazole nitrogen is not mediated by water molecules 
in p38α and should therefore account for higher enthalpic gains; and second, the type I ½-like 
binding discussed in chapter 5.2 enables the inhibitor to interact with p38α by additional 
π-π-stacking. Consequently, inhibitors that share teardrop-related scaffolds such as 120 
consisting of a 4-fluorophenyl moiety penetrating into HPI and a 2-aminopyridine acting as a 
bidentate hinge-binder are unlikely to achieve selectivity as the addressed domains are highly 
conserved within the kinases in question and account for intrinsic efficacy. Nevertheless, the use 
of various side chains exhibited differently pronounced discrimination of CK1ε and p38α up to 
approximately 18-fold indicating HRII to be an important, if not the main determinant for 
selectivity in this context. It might therefore be beneficial for future approaches to focus on this 
domain while reducing or even relinquishing the teardrop-like pharmacophore, although an 
initial loss of potency has to be expected. Especially approaches that concentrate on 
thienopyrimidine-like (IWP-like) scaffolds (cp. 266, 267) might prove promising for further 
optimization, potentially amplified by methoxy substitution. 
Finally, 191 has been identified as an extremely potent dual-specific inhibitor of CK1 isoforms δ 
and ε as well as p38α with good specificity regarding 321 protein kinases that is among the most 
effective CK1 inhibitors published to date. Although it is yet active in cellular systems with an 
EC50 value of at best 1.5 µM, optimization of its physicochemical properties will provide a bio-
chemical tool that might be highly valuable in order to uncover further details regarding the 
physiological and pathophysiological characteristics of CK1δ. 
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7 Experimental 
7.1 Molecular Modeling 
7.1.1 Software and Computational Resources 
Molecular modeling was performed on a DELL Precision T5500 eight core workstation utilizing 
Schrödinger software. Visualization was achieved by Maestro, version 10.6, Schrödinger, LLC, 
New York, NY, 2016, the interface of Schrödinger technologies. In general, molecular modeling 
calculations are energybb-driven and therefore rely on force field-mediated local minimization of 
both protein and ligands. Energetic calculations of the present work were mainly obtained based 
on the Optimized Potentials for Liquid Simulations of 2005 force field (OPLS_2005)252. In 2015, 
the advanced OPLS3253 has been presented which reportedly possesses a 30 % improvement in 
relation to the earlier variant. In fact, the main upgrade seems to refer to peptide modeling and 
validation of earlier results did not reveal significant differences. 
7.1.2 Protein Preparation 
Protein crystal structures were taken from the Research Collaboratory for Structural 
Bioinformatics (RCSB) protein data bank (PDB). CK1δ-based screenings were performed using a 
crystal structure (PDB code 3UZP) by LONG et al.184 which was selected from a rather limited 
pool at that time. The enormous advantage of the chosen crystal structure referred to the co-
crystallized ligand (PDB code 0CK) exhibiting structural similarity towards lead compound 12. 
The most important determinants showed acceptable values, though occupancy has not been 
given: resolution = 1.94 Å, R-factor = 22.2 %, B-factor = 37 Å2. 
Prior to docking, crystal structures were prepared by the implemented Protein Preparation 
Wizard205 synchronizing the following Schrödinger modules: Epik254, version 3.6, 2016; Impact, 
version 7.1, 2016; Prime255, version 4.4, 2016. In order to achieve high Enrichment-factors, the 
common refinement protocol by SASTRY et al.205 has been adjusted: the process involved 
assignment of bond orders, addition of hydrogen atoms, identification of disulfide bonds, and the 
conversion of artificial selenomethionines to methionines (default settings). Missing side chains 
                                                             
bb binding free energy and solvation free energy 
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were filled in using Prime. Missing loops have not been detected. Water molecules beyond 5.0 Å 
from hetero atoms have been deleted automatically while water molecules within this range 
were reviewed manually: the previously discussed (chapter 3.1.4) structural water molecule 
was kept exclusively. H-bond optimization was performed in a standard sampling, the Root-
mean-square deviation for atomic positions (RMSD) cutoff for heavy atoms in subsequent 
protein minimization was set to 0.3 Å. Manual inspection of the protein model and the 
RAMACHANDRAN plot (Figure 106) offered suitable quality: three residues were detected within 
RAMACHANDRAN outlier regions, though not in close proximity to the active site. The docking Grid 
was generated with Glide default settings picking the co-crystallized ligand to characterize the 
Grid box center (Glide, version 7.1, Schrödinger, LLC, New York, NY, 2016). 
Analysis of the kinase active site regarding its druggability has been supported by the use of 
SiteMap, version 3.9, Schrödinger, LLC, New York, NY, 2016. SiteMap256 has also proved benefi-
cial for the identification of binding sites in kinase apo-structures. 
 
Figure 106 | RA MA CHA N D R AN  plot of the protein model used for CK1δ screening .  The colored 
squares refer to energetically favored (red), a llowed (yel low), and disallowed (white) regions for 
amino acid residue dihedrals. Glycines ar e depicted as black triangles, p rolines as black squares.  
All remaining amino acid residues are represented by black dots. The model refers to a crystal  
structure by LON G  et al .  (PDB code 3UZP) 1 8 4 .  
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7.1.3 Ligand Preparation 
Ligands were prepared to generate energetically minimized three-dimensional coordinates with 
an extended cutoff by MacroModel, version 11.2, Schrödinger, LLC, New York, NY, 2016. Ioniza-
tion and tautomeric states were estimated at pH 7 ± 2 by LigPrep205, version 3.8, Schrödinger, 
LLC, New York, NY, 2016, utilizing HAMMETT and TAFT methodology-based Epik254. Additionally, 
Epik state penalties (kcal ∙ mol-1) were calculated for each ligand to quantify the energetic cost 
for state transition in solution205. In order to indicate ligand flexibility, up to 50 bioactive con-
formers per ligand were identified and prioritized utilizing the conformational search module in 
the fast mode (ConfGen, version 3.6, Schrödinger, LLC, New York, NY, 2016)257. Core Hopping 
was performed with the homonymous module (Core Hopping, version 2.5, Schrödinger, LLC, 
New York, NY, 2016) by the use of the Glide fragment library (Schrödinger fragment collection). 
7.1.4 Ligand Docking 
Ligand docking was mainly performed with the extra precision (XP) Glide methodology258. The 
aim of this procedure is to semiquantitatively screen and rank ligand libraries to a specified and 
presumably rigid receptor conformation. Ligand affinity is thereby generally characterized by 
the Glide XP scoring module which is based on the following aspects: first, retainment of favora-
ble VAN DER WAALS contacts in order to displace water from hydrophobic regions into the bulk 
leading to entropy-driven energetic gains; second, the ability of hydrogen-bonding and other 
strong electrostatic interactions with specific key structural motifs. H-bonds are therefore divid-
ed into three types referring to their long-range solvation (BORN) energy and electrostatic be-
havior as neutral-neutral, neutral-charged, and charged-charged; and third, the achievement of 
reasonable RMSD values in relation to the native complex. In contrast, desolvation effects and 
motional restriction of ligand and protein are considered to reduce binding affinity. These terms 
are implemented in the XP Glide score which is specified in detail by the following equations and 
ideally corresponds to the binding free energy ΔG (kcal ∙ mol-1)258. A short description of these 
parameters is given in Table 27. 
𝐺𝑙𝑖𝑑𝑒 𝑠𝑐𝑜𝑟𝑒 = 𝐸𝑐𝑜𝑢𝑙 + 𝐸𝑣𝑑𝑊 + 𝐸𝑏𝑖𝑛𝑑 + 𝐸𝑝𝑒𝑛𝑎𝑙𝑡𝑦 
𝐸𝑏𝑖𝑛𝑑 = 𝐸ℎ𝑦𝑑_𝑒𝑛𝑐𝑙𝑜𝑠𝑢𝑟𝑒 + 𝐸ℎ𝑏_𝑛𝑛_𝑚𝑜𝑡𝑖𝑓 + 𝐸ℎ𝑏_𝑐𝑐_𝑚𝑜𝑡𝑖𝑓 + 𝐸𝑃𝐼 + 𝐸ℎ𝑏_𝑝𝑎𝑖𝑟 + 𝐸𝑝ℎ𝑜𝑏𝑖𝑐_𝑝𝑎𝑖𝑟 
𝐸𝑝𝑒𝑛𝑎𝑙𝑡𝑦 = 𝐸𝑑𝑒𝑠𝑜𝑙𝑣 + 𝐸𝑙𝑖𝑔𝑎𝑛𝑑_𝑠𝑡𝑟𝑎𝑖𝑛 
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In addition, the sum of Glide score and the discussed Epik state penalty is referred to as the 
docking score205. Despite the advantages of this score it is reportedly error-prone leading to false 
positives and negatives205. Consequently, the Glide score has been favored over the docking 
score in the context of the present dissertation. 
Table 27 | Energetic parameters for Glide score calculations2 5 8 , 2 5 9 .  
 Parameter Description 
   
 Ecoul Coulomb energy 
 EvdW VAN DER WAALS energy 
 Ebind Energetic terms that favor binding 
 Ephobic_pair Hydrophobic atom-atom pair energy term including interatomic distances which heuristi-
cally represents the displacement of water by hydrophobic ligand atoms 
 Ehyd_enclosure Hydrophobic enclosure: advanced Ephobic_pair term discriminating between different envi-
ronmental geometries 
 Ehb_pair Hydrogen bond term calculated for all complementary possibilities of hydrogen bonds 
between ligand and protein atoms 
 Ehb_nn_motif Special neutral-neutral hydrogen bond motif: advanced Ehb_pair term 
 Ehb_cc_motif Special charged-charged hydrogen bond motif: advanced Ehb_pair term 
 EPI Minor term rewarding π-stacking and π-cation interaction, placement of halogen atoms in 
hydrophobic regions, and empirical correction favoring the binding of smaller ligands over 
larger ones 
 Epenalty Energetic terms that hinder binding 
 Edesolv Desolvation penalties 
 Eligand_strain Strain energy penalties 
   
 
In cases when Glide Docking approaches failed, an Induced Fit Docking protocol has been per-
formed260: the procedure repetitively combines rigid docking (Glide) and protein structure pre-
diction (Prime) to account for both ligand and receptor flexibility. Default settings of the stand-
ard protocol were used, complemented by the side chain trimming function. Glide redocking was 
performed with the extra precision methodology. The final scoring is achieved by the equation: 
𝐼𝐹𝐷 𝑆𝑐𝑜𝑟𝑒 = 𝐺𝑙𝑖𝑑𝑒 𝑠𝑐𝑜𝑟𝑒 + 0.05 ∙ 𝑃𝑟𝑖𝑚𝑒 𝐸𝑛𝑒𝑟𝑔𝑦 
The less-dominant Prime Energy term is essential to separate predicted models from the ran-
dom noise that is introduced by minor steric clashes260. 
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7.2 Material and Methods 
7.2.1 Reagents and Solvents 
All reagents and solvents that have been applied in synthetic and analytic approaches were, if 
not specified otherwise, obtained from the commercial companies abcr GmbH (Karlsruhe, 
Germany), Sigma-Aldrich Chemie GmbH, Merck Group (Munich, Germany), Merck Millipore 
(Darmstadt, Germany), Acros Organics, Thermo Fisher Scientific (Geel, Belgium), and VWR 
International GmbH (Hannover, Germany). They were used without further purification. 
7.2.2 Methods and Instruments 
The following methods and instruments were used for synthesis, purification, and characteriza-
tion of the specified (chapter 7.2.3) compounds: 
High Pressure Reactor 
Syntheses under high pressure were performed in a highpreactorTM BR-25 (Berghof Products + 
Instruments GmbH, Eningen, Germany) at 180 °C and 20-30 bar. The reactor vessel consists of 
stainless steel with PTFE inserts and seals and a manometer. Consistent heating was achieved in 
a corresponding heating block on a Heidolph MR Hei-Standard laboratory heating plate 
(Heidolph Instruments GmbH & Co KG, Schwabach, Germany). 
Microwave Synthesis 
Syntheses were performed in a CEM Discover Microwave Synthesizer (CEM GmbH, Kamp-
Lintfort, Germany) under air cooling and high stirring with a maximal power of 100 W. The 
reaction mixtures were scheduled in convenient thick-walled and snap-lid capped glass reaction 
vessels.
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Photosynthesis 
Irradiation was performed using light in the ultraviolet range of 365 nm with a LED-illuminant 
(12 ∙ Nichia NCSU033B, Sahlmann Photochemical Solutions, Kiel, Germany). 
TLC 
Thin layer chromatography (TLC) was the main method of monitoring reaction progress and 
evaluating solvent gradients for column chromatography. Pre-coated silica gel polyester sheets 
(Polygram® SIL G/UV254, 0.2 mm, Macherey-Nagel, Düren, Germany) and RP-18 modified silica 
gel aluminum plates (Silicagel 60 RP-18 F254S, Merck Millipore, Darmstadt, Germany) were used. 
HPLC 
High-performance liquid chromatography (HPLC) was performed with a Hewlett Packard 1050 
Series (Agilent Technologies, Waldbronn, Germany) and served for monitoring of reaction 
progress and purity control: all test compounds submitted to biological evaluation and X-ray 
structure analysis were proven to possess ≥ 95 % HPLC purity. All substances were dissolved in 
methanol for HPLC measurement. 
The column was either a ZORBAX® Eclipse XDB-C8, 5 µm (150 ∙ 4.6 mm, Agilent Technologies, 
Santa Clara, United States) or a Kinetex® C8, 5 µm (150 ∙ 4.6 mm, Phenomenex, Aschaffenburg, 
Germany). For the mobile phase three different gradients of methanol and KH2PO4 buffer 
(10 mM, pH 2.3) were used (Methods 1, 2, 3, Table 28) with a fixed flow rate (1.5 ml ∙ min-1). 
UV detection was achieved at 254 nm. 
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Table 28 | HPLC gradient-dependent methods .  
  Time (min) Methanol (%) KH2PO4 buffer (%) 
     
 Method 1 0 40 60 
  8 85 15 
  13 85 15 
  14 40 60 
  16 40 60 
     
 Method 2 0 20 80 
  8 85 15 
  13 85 15 
  14 20 80 
  15 20 80 
     
 Method 3 0 40 60 
  8 85 15 
  11 85 15 
  12 40 60 
  14 40 60 
     
 
Flash Chromatography 
Column chromatography was performed using a LaFlash system, VWR International GmbH 
(Hannover Germany). The crude product was loaded on silica gel 60 (63-200 µm, Macherey-
Nagel, Düren, Germany) or RP-18 modified silica gel (PuriFlash IR-50 C18, 50 µm, Interchim, 
Montluçon, France) and packed in dry-load precolumns (PuriFlash-DLE/12G, Interchim). Pre-
packed silica gel columns (PuriFlash-30SIHP, 30 µm, 40 g, Interchim) and RP-18 modified silica 
gel columns (PuriFlash-15C18HP, 15 µm, 55 g, Interchim) were used for separation. 
Composition and gradients of the mobile phases are given with the appropriate synthetic 
procedures (cp. chapter 7.3). Flow rates were usually adjusted to 30 ml ∙ min-1 (PuriFlash-
30SIHP) or 20.5 ml ∙ min-1 (PuriFlash-15C18HP), respectively. 
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NMR 
NMR spectra were recorded on a Bruker Avance III 300, tempered at 298 K: 1H (300 MHz), 
13C (75 MHz), 19F (282 MHz). Spectra were referenced to the respective deuterated solvents sig-
nals of DMSO-d6 (δ 1H NMR: 2.50 ppm, δ 13C NMR: 39.52 ppm) and CDCl3 (δ 1H NMR: 7.26 ppm, 
δ 13C NMR: 77.00 ppm) as an internal standard. H,H-COSY, HSQC, HMBC spectra were consulted 
in order to assign signals of complex structures if necessary. 
The use of the relatively viscous DMSO-d6 often led to different sets of signals with a maximal 
ratio of 1:3 which are most likely due to atropisomers and tautomers (imidazole). Although such 
sets have not been observed whenever CDCl3 was used, DMSO-d6 was the most frequented 
solvent regarding its favorable solubility-mediating properties. For reasons of clarity, only the 
dominant set of signals is given in the experimental section. The following abbreviations have 
been used to classify the appropriate signals: v (very), b (broad), s (singlet), d (doublet), 
t (triplet), q (quartet), quint (quintet), m (unresolved multiplet). 
LC-MS 
Liquid chromatographic (LC) separation was performed with an Agilent 1100 HPLC system 
(Agilent Technologies, Waldbronn, Germany) over an Agilent Eclipse XDB-C8 column 
(150 ∙ 4.6 mm, 5 µm) using a 0.1 % acetic acid/acetonitrile gradient for mobile phase 
(flow rate = 1 ml ∙ min-1). 
Mass spectra were recorded on a Bruker Esquire ~LC ion trap mass spectrometer (Bruker 
Daltonics, Bremen, Germany) with electron spray ionization (ESI) in the positive ion mode (dry 
gas 9 l ∙ min-1, nebulizer 35 psi, drying temperature 350 °C). 
HRMS 
High resolution mass spectra were recorded on an electron ionization (EI)/field desorption (FD) 
mass spectrometer JEOL AccuTOFTM GCv 4G (JEOL GmbH, Freising, Germany) at the Institute of 
Organic Chemistry, Christian-Albrechts University (Kiel, Germany). 
IR spectrometry 
IR spectra were recorded on a Shimadzu Fourier Transform Infrared Spectrometer IRAffinity-1S 
(Shimadzu Deutschland GmbH, Duisburg, Germany). 
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Melting Point 
Melting points (uncorrected) were determined on a Stuart Scientific Melting Point Apparatus 
SMP3 (Bibby Scientific Limited, Staffordshire, United Kingdom). 
X-ray Crystallography 
X-ray ligand crystal structure analysis was performed by DR. DIETER SCHOLLMEYER at the Institute 
of Organic Chemistry, Johannes Gutenberg University (Mainz, Germany) on a Stoe IPDS 2T with 
Cu and Mo-X ray tubes and Oxford Cryostream. 
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7.3 Synthetic Procedures 
7.3.1 Synthesis of Building Block 120 
tert-Butyl (4-methylpyridin-2-yl)carbamate (132) 
 
C11H16N2O2 (Mr 208.26) 
2-Amino-4-methylpyridine (3.00 g, 27.7 mmol) and Boc2O (6.70 g, 30.5 mmol) were stirred in 
70 ml tert-butanol at rt for 12 h. The solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography (SiO2, 10-50 % ethyl acetate/petrol ether) 
and crystallized from 2-propanol to afford 132 as colorless crystals (100 % HPLC purity). 
Yield: 5.35 g (25.7 mmol, 93 %) (Lit.202: 84 %). 
m.p.: 125 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.53 (s, 9 H, tBu), 2.35 (s, 3 H, CH3), 6.79 (dq, 3J = 5.3 Hz, 
4J = 0.6 Hz, 1 H, C5H, Pyr), 7.88 (m, 1 H, C3H, Pyr), 8.13 (dd, 3J = 5.2 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr), 
8.84 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.6 (CH3), 28.5 (C(CH3)3), 81.1 (C(CH3)3), 113.2 (C3H, Pyr), 119.6 
(C5H, Pyr), 146.6 (C6H, Pyr), 150.5 (CO), 152.3 (C4, Pyr), 152.8 (C2, Pyr) ppm. 
IR (ATR): ν̃ = 2990, 1717, 1616, 1576, 1526, 1474, 1418, 1389, 1364, 1292, 1273, 1250, 1229, 
1148, 1115, 1055, 1036, 1007, 995, 889, 864, 804, 770, 743, 625 cm-1. 
HPLC (Method 1): tR = 4.7 min. 
LC-MS (ESI, 70 eV): m/z = 153 [MH2- tBu]+ (calc. m/z = 208). 
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1,3-Bis(4-methylpyridin-2-yl)carbamide (134) 
 
C13H14N4O (Mr 242.28) 
2-Amino-4-methylpyridine (1.00 g, 9.25 mmol) and Boc2O (2.42 g, 11.1 mmol) were stirred in 
10 ml THF at rt for 12 h. The precipitate was filtered off and rinsed with THF to afford 134 as a 
colorless solid (100 % HPLC purity). 
Yield: 1.11 g (4.58 mmol, quant.). 
m.p.: 227 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.37 (s, 6 H, CH3), 6.83 (dq, 3J = 5.3 Hz, 4J = 0.8 Hz, 2 H, C5H, Pyr), 
7.45 (bs, 2 H, C3H, Pyr), 8.22 (d, 3J = 5.3 Hz, 2 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.5 (CH3), 113.7 (C3H, Pyr), 119.7 (C5H, Pyr), 146.5 (C6H, Pyr), 
150.2 (CO), 152.4 (C4, Pyr), 153.6 (C2, Pyr) ppm. 
IR (ATR): ν̃ = 3090, 1690, 1616, 1566, 1551, 1512, 1476, 1454, 1412, 1383, 1312, 1289, 1256, 
1231, 1179, 1165, 1122, 989, 954, 878, 866, 831, 810, 774, 721, 687, 561 cm-1. 
HPLC (Method 1): tR = 4.0 min. 
LC-MS (ESI, 70 eV): m/z = 243 [MH]+, 135 [M-C6H7N2]+, 109 [MH2-C7H7N2O]+ (calc. m/z = 242). 
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Di-N-tert-butoxycarbonyl-2-amino-4-methylpyridine (133) 
 
C16H24N2O4 (Mr 308.38) 
4-DMAP (147 mg, 1.20 mmol) was added to a solution of 132 (500 mg, 2.40 mmol) and Boc2O 
(790 mg, 3.60 mmol) in 4 ml THF and the mixture was stirred at rt for 24 h. The solvent was 
removed under reduced pressure, the residue was resuspended in ethyl acetate, washed with 
water and sat. aq. NaCl solution, and dried over anhyd. Na2SO4. The crude product was purified 
by flash chromatography (SiO2, 10 % ethyl acetate/petrol ether) to afford 133 as colorless oil 
(96 % HPLC purity). 
Yield: 300 mg (0.97 mmol, 41 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.40 (s, 18 H, tBu), 2.34 (s, 3 H, CH3), 7.14-7.18 (m, 2 H, C3/5H, 
Pyr), 8.28 (dd, 3J = 5.0 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 20.3 (CH3), 27.4 (C(CH3)3), 82.4 (C(CH3)3), 121.8 (C3H, Pyr), 
123.3 (C5H, Pyr), 147.9 (C6H, Pyr), 149.3 (C2, Pyr), 151.0 (CO), 151.8 (C3, Pyr) ppm. 
HPLC (Method 3): tR = 5.0 min. 
LC-MS (ESI, 70 eV): m/z = 309 [MH]+ (calc. m/z = 308). 
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1-(4-Fluorophenyl)-2-(2-fluoropyridin-4-yl)-ethan-1-one (123) 
 
C13H9F2NO (Mr 233.22) 
NaHMDS (66.7 ml 2 M solution in THF, 133 mmol) was slowly added dropwise to a stirred solu-
tion of 2-fluoro-4-methylpyridine (10.6 ml, 103 mmol) and ethyl 4-fluorobenzoate (18.1 ml, 
123 mmol) in 40 ml anhyd. THF at 0 °C under a nitrogen atmosphere. After stirring at 0 °C for 
2 h the reaction was allowed to reach rt and stirring continued for 1 h. The mixture was diluted 
with ethyl acetate and washed twice with 10 % aq. HCl. The organic layer was dried over anhyd. 
Na2SO4 and the solvent was removed under reduced pressure. The crude product was recrystal-
lized from ethyl acetate to afford 123 as a colorless solid (100 % HPLC purity). 
Yield: 23.9 g (103 mmol, quant.) (Lit.203: 86 %). 
m.p.: 102 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 4.59 (s, 2 H, CH2), 7.10 (s, 1 H, C3H, Pyr), 7.25-7.27 (m, 1 H, 
C5H, Pyr), 7.37-7.43 (m, 2 H, C3/5H, F-Phe), 8.11-8.19 (m, 3 H, C2/6H, F-Phe, C6H, Pyr) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 43.6 (d, 4JCF = 2.8 Hz, CH2), 110.8 (d, 2JCF = 37.6 Hz, C3H, Pyr), 
115.8 (d, 2JCF = 22.0 Hz, C3/5H, F-Phe), 123.8 (d, 4JCF = 3.8 Hz, C5H, Pyr), 131.3 (d, 3JCF = 9.6 Hz, 
C2/6H, F-Phe), 132.9 (d, 4JCF = 2.7 Hz, C1, F-Phe), 147.0 (d, 5JCF = 15.5 Hz, C6H, Pyr), 150.7 (d, 
3JCF = 8.5 Hz, C1, Pyr), 163.1 (d, 1JCF = 234.3 Hz, C2F, Pyr), 165.2 (d, 1JCF = 252.0 Hz, C4F, F-Phe), 
194.6 (CO) ppm. 
IR (ATR): ν̃ = 3100, 2490, 1684, 1614, 1597, 1568, 1553, 1508, 1483, 1412, 1341, 1306, 1292, 
1271, 1234, 1206, 1161, 118, 1115, 1103, 999, 964, 952, 921, 872, 853, 829, 812, 793, 760, 627, 
582, 559 cm-1. 
HPLC (Method 1): tR = 3.9 min. 
LC-MS (ESI, 70 eV): m/z = 234 [MH]+ (calc. m/z = 233). 
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2-(2-Bromopyridin-4-yl)-1-(4-fluorophenyl)ethan-1-one (128) 
 
C13H9FBrNO (Mr 294.12) 
128 was synthesized according to the procedure for 123 from 2-bromo-4-methylpyridine 
(190 µl, 1.74 mmol), ethyl 4-fluorobenzoate (260 µl, 1.74 mmol) in 6 ml anhyd. THF and 
NaHMDS (1.74 ml 2 M solution in THF, 3.49 mmol). 128 was obtained as a brown solid (100 % 
HPLC purity). 
Yield: 260 mg (884 µmol, 51 %) (Lit.203: 87 %). 
1H NMR (300 MHz, DMSO-d6): δ = 4.54 (s, 2 H, CH2), 7.35 (dd, 3J = 5.0 Hz, 4J = 1.4 Hz, 1 H, C5H, 
Pyr), 7.37-7.43 (m, 2 H, C3/5H, F-Phe), 7.59 (d, 5J = 0.7 Hz, 1 H, C3H, Pyr), 8.11-8.15 (m, 2 H, C2/6H, 
F-Phe), 8.33 (dd, 3J = 5.0 Hz, 5J = 0.6 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 43.3 (CH2), 115.9 (d, 2JCF = 22.0 Hz, C3/5H, F-Phe), 125.3 (C5H, 
Pyr), 129.5 (C3H, Pyr), 131.3 (d, 3JCF = 9.6 Hz, C2/6H, F-Phe), 132.9 (d, 4JCF = 2.9 Hz, C1, F-Phe), 
141.2 (CBr), 148.1 (C4, Pyr), 150.0 (C6H, Pyr), 165.2 (d, 1JCF = 252.3 Hz, CF), 194.6 (CO) ppm. 
HPLC (Method 1): tR = 4.6 min. 
LC-MS (ESI, 70 eV): m/z = 294, 296 [MH]+ (calc. m/z = 294). 
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tert-Butyl (4-(2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-yl)carbamate (135) 
 
C18H19FN2O3 (Mr 330.36) 
Method A. A solution of 132 (200 mg, 960 µmol) in 4 ml anhyd. THF under a nitrogen 
atmosphere was cooled down to -78 °C and NaHMDS (960 µl 2 M solution in THF, 1.92 mmol) 
was added dropwise. After stirring at 0 °C for 30 min the reaction was cooled to -78 °C before 
ethyl 4-fluorobenzoate (141 µl, 960 µmol) in 4 ml anhyd. THF was added very slowly over a 
syringe. The mixture was allowed to reach rt over 1 h and stirring continued at the same temp. 
for another 2 h. The suspension was diluted with ethyl acetate and washed twice with 10 % aq. 
HCl. The organic layer was dried over anhyd. Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography (SiO2, 5-25 % ethyl 
acetate/petrol ether) to afford 135 as a colorless solid (100 % HPLC purity). 
Yield: 35.5 mg (107 µmol, 11 %). 
Method B. 135 was synthesized according to the procedure for 123 from 133 (300 mg, 
973 µmol), ethyl 4-fluorobenzoate (143 µl, 973 µmol) in 1.2 ml anhyd. THF, and NaHMDS (973 µl 
2 M solution in THF, 1.95 mmol), but required further purification by flash chromatography 
(SiO2, 20-50 % ethyl acetate/petrol ether) to give 135 as a colorless solid (100 % HPLC purity). 
Yield: 88.5 mg (268 µmol, 28 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.46 (s, 9 H, tBu), 4.46 (s, 2 H, CH2), 6.93 (dd, 3J = 5.1 Hz, 
4J = 1.5 Hz, 1 H, C5H, Pyr), 7.35-7.41 (m, 2 H, C3/5H, F-Phe), 7.73 (d, 5J = 0.6 Hz, 1 H, C3H, Pyr), 
8.10-8.15 (m, 2 H, C2/6H, F-Phe), 8.16 (dd, 3J = 5.1 Hz, 5J = 0.7 Hz, 1 H, C6H, Pyr), 9.73 (bs, 1 H, NH) 
ppm. 
13C NMR (75 MHz, CDCl3): δ = 28.0 (C(CH3)3), 44.3 (CH2), 79.5 (C(CH3)3), 113.5 (C3H, Pyr), 115.8 
(d, 2JCF = 21.9 Hz, C3/5H, F-Phe), 120.1 (C5H, Pyr), 131.4 (d, 3JCF = 9.6 Hz, C2/6H, F-Phe), 133.0 (d, 
4JCF = 2.9 Hz, C1, F-Phe), 145.9 (C4, Pyr), 147.5 (C6H, Pyr), 152.49 (COOtBu), 152.7 (C1, Pyr), 165.2 
(d, 1JCF = 252.2 Hz, CF), 195.31 (CO) ppm. 
HPLC (Method 1): tR = 5.8 min. 
LC-MS (ESI, 70 eV): m/z = 331 [MH]+, 275 [MH2- tBu]+ (calc. m/z = 330). 
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1-(4-Fluorophenyl)-2-(2-fluoropyridin-4-yl)-2-(hydroximino)ethan-1-one (124) 
 
C13H8F2N2O2 (Mr 262.22) 
Sodium nitrite (2.06 g, 29.8 mmol) in 12 ml H2O was added dropwise to a stirred solution of 1 
(2.30 g, 9.86 mmol) in 17 ml glacial acetic acid at 10 °C over 10 min. After stirring at rt for 1 h, 
30 ml H2O were added and the resulting bright yellow suspension was stirred for another 3.5 h 
at the same temperature. The suspension was cooled to 8 °C, filtered, and the residue was 
washed with H2O and dried under reduced pressure to afford 124 as a colorless solid (98 % 
HPLC purity). 
Yield: 2.46 g (9.38 mmol, 95 %) (Lit.203: 84 %). 
m.p.: 185 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 7.19 (bs, 1 H, C3H, Pyr), 7.37-7.46 (m, 3 H, C5H, Pyr and C3/5H, 
F-Phe), 7.92-7.98 (m, 2 H, C2/6H, F-Phe), 8.30 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr), 12.67 (s, 1 H, OH) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 105.4 (d, 2JCF = 38.9 Hz, C3H, Pyr), 116.7 (d, 2JCF = 22.5 Hz, C3/5H, 
F-Phe), 118.2 (d, 4JCF = 4.2 Hz, C5H, Pyr), 130.8 (d, 4JCF = 2.7 Hz, C1, F-Phe), 132.2 (d, 3JCF = 10.1 Hz, 
C2/6H, F-Phe), 144.3 (d, 3JCF = 8.4 Hz, C4, Pyr), 148.8 (d, 5JCF = 15.6 Hz, C6H, Pyr), 151.9 (d, 
4JCF = 4.0 Hz, CNOH), 163.5 (d, 1JCF = 235.6 Hz, C2F, Pyr), 166.0 (d, 1JCF = 254.8 Hz, C4F, F-Phe), 
192.04 (CO) ppm. 
IR (ATR): ν̃ = 2860, 2373, 1667, 1593, 1543, 1504, 1417, 1289, 1262, 1233, 1192, 1153, 1074, 
995, 945, 893, 868, 839, 752, 733, 694, 663, 637, 617, 588 cm-1. 
HPLC (Method 1): tR = 4.4 min. 
LC-MS (ESI, 70 eV): m/z = 263 [MH]+ (calc. m/z = 262). 
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2-(2-Bromopyridin-4-yl)-1-(4-fluorophenyl)-2-hydroximino)ethan-1-one (129) 
 
C13H8BrFN2O2 (Mr 323.12) 
129 was synthesized according to the procedure for 124 from 128 (150 mg, 510 µmol) in 1 ml 
glacial acetic acid and sodium nitrite (106 mg, 1.54 mmol in 0.6 ml H2O). 129 was obtained as a 
colorless solid (99 % HPLC purity). 
Yield: 151 mg (466 µmol, 92 %) (Lit.203: 82 %). 
1H NMR (300 MHz, DMSO-d6): δ = 7.40-7.46 (m, 3 H, C5H, Pyr and C3/5H, F-Phe), 7.63 (s, 1 H, C3H, 
Pyr), 7.94-7.98 (m, 2 H, C2/6H, F-Phe), 8.44 (d, 3J = 5.0 Hz, 1 H, C6H, Pyr), 12.70 (s, 1 H, NOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 116.8 (d, 2JCF = 22.5 Hz, C3/5H, F-Phe), 119.5 (C5H, Pyr), 123.3 
(C3H, Pyr), 130.8 (d, 4JCF = 2.7 Hz, C1, F-Phe), 132.3 (d, 3JCF = 10.1 Hz, C2/6H, F-Phe), 141.7 (C4, Pyr), 
142.1 (CBr), 151.4 (C6H, Pyr), 151.6 (CNOH), 166.1 (d, 1JCF = 254.9 Hz, CF), 192.0 (CO) ppm. 
HPLC (Method 3): tR = 5.3 min. 
LC-MS (ESI, 70 eV): m/z = 323, 324, 325 [MH]+ (calc. m/z = 323). 
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tert-Butyl (4-(2-(4-fluorophenyl)-1-(hydroxyimino)-2-oxoethyl)pyridin-2-yl)carbamate 
(136) 
 
C18H18FN3O4 (Mr 359.36) 
136 was synthesized according to the procedure for 124 from 135 (84.4 mg, 255 µmol) in 3 ml 
glacial acetic acid and sodium nitrite (53.3 mg, 772 µmol in 0.3 ml H2O). 136 was obtained as a 
colorless solid (100 % HPLC purity). 
Yield: 90.0 mg (250 µmol, 98 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.43 (s, 9 H, tBu), 7.04 (dd, 3J = 5.2 Hz, 4J = 1.5 Hz, 1 H, C5H, 
Pyr), 7.40-7.46 (m, 2 H, C3/5H, F-Phe), 7.91-7.96 (m, 2 H, C2/6H, F-Phe), 7.98 (bs, 1 H, C3H, Pyr), 
8.27 (dd, 3J = 5.2 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr), 9.93 (s, 1 H, NH), 12.36 (s, 1 H, NOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 28.0 (C(CH3)3), 79.9 (C(CH3)3), 107.8 (C3H, Pyr), 114.3 (C5H, 
Pyr), 116.8 (d, 2JCF = 22.4 Hz, C3/5H, F-Phe), 131.0 (d, 4JCF = 2.2 Hz, C1, F-Phe), 132.1 (d, 
3JCF = 10.0 Hz, C2/6H, F-Phe), 140.3 (C4, Pyr), 148.9 (C6H, Pyr), 152.6 (COOtBu), 153.0 (CNOH), 
153.2 (C2, Pyr), 165.9 (d, 1JCF = 254.9 Hz, CF), 192.7 (CO) ppm. 
HPLC (Method 3): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 304 [MH2- tBu]+ (calc. m/z = 359). 
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2-(4-Fluorophenyl)-1-(2-fluoropyridin-4-yl)-2-oxoethan-1-aminium chloride (125) 
 
C13H11ClF2N2O (Mr 284.69) 
To an intensely stirred solution of 124 (1.60 g, 6.10 mmol) in 15 ml 2-propanol and 20 ml 
HCl-sat. 2-propanol, Pd/C 10 % (279 mg) was added in one portion under a nitrogen atmos-
phere and stirring continued for 12 h at rt. The crude product was obtained by filtration, the 
residue was resuspended in methanol, filtered again, and the solvent was removed under re-
duced pressure. Recrystallization from methanol/diethyl ether provided 125 as beige solid 
(98 % HPLC purity). 
Yield: 1.43 g (5.03 mmol, 82 %) (Lit.203: quant.). 
m.p.: 216 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 6.56 (s, 1 H, CH), 7.35-7.41 (m, 2 H, C3/5H, F-Phe), 7.52-7.54 
(m, 2 H, C3/5H, Pyr), 8.21 (dd, 3J = 8.4 Hz, 4J = 5.6 Hz, 2 H, C2/6H, F-Phe), 8.31 (d, 3J = 5.4 Hz, 1 H, 
C6H, Pyr), 9.36 (bs, 3 H, NH3+) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 56.8 (CNH3+), 110.5 (d, 2JCF = 39.3 Hz, C3H, Pyr), 116.9 (d, 
2JCF = 22.1 Hz, C3/5H, F-Phe), 122.3 (d, 4JCF = 4.2 Hz, C5H, Pyr), 130.0 (d, 4JCF = 2.7 Hz, C1, F-Phe), 
132.9 (d, 3JCF = 9.8 Hz, C2/6H, F-Phe), 147.4 (d, 3JCF = 8.0 Hz, C4, Pyr), 149.4 (d, 5JCF = 15.0 Hz, C6H, 
Pyr), 163.5 (d, 1JCF = 236.7 Hz, C2F, Pyr), 166.3 (d, 1JCF = 255.1 Hz, C4F, F-Phe), 191.4 (CO) ppm. 
IR (ATR): ν̃ = 2810, 2361, 1694, 1616, 1597, 1560, 1521, 1508, 1419, 1281, 1256, 1238, 1161, 
1007, 974, 945, 849, 835, 792, 725, 681, 652, 606, 565, 554 cm-1. 
HPLC (Method 1): tR = 2.3 min. 
LC-MS (ESI, 70 eV): m/z 249 =  [M-Cl]+ (calc. m/z = 285). 
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1-(2-Bromopyridin-4-yl)-2-(4-fluorophenyl)-2-oxoethan-1-aminium chloride (130) 
 
C13H12ClFN2O (Mr 266.70) 
130 was synthesized according to the procedure for 125 from 129 (140 mg, 433 µmol) in 1 ml 
2-propanol and 1.5 ml HCl-sat. 2-propanol, and Pd/C 10 % (24 mg). The crude product was ob-
tained by filtration, the residue was resuspended in methanol, filtered again, and the solvent was 
removed under reduced pressure. 130 was obtained as a colorless solid (86 % HPLC purity).  
Yield: 103 mg (298 µmol, 69 %) (Lit.203: quant.). 
HPLC (Method 3): tR = 1.7 min. 
LC-MS (ESI, 70 eV): m/z = 231 [M-Cl]+ (calc. m/z = 267).  
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1-(2-((tert-Butoxycarbonyl)amino)pyridin-4-yl)-2-(4-fluorophenyl)-2-oxoethan-1-
aminium chloride and 4-(1-ammonio-2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-aminium 
chloride (137) 
 
C18H21ClFN3O3 (Mr 381.83) and C13H14Cl2FN3O (Mr 318.17) 
137 was synthesized according to the procedure for 125 from 136 (80.0 mg, 223 µmol) in 
0.5 ml 2-propanol and 1.0 ml HCl-sat. 2-propanol and Pd/C 10 % (14 mg) to afford 137 as a 
beige mixture of two solid derivatives (together 100 % HPLC purity). 
Yield: 75.5 mg (approx. 205 µmol, 92 %). 
HPLC (Method 3): tR1 = 3.4 min, tR2 = 1.4 min. 
LC-MS (ESI, 70 eV): m/z = 346 [MH-Cl]+, 290 [MH- tBu, Cl]+ and m/z 246 [M-H]+ (calc. m/z = 382, 
318). 
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2-Fluoro-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridine (119) 
 
C15H11F2N3S (Mr 303.33) 
A mixture of 125 (4.41 g, 15.5 mmol) and methyl thiocyanate (3.18 ml, 46.5 mmol) was refluxed 
under a nitrogen atmosphere for 45 min in 140 ml anhyd. DMF and stirred 45 min at rt before 
ice-cold H2O (400 ml) was added. The suspension was cooled to 8 °C, filtered, the residue was 
washed with H2O, and dried under reduced pressure to afford 119 as fine yellow solid (100 % 
HPLC purity). 
Yield: 3.59 g (11.8 mmol, 76 %) (Lit.203: 77 %). 
m.p.: 205 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3 H, SCH3), 7.09 (bs, 1 H, C3H, Pyr), 7.26-7.34 (m, 3 H, 
C5H, Pyr and C3/5H, F-Phe), 7.49-7.54 (m, 2 H, C2/6H, F-Phe), 8.09 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr), 
12.84 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.9 (SCH3), 105.0 (d, 2JCF = 39.5 Hz, C3H, Pyr), 115.9 (d, 
2JCF = 21.6 Hz, C3/5H, F-Phe), 118.5 (d, 4JCF = 2.5 Hz, C5H, Pyr), 126.5 (C1, F-Phe), 130.9 (C2/6H, 
F-Phe), 132.9 (d, 3JCF = 8.6 Hz, C4, Pyr), 143.0 (C2, Imdz), 147.6 (d, 3JCF = 16.1 Hz, C6H, Pyr), 162.1 
(d, 1JCF = 246.4 Hz, CF, F-Phe), 163.7 (d, 1JCF = 233.3 Hz, CF, Pyr) ppm. 
IR (ATR): ν̃ = 2980, 1613, 1553, 1506, 1423, 1292, 1238, 1219, 1157, 1098, 1003, 982, 885, 868, 
851, 829, 816, 702, 679, 635, 617, 586 cm-1. 
HPLC (Method 1): tR = 4.8 min. 
LC-MS (ESI, 70 eV): m/z = 304 [MH]+ (calc. m/z = 303). 
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4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-amine (120) 
 
C15H13FN4S (Mr 300.36) 
Method A. A solution of 119 (1.00 g, 3.30 mmol) in 15 ml 32 % aq. ammonia solution was heat-
ed in a high pressure reactor at 180 °C for 18 h. The reactor was allowed to reach rt and H2O was 
added. The crude product was obtained by filtration, washed with H2O and diisopropyl ether and 
purified by flash chromatography (SiO2, 50-100 % ethyl acetate/petrol ether) to afford 120 as a 
beige solid (100 % HPLC purity). 
Yield: 852 mg (2.84 mmol, 86 %) (Lit.193: 80 %). 
Method B. 120 was synthesized according to the procedure for 119 from 137 (75.5 mg, approx. 
205 µmol) and methyl thiocyanate (41.1 µl, 602 µmol) in 2 ml anhyd. DMF. The crude product 
was stirred in diluted aq. trifluoroacetic acid for 12 h, followed by neutralization with sat. aq. 
NaHCO3 solution. The mixture was extracted with ethyl acetate, washed with H2O and sat. aq. 
NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed under reduced pressure 
to afford 120 as a beige solid (97 % HPLC purity). 
Yield: 7.00 mg (233 µmol, 9 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (s, 1 H, SCH3), 5.79-5.95 (m, 2 H, NH2), 6.42-6.67 (m, 2 H, 
C3/5H, Pyr), 7.17-7.27 (m, 2 H, C3/5H, F-Phe), 7.48 (bs, 2 H, C2/6H, F-Phe), 7.74-7.86 (m, 1 H, C6H, 
Pyr), 12.58 (s, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 105.1 (C5H, Pyr), 110.0 (C3H, Pyr), 115.7 (d, 
3JCF = 21.1 Hz, C3/5H, F-Phe), 127.0 (s, C4/C5, Imdz), 129.2 (s, C1, F-Phe), 130.5 (d, 4JCF = 6.6 Hz, 
C2/6-H, F-Phe), 147.5 (C6H, Pyr), 160.1 (CF) ppm. 
HPLC (Method 2): tR = 4.4 min. 
LC-MS (ESI, 70 eV): m/z = 301 [MH]+ (calc. m/z = 300). 
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1-(4-Fluorophenyl)-2-(2-fluoropyridin-4-yl)ethane-1,2-dione (138) 
 
C13H7F2NO2 (Mr 247.20) 
123 (1.00 g, 4.29 mmol) and selenium dioxide (523 mg, 4.72 mmol) were dissolved in 25 ml 
glacial acetic acid under intense stirring and heated to 95 °C for 1.5 h. After completion, the 
reaction was cooled to rt, extracted with ethyl acetate, washed with sat. aq. NaHCO3 solution and 
sat. aq. NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (SiO2, 40-60 % ethyl 
acetate/petrol ether) to afford 138 as a yellow solid (100 % HPLC purity). 
Yield: 448 mg (1.81 mmol, 42 %) (Lit.218: 45 %). 
1H NMR (300 MHz, DMSO-d6): δ = 7.43-7.51 (m, 2 H, C3/5H, F-Phe), 7.67 (bs, 1 H, C3H, Pyr), 
7.81-7.83 (m, 1 H, C5H, Pyr), 8.10-8.16 (m, 2 H, C2/6H, F-Phe), 8.54 (d, 3J = 5.1 Hz, 1 H, C6H, Pyr) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 109.5 (d, 2JCF = 39.5 Hz, C3H, Pyr), 116.5 (d, 2JCF = 22.4 Hz, C3/5H, 
F-Phe), 121.3 (d, 4JCF = 4.6 Hz, C5H, Pyr), 128.7 (d, 4JCF = 2.7 Hz, C1, F-Phe), 133.6 (d, 3JCF = 10.1 Hz, 
C2/6H, F-Phe), 144.4 (d, 3JCF = 7.2 Hz, C4, Pyr), 149.4 (d, 3JCF = 14.5 Hz, C6H, Pyr), 163.5 (d, 
1JCF = 237.7 Hz, CF, Pyr), 166.3 (d, 1JCF = 255.7 Hz, CF, F-Phe), 189.6 (Pyr-COCO-Phe), 190.2 (d, 
4JCF = 3.2 Hz, Pyr-COCO-Phe) ppm. 
HPLC (Method 2): tR = 5.3 min. 
LC-MS (ESI, 70 eV): m/z = 248 [MH]+ (calc. m/z = 247). 
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2-Fluoro-4-(5-(4-fluorophenyl)-1H-imidazol-5-yl)pyridine (139) 
 
C14H9F2N3 (Mr 257.24) 
A few drops (catalytic amount) of glacial acetic acid were added to 138 (105 mg, 425 µmol), 
methenamine (11.8 mg, 84.0 µmol), and ammonium acetate (276 mg, 3.58 mmol) in a 
microwave reaction vessel. The mixture was heated in a microwave oven (117 °C) for 4 min 
(100 W), poured into H2O and 32 % aq. ammonia solution was added until pH 8 was reached. 
The precipitate was collected by filtration and purified by flash chromatography (SiO2, 20-100 % 
ethyl acetate/petrol ether) to afford 139 as a voluminous colorless solid (100 % HPLC purity). 
Yield: 60.1 mg (234 µmol, 55 %). 
1H NMR (300 MHz, DMSO-d6): δ = 7.12-7.13 (m, 1 H, C3H, Pyr), 7.30-7.36 (m, 3 H, C3/5H, F-Phe 
and C5H, Pyr), 7.50-7.55 (m, 2 H, C2/6H, F-Phe), 7.92 (bs, 1 H, C2H, Imdz), 8.10 (bs, 1 H, C6H, Pyr), 
12.84 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 105.3 (C3H, Pyr), 116.0 (d, 2JCF = 23.9 Hz, C3/5H, F-Phe), 118.7 
(d, 4JCF = 2.2 Hz, C5H, Pyr), 122.0 (C1, F-Phe), 127.1 (d, 3JCF = 10.5 Hz, C4, Pyr), 129.3 (C5, Imdz), 
131.0 (C2/6H, F-Phe), 132.1 (C4, Imdz), 136.5 (C2H, Imdz), 147.6 (d, 3JCF = 15.9 Hz, C6H, Pyr), 162.2 
(d, 1JCF = 253.8 Hz, CF, F-Phe), 163.7 (d, 1JCF = 233.2 Hz, CF, Pyr) ppm. 
HPLC (Method 2): tR = 4.9 min. 
LC-MS (ESI, 70 eV): m/z = 258 [MH]+ (calc. m/z = 257). 
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7.3.2 Syntheses of Series 1: Pyridine-2-amines and -piperazines 
General procedure for preparation of 4-(5-fluorophenyl-2-(methylthio)-1H-imidazol-4-
yl)pyridin-2-amines/piperazines (148-155) 
119 (1.0 equiv) was suspended in the respective amine/piperazine (4.0 to 6.0 equiv) in a glass 
screw cap tube and the intensely stirred mixture was heated to 160 °C. Progress of the reaction 
was monitored by HPLC control. After complete conversion the mixture was diluted with ethyl 
acetate, washed with sat. aq. NaHCO3 solution and H2O, dried over anhyd. Na2SO4, and concen-
trated under reduced pressure. The crude product was purified by flash chromatography (sta-
tionary phase, eluent, and mixing ratio given for each compound, respectively) to afford the par-
ticular compound. 
Syntheses were performed by LYDIA KUHL during her Bachelor thesis220. 
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N-(2,4-Dimethoxyphenyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-amine (148) 
 
C23H21FN4O2S (Mr 436.51) 
148 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
2,4-dimethoxyaniline (808 mg, 5.27 mmol). Purification was achieved by flash chromatography 
(SiO2, 20-90 % ethyl acetate/petrol ether) to afford 148 as greyish crystals (97 % HPLC purity). 
Yield: 312 mg (715 µmol, 54 %). 
m.p.: 206 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (s, 3 H, SCH3), 3.75 (s, 6 H, 2 OCH3), 6.39-6.44 (m, 1 H, 
C5H, (OCH3)2-Phe), 6.56-6.58 (m, 1 H, C3H, (OCH3)2-Phe), 6.63 (dd, 3J = 5.3 Hz, 4J = 1.2 Hz, 1 H, C5H, 
Pyr), 6.82 (s, 1 H, C3H, Pyr), 7.18-7.28 (m, 2 H, C3/5H, F-Phe), 7.41-7.46 (m, 2 H, C2/6H, F-Phe), 7.52 
(d, 3J = 8.7 Hz, 1 H, C6H, (OCH3)2-Phe), 7.71 (s, 1 H, NH), 7.95 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr), 12.60 
(s, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 55.2 (OCH3), 55.2 (OCH3), 99.0 (C3H, (OCH3)2-Phe), 
104.0 (C5H, (OCH3)2-Phe), 105.4 (C3H, Pyr), 111.5 (C5H, Pyr), 115.4 (dd, 2JCF = 21.8 Hz, C3/5H, 
F-Phe), 122.5 (C, Imdz), 123.6 (C6H, (OCH3)2-Phe), 126.8 (d, 4JCF = 3.1 Hz, C1, F-Phe), 130.0 (d, 
3JCF = 8.1 Hz, C2/6H, F-Phe), 134.9 (C1, (OCH3)2-Phe), 138.8 (C, Imdz), 141.7 (C2OCH3), 142.7 (C2, 
Imdz), 147.6 (C6H, Pyr), 152.2 (C4OCH3), 155.9 (C4, Pyr), 157.4 (C2, Pyr), 161.8 (d, 1JCF = 245.0 Hz, 
CF) ppm. 
HPLC (Method 1): tR = 3.4 min. 
LC-MS (ESI, 70 eV): m/z = 437 [MH]+, 219 [C12H15N2O2]+ (calc. m/z = 436). 
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N-(2-Ethoxyphenyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-
amine (149) 
 
C23H21FN4OS (Mr 420.51) 
149 was synthesized according to the general procedure from 119 (1.50 g, 4.95 mmol) and 
2-ethoxyaniline (3.88 ml, 29.7 mmol). Purification was achieved by flash chromatography (SiO2, 
20-90 % ethyl acetate/petrol ether) to afford 149 as dark red crystals (100 % HPLC purity). 
Yield: 1.10 g (2.62 mmol, 52 %). 
m.p.: 179 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.39 (t, 3J = 7.0 Hz, 3 H, CH2CH3), 2.63 (s, 3 H, SCH3), 4.03 (q, 
3J = 7.0 Hz, 2 H, CH2CH3), 6.76 (t, 3J = 7.7 Hz, 1 H, C5H, EtO-Phe), 6.81-6.84 (m, 2 H, C5H, Pyr and 
C3H, EtO-Phe), 6.91 (t, 3J = 7.7 Hz, 1 H, C4H, EtO-Phe), 6.97 (bs, 1 H, C3H, Pyr), 7.00-7.05 (t, 
3J = 8.7 Hz, 2 H, C3/5H, F-Phe), 7.21 (bs, 1 H, NH), 7.37-7.41 (m, 2 H, C2/6H, F-Phe), 7.49 (d, 
3J = 7.7 Hz, 1 H, C6H, EtO-Phe), 8.00 (d, 3J = 5.5 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 15.0 (CH3CH2), 16.6 (SCH3), 64.3 (CH2CH3), 106.5 (C3H, Pyr), 111.7 
(C3H, EtO-Phe), 112.9 (C5H, Pyr), 116.0 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 120.0 (C6H, EtO-Phe), 
120.7 (C5H, EtO-Phe), 122.6 (C4H, EtO-Phe), 129.4 (C1, EtO-Phe), 130.5 (d, 3JCF = 8.1 Hz, C2/6H, 
F-Phe), 143.2 (C2, Imdz), 146.8 (C6H, Pyr), 148.7 (COEt), 155.5 (C2, Pyr), 162.5 (d, 1JCF = 249.0 Hz, 
CF) ppm. 
HPLC (Method 1): tR = 4.5 min. 
LC-MS (ESI, 70 eV): m/z = 421 [MH]+, 393 [M-C2H5]+ (calc. m/z = 420). 
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N-(3,4-Dimethoxyphenethyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-amine (150) 
 
C25H25FN4O2S (Mr 464.56) 
150 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
3,4-dimethoxyphenethylamine (900 µl, 5.31 mmol). Purification was achieved by flash chroma-
tography (SiO2, 20-90 % ethyl acetate/petrol ether) to afford 150 as yellow crystals (100 % 
HPLC purity). 
Yield: 550 mg (1.18 mmol, 90 %). 
m.p.: 87 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.55 (s, 3 H, SCH3), 2.69 (t, 3J = 6.9 Hz, 2 H, CH2CH2NH), 3.29 (m, 
2 H, CH2CH2NH), 3.74 (s, 3 H, C3OCH3), 3.75 (s, 3 H, C4OCH3), 4.86 (bs, 1 H, CH2CH2NH), 6.51 (d, 
3J = 5.2 Hz, 1 H, C5H, Pyr), 6.57 (d, 4J = 2.0 Hz, 1 H, C3H, Pyr), 6.57-6.70 (m, 3 H, C2/5/6H, 
(OCH3)2-Phe), 6.91-6.96 (m, 2 H, C3/5H, F-Phe), 7.32-7.36 (m, 2 H, C2/6H, F-Phe), 7.74 (d, 
3J = 5.8 Hz, 1 H, C6H, Pyr), 10.77 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 16.4 (SCH3), 35.1 (CH2CH2NH), 43.5 (CH2CH2NH), 55.9 (C3OCH3), 
55.9 (C4OCH3), 104.1 (C3H, Pyr), 111.0 (C5H, Pyr), 111.4 (C5H, (OCH3)2-Phe), 112.1 (C2H, 
(OCH3)2-Phe), 115.7 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 120.7 (C6H, (OCH3)2-Phe), 130.3 (d, 
3JCF = 8.2 Hz, C2/6H, F-Phe), 131.4 (C4/5, Imdz), 142.9 (C4, Pyr), 146.7 (C6H, Pyr, 147.7 (C4OCH3), 
149.0 (C3OCH3), 158.3 (C2, Pyr), 162.6 (d, 1JCF = 248.5 Hz, CF) ppm. 
HPLC (Method 1): tR = 3.5 min. 
LC-MS (ESI, 70 eV): m/z = 465 [MH]+, 301 [MH-C10H13O2]+, 165 [C10H13O2]+ (calc. m/z = 464). 
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N-(2-(1H-Indol-3-yl)-ethyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-amine (151) 
 
C25H22FN5S (Mr 443.54) 
151 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
tryptamine (845 mg, 5.27 mmol). Purification was achieved by flash chromatography (SiO2, 
20-90 % ethyl acetate/petrol ether) to afford 151 as yellowish-brown crystals (100 % HPLC 
purity). 
Yield: 427 mg (963 µmol, 73 %). 
m.p.: 122 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.61 (s, 3 H, SCH3), 2.95 (t, 3J = 6.6 Hz, 2 H, CH2CH2NH), 3.39 (t, 
3J = 6.6 Hz, 2 H, CH2CH2NH), 6.52 (d, 3J = 5.7 Hz, 1 H, C5H, Pyr), 6.52 (bs, 1 H, C2H, Indole), 6.87 (d, 
4J = 2.1 Hz, 1 H, C3H, Pyr), 6.95-7.01 (m, 2 H, C3/5H, F-Phe), 7.08 (t, 3J = 7.8 Hz, 1 H, C6H, Indole), 
7.16 (t, 3J = 7.9 Hz, 1 H, C5H, Indole), 7.30 (d, 3J = 7.9 Hz, 1 H, C4H, Indole), 7.35-7.39 (m, 2 H, 
C2/6H, F-Phe), 7.52 (d, 3J = 7.7 Hz, 1 H, C7H, Indole), 7.71 (d, 3J = 5.7 Hz, 1 H, C6H, Pyr), 8.38 (s, 1 H, 
NH, Indole) ppm. 
13C NMR (75 MHz, CDCl3): δ = 16.4 (SCH3), 25.1 (CH2CH2NH), 42.2 (CH2CH2NH), 104.0 (C3H, Pyr), 
110.6 (C5H, Pyr), 111.3 (C4H, Indole), 112.6 (C3, Indole), 115.8 (d, 2JCF = 21.6 Hz, C3/5H, F-Phe), 
118.6 (C7H, Indole), 119.4 (C6H, Indole), 122.1 (C5H, Indole), 122.5 (C2H, Indole), 127.2 (C8a, 
Indole), 130.3 (3JCF = 8.3 Hz, C2/6H, F-Phe), 136.4 (C3a, Indole), 143.3 (C2, Imdz), 145.1 (C6H, Pyr), 
158.0 (C2, Pyr) ppm. 
HPLC (Method 1): tR = 3.9 min. 
LC-MS (ESI, 70 eV): m/z = 444 [MH]+, 301 [MH-C10H9N]+, 144 [C10H9N]+ (calc. m/z = 443). 
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N-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-N',N'-dimethyl-
propan-1,3-diamine (152) 
 
C20H24FN5S (Mr 385.51) 
152 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
N1,N1-dimethylpropane-1,3-diamine (1.00 ml, 7.93 mmol). Purification was achieved by flash 
chromatography (SiO2, 20-90 % ethyl acetate/petrol ether, then methanol) and subsequent 
filtration, to afford 152 as a yellow solid (100 % HPLC purity). 
Yield: 175 mg (454 µmol, 35 %). 
m.p.: 129 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.61 (t, 3J = 6.8 Hz, 2 H, CH2CH2CH2), 2.13 (s, 6 H, N(CH3)2), 2.29 (t, 
3J = 6.9 Hz, 2 H, CH2N(CH3)2), 2.58 (s, 3 H, SCH3), 3.11 (t, 3J = 6.7 Hz, 2 H, CH2NH), 5.22 (bs, 1 H, 
CH2NH), 6.42-6.46 (m, 2 H, C3/5H, Pyr), 6.95-7.01 (m, 2 H, C3/5H, F-Phe), 7.35-7.39 (m, 2 H, C2/6H, 
F-Phe), 7.78 (dd, 3J = 5.4 Hz, 5J = 0.6 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 16.5 (SCH3), 26.7 (CH2CH2CH2), 45.2 (N(CH3)2), 57.6 (CH2N(CH3)2), 
104.0 (C3H, Pyr), 111.1 (C5H, Pyr), 115.5 (d, 2JCF = 21.5 Hz, C3/5H, F-Phe), 130.2 (d, 3JCF = 8.1 Hz, 
C2/6H, F-Phe), 142.7 (C2, Imdz), 147.9 (C6H, Pyr), 159.2 (C2, Pyr), 162.4 (d, 1JCF = 247.7 Hz, CF) 
ppm. 
HPLC (Method 1): tR = 1.9 min. 
LC-MS (ESI, 70 eV): m/z = 386 [MH]+, 301 [MH-C5H12N]+ (calc. m/z = 385). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-piperazine 
(153) 
 
C19H20FN5S (Mr 369.46) 
153 was synthesized according to the general procedure from 119 (300 mg, 989 µmol) and 
piperazine (341 mg, 3.96 mmol). Purification was achieved by flash chromatography (bas. Al2O3, 
100 % methanol) to afford 153 as a yellow solid (100 % HPLC purity). 
Yield: 63.0 mg (171 µmol, 17 %). 
m.p.: 146 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (bs, 3 H, SCH3), 2.73 (t, 3J = 4.5 Hz, 4 H, C2/6H2, Pipera-
zine), 3.31 (t, 3J = 4.6 Hz, 4 H, C3/5H2, Piperazine), 6.56 (d, 3J = 5.1 Hz, 1 H, C5H, Pyr), 6.80 (bs, 1 H, 
C3H, Pyr), 7.20-7.26 (m, 2 H, C3/5H, F-Phe), 7.47-7.51 (m, 2 H, C2/6H, F-Phe), 7.97 (d, 3J = 5.1 Hz, 
1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 45.3 (C2/6H2, Piperazine), 45.8 (C3/5H2, Piperazine), 
103.8 (C3H, Pyr), 110.6 (C5H, Pyr), 115.4 (d, 2JCF = 21.6 Hz, C3/5H, F-Phe), 130.3 (d, 3JCF = 7.6 Hz, 
C2/6H, F-Phe), 142.3 (C2, Imdz), 147.6 (C6H, Pyr), 159.6 (C2, Pyr), 161.6 (d, 1JCF = 245.1 Hz, CF) 
ppm. 
HPLC (Method 1): tR = 2.9 min. 
LC-MS (ESI, 70 eV): m/z = 370 [MH]+, 327 [C17H16FN4S]+, 164 [C9H14N3]+ (calc. m/z = 369). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-4-methyl-
piperazine (154) 
 
C20H22FN5S (Mr 383.49) 
154 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
N-methylpiperazine (600 µl, 5.39 mmol). Purification was achieved by flash chromatography 
(RP-18, 20-90 % methanol/H2O) to afford 154 as a pale yellow solid (95 % HPLC purity). 
Yield: 115 mg (300 µmol, 23 %). 
m.p.: 111 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.28 (s, 3 H, CH3), 2.45 (t, 3J = 4.8 Hz, 4 H, C3/5H2, Piperazine), 2.57 
(s, 3 H, SCH3), 3.40 (t, 3J = 4.8 Hz, 4 H, C2/6H2, Piperazine), 6.54 (dd, 3J = 5.3 Hz, 4J = 1.1 Hz, 1 H, 
C5H, Pyr), 6.73 (bs, 1 H, C3H, Pyr), 6.91-6.97 (m, 2 H, C3/5H, F-Phe), 7.32-7.37 (m, 2 H, C2/6H, 
F-Phe), 7.94 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 16.5 (SCH3), 44.7 (C2/6H2, Piperazine), 45.6 (CH3), 54.4 (C3/5H2, 
Piperazine), 104.9 (C3H, Pyr), 111.9 (C5H, Pyr), 115.7 (d, 2JCF = 21.6 Hz, C3/5H, F-Phe), 128.2 (d, 
4JCF = 4.1 Hz, C1, F-Phe), 130.2 (d, 3JCF = 8.1 Hz, C2/6H, F-Phe), 142.8 (C2, Imdz), 147.9 (C6H, Pyr), 
159.6 (C2, Pyr), 162.5 (d, 1JCF = 248.3 Hz, CF) ppm. 
HPLC (Method 1): tR = 2.8 min. 
LC-MS (ESI, 70 eV): m/z = 384 [MH]+, 327 [C17H16FN4S]+, 192 [C10H8FNS]+, 177 [C10H15N3]+ 
(calc. m/z = 383). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-4-phenyl-
piperazine (155) 
 
C20H22FN5S (Mr 445.56) 
155 was synthesized according to the general procedure from 119 (400 mg, 1.32 mmol) and 
N-phenylpiperazine (800 µl, 5.23 mmol). The combined organic phases were extracted with 2 M 
aq. HCl solution, the aq. layer was neutralized with 2 M aq. KOH solution, and the pale yellow 
precipitate was collected by filtration, and purified by flash chromatography (SiO2, 20-90 % 
ethyl acetate/petrol ether) to afford 155 as yellow crystals (100 % HPLC purity). 
Yield: 291 mg (653 µmol, 50 %). 
m.p.: 101 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.64 (s, 3 H, SCH3), 3.19 (t, 3J = 5.1 Hz, 4 H, C2/6H2, Piperazine), 
3.58 (t, 3J = 5.1 Hz, 4 H, C3/5H2, Piperazine), 6.64 (dd, 3J = 5.4 Hz, 4J = 1.2 Hz, 1 H, C5H, Pyr), 
6.93-6.85 (m, 4 H, C3H, Pyr and C2/4/6H, Phe), 6.99-7.05 (m, 2 H, C3/5H, F-Phe), 7.26 (t, 3J = 8.0 Hz, 
2 H, C3/5H, Phe), 7.39-7.44 (m, 2 H, C2/6H, F-Phe), 8.00 (d, 3J = 5.5 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 16.5 (SCH3), 45.4 (C2/6H2, Piperazine), 49.0 (C3/5H2, Piperazine), 
105.1 (C3H, Pyr), 111.6 (C5H, Pyr), 115.8 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 116.3 (C2/6H, Phe), 120.2 
(C4H, Phe), 129.2 (C3/5H, Phe), 130.3 (d, 3JCF = 8.1 Hz, C2/6H, F-Phe), 143.0 (C2, Imdz), 146.9 (C6H, 
Pyr), 151.1 (C1, Phe), 159.0 (C2, Pyr), 162.6 (d, 1JCF = 248.5 Hz, CF) ppm. 
HPLC (Method 1): tR = 6.2 min. 
LC-MS (ESI, 70 eV): m/z = 446 [MH]+ (calc. m/z = 445). 
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3-(2,4-Dimethoxyphenyl)propionic acid (158) 
 
C11H14FO4 (Mr 210.23) 
2,4-Dimethoxycinnamic acid (100 mg, 471 µmol), one spatula of Pd/C 10 % and cyclohexene 
(0.2 ml) were dissolved in 5 ml methanol and the mixture was heated for 3 min to 95 °C in a 
microwave oven (100 W). After cooling to rt, the solids were filtered off and the solvent was 
removed under reduced pressure to afford 158 as a colorless solid (100 % HPLC purity). 
Yield: 96.0 mg (457 µmol, 95 %) (Lit.221: n.d.). 
1H NMR (300 MHz, CDCl3): δ = 2.60-2.65 (m, 2 H, CH2CH2COOH), 2.85-2.90 (m, 2 H, 
CH2CH2COOH), 3.79 (s, 3 H, C4OCH3), 3.80 (s, 3 H, C2OCH3), 6.41 (dd, 3J = 8.1 Hz, 4J = 2.4 Hz, 1 H, 
C5H, (OCH3)2-Phe), 6.44 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 7.05 (dd, 3J = 8.1 Hz, 5J = 0.3 Hz, 
1 H, C6H, (OCH3)2-Phe), 10.30 (vbs, 1 H, COOH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 24.4 (CH2CH2COOH), 33.3 (CH2CH2COOH), 54.3 (C4OCH3), 54.5 
(C2OCH3), 97.6 (C3H, (OCH3)2-Phe), 103.0 (C5H, (OCH3)2-Phe), 120.1 (C1, (OCH3)2-Phe), 129.3 
(C6H, (OCH3)2-Phe), 157.5 (C2OCH3), 158.8 (C4OCH3), 178.7 (COOH) ppm. 
HPLC (Method 2): tR = 5.1 min. 
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3-(2,4-Dimethoxyphenyl)propan-1-ol (159) 
 
C11H16O3 (Mr 196.25) 
Under a nitrogen atmosphere a solution of lithium aluminum hydride (120 mg, 3.16 mmol) in 
3 ml anhyd. THF was added dropwise to 158 (508 mg, 2.42 mmol) in 6 ml anhyd. THF at rt with 
intense stirring that continued for 1 h at the same temp. After completion, the reaction was 
cooled down in an ice-bath and quenched by successive addition of H2O (120 µl), 15 % aq. NaOH 
solution (120 µl), and H2O (360 µl). The precipitate was filtered off, washed with THF, and the 
filtrate was concentrated under reduced pressure. The crude product was purified by flash 
chromatography (SiO2, 20-30 % ethyl acetate/petrol ether) to afford 159 as colorless oil (97 % 
HPLC purity). 
Yield: 457 mg (2.33 mmol, 96 %) (Lit.221: n.d.). 
1H NMR (300 MHz, CDCl3): δ = 1.78-1.83 (m, 2 H, CH2CH2CH2OH), 2.65 (t, 3J = 7.3 Hz, 2 H, 
CH2CH2CH2OH), 3.59 (t, 3J = 6.3 Hz, 1 H, CH2CH2CH2OH), 3.78 (s, 1 H, OH), 3.79 (s, 3 H, C4OCH3), 
3.81 (s, 3 H, C2OCH3), 6.42-6.46 (m, 2 H, C3/5H, (OCH3)2-Phe), 7.03 (dd, 3J = 7.7 Hz, 5J = 0.6 Hz, 1 H, 
C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 25.4 (CH2CH2CH2OH), 33.2 (CH2CH2CH2OH), 55.5 (C2/4OCH3), 62.1 
(CH2CH2CH2OH), 98.6 (C3H, (OCH3)2-Phe), 104.3 (C5H, (OCH3)2-Phe), 122.4 (C1, (OCH3)2-Phe), 
130.4 (C6H, (OCH3)2-Phe), 158.3 (C2OCH3), 159.3 (C4OCH3) ppm. 
HPLC (Method 2): tR = 5.0 min. 
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1-(3-Bromopropyl)-2,4-dimethoxybenzene (156) 
 
C11H15BrO (Mr 259.14) 
To an ice-cold solution of 159 (260 mg, 1.33 mmol) in 4 ml anhyd. DCM, triphenylphosphine 
(412 mg, 1.57 mmol) and N-bromosuccinimide (263 mg, 1.48 mmol) were added under a 
nitrogen atmosphere and the reaction was stirred for 2 h at the same temp. The mixture was 
washed with H2O and sat. aq. NaCl solution, dried over anhyd. Na2SO4, and the solvent was 
removed under reduced pressure. Diethyl ether was added, the precipitate filtered off, and the 
filtrate was concentrated and purified by flash chromatography (SiO2, 2-10 % ethyl 
acetate/petrol ether) to afford 156 as colorless oil (95 % HPLC purity). 
Yield: 205 mg (791 µmol, 60 %) (Lit.222: 76 %). 
1H NMR (300 MHz, CDCl3): δ = 2.11 (quint, 3J = 5.6 Hz, 2 H, CH2CH2CH2Br), 2.70 (t, 3J = 7.2 Hz, 2 H, 
CH2CH2CH2Br), 3.39 (t, 3J = 6.8 Hz, 2 H, CH2CH2CH2Br), 3.80 (s, 6 H, C2/4OCH3), 6.42 (dd, 
3J = 8.0 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.45 (d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 7.05 
(dd, 3J = 8.0 Hz, 5J = 0.5 Hz, 1 H, C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 28.4 (CH2CH2CH2Br), 33.0 (CH2CH2CH2Br), 33.9 (CH2CH2CH2Br), 
55.3 (C4OCH3), 55.5 (C2OCH3), 98.7 (C3H, (OCH3)2-Phe), 103.9 (C5H, (OCH3)2-Phe), 121.4 (C1, 
(OCH3)2-Phe), 130.5 (C6H, (OCH3)2-Phe), 158.5 (C2OCH3), 159.6 (C4OCH3) ppm. 
HPLC (Method 2): tR = 6.5 min. 
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tert-Butyl benzyl(4-methylpyridin-2-yl)carbamate (161) 
 
C18H22N2O2 (Mr 298.39) 
A suspension of sodium hydride (1.30 g 60 % dispersion in mineral oil, 31.3 mmol) in 50 ml 
anhyd. DMF was added dropwise to a stirred solution of 132 (5.20 g, 25.0 mmol) in 57 ml anhyd. 
DMF at 0 °C under a nitrogen atmosphere, whereupon the temp. had to stay below 5 °C. The 
mixture was stirred for 20 min at 0 °C before benzyl bromide (3.40 ml, 28.8 mmol) was slowly 
added dropwise and stirring continued at the same temp. for 30 min. The mixture was allowed 
to reach rt over 1 h and stirring continued for another 1 h. The reaction was quenched by 
addition of H2O and extracted with ethyl acetate. The organic phase was washed with sat. aq. 
NaHCO3 solution and sat. aq. NaCl solution, dried over anhyd. Na2SO4, and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography 
(SiO2, 10-25 % ethyl acetate/petrol ether) to afford 161 as a colorless solid (100 % HPLC 
purity). 
Yield: 6.62 g (22.2 mmol, 87 %). 
1H NMR (300 MHz, CDCl3): δ = 1.43 (s, 9 H, tBu), 2.37 (s, 3 H, CH3), 5.23 (s, 2 H, CH2, Bn), 6.89 (dd, 
3J = 5.1 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 7.21-7.29 (m, 5 H, arCH, Bn), 7.54 (bs, 1 H, C3H, Pyr), 8.23 (d, 
3J = 5.2 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.4 (CH3), 28.3 (C(CH3)3), 50.3 (CH2, Bn), 81.5 (C(CH3)3), 120.5 
(C3H, Pyr), 121.1 (s, C5H, Pyr), 126.9 (s, arC4H, Bn), 127.3 (arC2/6H, Bn), 128.3 (arC3/5H, Bn), 139.5 
(arC1, Bn), 146.9 (C6H, Pyr), 149.0 (C4, Pyr), 154.3 (CO) ppm. 
IR (ATR): ν̃ = 2990, 1701, 1595, 1559, 1495, 1451, 1377, 1366, 1289, 1269, 1240, 1153, 1138, 
1105, 1074, 1063, 990, 955, 893, 883, 858, 822, 795, 774, 748, 733, 708 cm-1. 
HPLC (Method 1): tR = 6.9 min. 
LC-MS (ESI, 70 eV): m/z = 299 [MH]+, 243 [MH2-tBu]+ (calc. m/z = 298). 
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3-(2,4-Dimethoxyphenyl)-N-(4-methylpyridin-2-yl)propanamide (171) 
 
C17H20N2O3 (Mr 300.36) 
3-(2,4-Dimethoxyphenyl)propionic acid (600 mg, 2.85 mmol), PyBOP (1.78 g, 3.42 mmol), and 
DIPEA (1.49 ml, 8.53 mmol) were stirred in 10 ml anhyd. DMF at rt under a nitrogen atmosphere 
before 2-amino-4-methylpyridine (430 mg, 3.98 mmol) was added in one portion. The reaction 
was stirred for 12 h at 110 °C, quenched by addition of H2O, cooled to rt, and extracted with 
ethyl acetate. The combined organic phases were washed with H2O and sat. aq. NaCl solution, 
dried over anhyd. Na2SO4, and the solvent was removed under reduced pressure. The crude 
product was purified by flash chromatography (SiO2, 20-40 % ethyl acetate/petrol ether and 
RP-18, 50-100 % methanol/H2O) to afford 171 as a colorless solid (100 % HPLC purity). 
Yield: 248 mg (826 µmol, 29 %). 
m.p.: 87 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.36 (s, 3 H, CH3), 2.63 (t, 3J = 7.6 Hz, 2 H, CH2CH2CONH), 2.96 (t, 
3J = 7.7 Hz, 2 H, CH2CH2CONH), 3.77 (s, 3 H, C4OCH3), 3.78 (s, 3 H, C2OCH3), 6.39 (dd, 3J = 8.1 Hz, 
4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.43 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 6.83 (dq, 
3J = 5.1 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 7.06 (d, 3J = 8.1 Hz, 1 H, C6H, (OCH3)2-Phe), 8.07 (dd, 
3J = 5.3 Hz, 5J = 0.4 Hz, 1 H, C6H, Pyr), 8.09 (bs, 1 H, C3H, Pyr), 8.46 (vbs, 1 H, NH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.5 (CH3), 26.0 (CH2CH2CONH), 38.2 (CH2CH2CONH), 55.3 
(COCH3), 55.5 (COCH3), 98.6 (C3H, (OCH3)2-Phe), 104.1 (C5H, (OCH3)2-Phe), 114.7 (C3H, Pyr), 
120.9 (C5H, Pyr), 121.2 (C1, (OCH3)2-Phe), 130.4 (C6H, (OCH3)2-Phe), 147.1 (C6H, Pyr), 150.2 (C4, 
Pyr), 151.6 (C2, Pyr), 158.4 (C2OCH3), 159.7 (C4OCH3), 171.7 (CO) ppm. 
HPLC (Method 2): tR = 4.8 min. 
LC-MS (ESI, 70 eV): m/z = 301 [MH]+ (calc. m/z = 300). 
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N-(3-(2,4-Dimethoxyphenyl)propyl)-4-methylpyridin-2-amine (172) 
 
C17H22N2O2 (Mr 286.38) 
172 was synthesized according to the procedure for 159 from 171 (500 mg, 1.67 mmol) in 5 ml 
anhyd. THF and lithium aluminum hydride solution (78.0 mg, 2.06 mmol in 2 ml anhyd. THF). 
The crude product was purified by flash chromatography (SiO2, 20-40 % ethyl acetate/petrol 
ether and RP-18, 50-100 % methanol/H2O) to afford 172 as a colorless crystalline solid (100 % 
purity, HPLC). 
Yield: 133 mg (464 µmol, 28 %). 
m.p.: 88 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.87 (quint, 3J = 7.2 Hz, 2 H, CH2CH2CH2NH), 2.22 (s, 3 H, CH3), 
2.65 (t, 3J = 7.5 Hz, 2 H, CH2CH2CH2NH), 3.23 (q, 3J = 6.5 Hz, 2 H, CH2CH2CH2NH), 3.79 (s, 6 H, 
2 OCH3), 4.59 (m, 1 H, NH), 6.15-6.16 (m, 1 H, C3H, Pyr), 6.38-6.41 (m, 1 H, C5H, Pyr), 6.42 (dd, 
3J = 8.1 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.45 (d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 7.03 (d, 
3J = 8.0 Hz, 1 H, C6H, (OCH3)2-Phe), 7.93 (d, 3J = 5.2 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.4 (CH3), 27.1 (CH2CH2CH2NH), 29.9 (CH2CH2CH2NH), 41.9 
(CH2CH2CH2NH), 55.4 (OCH3), 55.5 (OCH3), 98.6 (C3H, (OCH3)2-Phe), 104.0 (C5H, (OCH3)2-Phe), 
106.7 (C3H, Pyr), 114.3 (C5H, Pyr), 122.5 (C1, (OCH3)2-Phe), 130.2 (C6H, (OCH3)2-Phe), 147.8 (C6H, 
Pyr), 148.6 (C4, Pyr), 158.4 (C2OCH3), 159.3 (C2, Pyr), 159.4 (C4OCH3) ppm. 
HPLC (Method 2): tR = 4.2 min. 
LC-MS (ESI, 70 eV): m/z = 287 [MH]+ (calc. m/z = 286). 
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tert-Butyl (3-(2,4-dimethoxyphenyl)propyl)(4-methylpyridin-2-yl)carbamate (167) 
 
C22H30N2O4 (Mr 386.49) 
Method A. 132 (138 mg, 663 µmol) was dissolved in 1.5 ml anhyd. DMF at 0 °C under a nitrogen 
atmosphere before sodium hydride (39.0 mg 60 % dispersion in mineral oil, 975 µmol) in 2 ml 
anhyd. DMF was slowly added whereas the temp. was kept below 5 °C. The mixture was stirred 
at the same temp. for 20 min, 156 (144 mg, 556 µmol) in 3 ml anhyd. DMF was added, and stir-
ring continued for another 30 min at 0 °C. The reaction was allowed to reach rt over 1 h, stirred 
for another 1 h, and quenched with H2O. The mixture was extracted with ethyl acetate, washed 
with 0.1 M aq. HCl, sat. aq. NaHCO3 solution, and sat. aq. NaCl solution, dried over anhyd. Na2SO4, 
and the solvent was removed under reduced pressure to afford 167 as pale yellowish oil (100 % 
HPLC purity). 
Yield: 202 mg (523 µmol, 94 %). 
Method B. A solution of 172 (120 mg, 419 µmol), Boc2O (134 mg, 614 µmol) and 4-DMAP 
(30.0 mg, 246 µmol) in anhyd. THF was stirred for 24 h at rt. The solvent was removed under 
reduced pressure, the residue was resuspended in ethyl acetate, washed with H2O and sat. aq. 
NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed under reduced pressure 
and the crude product was purified by flash chromatography (SiO2, 10-40 % ethyl acetate/petrol 
ether) to afford 167 as colorless oil (100 % HPLC purity) 
Yield: 109 mg (282 µmol, 67 %). 
1H NMR (300 MHz, CDCl3): δ = 1.48 (s, 9 H, tBu), 1.79-1.90 (m, 2 H, CH2CH2CH2NR2), 2.33 (s, 3 H, 
CH3), 2.54 (t, 3J = 7.8 Hz, 2 H, CH2CH2CH2NR2), 3.75 (s, 3 H, C2OCH3), 3.77 (s, 3 H, C4OCH3), 3.95 (t, 
3J = 7.4 Hz, 2 H, CH2CH2CH2NR2), 6.38 (dd, 3J = 8.0 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.41 (d, 
4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 6.83 (dq, 3J = 5.1 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 6.99 (dd, 
3J = 8.0 Hz, 5J = 0.3 Hz, 1 H, C6H, (OCH3)2-Phe), 7.39 (m, 1 H, C3H, Pyr), 8.23 (dd, 3J = 5.1 Hz, 
5J = 0.5 Hz, 1 H, C6H, Pyr) ppm. 
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13C NMR (75 MHz, CDCl3): δ = 21.2 (CH3), 27.1 (CH2CH2CH2NR2), 28.4 (C(CH3)3), 29.2 
(CH2CH2CH2NR2), 47.0 (CH2CH2CH2NR2), 55.3 (C2OCH3), 55.5 (C4OCH3), 80.7 (C(CH3)3), 98.5 (C3H, 
(OCH3)2-Phe), 103.8 (C5H, (OCH3)2-Phe), 121.0 (C5H, Pyr), 121.0 (C3H, Pyr), 122.9 (C1, 
(OCH3)2-Phe), 129.9 (C6H, (OCH3)2-Phe), 147.4 (C6H, Pyr), 148.1 (C4, Pyr), 154.5 (CO), 154.9 (C2, 
Pyr), 158.4 (C2OCH3), 159.2 (C4OCH3) ppm. 
HPLC (Method 2): tR = 6.6 min. 
LC-MS (ESI, 70 eV): m/z = 387 [MH]+, 331[MH2-tBu]+, 287 [MH2-Boc]+ (calc. m/z = 386). 
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tert-Butyl benzyl(4-(2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-yl)carbamate (163) 
 
C25H25FN2O3 (Mr 420.48) 
163 was synthesized according to the procedure for 123 from 161 (6.38 g, 21.4 mmol), ethyl 
4-fluorobenzoate (6.28 ml, 42.8 mmol) in 26 ml anhyd. THF, and NaHMDS (21.4 ml 2 M solution 
in THF, 42.8 mmol), but required further purification by flash chromatography (SiO2, 5-20 % 
ethyl acetate/petrol ether). 163 was obtained as a colorless solid (98 % HPLC purity). 
Yield: 8.40 g (20.0 mmol, 93 %). 
1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 9 H, tBu), 4.16 (s, 2 H, CH2), 5.11 (s, 2 H, CH2, Bn), 6.83 (dd, 
3J = 5.1 Hz, 4J = 1.5 Hz, 2 H, C5H, Pyr), 7.02-7.19 (m, 7 H, arCH, Bn and C3/5H, F-Phe), 7.60 (d, 
5J = 0.6 Hz, 1 H, C3H, Pyr), 7.90-7.95 (m, 2 H, C2/6H, F-Phe), 8.23 (dd, 3J = 5.1 Hz, 5J = 0.6 Hz, 1 H, 
C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 28.2 (C(CH3)3), 44.9 (CH2), 50.2 (CH2, Bn), 81.5 (C(CH3)3), 116.0 (d, 
2JCF = 22.0 Hz, C3/5H, F-Phe), 120.2 (C3H, Pyr), 120.7 (C5H, Pyr), 126.8 (arC4H, Bn), 127.3 (arC2/6H, 
Bn), 128.2 (arC3/5H, Bn), 131.3 (d, 3JCF = 9.4 Hz, C2/6H, F-Phe), 132.8 (d, 4JCF = 3.0 Hz, C1, F-Phe), 
139.6 (arC1, Bn), 144.5 (C4, Pyr), 147.7 (C6H, Pyr), 154.3 (C2, Pyr), 154.9 (COOtBu), 166.0 (d, 
1JCF = 255.5 Hz, CF), 194.5 (CO) ppm. 
HPLC (Method 1): tR = 7.2 min. 
LC-MS (ESI, 70 eV): m/z = 421 [MH]+, 365 [MH2-tBu]+ (calc. m/z = 420). 
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tert-Butyl (3-(2,4-dimethoxyphenyl)propyl)(4-(2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-
yl)carbamate (168) 
 
C29H33FN2O5 (Mr 508.59) 
168 was synthesized according to the procedure for 123 from 167 (202 mg, 517 µmol), ethyl 
4-fluorobenzoate (200 µl, 1.36 mmol) in 3 ml anhyd. THF, and NaHMDS (500 µl 2 M solution in 
THF, 1.00 mmol), but required further purification by flash chromatography (SiO2, 5-35 % ethyl 
acetate/petrol ether). 168 was obtained as yellow oil (100 % HPLC purity). 
Yield: 126 mg (249 µmol, 48 %). 
1H NMR (300 MHz, CDCl3): δ = 1.47 (s, 9 H, tBu), 1.85-1.90 (m, 2 H, CH2CH2CH2NR2), 2.55 (t, 
3J = 7.7 Hz, 2 H, CH2CH2CH2NR2), 3.75 (s, 3 H, C2OCH3), 3.77 (s, 3 H, C4OCH3), 3.97 (t, 3J = 7.5 Hz, 
2 H, CH2CH2CH2NR2), 4.24 (s, 2 H, CH2), 6.38 (dd, 3J = 8.0 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 
6.41 (d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 6.90 (dd, 3J = 5.1 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 6.99 (d, 
3J = 8.1 Hz, 1 H, C6H, (OCH3)2-Phe), 7.10-7.16 (m, 2 H, C3/5H, F-Phe), 7.57 (bs, 1 H, C6H, Pyr), 
7.99-8.04 (m, 2 H, C2/6H, F-Phe), 8.32 (dd, 3J = 5.1 Hz, 5J = 0.6 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 27.1 (CH2CH2CH2NR2), 28.4 (C(CH3)3), 29.2 (CH2CH2CH2NR2), 44.9 
(CH2), 47.0 (CH2CH2CH2NR2), 55.3 (C2OCH3), 55.5 (C4OCH3), 81.0 (C(CH3)3), 98.5 (C3H, 
(OCH3)2-Phe), 103.8 (C5H, (OCH3)2-Phe), 116.1 (d, 2JCF = 22.0 Hz, C3/5H, F-Phe), 120.6 (C5H, Pyr), 
120.8 (C6H, Pyr), 122.8 (C1, (OCH3)2-Phe), 129.9 (C6H, (OCH3)2-Phe), 131.3 (d, 3JCF = 9.4 Hz, C2/6H, 
F-Phe), 132.8 (d, 4JCF = 2.9 Hz, C1, F-Phe), 144.3 (C4, Pyr), 147.6 (C3H, Pyr), 154.3 (COOtBu), 155.1 
(C2, Pyr), 158.4 (C2OCH3), 159.2 (C4OCH3), 166.1 (d, 1JCF = 255.7 Hz, CF), 194.5 (CO) ppm. 
HPLC (Method 2): tR = 6.8 min. 
LC-MS (ESI, 70 eV): m/z = 509 [MH]+, 453 [MH2-tBu]+ (calc. m/z = 508). 
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tert-Butyl benzyl(4-(2-(4-fluorophenyl)-1-(hydroxyimino)-2-oxoethyl)pyridin-2-yl)-
carbamate (165) 
 
C25H24FN3O4 (Mr 449.48) 
165 was synthesized according to the procedure for 124 from 163 (8.40 g, 20.0 mmol) in 95 ml 
glacial acetic acid, and sodium nitrite (4.17 g, 60.4 mmol in 23 ml H2O). 165 was obtained as a 
pale beige solid (97 % HLC purity). 
Yield: 8.61 g (19.2 mmol, 96 %). 
1H NMR (300 MHz, CDCl3): δ = 1.35 (s, 9 H, tBu), 5.17 (s, 2 H, CH2, Bn), 7.09 (dd, 3J = 5.3 Hz, 
4J = 1.5 Hz, 1 H, C5H, Pyr), 7.12-7.24 (m, 7 H, arCH, Bn and C3/5H, F-Phe), 7.87 (bs, 1 H, C3H, Pyr), 
7.91-7.95 (m, 2 H, C2/6H, F-Phe), 8.35 (dd, 3J = 5.3 Hz, 5J = 0.7 Hz, 1 H, C6H, Pyr), 9.09 (bs, 1 H, 
NOH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 28.2 (C(CH3)3), 50.4 (CH2, Bn), 82.5 (C(CH3)3), 116.2 (C3H, Pyr), 
116.4 (C5H, Pyr), 116.6 (d, 2JCF = 22.3 Hz, C3/5H, F-Phe), 127.1 (arC4H, Bn), 127.3 (arC2/6H, Bn), 
128.4 (arC3/5H, Bn), 131.1 (d, 4JCF = 3.1 Hz, C1, F-Phe), 132.4 (d, 3JCF = 9.7 Hz, C2/6H, F-Phe), 138.8 
(arC1, Bn), 140.6 (C4, Pyr), 147.7 (C6H, Pyr), 154.0 (CNOH), 154.4 (C2, Pyr), 154.8 (COOtBu), 167.0 
(d, 1JCF = 258.0 Hz, CF), 191.8 (CO) ppm. 
HPLC (Method 1): tR = 7.1 min. 
LC-MS (ESI, 70 eV): m/z = 450 [MH]+, 394 [MH-tBu]+ (calc. m/z = 449). 
E x p e r i m e n t a l  | 195 
 
 
tert-Butyl (3-(2,4-dimethoxyphenyl)propyl)(4-(2-(4-fluorophenyl)-1-(hydroxyimino)-2-
oxoethyl)pyridin-2-yl)carbamate (169) 
 
C29H32FN3O6 (Mr 537.59) 
169 was synthesized according to the procedure for 124 from 168 (110 mg, 216 µmol) in 3 ml 
glacial acetic acid, and sodium nitrite (45.0 mg, 652 µmol in 0.5 ml H2O). 169 was obtained as 
brownish oil (98 % HPLC purity). 
Yield: 114 mg (212 µmol, quant.). 
1H NMR (300 MHz, CDCl3): δ = 1.41 (s, 9 H, tBu), 1.81-1.86 (m, 2 H, CH2CH2CH2NR2), 2.52 (t, 
3J = 7.7 Hz, 2 H, CH2CH2CH2NR2), 3.73 (s, 3 H, C2OCH3), 3.77 (s, 3 H, C4OCH3), 3.94 (t, 3J = 7.4 Hz, 
2 H, CH2CH2CH2NR2), 6.37 (dd, 3J = 8.1 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.40 (d, 4J = 2.3 Hz, 
1 H, C3H, (OCH3)2-Phe), 6.96 (d, 3J = 8.1 Hz, 1 H, C6H, (OCH3)2-Phe), 7.09 (dd, 3J = 5.3 Hz, 
4J = 1.5 Hz, 1 H, C5H, Pyr), 7.12-7.18 (m, 2 H, C3/5H, F-Phe), 7.77 (bs, 1 H, C3H, Pyr), 7.93-7.98 (m, 
2 H, C2/6H, F-Phe), 8.35 (dd, 3J = 5.3 Hz, 5J = 0.8 Hz, 1 H, C6H, Pyr), 9.01 (vbs, 1 H, CNOH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 27.0 (CH2CH2CH2NR2), 28.3 (C(CH3)3), 29.1 (CH2CH2CH2NR2), 47.2 
(CH2CH2CH2NR2), 55.3 (C2OCH3), 55.5 (C4OCH3), 81.5 (C(CH3)3), 98.6 (C3H, (OCH3)2-Phe), 103.9 
(C5H, (OCH3)2-Phe), 116.2 (C5H, Pyr), 116.6 (d, 2JCF = 22.4 Hz, C3/5H, F-Phe), 116.8 (C3H, Pyr), 
122.7 (C1, (OCH3)2-Phe), 129.9 (C6H, (OCH3)2-Phe), 131.2 (d, 4JCF = 2.9 Hz, C1, F-Phe), 132.4 (d, 
3JCF = 9. 8 Hz, C2/6H, F-Phe), 139.8 (C4, Pyr), 148.3 (C6H, Pyr), 154.1 (COOtBu), 154.8 (CNOH), 
155.5 (C2, Pyr), 158.4 (C2OCH3), 159.2 (C4OCH3), 166.9 (d, 1JCF = 258.0 Hz, CF), 191.8 (CO) ppm. 
HPLC (Method 2): tR = 6.8 min. 
LC-MS (ESI, 70 eV): m/z = 538 [MH]+, 482 [MH2-tBu]+ (calc. m/z = 537). 
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1-(2-(Benzyl(tert-butoxycarbonyl)amino)pyridin-4-yl)-2-(4-fluorophenyl)-2-oxoethan-1-
aminium chloride (166) 
 
C20H19ClFN3O (Mr 371.84) 
166 was synthesized according to the procedure for 125 from 165 (8.18 g, 18.2 mmol) in 34 ml 
2-propanol and 66 ml HCl-sat. 2-propanol, and Pd/C 10 % (1.4 g). Recrystallization from diethyl 
ether afforded 166 as a beige solid (100 % HPLC purity). 
Yield: 6.49 g (17.5 mmol, 96 %). 
1H NMR (300 MHz, DMSO-d6): δ = 4.65 (s, 2 H, CH2, Bn), 6.52 (s, 1 H, CH), 6.98 (dd, 3J = 6.5 Hz, 
4J = 1.4 Hz, 1 H, C5H, Pyr), 7.28-7.41 (m, 9 H, arCH, Bn and NH and C3H, Pyr and C3/5H, F-Phe), 8.02 
(d, 3J = 6.5 Hz, 1 H, C6H, Pyr), 8.14-8.19 (m, 2 H, C2/6H, F-Phe), 9.36 (bs, 3 H, NH3+) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 45.2 (CH2, Bn), 56.6 (CNH3+), 111.3 (C5H, Pyr), 113.2 (C3H, Pyr), 
116.4 (d, 2JCF = 22.3 Hz, C3/5H, F-Phe), 127.6 (arC4H, Bn), 127.8 (arC2/6H, Bn), 128.5 (arC3/5H, Bn), 
129.6 (d, 4JCF = 2.7 Hz, C1, F-Phe), 132.4 (d, 3JCF = 9.7 Hz, C2/6H, F-Phe), 136.7 (arC1, Bn), 138.6 (C6H, 
Pyr), 146.9 (C4, Pyr), 153.0 (C2, Pyr), 165.8 (d, 1JCF = 255.0 Hz, CF), 190.7 (CO) ppm. 
HPLC (Method 1): tR = 3.4 min. 
LC-MS (ESI, 70 eV): m/z = 336 [M-Cl]+ (calc. m/z = 371). 
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1-(2-((3-(2,4-Dimethoxyphenyl)propyl)amino)pyridin-4-yl)-2-(4-fluorophenyl)-2-
oxoethan-1-aminium chloride (170) 
 
C24H27ClFN3O3 (Mr 459.95) 
170 was synthesized according to the procedure for 125 from 169 (110 mg, 205 µmol) in 1 ml 
2-propanol and 1.5 ml HCl-sat. 2-propanol, and Pd/C 10 % (20 mg). The crude product was 
obtained by filtration, the residue was rinsed with methanol. The filtrate was concentrated 
under reduced pressure. 170 was obtained by crystallization from diethyl ether as a colorless 
solid (97 % HPLC purity). 
Yield: 94.0 mg (204 µmol, 99 %). 
HPLC (Method 2): tR = 3.7 min. 
LC-MS (ESI, 70 eV): m/z = 424 [M-Cl]+ (calc. m/z = 459). 
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tert-Butyl (4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-
carbamate (160) 
 
C20H21FN4O2S (Mr 400.47) 
160 was synthesized according to the procedure described for 132 from 120 (200 mg, 
666 µmol) and Boc2O (189 mg, 866 µmol) in 2 ml tert-butanol. After completion, the mixture 
was diluted with ethyl acetate, washed with sat. aq. NaHCO3 solution, H2O, and sat. aq. NaCl 
solution, and dried over anhyd. Na2SO4. The solvent was removed under reduced pressure to 
afford 160 as a colorless solid (97 % HPLC purity). 
Yield: 134 mg (335 mmol, 50 %). 
m.p.: 177 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.43 (s, 9 H, tBu), 2.62 (s, 3 H, SCH3), 6.93-6.97 (m, 1 H, C5H, Pyr), 
7.13-7.31 (m, 2 H, C3/5H, F-Phe), 7.44-7.52 (m, 2 H, C2/6H, F-Phe), 7.85-8.01 (m, 1 H, C3H, Pyr), 
8.05-8.18 (m, 1 H, C6H, Pyr), 9.59-9.78 (m, 1 H, NH), 12.70-12.76 (m, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, CDCl3): δ = 15.2 (SCH3), 28.0 (C(CH3)3), 79.4 (C(CH3)3), 109.4 (C3H, Pyr), 115.0 
(C5H, Pyr), 115.8 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 126.7 (C2, Imdz), 130.8 (d, 3JCF = 8.5 Hz, C2/6H, 
F-Phe), 134.5 (C4, Pyr), 138.7, 139.5 (C4/5, Imdz), 143.6 (C2, Pyr), 147.5 (C6H, Pyr), 152.9 (CO), 
162.0 (d, 1JCF = 244.8 Hz, CF) ppm. 
IR (ATR): ν̃ = 2990, 2400, 1730, 1607, 1559, 1505, 1418, 1368, 1292, 1271, 1231, 1155, 1117, 
1053, 995, 837, 814, 766, 740, 698 cm-1. 
HPLC (Method 1): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 401 [MH]+, 345 [MH2-tBu]+, 301 [MH2-C5H9O2]+ (calc. m/z = 400). 
HRMS (EI, 70 eV): m/z = 400.1369 [M]+ (calc. m/z = 400.1369). 
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N-Benzyl-4-(4-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-amine (162) 
 
C22H19FN4S (Mr 390.48) 
Method A. 162 was synthesized according to the procedure for 161 from 120 (107 mg, 
356 µmol), sodium hydride (14.4 mg 60 % dispersion in mineral oil, 360 µmol), and benzyl 
bromide (50.0 ml, 418 µmol) in 2 ml anhyd. DMF. The crude product was purified by flash 
chromatography (SiO2, 10-60 % ethyl acetate/petrol ether) to afford 162 as a yellow solid (95 % 
HPLC purity). 
Yield: 23.0 mg (58.9 µmol, 17 %). 
Method B. 162 was synthesized according to the procedure for 161 from 160 (117 mg, 
292 µmol), sodium hydride (12.0 mg 60 % dispersion in mineral oil, 300 µmol), and benzyl 
bromide (50.0 ml, 418 µmol) in 2 ml anhyd. DMF. The crude product was stirred in diluted aq. 
trifluoroacetic acid at rt for 12 h. The mixture was neutralized, concentrated, and purified by 
flash chromatography (SiO2, 10-60 % ethyl acetate/petrol ether) to afford 162 as a yellow solid 
(95 % HPLC purity). 
Yield: 42.0 mg (108 µmol, 32 %). 
Method C. 162 was synthesized according to the procedure for 119 from 166 (156 mg, 
420 µmol) in 4 ml anhyd. DMF, and methyl thiocyanate (100 µl, 1.45 mmol), but required further 
purification by flash chromatography (SiO2, 10-60 % ethyl acetate/petrol ether). 162 was 
obtained as a yellow solid (95 % HPLC purity). 
Yield: 99.0 mg (254 µmol, 60 %). 
m.p.: 175 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (s, 3 H, SCH3), 4.42 (d, 4J = 6.0 Hz, 2 H, CH2, Bn), 6.48 (dd, 
3J = 5.3 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 6.73 (bs, 1 H, C3H, Pyr), 7.10-7.29 (m, 8 H, C3/5H, F-Phe and 
arCH, Bn and NH), 7.46 (m, 2 H, C2/6H, F-Phe), 7.81-7.90 (m, 1 H, C6H, Pyr), 12.60 (bs, 1 H, NH, 
Imdz) ppm. 
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13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 44.2 (CH2, Bn), 105.2 (C3H, Pyr), 110.1 (C5H, Pyr), 
115.5 (C3/5H, F-Phe), 126.5 (arC4H, Bn), 127.1 (arC2/6H, Bn), 128.1 (arC3/5H, Bn), 129.4 (C4/5, Imdz), 
130.6 (C2/6H, F-Phe), 134.9 (C4, Pyr), 140.5 (arC1, Bn), 142.0 (C2, Imdz), 146.7 (C6H, Pyr), 158.8 
(C1, Pyr) ppm. 
HPLC (Method 1): tR = 4.3 min. 
LC-MS (ESI, 70 eV): m/z = 391 [MH]+, 301 [MH2-Bn]+, 286 [MH2-NHBn]+, 91 [Bn]+ 
(calc. m/z = 390). 
HRMS (EI, 70 eV): m/z = 390.1314 [M]+ (calc. m/z = 390.1314). 
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N-(3-(2,4-Dimethoxyphenyl)propyl)-4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-
4-yl)pyridin-2-amine (164) 
 
C26H27FN4O2S (Mr 478.59) 
164 was synthesized according to the procedure for 119 from 170 (90.0 mg, 196 µmol) in 3 ml 
anhyd. DMF, and methyl thiocyanate (50.0 µl, 725 µmol), but required further purification by 
flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether and RP-18, 50-100 % 
methanol/H2O). 164 was obtained as a yellow solid (100 % HPLC purity). 
Yield: 36.0 mg (75.2 µmol, 38 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.67-1.72 (m, 2 H, CH2CH2CH2NH), 2.48-2.52 (m, 2 H, 
CH2CH2CH2NH), 2.60 (s, 3 H, SCH3), 3.13-3.17 (m, 2 H, CH2CH2CH2NH), 3.72 (s, 3 H, C4OCH3), 3.74 
(s, 3 H, C2OCH3), 6.41-6.50 (m, 5 H, C3/5H, Pyr and C3/5H, (OCH3)2-Phe and CH2CH2CH2NH), 7.01 
(d, 3J = 8.2 Hz, 1 H, C6H, (OCH3)2-Phe), 7.22 (m, 2 H, C3/5H, F-Phe), 7.48 (m, 2 H, C2/6H, F-Phe), 7.85 
(bs, C6H, Pyr), 12.58 (bs, 1H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 26.6 (CH2CH2CH2NH), 29.3 (CH2CH2CH2NH), 40.7 
(CH2CH2CH2NH), 55.1 (C4OCH3), 55.2 (C2OCH3), 98.3 (C3H, (OCH3)2-Phe), 104.3 (C5H, 
(OCH3)2-Phe), 104.9 (C3H, Pyr), 109.7 (C5H, Pyr), 115.4 (C3/5H, F-Phe), 121.8 (C1, (OCH3)2-Phe), 
126.5 (C4, Imdz), 127.0 (C5, Imdz), 129.7 (C1, F-Phe), 129.7 (C6H, (OCH3)2-Phe), 130.1 (C2/6H, 
F-Phe), 142.1 (C2, Imdz), 147.5 (C6H, Pyr), 157.9 (C2OCH3), 158.8 (C4OCH3), 159.3 (C2, Pyr) ppm. 
HPLC (Method 2): tR = 5.4 min. 
LC-MS (ESI, 70 eV): m/z = 479 [MH]+ (calc. m/z = 478). 
HRMS (EI, 70 eV): m/z = 478.1839 [M]+ (calc. m/z = 478.1839). 
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7.3.3 Syntheses of Series 2: Amide Coupling  
3-(2,5-Dimethoxyphenyl)-N-(4-methylpyridin-2-yl)propanamide (174) 
 
C17H20N2O3 (Mr 300.36) 
Method A. 3-(2,5-Dimethoxyphenyl)propionic acid (203 mg, 966 µmol) and CDI (190 mg, 
1.17 mmol) were stirred in 5 ml anhyd. DMF at rt until no further formation of CO2 was 
observed. Excess CDI was eliminated by heating to 50 °C for 2 h. The mixture was cooled to rt 
and added dropwise to a solution of 2-amino-4-methylpyridine (146 mg, 1.35 mmol) and DIPEA 
(500 µl, 2.86 mmol) in 3 ml anhyd. DMF under a nitrogen atmosphere. The reaction was stirred 
at 110 °C for 12 h, quenched by addition of H2O, cooled to rt, and extracted with ethyl acetate. 
The combined organic phases were washed with H2O and sat. aq. NaCl solution, dried over 
anhyd. Na2SO4, and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography (SiO2, 20-40 % ethyl acetate/petrol ether) to afford 174 as a 
colorless solid (100 % HPLC purity). 
Yield: 209 mg (696 µmol, 72 %). 
Method B. 3-(2,5-Dimethoxyphenyl)propionic acid (210 mg, 994 µmol), PyBOP (602 mg, 
1.16 mmol), and DIPEA (500 µl, 2.86 mmol) were stirred in 5 ml anhyd. DMF at rt under a 
nitrogen atmosphere before 2-amino-4-methylpyridine (146 mg, 1.35 mmol) was added in one 
portion. The reaction was stirred for 12 h at 110 °C, quenched by addition of H2O, and cooled to 
rt. Purification was achieved as described above (Method A) to afford 174 as a colorless solid 
(100 % HPLC purity). 
Yield: 234 mg (778 µmol, 78 %). 
Method C. 3-(2,5-Dimethoxyphenyl)propionic acid (212 mg, 1.01 mmol), HATU (453 mg, 
1.19 mmol), and DIPEA (500 µl, 2.86 mmol) were stirred in 5 ml anhyd. DMF at rt under a 
nitrogen atmosphere before 2-amino-4-methylpyridine (148 mg, 1.37 mmol) was added in one 
portion. The reaction was stirred for 12 h at 110 °C, quenched by addition of H2O, and cooled to 
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rt. Purification was achieved as described above (Method A) to afford 174 as a colorless solid 
(100 % HPLC purity). 
Yield: 226 mg (753 µmol, 75 %). 
Method D. 3-(2,5-Dimethoxyphenyl)propionic acid (202 mg, 961 µmol), 2-amino-4-methyl-
pyridine (140 mg, 1.30 mmol), and HOBt (157 mg, 1.16 mmol) were dissolved in 5 ml anhyd. 
DMF at rt under a nitrogen atmosphere. EDCI (240 mg, 1.25 mmol) and DIPEA (500 µl, 
2.86 mmol) were added and the reaction was stirred for 12 h at 110 °C, quenched by addition of 
H2O, and cooled to rt. Purification was achieved as described above (Method A) to afford 174 as 
a colorless solid (100 % HPLC purity). 
Yield: 159 mg (528 µmol, 55 %). 
Method E. 3-(2,5-Dimethoxyphenyl)propionic acid (203 mg, 966 µmol), 2-amino-4-methyl-
pyridine (146 mg, 1.35 mmol), 4-DMAP (10.0 mg, 82.0 µmol), and HOBt (155 mg, 1.15 mmol) 
were dissolved in 5 ml anhyd. DMF at rt under a nitrogen atmosphere. DCC (254 mg, 1.23 mmol) 
and DIPEA (500 µl, 2.86 mmol) were added and the reaction was stirred for 12 h at 110 °C, 
quenched by addition of H2O, and cooled to rt. Purification was achieved as described above 
(Method A) to afford 174 as a colorless solid (100 % HPLC purity). 
Yield: n.d. 
m.p.: 111 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.37 (s, 3 H, CH3), 2.68 (t, 3J = 7.7 Hz, 2 H, CH2CH2CONH), 3.00 (t, 
3J = 7.7 Hz, 2 H, CH2CH2CONH), 3.72 (s, 3 H, C5OCH3), 3.77 (s, 3 H, C2OCH3), 6.70 (dd, 3J = 8.9 Hz, 
4J = 2.8 Hz, 1 H, C4H, (OCH3)2-Phe), 6.74-6.77 (m, 2 H, C3/6H, (OCH3)2-Phe), 6.86 (dq, 3J = 5.2 Hz, 
5J = 0.8 Hz, 1 H, C5H, Pyr), 8.06 (dd, 3J = 5.3 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr), 8.12 (bs, 1 H, C3H, Pyr), 
8.86 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.7 (CH3), 26.7 (CH2CH2CONH), 37.9 (CH2CH2CONH), 55.8 
(C5OCH3), 55.9 (C2OCH3), 111.2 (C6H, (OCH3)2-Phe), 111.9 (C4H, (OCH3)2-Phe), 115.0 (C3H, Pyr), 
116.5 (C3H, (OCH3)2-Phe), 120.9 (C5H, Pyr), 129.9 (C1, (OCH3)2-Phe), 146.1 (C6H, Pyr), 151.0 (C4, 
Pyr), 151.4 (C2, Pyr), 151.7 (C2OCH3), 153.6 (C5OCH3), 171.7 (CO) ppm. 
IR (ATR): ν̃ = 3000, 1688, 1611, 1578, 1537, 1503, 1418, 1279, 1221, 1177, 1126, 1055, 1034, 
868, 799, 754, 708 cm-1. 
HPLC (Method 2): tR = 4.8 min. 
LC-MS (ESI, 70 eV): m/z = 301 [MH]+ (calc. m/z = 300). 
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3-(2,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (190) 
 
C26H25FN4O3S (Mr 492.57) 
158 (560 mg, 2.66 mmol) and CDI (475 mg, 2.93 mmol) were stirred in 3 ml anhyd. DMF until 
formation of CO2 was undetectable. 120 (400 mg, 1.33 mmol) was added to the reaction and the 
mixture was heated at 110 °C under a nitrogen atmosphere for 12 h. The reaction was cooled to 
rt and ethyl acetate was added. The resulting mixture was washed with H2O and sat. aq. NaCl 
solution, dried over anhyd. Na2SO4, and the solvent was removed under reduced pressure. The 
crude product was purified by flash chromatography (SiO2, 30-50 % ethyl acetate/petrol ether 
and RP-18, 30-80 % methanol/H2O) to afford 190 as a beige solid (98 % HPLC purity). 
Yield: 177 mg (359 µmol, 27 %). 
m.p.: 90 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.57 (t, 3J = 7.4 Hz, 2 H, COCH2CH2), 2.62 (s, 3 H, SCH3), 2.75 (t, 
3J = 7.5 Hz, 2 H, COCH2CH2), 3.72 (s, 3 H, C2OH3), 3.77 (s, 3 H, C4OCH3), 6.42 (dd, 3J = 8.3 Hz, 
4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 6.51 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 6.99 (dd, 
3J = 5.3 Hz, 1 H, C5H, Pyr), 7.03 (d, 3J = 8.3 Hz, 1 H, C6H, (OCH3)2-Phe), 7.28 (bs, 2 H, C3/5H, F-Phe), 
7.46-7.51 (m, 2 H, C2/6H, F-Phe), 8.12 (bs, 1 H, C6H, Pyr), 8.32 (bs, 1 H, C3H, Pyr), 10.29 (bs, 1 H, 
CONH), 12.72 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 24.7 (COCH2CH2), 36.3 (COCH2CH2), 55.1 (C2OCH3), 
55.3 (C4OCH3), 98.3 (C3H, (OCH3)2-Phe), 104.3 (C5H, (OCH3)2-Phe), 110.6 (C3H, Pyr), 115.8 (d, 
2JCF = 24.1 Hz, C3/5H, F-Phe), 116.4 (C5H, Pyr), 120.9 (C1, (OCH3)2-Phe), 126.7 (C1, F-Phe), 129.8 
(C6H, (OCH3)2-Phe), 130.7 (C5, Imdz and C2/6H, F-Phe), 134.5 (C4, Imdz), 143.7 (C2, Imdz), 147.6 
(C6H, Pyr), 148.0 (C4, Pyr), 152.5 (C2, Pyr), 157.9 (C4, (OCH3)2-Phe), 159.0 (C2, (OCH3)2-Phe), 
161.9 (d, 1JCF = 246.7 Hz, CF), 171.4 (CO) ppm. 
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IR (ATR): ν̃ = 2935, 1670, 1609, 1547, 1505, 1414, 1289, 1262, 1221, 1207, 1153, 1121, 1036, 
835 cm-1. 
HPLC (Method 1): tR = 5.3 min. 
LC-MS (ESI, 70 eV): m/z = 493 [MH]+ (calc. m/z = 492). 
HRMS (EI, 70 eV): m/z = 492.1631 [M]+ (calc. m/z = 492.1631). 
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3-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (191) 
 
C26H25FN4O3S (Mr 492.57) 
191 was synthesized according to the procedure for 190 from 3-(2,5-dimethoxy-
phenyl)propionic acid (560 mg, 2.66 mmol), CDI (475 mg, 2.93 mmol), and 120 (400 mg, 
1.33 mmol) in 3 ml of anhyd. DMF. The crude product was purified by flash chromatography 
(SiO2, 20-100 % ethyl acetate/petrol ether and RP-18, 20-100 % methanol/H2O) to afford 191 as 
a colorless solid (100 % HPLC purity). 
Yield: 255 mg (518 µmol, 39 %). 
m.p.: 91 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.59-2.64 (m, 5 H, SCH3 and COCH2CH2), 2.80 (t, 3J = 7.5 Hz, 
2 H, COCH2CH2), 3.66 (s, 3 H, C5OCH3), 3.73 (s, 3 H, C2OCH3), 6.72 (dd, 3J = 8.8 Hz, 4J = 3.1 Hz, 1 H, 
C4H, (OCH3)2-Phe), 6.78 (d, 4J = 3.0 Hz, 1 H, C6H, (OCH3)2-Phe), 6.86 (d, 3J = 8.8 Hz, 1 H, C3H, 
(OCH3)2-Phe), 6.99 (dd, 3J = 5.2 Hz, 4J = 1.6 Hz, 1 H, C5H, Pyr), 7.26 (bs, 2 H, C3/5H, F-Phe), 
7.46-7.51 (m, 2 H, C2/6H, F-Phe), 8.13 (bs, 1 H, C6H, Pyr), 8.32 (bs, 1 H, C3H, Pyr), 10.34 (bs, 1 H, 
CONH), 12.72 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 25.3 (COCH2CH2), 36.0 (COCH2CH2), 55.2 (C5OCH3), 
55.8 (C2OCH3), 110.6 (C3H, Pyr), 111.2 (C4H, (OCH3)2-Phe), 111.5 (C3H, (OCH3)2-Phe), 115.6 
(C3/5H, F-Phe), 115.9 (C6H, (OCH3)2-Phe), 116.5 (C5H, Pyr), 126.7 (C1, F-Phe), 130.0 (C1, 
(OCH3)2-Phe), 130.6 (C5, Imdz and C2/6H, F-Phe), 134.5 (C4, Imdz), 142.3 (C2, Imdz), 147.7 (C4 and 
C6H, Pyr), 151.2 (C2, (OCH3)2-Phe), 152.5 (C2, Pyr), 153.0 (C5, (OCH3)2-Phe), 161.9 (d, 1JCF = 247.3, 
CF), 171.3 (CO) ppm. 
IR (ATR): ν̃ = 2925, 2400, 1668, 1607, 1551, 1499, 1416, 1221, 1157, 1045, 837, 814, 708 cm-1. 
HPLC (Method 2): tR = 4.1 min. 
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LC-MS (ESI, 70 eV): m/z = 494 [MH]+ (calc. m/z = 492). 
HRMS (EI, 70 eV): m/z = 492.1631 [M]+ (calc. m/z = 492.1631). 
 
Figure 107 | Molecular structure of 191 .  Determined by X-ray crystallography  by D R .  D I E T ER  
SCHO LL M EY E R .  
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3-(2,3-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (192) 
 
C26H25FN4O3S (Mr 492.57) 
192 was synthesized according to the procedure for 190 from 3-(2,3-dimethoxy-
phenyl)propionic acid (700 mg, 3.33 mmol), CDI (594 mg, 3.66 mmol), and 120 (500 mg, 
1.67 mmol) in 4 ml of anhyd. DMF. The crude product was purified by flash chromatography 
(SiO2, 30-100 % ethyl acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 192 as 
a colorless solid (100 % HPLC purity). 
Yield: 515 mg (1.05 mmol, 63 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3 H, SCH3), 2.59-2.66 (m, 2 H, COCH2CH2), 2.84 (t, 
3J = 7.7 Hz, 2 H, COCH2CH2), 3.73 (s, 3 H, C2OCH3), 3.78 (s, 3 H, C3OCH3), 6.79 (dd, 3J = 7.5 Hz, 
4J = 1.6 Hz, 1 H, C6H, (OCH3)2-Phe), 6.88 (dd, 3J = 8.1 Hz, 4J = 1.2 Hz, 1 H, C4H, (OCH3)2-Phe), 6.97 
(t, 3J = 7.8 Hz, 1 H, C5H, (OCH3)2-Phe), 7.01 (dd, 3J = 5.3 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.26-7.32 
(m, 2 H, C3/5H, F-Phe), 7.45-7.51 (m, 2 H, C2/6H, F-Phe), 8.11 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr), 8.34 
(bs, 1 H, C3H, Pyr), 10.35 (s, 1 H, CONH), 12.70 (s, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 24.8 (COCH2CH2), 36.8 (COCH2CH2), 55.3 (C3OCH3), 
60.0 (C2OCH3), 110.6 (C3H, Pyr), 110.9 (C4H, (OCH3)2-Phe), 115.8 (d, 2JCF = 21.8 Hz, C3/5H, F-Phe), 
116.4 (C5H, Pyr), 121.4 (C6H, (OCH3)2-Phe), 123.7 (C5H, (OCH3)2-Phe), 126.6 (d, 4JCF = 3.1 Hz, C1, 
F-Phe), 130.1 (C5, Imdz), 130.7 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 134.4 (C1, (OCH3)2-Phe), 134.5 (C4, 
Imdz), 142.2 (C2, Imdz), 143.8 (C4, Pyr), 146.6 (C2OCH3), 147.6 (C6H, Pyr), 152.4 (C3OCH3), 152.5 
(C2, Pyr), 162.0 (d, 1JCF = 244.7 Hz, CF), 171.1 (CO) ppm. 
HPLC (Method 2): tR = 5.7 min. 
LC-MS (ESI, 70 eV): m/z = 493 [MH]+ (calc. m/z = 492). 
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3-(3,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (193) 
 
C26H25FN4O3S (Mr 492.57) 
193 was synthesized according to the procedure for 190 from 3-(3,4-dimethoxy-
phenyl)propionic acid (700 mg, 3.33 mmol), CDI (594 mg, 3.66 mmol), and 120 (500 mg, 
1.67 mmol) in 4 ml of anhyd. DMF. The crude product was purified by flash chromatography 
(SiO2, 30-100 % ethyl acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 193 as 
a colorless solid (97 % HPLC purity). 
Yield: 468 mg (950 µmol, 57 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3 H, SCH3), 2.62-2.67 (m, 2 H, COCH2CH2), 2.81 (t, 
3J = 7.4 Hz, 2 H, COCH2CH2), 3.70 (s, 3 H, C4OCH3), 3.72 (s, 3 H, C3OCH3), 6.73 (dd, 3J = 8.2 Hz, 
4J = 1.9 Hz, 1 H, C6H, (OCH3)2-Phe), 6.84 (d, 3J = 8.3 Hz, 1 H, C5H, (OCH3)2-Phe), 6.85 (bs, 1 H, C2H, 
(OCH3)2-Phe), 7.00 (dd, 3J = 5.2 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.26-7.31 (m, 2 H, C3/5H, F-Phe), 
7.46-7.50 (m, 2 H, C2/6H, F-Phe), 8.10-8.34 (m, 2 H, C3/6H Pyr), 10.33 (s, 1 H, CONH), 12.71 (s, 1 H, 
NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 30.4 (COCH2CH2), 38.0 (COCH2CH2), 55.4 (C4OCH3), 
55.5 (C3OCH3), 110.6 (C3H, Pyr), 111.9 (C5H, (OCH3)2-Phe), 112.3 (C2H, (OCH3)2-Phe), 115.8 (d, 
2JCF = 22.5 Hz, C3/5H, F-Phe), 116.4 (C5H, Pyr), 120.0 (C6H, (OCH3)2-Phe), 130.6 (C2/6H, F-Phe), 
133.5 (C1, (OCH3)2-Phe), 147.1 (C4OCH3), 147.6 (C6H, Pyr), 148.6 (C3OCH3), 152.5 (C2, Pyr), 165.8 
(d, 1JCF = 242.6 Hz, CF), 171.2 (CO) ppm. 
HPLC (Method 2): tR = 5.5 min. 
LC-MS (ESI, 70 eV): m/z = 493 [MH]+ (calc. m/z = 492). 
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3-(3,4,5-Trimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (194) 
 
C27H27FN4O4S (Mr 522.60) 
194 was synthesized according to the procedure for 190 from 3-(3,4,5-trimethoxy-
phenyl)propionic acid (800 mg, 3.33 mmol), CDI (594 mg, 3.66 mmol), and 120 (500 mg, 
1.67 mmol) in 4 ml of anhyd. DMF. The crude product was purified by flash chromatography 
(SiO2, 20-100 % ethyl acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 194 as 
a pale yellowish solid (99 % HPLC purity). 
Yield: 422 mg (807 µmol, 49 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3 H, SCH3), 2.62-2.69 (m, 2 H, COCH2CH2), 2.80-2.85 
(m, 2 H, COCH2CH2), 3.61 (s, 3 H, C4OCH3), 3.74 (bs, 6 H, C3/5OCH3), 6.56 (s, 2 H, C2/6H, 
(OCH3)3-Phe), 7.01 (dd, 3J = 5.3 Hz, 4J = 1.6 Hz, 1 H, C5H, Pyr), 7.26-7.32 (m, 2 H, C3/5H, F-Phe), 
7.46-7.51 (m, 2 H, C2/6H, F-Phe), 8.11 (dd, 3J = 5.3 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr), 8.36 (bs, 1 H, C3H, 
Pyr), 10.36 (s, 1 H, CONH), 12.70 (s, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 31.3 (COCH2CH2), 37.9 (COCH2CH2), 55.7 
(C3/5OCH3), 59.9 (C4OCH3), 105.5 (C2/6H, (OCH3)3-Phe), 110.6 (C3H, Pyr), 115.8 (d, 2JCF = 21.7 Hz, 
C3/5H, F-Phe), 116.4 (C5H, Pyr), 126.6 (d, 4JCF = 3.3 Hz, C1, F-Phe), 130.1 (C5, Imdz), 130.7 (d, 
3JCF = 8.4 Hz, C2/6H, F-Phe), 134.5 (C4, Imdz), 135.7 (C4OCH3), 136.8 (C1, (OCH3)3-Phe), 142.2 (C2, 
Imdz), 143.8 (C4, Pyr), 147.6 (C6H, Pyr), 152.5 (C2, Pyr), 152.7 (C3/5OCH3), 162.0 (d, 
1JCF = 245.4 Hz, CF), 171.2 (CO) ppm. 
HPLC (Method 2): tR = 5.5 min. 
LC-MS (ESI, 70 eV): m/z = 523 [MH]+ (calc. m/z = 522). 
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7.3.4 Syntheses of Series 3: Carbamide Derivatives 
General procedure for the preparation of carbamide derivatives (204-212) 
Compound 120 (1.0 equiv) and the respective isocyanate (1.1 equiv) were dissolved in 5 ml 
anhyd. DMF under a nitrogen atmosphere. DIPEA (1.2 equiv) was added and stirring continued 
at rt for 12 h. The solvent was removed under reduced pressure, the residue resuspended in 
ethyl acetate, and washed with 0.1 M aq. HCl, sat. aq. NaHCO3 solution, and sat. aq. NaCl solution, 
dried over anhyd. Na2SO4, and concentrated under reduced pressure. The crude product was 
purified by flash chromatography (SiO2 and RP-18, eluent and mixing ratio given for each 
compound, respectively) to afford the particular compound. 
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1-(2,4-Dimethoxyphenyl)-3-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)carbamide (204) 
 
C24H22FN5O3S (Mr 479.53) 
204 was synthesized according to the general procedure from 120 (400 mg, 1.33 mmol), 
2,4-dimethoxyphenyl isocyanate (262 mg, 1.47 mmol), and DIPEA (300 µl, 1.60 mmol). Purifica-
tion was achieved by flash chromatography (SiO2, 0-10 % methanol/dichloromethane and 
RP-18, 50-100 % methanol/H2O) to afford 204 as a colorless solid (100 % HPLC purity). 
Yield: 135 mg (280 µmol, 21 %). 
m.p.: 214 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3 H, SCH3), 3.74 (s, 3 H, C4OCH3), 3.88 (s, 3 H, C2OCH3), 
6.48 (dd, 3J = 8.9 Hz, 4J = 2.7 Hz, 1 H, C5H, (OCH3)2-Phe), 6.62 (d, 4J = 2.7 Hz, 1 H, C3H, 
(OCH3)2-Phe), 6.92 (dd, 3J = 5.4 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.30-7.51 (m, 5 H, C3/5H, F-Phe and 
C3H, Pyr and C2/6H, F-Phe), 8.03 (d, 3J = 8.9 Hz, 1 H, C6H, (OCH3)2-Phe), 8.12 (bs, 1 H, C6H, Pyr), 
9.64 (bs, 1 H, NH), 10.89-11.26 (m, 1 H, NH), 12.74 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 55.3 (C4OCH3), 56.0 (C2OCH3), 98.8 (C3H, 
(OCH3)2-Phe), 104.1 (C5H, (OCH3)2-Phe), 108.6 (C3H, Pyr), 114.6 (C5H, Pyr), 115.7 (C2/6H, F-Phe), 
119.7 (C6H, (OCH3)2-Phe), 121.9 (C1, (OCH3)2-Phe), 130.7 (C3/5H, F-Phe), 134.2 (C4, Pyr), 142.3 
(C2, Imdz), 146.1 (C6H, Pyr), 149.4 (C2, (OCH3)2-Phe), 152.2 (CO), 153.6 (C2, Pyr), 155.2 (C4, 
(OCH3)2-Phe), 161.8 (d, 1JCF = 241.6 Hz, CF) ppm. 
IR (ATR): ν̃ = 3220, 1663, 1614, 1582, 1572, 1541, 1520, 1456, 1366, 1279, 1207, 1155, 1051, 
1036, 837, 824, 787, 763, 669, 613 cm-1. 
HPLC (Method 3): tR = 5.4 min. 
LC-MS (ESI, 70 eV): m/z = 480 [MH]+ (calc. m/z = 479). 
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1,3-Bis(2,4-dimethoxyphenyl)carbamide (215) 
 
C17H20N2O5 (Mr 332.36) 
215 was isolated as a by-product from the synthesis of 204. The crude product was purified by 
flash chromatography (SiO2, 0-10 % methanol/dichloromethane and RP-18, 50-100 % 
methanol/H2O) to afford 215 as a colorless solid (100 % HPLC purity). 
m.p.: 200 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.72 (s, 6 H, C4OCH3), 3.84 (s, 6 H, C2OCH3), 6.45 (dd, 
3J = 8.9 Hz, 4J = 2.7 Hz, 2 H, C5H, (OCH3)2-Phe), 6.59 (d, 4J = 2.6 Hz, 2 H, C3H, (OCH3)2-Phe), 7.87 (d, 
3J = 8.9 Hz, 2 H, C6H, (OCH3)2-Phe), 8.47 (s, 2 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.2 (C4OCH3), 55.7 (C2OCH3), 98.7 (C3H, (OCH3)2-Phe), 104.0 
(C5H, (OCH3)2-Phe), 120.4 (C6H), 122.1 (C1, (OCH3)2-Phe), 149.5 (C2OCH3), 153.0 (CO), 154.8 
(C4OCH3) ppm. 
IR (ATR): ν̃ = 3296, 1645, 1613, 1557, 1497, 1464, 1414, 1277, 1159, 1134, 1057, 1036, 1028, 
922, 829, 808, 795, 654 cm-1. 
HPLC (Method 3): tR = 3.8 min. 
LC-MS (ESI, 70 eV): m/z = 333 [MH]+ (calc. m/z = 332). 
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1-(2,5-Dimethoxyphenyl)-3-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)carbamide (205) 
 
C24H22FN5O3S (Mr 479.53) 
205 was synthesized according to the general procedure from 120 (323 mg, 1.08 mmol), 
2,5-dimethoxyphenyl isocyanate (300 mg, 1.67 mmol), and DIPEA (300 µl, 1.72 mmol). Purifica-
tion was achieved by flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether) to afford 
205 as a pale yellowish solid (100 % HPLC purity). 
Yield: 79.9 mg (167 µmol, 15 %). 
m.p.: 184 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3 H, SCH3), 3.70 (s, 3 H, C5OCH3), 3.84 (s, 3 H, C2OCH3), 
6.52 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 1 H, C4H, (OCH3)2-Phe), 6.91-6.96 (m, 1 H, C3H, (OCH3)2-Phe), 
6.95 (dd, 3J = 5.5 Hz, 4J = 1.4 Hz, 1 H, C5H, Pyr), 7.28-7.38 (m, 2 H, C3/5H, F-Phe), 7.47-7.51 (m, 3 H, 
C2/6H, F-Phe and C3H, Pyr), 7.92 (d, 4J = 2.9 Hz, 1 H, C6H, (OCH3)2-Phe), 8.13 (d, 3J = 5.4 Hz, 1 H, 
C6H, Pyr), 9.76 (bs, 1 H, NH), 11.52 (vbs, 1 H, NH), 12.74 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 55.3 (C5OCH3), 55.6 (C2OCH3), 105.6 (C6H, 
(OCH3)2-Phe), 105.8 (C4H, (OCH3)2-Phe), 108.5 (C3H, Pyr), 111.7 (C3H, (OCH3)2-Phe), 114.7 (C5H, 
Pyr), 115.9 (d, 2JCF = 22.0 Hz, C3/5H, F-Phe), 126.5 (d, 4JCF = 3.3 Hz, C1, F-Phe), 129.6 (C1, 
(OCH3)2-Phe), 130.4 (C5, Imdz), 130.8 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 134.1 (C4, Imdz), 142.3 (C2, 
Imdz), 142.4 (C2OCH3), 144.2 (C4, Pyr), 146.1 (C6H, Pyr), 152.2 (CO), 153.4 (C5OCH3), 153.4 (C2, 
Pyr), 162.1 (d, 1JCF = 245.9 Hz, CF) ppm. 
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IR (ATR): ν̃ = 3098, 2960, 2832, 1672, 1599, 1574, 1539, 1506, 1489, 1462, 1368, 1304, 1279, 
1244, 1221, 1198, 1165, 1140, 1047, 1026, 976, 868, 845, 814, 743, 712 cm-1. 
HPLC (Method 2): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 480 [MH]+ (calc. m/z = 479). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-3-(4-methoxy-
phenyl)carbamide (206) 
 
C23H20FN5O2S (Mr 449.50) 
206 was synthesized according to the general procedure from 120 (347 mg, 1.16 mmol), 
4-methoxyphenyl isocyanate (165 µl, 1.27 mmol), and DIPEA (200 µl, 1.39 mmol). Purification 
was achieved by flash chromatography (SiO2, 50-100 % ethyl acetate/petrol ether and RP-18, 
60-100 % methanol/H2O) to afford 206 as a pale yellow solid (99 % HPLC purity). 
Yield: 137 mg (305 µmol, 26 %). 
m.p.: 201 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3 H, SCH3), 3.72 (s, 3 H, OCH3), 6.86-6.90 (m, 2 H, C3/5H, 
H3CO-Phe), 6.92 (dd, 3J = 5.4 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.30 (bs, 2 H, C3/5H, F-Phe), 7.39-7.44 
(m, 2 H, C2/6H, H3CO-Phe), 7.47-7.51 (m, 2 H, C2/6H, F-Phe), 7.58 (bs, 1 H, C3H, Pyr), 8.11 (bs, 1 H, 
C6H, Pyr), 9.40 (bs, 1 H, NH), 10.35-10.71 (m, 1 H, NH), 12.74 (s, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 55.2 (OCH3), 105.3 (C4, Pyr), 108.7 (C3H, Pyr), 
114.0 (C3/5H, H3CO-Phe), 114.6 (C5H, Pyr), 115.8 (d, 2JCF = 22.0 Hz, C3/5H, F-Phe), 120.6 (C2/6H, 
H3CO-Phe), 130.6-130.8 (C2/6H, F-Phe), 132.0 (C1, H3CO-Phe), 142.3 (C2, Imdz), 146.4 (C6H, Pyr), 
152.3 (CO), 153.5 (C2, Pyr), 154.9 (C4, H3CO-Phe), 162.1 (d, 1JCF = 252.6 Hz, CF) ppm. 
IR (ATR): ν̃ = 3400, 1668, 1607, 1574, 1541, 1510, 1466, 1418, 1370, 1296, 1244, 1223, 1030, 
843, 822, 750 cm-1. 
HPLC (Method 3): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 450 [MH]+ (calc. m/z = 449). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-3-(m-tolyl)-
carbamide (208) 
 
C23H20FN5OS (Mr 433.51) 
208 was synthesized according to the general procedure from 120 (600 mg, 2.00 mmol), 
3-methylphenyl isocyanate (284 µl, 2.20 mmol), and DIPEA (420 µl, 2.40 mmol). Purification 
was achieved by flash chromatography (SiO2, 30-100 % ethyl acetate/petrol ether and RP-18, 
60-80 % methanol/H2O) to afford 208 as a pale colorless solid (100 % HPLC purity). 
Yield: 241 mg (557 µmol, 28 %). 
m.p.: 211 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3 H, CH3), 2.63 (s, 3 H, SCH3), 6.83 (d, 3J = 7.4 Hz, 1 H, 
C4H, Tol), 6.95 (dd, 3J = 5.4 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.15-7.35 (m, 2 H, C3/5H, F-Phe), 7.17 (t, 
3J = 7.6 Hz, 1 H, C5H, Tol), 7.31 (d, 3J = 8.0 Hz, 1 H, C6H, Tol), 7.35 (s, 1 H, C2H, Tol), 7.47-7.52 (m, 
2 H, C2/6H, F-Phe), 7.61 (bs, 1 H, C3H, Pyr), 8.13 (bs, 1 H, C6H, Pyr), 9.44 (s, 1 H, NH), 10.42-10.78 
(m, 1 H, NH), 12.74 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 21.2 (CH3), 108.7 (C3H, Pyr), 114.8 (C5H, Pyr), 
115.8 (d, 2JCF = 22.3 Hz, C3/5H, F-Phe), 116.0 (C6H, Tol), 119.3 (C2H, Tol), 123.2 (C4H, Tol), 126.6 
(d, 4JCF = 2.6 Hz, C1, F-Phe), 128.7 (C5H, Tol), 129.7 (C5, Imdz), 130.8 (C2/6H, F-Phe), 134.2 (C4, 
Imdz), 138.1 (C3, Tol), 139.0 (C1, Tol), 142.4 (C2, Imdz), 144.3 (C4, Pyr), 146.4 (C6H, Pyr), 152.1 
(CO), 153.4 (C2, Pyr), 162.0 (d, 1JCF = 243.0 Hz, CF) ppm. 
IR (ATR): ν̃ = 3358, 3200, 2980, 1674, 1607, 1581, 1549, 1518, 1476, 1462, 1366, 1294, 1219, 
1207, 1157, 1094, 843, 810, 770, 737, 725, 679, 611 cm-1. 
HPLC (Method 3): tR = 6.8 min. 
LC-MS (ESI, 70 eV): m/z = 434 [MH]+ (calc. m/z = 433). 
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1-(3-Chloro-4-methylphenyl)-3-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)carbamide (209) 
 
C23H19ClFN5OS (Mr 467.95) 
209 was synthesized according to the general procedure from 120 (400 mg, 1.33 mmol), 
3-chloro-4-methylyphenyl isocyanate (205 µl, 1.47 mmol), and DIPEA (279 µl, 1.60 mmol). Puri-
fication was achieved by flash chromatography (SiO2, 0-10 % methanol/dichloromethane and 
RP-18, 70-100 % methanol/H2O and SiO2, 20-100 % ethyl acetate/petrol ether) to afford 209 as 
a colorless solid (98 % HPLC purity). 
Yield: 210 mg (450 µmol, 34 %). 
m.p.: 210 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.27 (s, 3 H, CH3), 2.63 (s, 3 H, SCH3), 6.96 (dd, 3J = 5.5 Hz, 
4J = 1.4 Hz, 1 H, C5H, Pyr), 7.26 (m, 2 H, C5/6H, Cl-Tol), 7.28-7.34 (m, 2 H, C3/5H, F-Phe), 7.46-7.50 
(m, 2 H, C2/6H, F-Phe), 7.59 (bs, 1 H, C3H, Pyr), 7.77 (s, 1 H, C2H, Cl-Tol), 8.12 (d, 3J = 5.4 Hz, 1 H, 
C6H, Pyr), 9.51 (s, 1 H, NH), 10.99 (s, 1 H, NH), 12.73 (s, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 18.8 (CH3), 108.7 (C3H, Pyr), 114.8 (C5H, Pyr), 
115.9 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 117.6 (C6H, Cl-Tol), 118.7 (C2H, Cl-Tol), 126.5 (d, 
4JCF = 3.1 Hz, C1, F-Phe), 128.9 (C4, Cl-Tol), 130.4 (C5, Imdz), 130.8 (d, 3JCF = 8.3 Hz, C2/6H, F-Phe), 
131.2 (C5H, Cl-Tol), 133.2 (C3, Cl-Tol), 134.1 (C4, Imdz), 138.2 (C1, Cl-Tol), 142.3 (C2, Imdz), 144.3 
(C4, Pyr), 146.4 (C6H, Pyr), 152.2 (CO), 153.2 (C2, Pyr), 162.1 (d, 1JCF = 245.5 Hz, CF) ppm. 
IR (ATR): ν̃ = 3400, 2920, 1672, 1605, 1543, 1520, 1499, 1464, 1364, 1368, 1302, 1265, 1272, 
1159, 880, 860, 839, 816, 754 cm-1. 
HPLC (Method 3): tR = 6.9 min. 
LC-MS (ESI, 70 eV): m/z = 468 [MH]+ (calc. m/z = 467). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-3-(3-(trifluoro-
methyl)phenyl)carbamide (210) 
 
C23H17FN5OS (Mr 487.48) 
210 was synthesized according to the general procedure from 120 (600 mg, 2.00 mmol), 
3-(trifluoromethyl)phenyl isocyanate (300 µl, 2.20 mmol), and DIPEA (420 µl, 2.40 mmol). Puri-
fication was achieved by flash chromatography (SiO2, 40 % methanol/dichloromethane) and 
subsequent filtration to afford 210 as a colorless solid (98 % HPLC purity). 
Yield: 255 mg (523 µmol, 26 %). 
m.p.: 234 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3 H, SCH3), 6.99 (dd, 3J = 5.6 Hz, 4J = 1.2 Hz, 1 H, C5H, 
Pyr), 7.28-7.37 (m, 3 H, C3/5H, F-Phe and C4H, F3C-Phe), 7.46-7.66 (m, 5 H, C3H, Pyr and C2/6H, 
F-Phe and C5/6H, F3C-Phe), 8.08 (bs, 1 H, C2H, F3C-Phe), 8.14 (d, 3J = 5.5 Hz, 1 H, C6H, Pyr), 9.56 (s, 
1 H, NH), 11.12 (s, 1 H, NH), 12.74 (s, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 108.7 (C3H, Pyr), 114.7 (C2H, F3C-Phe), 115.0 (C5H, 
Pyr), 115.9 (d, 2JCF = 21.8 Hz, C3/5H, F-Phe), 118.7 (C4H, F3C-Phe), 122.5 (C6H, F3C-Phe), 124.2 (q, 
1JCF = 272.1 Hz, CF3, F3C-Phe), 126.5 (d, 4JCF = 2.9 Hz, C1, F-Phe), 129.6 (q, 2JCF = 31.3 Hz, C3, 
F3C-Phe), 130.0 (C5H, F3C-Phe), 130.5 (C5, Imdz), 130.8 (d, 3JCF = 8.3 Hz, C2/6H, F-Phe), 134.0 (C4, 
Imdz), 139.9 (C1, F3C-Phe), 142.3 (C2, Imdz), 144.3 (C4, Pyr), 146.6 (C6H, Pyr), 152.2 (CO), 153.0 
(C2, Pyr), 162.0 (d, 1JCF = 245.2 Hz, CF) ppm. 
IR (ATR): ν̃ = 3300, 2900, 1670, 1609, 1581, 1541, 1520, 1497, 1464, 1381, 1370, 1331, 1312, 
1294, 1256, 1217, 1207, 1180, 1157, 1134, 1099, 1072, 986, 923, 889, 871, 839, 814, 791, 754, 
694 cm-1. 
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HPLC (Method 3): tR = 7.3 min. 
LC-MS (ESI, 70 eV): m/z = 488 [MH]+ (calc. m/z = 487). 
HRMS (EI, 70 eV): m/z = 487.1090 [M]+ (calc. m/z = 487.1090) 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-3-(naphthalen-
1-yl)carbamide (212) 
 
C26H20FN5OS (Mr 469.54) 
212 was synthesized according to the general procedure from 120 (400 mg, 1.33 mmol), 
naphthyl isocyanate (211 µl, 1.47 mmol), and DIPEA (280 µl, 1.60 mmol). Purification was 
achieved by flash chromatography (SiO2, 0-10 % methanol/dichloromethane and SiO2, 30-100 % 
ethyl acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 212 as a pale yellow 
solid (100 % HPLC purity). 
Yield: 257 mg (546 µmol, 41 %). 
m.p.: 249 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3 H, SCH3), 7.01 (dd, 3J = 5.5 Hz, 4J = 1.4 Hz, 1 H, C5H, 
Pyr), 7.30-7.36 (m, 2 H, C3/5H, F-Phe), 7.42-7.59 (m, 5 H, C3H, Pyr and C2/6H, F-Phe and C3/6H, 
Naph), 7.63-7.68 (m, 2 H, C4/7H, Naph), 7.95 (d, 3J = 8.1 Hz, 1 H, C5H, Naph), 8.16-8.22 (m, 2 H, 
C2/8H, Naph), 8.27 (d, 3J = 5.5 Hz, 1 H, C6H, Pyr), 9.87 (s, 1 H, NH), 11.86 (bs, 1 H, NH), 12.77 (s, 
1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 108.7 (C3H, Pyr), 114.7 (C5H, Pyr), 115.9 (d, 
2JCF = 21.7 Hz, C3/5H, F-Phe), 116.7 (C2H, Naph), 120.9 (C8H, Naph), 123.0 (C4H, Naph), 125.4 (C1, 
Naph), 126.0 (C3/6H, Naph), 126.3 (C7H, Naph), 126.5 (d, 4JCF = 3.2 Hz, C1, F-Phe), 128.6 (C5H, 
Naph), 130.6 (C5, Imdz), 130.8 (d, 3JCF = 8.3 Hz, C2/6H, F-Phe), 133.7 (C4a, Naph), 134.0 (C8a, Naph), 
134.2 (C4, Imdz), 142.4 (C2, Imdz), 144.5 (C4, Pyr), 146.1 (C6H, Pyr), 152.6 (CO), 153.5 (C2, Pyr), 
162.1 (d, 1JCF = 246.2 Hz, CF) ppm. 
IR (ATR): ν̃ = 3040, 1686, 1614, 1601, 1571, 1497, 1481, 1362, 1346, 1304, 1225, 976, 837, 791, 
770, 739, 716, 683 cm-1. 
HPLC (Method 3): tR = 7.6 min. 
LC-MS (ESI, 70 eV): m/z = 471 [MH]+ (calc. m/z = 469). 
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7.3.5 Syntheses of Series 4: Five-membered Heterocycles 
1-(tert-Butyl) 2-ethyl 4-bromo-1H-pyrrole-1,2-dicarboxylate (218) 
 
C12H16BrNO4 (Mr 318.17) 
4-DMAP (137 mg, 1.12 mmol) and Boc2O (3.18 g, 14.6 mmol) were added to a solution of ethyl 
4-bromo-1H-pyrrole-2-carboxylate (2.37 g, 10.9 mmol) in 18 ml anhyd. acetonitrile under a 
nitrogen atmosphere and the resulting mixture was stirred at rt for 1 h. Ethyl acetate was added 
and the mixture was washed with sat. aq. NaHSO4 solution, H2O, and sat. aq. NaCl solution. The 
organic phase was dried over anhyd. Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography (SiO2, 2-10 % ethyl 
acetate/petrol ether) to afford 218 as clear yellowish oil (98 % HPLC purity). 
Yield: 3.39 g (10.7 mmol, 98 %) (Lit.230: 93 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.26 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 1.52 (s, 9 H, tBu), 4.23 (q, 
3J = 7.1 Hz, 2 H, COOCH2CH3), 6.93 (d, 4J = 1.8 Hz, 1 H, C3H, Pyrrole), 7.62 (d, 4J = 1.8 Hz, 1 H, C5H, 
Pyrrole) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 13.9 (CH3), 27.0 (C(CH3)3), 61.0 (CH2), 85.7 (C(CH3)3), 98.1 
(CBr), 120.9 (C3H, Pyrrole), 125.5 (C5H, Pyrrole), 125.5 (C2, Pyrrole), 146.8 (CO), 159.3 
(COOCH2CH3) ppm. 
IR (ATR): ν̃ = 2982, 1755, 1726, 1456, 1397, 1370, 1348, 1296, 1267, 1258, 1217, 1150, 1067, 
922, 845, 771 cm-1. 
HPLC (Method 2): tR = 7.6 min. 
LC-MS (ESI, 70 eV): m/z = 340, 342 [NaM]+, 262, 263, 264, 265 [MH2-tBu]+, 216, 217, 218 
[MH2-C5H10O2]+ (calc. m/z = 317). 
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Ethyl 4-bromo-1-methyl-1H-pyrrole-2-carboxylate (226) 
 
C8H10BrNO2 (Mr 232.08) 
Sodium hydride (240 mg 60 % dispersion in mineral oil, 6.05 mmol) was added in one portion to 
a solution of 4-bromo-1H-pyrrole-2-carboxylate (1.17 g, 5.34 mmol) in 15 ml anhyd. DMF at 0 °C 
under a nitrogen atmosphere. The suspension was stirred for 20 min at the same temp. before 
methyl iodide (400 µl, 6.43 mmol) was carefully added dropwise and stirring continued at 0 °C 
for 15 min and another 2.5 h at rt. The reaction was quenched with H2O and extracted with ethyl 
acetate. The combined organic phases were washed with H2O and sat. aq. NaCl solution, dried 
over anhyd. Na2SO4, and the solvent was removed under reduced pressure. Purification was 
achieved by flash chromatography (SiO2, 2-10 % ethyl acetate/petrol ether) to afford 226 as 
clear colorless oil that crystallized on standing as colorless needles (100 % HPLC purity). 
Yield: 1.22 g (5.25 mmol, 98 %). 
m.p.: 43 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.26 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.83 (d, J = 0.2 Hz, 3 H, 
CH3), 4.21 (q, 3J = 7.1 Hz, 2 H, COOCH2CH3), 6.84 (d, 4J = 2.0 Hz, 1 H, C3H, Pyrrole), 7.28 (d, 
4J = 1.7 Hz, 1 H, C5H, Pyrrole) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.2 (COOCH2CH3), 36.6 (CH3), 59.8 (COOCH2CH3), 93.8 (CBr), 
118.1 (C3H, Pyrrole), 122.7 (C2, Pyrrole), 129.5 (C5H, Pyrrole), 159.5 (COOCH2CH3) ppm. 
IR (ATR): ν̃ = 3129, 2984, 1703, 1688, 1468, 1414, 1400, 1389, 1331, 1242, 1186, 1111, 1078, 
1057, 1022, 926, 818, 785, 750 cm-1. 
HPLC (Method 2): tR = 6.1 min. 
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Ethyl 4-(2,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylate (219) 
 
C15H17NO4 (Mr 275.30) 
To a stirred solution of 218 (1.40 g, 4.40 mmol), 2,4-dimethoxyphenyl boronic acid (2.41 g, 
13.3 mmol), and Pd(PPh3)4 (259 mg, 224 µmol) in 50 ml DMF, 22 ml 2 M aq. Na2CO3 solution 
were added. The mixture was stirred under reflux for 4 h and another 12 h at rt. After addition 
of H2O the mixture was extracted with ethyl acetate and the combined organic phases were 
washed with H2O and sat. aq. NaCl solution, dried over anhyd. Na2SO4, and the solvent was re-
moved under reduced pressure. The crude product was purified by flash chromatography (SiO2, 
5-10 % ethyl acetate/petrol ether) to afford 219 as a colorless solid (100 % HPLC purity). 
Yield: 1.15 g (4.19 mmol, 95 %). 
m.p.: 121 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.29 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.77 (s, 3 H, C2OCH3), 
3.84 (s, 3 H, C4OCH3), 4.25 (q, 3J = 7.1 Hz, 2 H, COOCH2CH3), 6.52 (dd, 3J = 8.5 Hz, 4J = 2.5 Hz, 1 H, 
C5H, (OCH3)2-Phe), 6.60 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 7.12 (dd, 4J = 2.6 Hz, 5J = 1.7 Hz, 
1 H, C5H, Pyrrole), 7.36 (dd, 4J = 3.1 Hz, 5J = 1.7 Hz, 1 H, C3H, Pyrrole), 7.48 (d, 3J = 8.5 Hz, 1 H, C6H, 
(OCH3)2-Phe), 11.85 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.5 (COOCH2CH3), 55.2 (C2OCH3), 55.4 (C4OCH3), 59.5 
(COOCH2CH3), 98.8 (C3H, (OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 113.4 (C5, Pyrrole), 115.8 (C1, 
(OCH3)2-Phe), 121.2 (C4, Pyrrole), 121.6 (C2, Pyrrole), 122.6 (C3H, Pyrrole), 127.9 (C6H, 
(OCH3)2-Phe), 156.7 (C4OCH3), 158.7 (C2OCH3), 160.5 (CO) ppm. 
IR (ATR): ν̃ = 3304, 2950, 1676, 1614, 1579, 1518, 1462, 1435, 1402, 1379, 1358, 1304, 1292, 
1244, 1207, 1165, 1148, 1130, 1051, 1030, 972, 936, 835, 804, 795, 770, 731, 604 cm-1. 
HPLC (Method 2): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 276 [MH]+ (calc. m/z = 275). 
E x p e r i m e n t a l  | 225 
 
 
Ethyl 4-(2,4-dimethoxyphenyl)-1-methyl-1H-pyrrole-2-carboxylate (227) 
 
C16H19NO4 (Mr 289.33) 
Method A. 227 was synthesized according to the procedure described for 219 from 226 (1.22 g, 
5.26 mmol), 2,4-dimethoxyphenyl boronic acid (2.89 g, 15.9 mmol), Pd(PPh3)4 (306 mg, 
265 µmol) in 80 ml DMF, and 27 ml 2 M aq. Na2CO3 solution. Purification was achieved by flash 
chromatography (SiO2, 5-10 % ethyl acetate/petrol ether and RP-18, 50-70 % methanol/H2O) to 
afford 227 as a colorless solid (100 % HPLC purity). 
Yield: 1.02 g (3.52 mmol, 67 %). 
Method B. 227 was synthesized according to the procedure for 226 from 219 (800 mg, 
2.91 mmol), sodium hydride (164 mg 60 % dispersion in mineral oil, 4.10 mmol), and methyl 
iodide (270 µl, 4.34 mmol) in 10 ml anhyd. DMF. 227 was obtained as a colorless solid (100 % 
HPLC purity). 
Yield: 720 mg (2.49 mmol, 86 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.29 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.77 (s, 3 H, C4OCH3), 
3.84 (s, 3 H, C2OCH3), 3.87 (s, 3 H, CH3), 4.23 (q, 3J = 7.1 Hz, 2 H, COOCH2CH3), 6.53 (dd, 3J = 8.5 Hz, 
4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.60 (d, 4J = 2.5 Hz, 1 H, C3H, (OCH3)2-Phe), 7.17 (d, 4J = 2.0 Hz, 
1 H, C3H, Pyrrole), 7.44 (d, 3J = 8.5 Hz, 1 H, C6H, (OCH3)2-Phe), 7.46 (dd, 4J = 2.0 Hz, 5J = 0.4 Hz, 
1 H, C5H, Pyrrole) ppm. 
226 | E x p e r i m e n t a l  
 
 
13C NMR (75 MHz, DMSO-d6): δ = 14.4 (COOCH2CH3), 36.4 (CH3), 55.2 (C4OCH3), 55.4 (C2OCH3), 
59.4 (CH2), 98.8 (C3H, (OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 115.4 (C3H, Pyrrole), 115.5 (C1, 
(OCH3)2-Phe), 119.0 (C4, Pyrrole), 121.3 (C2, Pyrrole), 127.7 (C6H, (OCH3)2-Phe), 129.0 (C5H, 
Pyrrole), 156.7 (C4OCH3), 158.74 (C2OCH3), 160.5 (COOCH2CH3) ppm. 
IR (ATR): ν̃ = 1676, 1613, 1559, 1495, 1466, 1435, 1412, 1360, 1287, 1204, 1180, 1128, 1109, 
1051, 1032, 947, 828, 756 cm-1. 
HPLC (Method 2): tR = 6.7 min. 
LC-MS (ESI, 70 eV): m/z = 290 [MH]+ (calc. m/z = 289). 
E x p e r i m e n t a l  | 227 
 
 
Ethyl 1-benzyl-4-(2,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylate (228) 
 
C22H23NO4 (Mr 365.43) 
228 was synthesized according to the procedure for 226 from 219 (216 mg, 783 µmol), sodium 
hydride (45.0 mg 60 % dispersion in mineral oil, 1.13 mmol), and benzyl bromide (180 µl, 
1.51 mmol) in 6 ml anhyd. DMF. The crude product was purified by flash chromatography (SiO2, 
2-10 % ethyl acetate/petrol ether) to afford 228 as a colorless solid (98 % HPLC purity). 
Yield: 186 mg (508 µmol, 65 %). 
1H NMR (300 MHz, DMSO-d6): δ = 1.22 (t, 3J = 7.1 Hz, 3 H, CH3), 3.77 (s, 3 H, OCH3), 3.83 (s, 3 H, 
OCH3), 4.17 (q, 3J = 7.1 Hz, 2 H, CH2), 5.57 (s, 2 H, CH2 Bn), 6.54 (dd, 3J = 8.5 Hz, 4J = 2.5 Hz, 1 H, 
C5H, (OCH3)2-Phe), 6.61 (d, 4J = 2.4 Hz, 1 H, C6H, (OCH3)2-Phe), 7.10-7.13 (m, 2 H, arCH, Bn), 
7.23-7.34 (m, 3 H, arCH, Bn), 7.27 (d, 4J = 2.0 Hz, 1 H, C3H, Pyrrole), 7.49 (d, 3J = 8.5 Hz, 1 H, C6H, 
(OCH3)2-Phe), 7.66 (d, 4J = 2.0 Hz, 1 H, C5H, Pyrrole) ppm. 
HPLC (Method 3): tR = 8.0 min. 
LC-MS (ESI, 70 eV): m/z = 366 [MH]+ (calc. m/z = 365). 
228 | E x p e r i m e n t a l  
 
 
Ethyl 4-(2,5-dimethoxyphenyl)-1-methyl-1H-pyrrole-2-carboxylate (229) 
 
C16H19NO4 (Mr 289.33) 
229 was synthesized according to the general procedure for 219 from 217 (1.11 g, 4.78 mmol), 
2,4-dimethoxyphenyl boronic acid (2.65 g, 14.6 mmol), Pd(PPh3)4 (289 mg, 250 µmol) in 80 ml 
DMF, and 25 ml 2 M aq. Na2CO3 solution. Purification was achieved by flash chromatography 
(SiO2, 2-10 % ethyl acetate/petrol ether and RP-18, 65 % methanol/H2O) to afford 229 as a 
colorless solid (100 % HPLC purity). 
Yield: 984 mg (3.40 mmol, 71 %). 
m.p.: > 360 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.30 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.74 (s, 3 H, C5OCH3), 
3.79 (s, 3 H, C2OCH3), 3.89 (s, 3 H, CH3), 4.24 (q, 3J = 7.1 Hz, 2 H, COOCH2CH3), 6.74 (dd, 3J = 8.9 Hz, 
4J = 3.1 Hz, 1 H, C4H, (OCH3)2-Phe), 6.96 (d, 3J = 8.9 Hz, 1 H, C3H, (OCH3)2-Phe), 7.09 (d, 4J = 3.1 Hz, 
1 H, C6H, (OCH3)2-Phe), 7.28 (d, 4J = 2.0 Hz, 1 H, C3H, Pyrrole), 7.60 (dd, 4J = 2.0 Hz, 5J = 0.4 Hz, 
1 H, C5H, Pyrrole) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.3 (COOCH2CH3), 36.5 (CH3), 55.4 (C5OCH3), 55.9 (C2OCH3), 
59.4 (COOCH2CH3), 111.7 (C4H, (OCH3)2-Phe), 112.5 (C6H, (OCH3)2-Phe), 112.9 (C3H, 
(OCH3)2-Phe), 116.1 (C3H, Pyrrole), 118.9 (C4, Pyrrole), 121.6 (C1, Pyrrole), 123.4 (C1, 
(OCH3)2-Phe), 130.0 (C5H, Pyrrole), 150.0 (C2OCH3), 153.4 (C5OCH3), 160.5 (COOCH2CH3) ppm. 
HPLC (Method 2): tR = 6.2 min. 
LC-MS (ESI, 70 eV): m/z = 290 [MH]+, 244 [MH-CH3CH2O]+ (calc. m/z = 289). 
E x p e r i m e n t a l  | 229 
 
 
4-(2,4-Dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid (216) 
 
C13H13NO4 (Mr 247.25) 
23 ml 4 M aq. NaOH were added to a solution of 219 (3.08 g, 11.2 mmol) in 60 ml THF and 30 ml 
methanol and the mixture was stirred at 50 °C for 5 h and then 12 h at rt. H2O was added to the 
reaction, the pH was adjusted to 3 using 1 M aq. HCl, and the mixture was extracted with ethyl 
acetate. The combined organic phases were washed with H2O and sat. aq. NaCl solution, the 
organic phase was dried over anhyd. Na2SO4, and the solvent was removed under reduced 
pressure to afford 216 as a beige solid (100 % purity, HPLC). 
Yield: 2.78 g (11.2 mmol, quant.). 
m.p.: 170 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.76 (s, 3 H, C2OCH3), 3.83 (s, 3 H, C4OCH3), 6.52 (dd, 
3J = 8.5 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.59 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 7.08 
(dd, 4J = 2.6 Hz, 5J = 1.7 Hz, 1 H, C3H, Pyrrole), 7.32 (dd, 4J = 3.0 Hz, 5J = 1.7 Hz, 1 H, C5H, Pyrrole), 
7.46 (d, 3J = 8.5 Hz, 1 H, C6H, (OCH3)2-Phe), 11.71 (bs, 1 H, NH), 12.22 (bs, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.2 (C2OCH3), 55.4 (C4OCH3), 98.8 (C3H, (OCH3)2-Phe), 105.2 
(C5H, (OCH3)2-Phe), 113.3 (C3H, Pyrrole), 116.1 (C1, (OCH3)2-Phe), 121.0 (C4, Pyrrole), 122.1 (C5H, 
Pyrrole), 122.4 (C2, Pyrrole), 127.8 (C6H, (OCH3)2-Phe), 156.7 (C4OCH3), 158.6 (C2OCH3), 162.0 
(COOH) ppm. 
IR (ATR): ν̃ = 3356, 2910, 1667, 1614, 1580, 1520, 1437, 1362, 1306, 1287, 1248, 1206, 1140, 
1130, 1051, 1032, 972, 934, 829, 789, 764, 623 cm-1. 
HPLC (Method 2): tR = 3.8 min. 
LC-MS (ESI, 70 eV): m/z = 248 [MH]+ (calc. m/z = 247). 
230 | E x p e r i m e n t a l  
 
 
4-(2,4-Dimethoxyphenyl)-1-methyl-1H-pyrrole-2-carboxylic acid (225) 
 
C14H15NO4 (Mr 261.28) 
Method A. 225 was synthesized according to the general procedure for 216 from 227 (990 mg, 
3.42 mmol) in 18 ml THF and 9 ml methanol, and 7 ml 4 M aq. NaOH to afford 225 as a brown 
solid (99 % HPLC purity). 
Yield: 894 mg (3.42 mmol, quant.). 
Method B. To a solution of 216 (130 mg, 526 µmol) in 5 ml anhyd. DMF under a nitrogen 
atmosphere at 0 °C, sodium hydride (32.0 mg 60 % dispersion in mineral oil, 800 µmol) was 
added in one portion. The suspension was stirred at the same temp. for 20 min before methyl 
iodide (46.0 µl, 739 µmol) was added dropwise. After stirring for another 15 min at 0 °C and 
2.5 h at rt, the reaction was quenched with H2O, and extracted with ethyl acetate. The combined 
organic phases were washed with H2O and sat. aq. NaCl solution, dried over anhyd. Na2SO4, and 
the solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography (SiO2, 2-30 % ethyl acetate/petrol ether) to afford 225 as a light pink solid 
(93 % HPLC purity). 
Yield: 70.9 mg (271 µmol, 52 %). 
m.p.: 164 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.76 (s, 3 H, C4OCH3), 3.83 (s, 3 H, C2OCH3), 3.86 (s, 3 H, CH3), 
6.53 (dd, 3J = 8.5 Hz, 4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 6.59 (d, 4J = 2.4 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.14 (d, 4J = 2.0 Hz, 1 H, C3H, Pyrrole), 7.41 (d, 4J = 2.0 Hz, 1 H, C5H, Pyrrole), 7.42 
(d, 3J = 8.4 Hz, 1 H, C6H, (OCH3)2-Phe), 12.17 (bs, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 36.3 (CH3), 55.2 (C4OCH3), 55.4 (C2OCH3), 98.8 (C3H, 
(OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 115.7 (C3H, Pyrrole), 115.7 (C1, (OCH3)2-Phe), 118.8 (C4, 
Pyrrole), 122.0 (C2, Pyrrole), 127.6 (C6H, (OCH3)2-Phe), 128.6 (C5H, Pyrrole), 156.7 (C2OCH3), 
158.7 (C4OCH3), 162.1 (COOH) ppm. 
E x p e r i m e n t a l  | 231 
 
 
IR (ATR): ν̃ = 3316, 1678, 1611, 1578, 1516, 1449, 1379, 1290, 1242, 1206, 1161, 1144, 1051, 
1032, 993, 936, 822, 797, 768, 725 cm-1. 
HPLC (Method 2): tR = 5.5 min. 
LC-MS (ESI, 70 eV): m/z = 262 [MH]+ (calc. m/z = 261). 
232 | E x p e r i m e n t a l  
 
 
1-Benzyl-4-(2,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic acid (230) 
 
C20H19NO4 (Mr 337.38) 
230 was synthesized according to the general procedure for 216 from 219 (186 mg, 508 µmol) 
in 3 ml THF and 1.5 ml methanol, and 2 ml 4 M aq. NaOH to afford 230 as a pale orange solid 
(100 % HPLC purity). 
Yield: 107 mg (318 µmol, 63 %). 
1H NMR (300 MHz, DMSO-d6): δ = 3.77 (s, 3 H, C4OCH3), 3.83 (s, 3 H, C2OCH3), 5.58 (s, 2 H, CH2, 
Bn), 6.54 (dd, 3J = 8.5 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.60 (d, 4J = 2.4 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.11-7.14 (m, 2 H, arC2/6H, Bn), 7.21-7.34 (m, 3 H, arC3-5H, Bn), 7.24 (d, 4J = 2.0 Hz, 
1 H, C3H, Pyrrole), 7.47 (d, 3J = 8.5 Hz, 1 H, C6H, (OCH3)2-Phe), 7.60 (d, 4J = 2.0 Hz, 1 H, C5H, 
Pyrrole), 12.20 (s, 1 H, COOH) ppm. 
13C NMR (75 MHZ, DMSO-d6): δ = 50.9 (CH2, Bn), 55.2 (C4OCH3), 55.4 (C2OCH3), 98.8 (C3H, 
(OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 115.4 (C1, (OCH3)2-Phe), 116.3 (C3H, Pyrrole), 119.4 (C4, 
Pyrrole), 121.6 (C2, Pyrrole), 126.6 (arC2/6H, Bn), 127.1 (arC4H, Bn), 127.7 (C6H, (OCH3)2-Phe), 
128.1 (C5H, Pyrrole), 128.4 (arC3/5H, Bn), 139.2 (arC1, Bn), 156.7 (C2OCH3), 158.8 (C4OCH3), 161.9 
(COOH) ppm. 
IR (ATR): ν̃ = 2924, 1661, 1611, 1576, 1508, 1451, 1433, 1375, 1296, 1254, 1206, 1182, 1150, 
1109, 1055, 1030, 937, 912, 837, 826, 785, 748, 727 cm-1. 
HPLC (Method 3): tR = 6.5 min. 
LC-MS (ESI, 70 eV): m/z = 338 [MH]+ (calc. m/z = 337). 
E x p e r i m e n t a l  | 233 
 
 
4-(2,5-Dimethoxyphenyl)-1-methyl-1H-pyrrole-2-carboxylic acid (222) 
 
C14H15NO4 (Mr 261.28) 
222 was synthesized according to the procedure for 216 from 229 (980 mg, 3.39 mmol) in 
19 ml THF and 10 ml methanol, and 7 ml 4 M aq. NaOH to afford 222 as a brown solid (100 % 
HPLC purity). 
Yield: 885 mg (3.39 mmol, quant.). 
m.p.: 149 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.74 (s, 3 H, C2OCH3), 3.79 (s, 3 H, C5OCH3), 3.88 (CH3), 6.72 
(dd, 3J = 8.9 Hz, 4J = 3.1 Hz, 1 H, C4H, (OCH3)2-Phe), 6.95 (d, 3J = 8.9 Hz, 1 H, C3H, (OCH3)2-Phe), 
7.08 (d, 4J = 3.1 Hz, 1 H, C6H, (OCH3)2-Phe), 7.25 (d, 4J = 2.0 Hz, 1 H, C3H, Pyrrole), 7.55 (d, 
4J = 2.0 Hz, 1 H, C5H, Pyrrole), 12.15 (bs, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 36.4 (CH3), 55.4 (C2OCH3), 55.9 (C5OCH3), 111.5 (C4H, 
(OCH3)2-Phe), 112.5 (C6H, (OCH3)2-Phe), 112.9 (C3H, (OCH3)2-Phe), 116.2 (C3H, Pyrrole), 118.7 
(C4, Pyrrole), 122.4 (C2, Pyrrole), 123.6 (C1, (OCH3)2-Phe), 129.6 (C5H, Pyrrole), 150.1 (C5OCH3), 
153.4 (C2OCH3), 162.1 (COOH) ppm. 
IR (ATR): ν̃ = 2940, 2832, 1667, 1603, 1553, 1505, 1462, 1437, 1410, 1352, 1300, 1273, 1258, 
1219, 1202, 1172, 1130, 1113, 1071, 1045, 1024, 889, 856, 842, 822, 806, 737, 708. 663 cm-1. 
HPLC (Method 2): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 262 [MH]+, 218 [M-CO2]+ (calc. m/z = 261). 
234 | E x p e r i m e n t a l  
 
 
1H-Benzo[d][1,2,3]triazol-1-yl 4-(2,4-dimethoxyphenyl)-1-methyl-1H-pyrrole-2-
carboxylate (224) 
 
C20H18N4O4 (Mr 378.39) 
225 (101 mg, 387 µmol) was dissolved in 5 ml anhyd. DMF and PyBOP (244 mg, 469 µmol) and 
DIPEA (210 µl, 1.20 mmol) were added. The mixture was stirred at rt for 1.5 h, quenched with 
H2O, and extracted with ethyl acetate. The combined organic phases were washed with H2O and 
sat. aq. NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash chromatography (SiO2, 2-30 % ethyl 
acetate/petrol ether) to afford 224 as a voluminous bright yellow solid (99 % HPLC purity). 
Yield: 119 mg (314 µmol, 82 %). 
1H NMR (300 MHz, DMSO-d6): δ = 3.80 (s, 3 H, C4OCH3), 3.89 (s, 3 H, C2OCH3), 3.93 (s, 3 H, CH3), 
6.59 (dd, 3J = 8.5 Hz, 4J = 2.5 Hz, 1 H, C5H, (OCH3)2-Phe), 6.66 (d, 4J = 2.4 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.51-7.56 (m, 1 H, C5H, Bt), 7.60 (d, 3J = 8.5 Hz, 1 H, C6H, (OCH3)2-Phe), 7.65-7.70 
(m, 1 H, C6H, Bt), 7.83 (d, 4J = 1.9 Hz, 1 H, C3H,Pyrrole), 7.86 (dt, 3J = 8.2 Hz, 4J = 0.8 Hz, 1 H, C7H, 
Bt), 7.91 (d, 4J = 1.9 Hz, 1 H, C5H, Pyrrole), 8.17 (dt, 3J = 8.4 Hz, 4J = 0.9 Hz, 1 H, C4H, Bt) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 36.5 (CH3), 55.2 (C4OCH3), 55.5 (C2OCH3), 98.9 (C3H, 
(OCH3)2-Phe), 105.4 (C5H, (OCH3)2-Phe), 109.3 (C7H, Bt), 114.4 (C1, (OCH3)2-Phe), 114.8 (C2, 
Pyrrole), 119.1 (C3H, Pyrrole), 119.8 (C4H, Bt), 121.0 (C4, Pyrrole), 125.2 (C5H, Bt), 128.1 (C6H, 
(OCH3)2-Phe), 128.7 (C7a, Bt), 129.1 (C6H, Bt), 133.5 (C5H, Pyrrole), 142.8 (C3a, Bt), 156.3 (CO), 
156.9 (C2OCH3), 159.3 (C4OCH3) ppm. 
HPLC (Method 3): tR = 7.1 min. 
LC-MS (ESI, 70 eV): m/z = 379 [MH]+ (calc. m/z = 378). 
E x p e r i m e n t a l  | 235 
 
 
N-(4-Methylpyridin-2-yl)-1H-pyrrole-2-carboxamide (221) 
 
C11H11N3O (Mr 201.23) 
A solution of 1H-pyrrole-2-carboxylic acid (201 mg, 1.81 mmol), PyBOP (1.13 g, 2.17 mmol), and 
DIPEA (950 µl, 5.44 mmol) in 5 ml anhyd. DMF was stirred under a nitrogen atmosphere for 
30 min at rt before 2-amino4-methylpyridine (270 mg, 2.50 mmol) was added in one portion. 
The reaction was stirred for 12 h at 110 °C, quenched with H2O, and extracted with ethyl acetate. 
The combined organic phases were washed with H2O and sat. aq. NaCl solution, dried over 
anhyd. Na2SO4, and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether) to afford 221 as a 
beige solid (99 % HLC purity). 
Yield: 99.7 mg (495 mmol, 27 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.33 (s, 3 H, CH3), 6.14-6.17 (m, 1 H, C4H, Pyrrole), 6.94 (dq, 
3J = 5.1 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 6.98-7.00 (m, 1 H, C3H, Pyrrole), 7.23-7.26 (m, 1 H, C5H, 
Pyrrole), 8.04 (m, 1 H, C3H, Pyr), 8.19 (dd, 3J = 5.0 Hz, 5J = 0.5 Hz, 1 H, C6H, Pyr), 10.21 (bs, 1 H, 
CONH), 11.67 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 20.7 (CH3), 108.9 (C4H, Pyrrole), 112.4 (C5H, Pyrrole), 114.2 
(C3H, Pyr), 119.8 (C5H, Pyr), 122.8 (C3H, Pyrrole), 125.3 (C1, Pyrrole), 147.1 (C6H, Pyr), 148.3 (C4, 
Pyr), 152.2 (C2, Pyr), 158.9 (CONH) ppm. 
IR (ATR): ν̃ = 3321, 3163, 3111, 2965, 2864, 1643, 1614, 1568, 1555, 1528, 1468, 1420, 1400, 
1323, 1298, 1269, 1179, 1138, 1113, 1068, 1042, 999, 959, 891, 880, 847, 810, 745, 677 cm-1. 
HPLC (Method 2): tR = 2.5 min. 
LC-MS (ESI, 70 eV): m/z = 425 [NaM2]+, 202 [MH]+ (calc. m/z = 201). 
236 | E x p e r i m e n t a l  
 
 
4-(2,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)-1H-pyrrole-2-carboxamide (220) 
 
C28H24FN5O3S (Mr 529.59) 
A solution of 216 (1.01 g, 4.07 mmol), PyBOP (2.54 g, 4.88 mmol), and DIPEA (2.15 ml, 
12.3 mmol) was stirred in 14 ml anhyd. DMF under a nitrogen atmosphere for 30 min at rt. 120 
(1.60 g, 5.31 mmol) was added in one portion and the mixture was stirred for 12 h at 110 °C. The 
reaction was quenched with H2O and extracted with ethyl acetate. The combined organic phases 
were washed with H2O and sat. aq. NaCl solution, dried over anhyd. Na2SO4, and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography 
(SiO2, 30-100 % ethyl acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 220 as 
a beige solid (95 % HPLC purity). 
Yield: 285 mg (538 µmol, 13 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3 H, SCH3), 3.78 (s, 3 H, C2OCH3), 3.85 (s, 3 H, C4OCH3), 
6.57 (dd, 3J = 8.5 Hz, 4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 6.61 (d, 4J = 2.3 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.07 (dd, 3J = 5.1 Hz, 4J = 1.0 Hz, 1 H, C5H, Pyr), 7.27-7.33 (m, 2 H, C3/5H, F-Phe), 
7.36 (bs, 1 H, C3H, Pyrrole), 7.4 (d, 3J = 8.4 Hz, 1 H, C6H, (OCH3)2-Phe), 7.49-7.58 (m, 2 H, C2/6H, 
F-Phe), 7.64 (bs, 1 H, C5H, Pyrrole), 8.19 (d, 3J = 5.2 Hz, 1 H, C6H, Pyr), 8.31 (bs, 1 H, C3H, Pyr), 
10.20 (bs, 1 H, CONH), 11.69 (bs, 1 H, NH, Pyrrole), 12.71 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.0 (SCH3), 55.2 (C2OCH3), 55.4 (C4OCH3), 98.9 (C3H, 
(OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 111.3 (C3H, Pyr), 111.3 (C5H, Pyrrole), 115.9 (d, 
2JCF = 21.7 Hz, C3/5H, F-Phe), 116.3 (C5H, Pyr), 122.0 (C2, Pyrrole), 125.1 (C1,F-Phe), 127.6 (C6H, 
(OCH3)2-Phe), 130.6 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 134.5 (C5, Imdz), 142.3 (C2, Imdz), 143.8 (C4, 
Imdz), 147.6 (C6H, Pyr), 152.8 (C2, Pyr), 156.7 (C4OCH3), 158.5 (C2OCH3), 159.1 (CONH), 160.8 (d, 
1JCF = 241.0 Hz, CF) ppm. 
E x p e r i m e n t a l  | 237 
 
 
HPLC (Method 2): tR = 5.7 min. 
LC-MS (ESI, 70 eV): m/z = 530 [MH]+, 546 [MOH]+ (calc. m/z = 529). 
 
238 | E x p e r i m e n t a l  
 
 
4-(2,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide (231) 
 
C29H26FN5O3S (Mr 543.62) 
231 was synthesized according to the procedure for 220 from 225 (604 mg, 2.31 mmol), PyBOP 
(1.44 g, 2.77 mmol), DIPEA (1.20 ml, 6.87 mmol), and 120 (904 mg, 2.99 mmol) in 12 ml anhyd. 
DMF. The crude product was purified by flash chromatography (SiO2, 30-100 % ethyl 
acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 231 as a beige solid (99 % 
HPLC purity). 
Yield: 303 mg (558 µmol, 24 %). 
m.p.: 236 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3 H, SCH3), 3.78 (s, 3 H, C2OCH3), 3.86 (s, 3 H, C4OCH3), 
3.90 (s, 3 H, CH3), 6.57 (dd, 3J = 8.5 Hz, 4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 6.61 (d, 4J = 2.3 Hz, 1 H, 
C3H, (OCH3)2-Phe), 7.06 (dd, 3J = 5.3 Hz, 4J = 1.2 Hz, 1 H, C5H, Pyr), 7.28-7.34 (m, 2 H, C3/5H, 
F-Phe), 7.41 (d, 4J = 1.3 Hz, 1 H, C3H, Pyrrole), 7.46 (d, 3J = 8.4 Hz, 1 H, C6H, (OCH3)2-Phe), 
7.49-7.54 (m, 2 H, C2/6H, F-Phe), 7.66 (d, 4J = 1.4 Hz, 1 H, C5H, Pyrrole), 8.18 (d, 3J = 5.2 Hz, 1 H, 
C6H, Pyr), 8.38 (bs, 1 H, C3H, Pyr), 10.10 (bs, 1 H, CONH), 12.73 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.3 (SCH3), 36.5 (CH3), 55.2 (C2OCH3), 55.5 (C4OCH3), 98.8 
(C3H, (OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 111.3 (C3H, Pyr), 113.2 (C5H, Pyrrole), 115.9 (d, 
2JCF = 21.9 Hz, C3/5H, F-Phe), 115.9 (C1, (OCH3)2-Phe), 116.3 (C5H, Pyr), 118.5 (C4, Pyrrole), 124.1 
(C2, Pyrrole), 126.7 (d, 4JCF = 3.5 Hz, C1, F-Phe), 127.5 (C6H, (OCH3)2-Phe), 128.5 (C3H, Pyrrole), 
130.8 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 134.5 (C5, Imdz), 142.1 (C2, Imdz), 143.6 (C4, Imdz), 147.6 
(C6H, Pyr), 152.7 (C2, Pyr), 156.7 (C4OCH3), 158.6 (C2OCH3), 159.8 (CONH), 162.0 (d, 
1JCF = 245.6 Hz, CF) ppm. 
E x p e r i m e n t a l  | 239 
 
 
IR (ATR): ν̃ = 3380, 2950, 1641, 1611, 1547, 1518, 1505, 1464, 1408, 1393, 1304, 1285, 1256, 
1217, 1204, 1155, 1038, 843, 829, 797, 737, 692 cm-1. 
HPLC (Method 2): tR = 6.0 min. 
LC-MS (ESI, 70 eV): m/z = 544 [MH]+ (calc. m/z = 543). 
HRMS (EI, 70 eV): m/z = 543.1740 [M]+ (calc. m/z = 543.1740). 
240 | E x p e r i m e n t a l  
 
 
4-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylthio)-1H-imidazol-4-yl)-
pyridin-2-yl)-1-methyl-1H-pyrrole-2-carboxamide (223) 
 
C29H26FN5O3S (Mr 543.62) 
224 was synthesized according to the procedure for 220 from 222 (604 mg, 2.31 mmol), PyBOP 
(1.45 g, 2.79 mmol), DIPEA (1.20 ml, 6.87 mmol), and 120 (904 mg, 3.01 mmol) in 12 ml anhyd. 
DMF. The crude product was purified by flash chromatography (SiO2, 30-100 % ethyl 
acetate/petrol ether and RP-18, 50-100 % methanol/H2O) to afford 223 as a pale yellowish solid 
(100 % HPLC purity). 
Yield: 255 mg (469 µmol, 20 %). 
m.p.: 127 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3 H, SCH3), 3.76 (s, 3 H, C5OCH3), 3.81 (s, 3 H, C2OCH3), 
3.92 (s, 3 H, CH3), 6.73 (dd, 3J = 8.9 Hz, 4J = 3.1 Hz, 1 H, C4H, (OCH3)2-Phe), 6.96 (d, 3J = 9.0 Hz, 1 H, 
C3H, (OCH3)2-Phe), 7.06 (dd, 3J = 5.3 Hz, 4J = 1.6 Hz, 1 H, C5H, Pyr), 7.17 (d, 4J = 3.1 Hz, 1 H, C6H, 
(OCH3)2-Phe), 7.24-7.30 (m, 2 H, C3/5H, F-Phe), 7.50-7.55 (m, 2 H, C2/6H, F-Phe), 7.56 (d, 
4J = 1.7 Hz, 1 H, C5H, Pyrrole), 7.80 (d, 4J = 1.8 Hz, 1 H, C3H, Pyrrole), 8.22 (d, 3J = 5.2 Hz, 1 H, C6H, 
Pyr), 8.35 (bs, 1 H, C3H, Pyr), 10.15 (bs, 1 H, CONH), 12.77 (vbs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.2 (SCH3), 36.7 (CH3), 55.4 (C5OCH3), 55.9 (C2OCH3), 111.3 
(C4H, (OCH3)2-Phe and C3H, Pyr), 112.5 (C6H, (OCH3)2-Phe), 112.8 (C3H, (OCH3)2-Phe), 113.6 (C3H, 
Pyrrole), 115.7 (d, 2JCF = 21.5 Hz, C3/5H, F-Phe), 116.5 (C5H, Pyr), 118.3 (C4, Pyrrole), 123.8 (C1, 
(OCH3)2-Phe), 124.3 (C2, Pyrrole), 129.7 (C5H, Pyrrole), 130.42 (C2/6H, F-Phe), 142.5 (C2, Imdz 
and C4, Pyr), 147.7 (C6H, Pyr), 150.1 (C2OCH3), 152.7 (C1, Pyr), 153.4 (C5OCH3), 159.8 (CONH), 
161.9 (d, 1JCF = 247.7 Hz, CF) ppm. 
E x p e r i m e n t a l  | 241 
 
 
IR (ATR): ν̃ = 2935, 2832, 1667, 1607, 1547, 1505, 1412, 1393, 1362, 1285, 1219, 1169, 1045, 
1024, 837, 814, 739, 721, 654 cm-1. 
HPLC (Method 2): tR = 6.1 min. 
LC-MS (ESI, 70 eV): m/z = 544 [MH]+ (calc. m/z = 543). 
HRMS (EI, 70 eV): m/z = 543.170 [M]+ (calc. m/z = 543.1740). 
242 | E x p e r i m e n t a l  
 
 
2-Bromo-1-phenylethan-1-one (141) 
 
C8H7BrO (Mr 199.05) 
Acetophenone (2.70 ml, 22.9 mmol) was dissolved in 8 ml glacial acetic acid and few droplets of 
hydrogen bromide in glacial acetic acid were added before dropwise addition of bromine 
(1.40 ml, 27.2 mmol) whereupon the temp. should not exceed 20 °C. The reaction was stirred for 
90 min at rt, poured into ice-cold H2O, filtered, and the residue was washed with 50 % (v/v) 
ethanol. The crude product was purified by flash chromatography (SiO2, 10 % ethyl 
acetate/petrol ether) to afford 241 as light green crystals (96 % HPLC purity). 
Yield: 2.63 g (13.2 mmol, 58 %) (Lit.231: 60 %). 
m.p.: 48 °C. 
1H NMR (300 MHz, CDCl3): δ = 4.46 (s, 2 H, CH2), 7.47-7.52 (m, 2 H, C3/5H, Phe), 7.59-7.64 (m, 
1 H, C4H, Phe), 7.97-8.01 (m, 2 H, C2/6H, Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 30.0 (CH2), 128.0 (C3/5H, Phe), 128.1 (C2/6H, Phe), 133.1 (C4, Phe), 
133.1 (C1, Phe), 190.4 (CO) ppm. 
HPLC (Method 2): tR = 5.0 min. 
E x p e r i m e n t a l  | 243 
 
 
2-Bromo-1-(5-bromo-2,4-dimethoxyphenyl)ethan-1-one (242) 
 
C10H10Br2O3 (Mr 338.00) 
Method A. 242 was synthesized according to the procedure for 241 from 2,4-dimethoxy-
acetophenone (1.01 g, 5.61 mmol) and bromine (340 µl, 6.62 mmol) in 10 ml glacial acetic acid. 
The crude product was crystallized from methanol to afford 242 as a pale pink solid (88 % HPLC 
purity). 
Yield: 979 mg (2.90 mmol, 52 %). 
Method B. Bromine (340 µl, 6.62 mmol) in 12 ml anhyd. chloroform was carefully added 
dropwise to a solution of 2,4-dimethoxyacetophenone (1.01 g, 5.61 mmol) in 10 ml anhyd. 
chloroform under a nitrogen atmosphere. The mixture was stirred for 30 min at rt and then 
heated to reflux for 2 h. The solvent was removed under reduced pressure and the crude 
product was purified by flash chromatography (SiO2, 15-40 % ethyl acetate/petrol ether) to 
afford 242 as a pale beige solid (79 % HPLC purity). 
Yield: 1.00 g (2.96 mmol, 53 %). 
1H NMR (300 MHz, CDCl3): δ = 3.97 (s, 3 H, OCH3), 3.98 (s, 3 H, OCH3), 4.52 (s, 2 H, CH2), 6.45 (s, 
1 H, C3H, (OCH3)2-Phe), 8.09 (s, 1 H, C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 37.5 (CH2), 56.3 (OCH3), 56.7 (OCH3), 95.8 (C3H, (OCH3)2-Phe), 
103.6 (C5Br), 118.3 (C1, (OCH3)2-Phe), 136.1 (C6H, (OCH3)2-Phe), 160.4 (COCH3), 161.1 (COCH3), 
189.3 (CO) ppm. 
HPLC (Method 2): tR = 5.9 min. 
244 | E x p e r i m e n t a l  
 
 
2-Bromo-1-(2,4-dimethoxyphenyl)ethan-1-one (237) 
 
C10H11BrO3 (Mr 259.10) 
Copper(II)bromide (1.26 g, 5.64 mmol) was added in one portion to 2,4-dimethoxy-
acetophenone (505 mg, 2.80 mmol) in 11 ml ethyl acetate and the mixture was heated to reflux 
for 90 min. After completion of the reaction the mixture was allowed to cool to rt, the solids 
were filtered off and washed with ethyl acetate. The filtrate was concentrated under reduced 
pressure and the crude product was purified by flash chromatography (SiO2, 10 % ethyl ace-
tate/petrol ether) to afford 237 as pale beige solid (100 % HPLC purity). 
Yield: 701 mg (2.70 mmol, 97 %). 
m.p.: 103 °C. 
1H NMR (300 MHz, CDCl3): δ = 3.87 (s, 3 H, C5OCH3), 3.92 (s, 3 H, C2OCH3), 4.57 (s, 2 H, CH2), 6.46 
(d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 6.56 (dd, 3J = 8.8 Hz, 4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 
7.91 (d, 3J = 8.8 Hz, 1 H, C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 38.1 (CH2), 55.8 (C5OCH3), 55.9 (C2OCH3), 98.4 (C3H, (OCH3)2-Phe), 
106.0 (C5H, (OCH3)2-Phe), 118.0 (C1, (OCH3)2-Phe), 134.0 (C6H, (OCH3)2-Phe), 161.0 (C2OCH3), 
165.5 (C5OCH3), 190.3 (CO) ppm. 
HPLC (Method 2): tR = 5.5 min. 
E x p e r i m e n t a l  | 245 
 
 
2-Chloro-1-(2,4-dimethoxyphenyl)ethan-1-one (238) 
 
C10H11ClO3 (Mr 214.65) 
1,3-Dimethoxybenzene (557 mg, 4.03 mmol) was carefully added to a solution of aluminum 
chloride (1.20 g, 9.00 mmol) in 10 ml chloroacetyl chloride at 0 °C under a nitrogen atmosphere 
and the mixture was stirred for 3 h at the same temp. The reaction was quenched with H2O, 
extracted with ethyl acetate, and the combined organic phases were washed with sat. aq. 
NaHCO3 solution, dried over anhyd. Na2SO4, and concentrated under reduced pressure. The 
crude product was purified by flash chromatography (SiO2, 10 % ethyl acetate/petrol ether) to 
afford 238 as a voluminous white solid (98 % HPLC purity). 
Yield: 664 mg (3.10 mmol, 77 %). 
m.p.: 113. 
1H NMR (300 MHz, CDCl3): δ = 3.86 (s, 3 H, C4OCH3), 3.91 (s, 3 H, C2OCH3), 4.74 (s, 2 H, CH2), 6.45 
(d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 6.56 (dd, 3J = 8.8 Hz, 4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 
7.94 (d, 3J = 8.8 Hz, 1 H, C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, CDCl3): δ = 51.4 (CH2), 55.8 (C2/4OCH3), 98.3 (C3H, (OCH3)2-Phe), 106.1 (C5H, 
(OCH3)2-Phe), 118.2 (C1, (OCH3)2-Phe), 133.7 (C6H, (OCH3)2-Phe), 161.1 (C2OCH3), 165.5 
(C4OCH3), 190.2 (CO) ppm. 
HPLC (Method 2): tR = 5.3 min. 
246 | E x p e r i m e n t a l  
 
 
Ethyl 4-(2,4-dimethoxyphenyl)-thiazole-2-carboxylate (239) 
 
C14H15NO4S (Mr 293.34) 
Method A. 237 (410 mg, 1.58 mmol) and ethyl 2-amino-2-thioxoacetate (330 mg, 2.45 mmol) in 
5 ml ethanol were implemented in a microwave reaction for 10 min at 80 °C (100 W). The 
solvent was removed under reduced pressure and the crude product was purified by flash 
chromatography (SiO2, 5-10 % ethyl acetate/petrol ether) to afford 239 as a colorless solid 
(96 % HPLC purity). 
Yield: 349 mg (1.19 mmol, 76 %). 
Method B. 239 was synthesized according to the procedure described above (Method A) from 
238 (300 mg, 1.40 mmol) and ethyl 2-amino-2-thioxoacetate (287 mg, 2.16 mmol) in 5 ml etha-
nol to afford 239 as a colorless solid (95 % HPLC purity). 
Yield: 236 mg (805 µmol, 58 %). 
m.p.: 98 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.35 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.83 (s, 3 H, C2OCH3), 
3.93 (s, 3 H, C4OCH3), 4.40 (q, 3J = 7.0 Hz, 2 H, COOCH2CH3), 6.65-6.71 (m, 2 H, C3/5H, 
(OCH3)2-Phe), 8.06 (d, 3J = 8.6 Hz, 1 H, C6H, (OCH3)2-Phe), 8.28 (s, 1 H, C5H, Thiazole) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.1 (COOCH2CH3), 55.4 (C4OCH3), 55.7 (C2OCH3), 62.1 
(COOCH2CH3), 98.7 (C3H, (OCH3)2-Phe), 105.6 (C5H, (OCH3)2-Phe), 114.8 (C1, (OCH3)2-Phe), 122.0 
(C5H, Thiazole), 130.3 (C6H, (OCH3)2-Phe), 152.5 (C4, Thiazole), 155.5 (C2, Thiazole), 157.9 
(C2OCH3), 159.5 (COOCH2CH3), 160.8 (C4OCH3) ppm. 
IR (ATR): ν̃ = 1724, 1614, 1578, 1522, 1491, 1435, 1414, 1319, 1283, 1256, 1240, 1211, 1169, 
1126, 1088, 1059, 1026, 1011, 928, 855, 831, 810, 793 cm-1. 
HPLC (Method 2): tR = 5.9 min. 
LC-MS (ESI, 70 eV): m/z = 294 [MH]+ (calc. m/z = 293). 
E x p e r i m e n t a l  | 247 
 
 
4-(2,4-Dimethoxyphenyl)thiazole (245) 
 
C11H11NO2S (Mr 221.27) 
0.5 ml of 4 M aq. NaOH were added to a solution of 239 (60.0 mg, 205 µmol) in 1.3 ml THF and 
0.6 ml methanol and the mixture was stirred 48 h at rt. H2O was added to the reaction, the pH 
was adjusted to 3 using 1 M aq. HCl, and the mixture was extracted with ethyl acetate. The com-
bined organic phases were washed with H2O and sat. aq. NaCl solution, the organic phase was 
dried over anhyd. Na2SO4, and the solvent was removed under reduced pressure to afford 245 as 
a light brown solid (99 % HPLC purity). 
Yield: 45.4 mg (205 µmol, quant.). 
m.p.: 62 °C. 
1H NMR (300 MHz, CDCl3): δ = 3.86 (s, 3 H, C4OCH3), 3.94 (s, 3 H, C2OCH3), 6.57 (d, 4J = 2.4 Hz, 
1 H, C3H, (OCH3)2-Phe), 6.62 (dd, 3J = 8.6 Hz, 4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 7.86 (d, 
4J = 2.1 Hz, 1 H, C5H, Thiazole), 8.19 (d, 3J = 8.6 Hz, 1 H, C6H, (OCH3)2-Phe), 8.93 (d, 4J = 2.1 Hz, 1 H, 
C2H, Thiazole) ppm. 
13C NMR (75 MHz, CDCl3): δ = 55.6 (C4OCH3), 55.7 (C2OCH3), 99.0 (C3H, (OCH3)2-Phe), 105.0 (C5H, 
(OCH3)2-Phe), 115.0 (C5H, Thiazole), 115.6 (C1, (OCH3)2-Phe), 131.0 (C6H, (OCH3)2-Phe), 151.3 
(C4, Thiazole), 151.4 (C2H, Thiazole), 158.0 (C2OCH3), 161.0 (C4OCH3) ppm. 
IR (ATR): ν̃ = 3152, 3082, 3001, 2972, 2938, 2837, 1605, 1576, 1516, 1483, 1462, 1435, 1410, 
1310, 1289, 1279, 1210, 1157, 1126, 1047, 1030, 924, 887, 828, 814, 748, 725 cm-1. 
HPLC (Method 2): tR = 5.7 min. 
LC-MS (ESI, 70 eV): m/z = 222 [MH]+ (calc. m/z = 221). 
248 | E x p e r i m e n t a l  
 
 
Methyl 5-(2,4-dimethoxyphenyl)oxazole-4-carboxylate (250) 
 
C13H13NO5 (Mr 263.25) 
2,4-Dimethoxybenzoic acid (500 mg, 2.75 mmol) and CDI (542 mg, 3.34 mmol) were stirred in 
5 ml anhyd. THF at rt until formation of CO2 was undetectable. The reaction was heated to 50 °C 
for 2 h, cooled to rt, and added dropwise to a solution of methyl isocyanoacetate (280 µl, 
3.08 mmol) and NaHMDS (500 ml 2 M solution in THF, 1.00 mmol) in 5 ml anhyd. THF. The 
resulting mixture was stirred for 12 h at rt. The solvent was removed under reduced pressure, 
the residue dissolved in ethyl acetate, washed with H2O and sat. aq. NaCl solution, dried over 
anhyd. Na2SO4, and the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography (SiO2, 5-40 % ethyl acetate/petrol ether) to afford 250 as a 
beige solid (100 % HPLC purity). 
Yield: 404 mg (1.54 mmol, 56 %). 
m.p.: 122 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.70 (s, 3 H, COOCH3), 3.76 (s, 3 H, C2OCH3), 3.84 (s, 3 H, 
C4OCH3), 6.65 (dd, 3J = 8.5 Hz, 4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 6.69 (d, 4J = 2.3 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.40 (d, 3J = 8.5 Hz, 1 H, C6H, (OCH3)2-Phe), 8.49 (s, 1 H, C2H, Oxazole) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 51.6 (COOCH3), 55.5 (C4OCH3), 55.7 (C2OCH3), 98.5 (C3H, 
(OCH3)2-Phe), 105.3 (C5H, (OCH3)2-Phe), 108.2 (C1, (OCH3)2-Phe), 127.2 (C4, Oxazole), 131.8 (C6H, 
(OCH3)2-Phe), 151.0 (C2H, Oxazole), 151.8 (C5, Oxazole), 158.3 (C2OCH3), 161.94 (COOCH3), 
162.54 (C4OCH3) ppm. 
IR (ATR): ν̃ = 3131, 2950, 1713, 1614, 1591, 1505, 1479, 1433, 1416, 1362, 1323, 1298, 1289, 
1277, 1236, 1217, 1194, 1180, 1117, 1090, 1067, 1030, 1001, 943, 934, 868, 821, 808, 793, 654, 
644 cm-1. 
HPLC (Method 2): tR = 4.9 min. 
LC-MS (ESI, 70 eV): m/z = 549 [NaM2-H]+, 527 [M2]+, 286 [NaM-H]+, 264 [MH]+, 232 [M-CH3OH]+ 
(calc. m/z = 263). 
E x p e r i m e n t a l  | 249 
 
 
2-(2,4-Dimethoxyphenyl)-2-oxoethan-1-aminium chloride (247) 
 
C10H14ClNO3 (Mr 231.68) 
Method A. A solution of 250 (78.0 mg, 296 µmol) in 4 ml methanol and 4 ml conc. aq. HCl was 
stirred under reflux for 4 h. The solvent was removed under reduced pressure, the residue was 
suspended in acetone, filtered, and the precipitate was washed with cold diethyl ether to afford 
247 as a pale yellowish solid (100 % HPLC purity). 
Yield: 65.0 mg (281 µmol, 95 %). 
Method B. Methenamine (110 mg, 786 µmol) was added in one portion to a stirred solution of 
237 (200 mg, 772 µmol) in 2 ml chloroform at rt and stirring continued at the same temp. for 
4 h. The precipitate was filtered off and refluxed in 3 ml methanol and 0.2 ml conc. aq. HCl for 
3 h. The precipitate was collected by filtration, rinsed with methanol, and the filtrate concentrat-
ed under reduced pressure to afford 247 as a brown solid (100 % HPLC purity). 
Yield: 178 mg (768 µmol, quant.). 
m.p.: 172 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.88 (s, 3 H, C4OCH3), 3.95 (s, 3 H, C2OCH3), 4.20 (bs, 2 H, CH2), 
6.68-6.72 (m, 2 H, H-3, C3/5H, (OCH3)2-Phe), 7.86 (d, 3J = 8.6 Hz, 1 H, C6H, (OCH3)2-Phe), 8.37 (bs, 
3 H, NH3) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 48.2 (CH2), 55.9 (C4OCH3), 56.2 (C2OCH3), 98.4 (C3H, 
(OCH3)2-Phe), 107.1 (C5H), 116.3 (C1, (OCH3)2-Phe), 132.2 (C6H, (OCH3)2-Phe), 162.0 (C2OCH3), 
165.8 (C4OCH3), 190.1 (CO) ppm. 
IR (ATR): ν̃ = 2950, 2900, 2698, 2612, 1667, 1597, 1568, 1493, 1458, 1430, 1298, 1252, 1231, 
1207, 1165, 1140, 1119, 1061, 1032, 1022, 970, 916, 843, 812, 802 cm-1. 
HPLC (Method 2): tR = 2.6 min. 
LC-MS (ESI, 70 eV): m/z = 391 [M2-HCl, Cl]+, 196 [M-Cl]+, 179 [M-NH4Cl]+ (calc. m/z = 231). 
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Ethyl 4-(2,4-dimethoxyphenyl)-1H-imidazole-2-carboxylate (246) 
 
C14H16N2O4 (Mr 276.29) 
Method A. A solution of 247 (180 mg, 777 µmol), ethyl 2-amino-2-thioxoacetate (129 mg, 
971 µmol), and sodium acetate (156 mg, 1.90 mmol) in 1 ml glacial acetic acid was heated to 
reflux for 3 h. After cooling to rt, the mixture was neutralized with Na2CO3 and extracted with 
ethyl acetate. The combined organic phases were washed with sat. aq. NaCl solution and dried 
over anhyd. Na2SO4. Flash chromatography (SiO2, 20-55 % ethyl acetate/petrol ether) afforded 
246 as a yellow solid (100 % HPLC purity). 
Yield: 74.5 mg (270 µmol, 35 %). 
Method B. Trimethyloxonium tetrafluoroborate (60.0 mg, 406 µmol) was added in three 
portions over 1 h to an intensely stirred solution of ethyl 2-amino-2-thioxoacetate (45.0 mg, 
338 µmol) in 2 ml DCM at rt and stirring continued for another 30 min. The solvent was 
removed under reduced pressure and sodium acetate (47.0 mg, 570 µmol), 247 (64.0 mg, 
275 µmol), and 1 ml glacial acetic acid were added. The resulting mixture was heated to 100 °C 
for 3 h. Afterwards, the reaction was cooled to rt, diluted with H2O, and extracted with ethyl 
acetate. The combined organic phases were washed with H2O and sat. aq. NaCl solution, dried 
over anhyd. Na2SO4, and the solvent was removed under reduced pressure. The crude product 
was purified by flash chromatography (SiO2, 20-55 % ethyl acetate/petrol ether) to afford 246 
as a yellow solid (100 % HPLC purity). 
Yield: 59.4 mg (215 µmol, 78 %). 
m.p.: 87 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.33 (t, 3J = 7.1 Hz, 3 H, COOCH2CH3), 3.79 (s, 3 H, C2OCH3), 
3.89 (s, 3 H, C4OCH3), 4.34 (q, 3J = 7.1 Hz, 2 H, COOCH2CH3), 6.06 (dd, 3J = 8.5 Hz, 4J = 2.4 Hz, 1 H, 
C5H, (OCH3)2-Phe), 6.63 (d, 4J = 2.2 Hz, 1 H, C3H, (OCH3)2-Phe), 7.56 (s, 1 H, C4H, Imdz), 7.95 (d, 
3J = 8.1 Hz, 1 H, C6H, (OCH3)2-Phe), 13.28 (bs, 1 H, NH) ppm. 
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13C NMR (75 MHz, DMSO-d6): δ = 14.3 (COOCH2CH3), 55.2 (C2OCH3), 55.4 (COCH3), 60.7 
(COOCH2CH3), 98.5 (C3H, (OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 113.6 (C1, (OCH3)2-Phe), 119.1 
(C5H, Imdz), 127.9 (C6H, (OCH3)2-Phe), 136.0 (C2, Imdz), 137.8 (C5H, Imdz), 157.0 (C4OCH3), 158.5 
(COOCH2CH3), 159.7 (C2OCH3) ppm. 
IR (ATR): ν̃ = 3302, 2930, 1713, 1694, 1622, 1582, 1560, 1522, 1481, 1456, 1439, 1383, 1354, 
1312, 1285, 1256, 1211, 1192, 1161, 1153, 1138, 1115, 1078, 1069, 949, 824, 789, 731, 
652 cm-1. 
HPLC (Method 2): tR = 5.0 min. 
LC-MS (ESI, 70 eV): m/z = 277 [MH]+, 249 [MH-C2H5]+, 553 [M2H]+, 575 [NaM2]+ 
(calc. m/z = 276). 
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2,4-Dimethoxybenzohydrazide (256) 
 
C9H12N2O3 (Mr 196.21) 
2,4-Dimethoxybenzoic acid (1.00 g, 5.50 mmol) in 6 ml anhyd. methanol and 0.1 ml sulfuric acid 
was stirred under reflux for 4 h. The solution was cooled to rt before hydrazine hydrate (2.20 ml, 
44.6 mmol) was added and the mixture was heated to reflux for another 30 min. The solvent was 
removed under reduced pressure, the residue heated to reflux in ethanol, filtered at that temp., 
and crystallized to afford 256 as a colorless solid (100 % HPLC purity). 
Yield: 1.07 g (5.47 mmol, quant.). 
m.p.: 109 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.81 (s, 3 H, C4OCH3), 3.88 (s, 3 H, C2OCH3), 4.48 (bs, 2 H, NH2), 
6.59-6.23 (m, 2 H, C3/5H, (OCH3)2-Phe), 7.76 (d, 3J = 8.9 Hz, 1 H, C6H, (OCH3)2-Phe), 9.00 (bs, 1 H, 
NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.5 (C4OCH3), 55.9 (C2OCH3), 98.4 (C3H, (OCH3)2-Phe), 105.5 
(C5H, (OCH3)2-Phe), 114.1 (C1, (OCH3)2-Phe), 131.1 (C6H, (OCH3)2-Phe), 158.4 (C2OCH3), 162.6 
(C4OCH3), 164.4 (CO) ppm. 
IR (ATR): ν̃ = 3348, 3296, 1622, 1599, 1481, 1451, 1445, 1327, 1265, 1215, 1182, 1163, 1098, 
1024, 957, 839, 829, 716, 652, 629, 602 cm-1. 
HPLC (Method 2): tR = 3.2 min. 
LC-MS (ESI, 70 eV): m/z = 415 [NaM2]+, 197 [MH]+ (calc. m/z = 196). 
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7.3.6 Syntheses of Series 5: Propiolic Acid 
1-(2,2-Dibromovinyl)-2,4-dimethoxybenzene (260) 
 
C10H10Br2O2 (Mr 322.00) 
2,4-Dimethoxybenzaldehyde (500 mg, 3.01 mmol) and triphenylphosphine (1.58 g, 6.02 mmol) 
were stirred in 7 ml anhyd. DCM at rt under a nitrogen atmosphere. The mixture was cooled to 
0 °C before tetrabromomethane (1.17 g, 3.54 mmol) in 1 ml anhyd. DCM was carefully added 
dropwise whereupon the temp. was kept below 5 °C. The reaction was stirred for 30 min at the 
same temp., filtered, and the filtrate concentrated under reduced pressure. The crude product 
was purified by flash chromatography (SiO2, 10 % ethyl acetate/petrol ether) to afford 260 as a 
colorless solid (99 % HPLC purity). 
Yield: 397 mg (1.23 mmol, 41 %). 
m.p.: 57 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.79 (s, 3 H, C4OCH3), 3.80 (s, 3 H, C2OCH3), 6.56-6.60 (m, 2 H, 
C3/5H, (OCH3)2-Phe), 7.51 (s, 1 H, CHCBr2), 7.56 (dd, 3J = 8.9 Hz, 4J = 0.6 Hz, 1 H, C6H, (OCH3)2-Phe) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.4 (C4OCH3), 55.7 (C2OCH3), 87.9 (CHCBr2), 98.2 (C3H, 
(OCH3)2-Phe), 105.0 (C5H, (OCH3)2-Phe), 116.1 (C1, (OCH3)2-Phe), 129.3 (C6H, (OCH3)2-Phe), 
132.4 (CHCBr2), 157.6 (C2OCH3), 161.1 (C4OCH3) ppm. 
IR (ATR): ν̃ = 2920, 1608, 1576, 1497, 1470, 1454, 1435, 1416, 1323, 1289, 1263, 1207, 1184, 
1161, 1121, 1030, 922, 868, 843, 828, 781, 766 cm-1. 
HPLC (Method 1): tR = 7.6 min. 
LC-MS (ESI, 70 eV): m/z = 321, 323, 325 [MH]+, 242, 244 [C10H12BrO2]+ (calc. m/z = 320). 
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Methyl 3-(2,4-dimethoxyphenyl)propiolate (258) 
 
C12H12O4 (Mr 220.22) 
n-Butyllithium (2.70 ml 1.6 M solution in hexanes, 4.32 mmol) was slowly added dropwise to a 
stirred solution of 260 (640 mg, 1.99 mmol) in 8 ml anhyd. THF at -78 °C under a nitrogen 
atmosphere. Stirring continued for 15 min at the same temp. and 1 h at rt before methyl 
chloroformate (190 µl, 2.46 mmol) was added dropwise at -78 °C. The mixture was stirred 
another 3 h at rt, quenched with sat. aq. NH4Cl solution, and extracted with ethyl acetate. The 
combined organic phases were dried over anhyd. Na2SO4 and the crude product was purified by 
flash chromatography (SiO2, 2-10 % ethyl acetate/petrol ether) to afford 258 as a colorless solid 
(100 % HPLC purity). 
Yield: 382 mg (1.73 mmol, 87 %). 
m.p.: 88 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.74 (s, 3 H, COOCH3), 3.83 (s, 3 H, C2OCH3), 3.86 (s, 3 H, 
C4OCH3), 6.60 (dd, 3J = 8.6 Hz, 4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 6.66 (d, 4J = 2.3 Hz, 1 H, C3H, 
(OCH3)2-Phe), 7.50 (d, 3J = 8.6 Hz, 1 H, C6H, (OCH3)2-Phe) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 52.7 (COOCH3), 55.7 (C2OCH3), 56.0 (C4OCH3), 83.5 
(CCCOOCH3), 84.6 (CCCOOCH3), 98.5 (C3H, (OCH3)2-Phe), 99.4 (C1, (OCH3)2-Phe), 106.5 (C5H, 
(OCH3)2-Phe), 136.0 (C6H, (OCH3)2-Phe), 154.0 (COOCH3), 163.1 (C4OCH3), 163.5 (C2OCH3) ppm. 
IR (ATR): ν̃ = 2212, 1750, 1611, 1568, 1508, 1456, 1436, 1416, 1310, 1292, 1256, 1215, 1196, 
1167, 1128, 1038, 1026, 990, 929, 874, 820, 791, 743 cm-1. 
HPLC (Method 1): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 221 [MH]+ (calc. m/z = 220). 
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3-(2,4-Dimethoxyphenyl)propiolic acid (257) 
 
C11H10O4 (Mr 206.20) 
Lithium hydroxide monohydrate (95 mg, 2.26 mmol) was added to a stirred solution of 258 
(350 mg, 1.59 mmol) in 6 ml THF, 1.5 ml water, and 1.5 ml methanol and stirring continued for 
12 h at rt. The mixture was extracted with ethyl acetate, the combined organic phases were 
washed with H2O and sat. aq. NaCl solution, and dried over anhyd. Na2SO4 to afford 257 as a 
beige solid (99 % HPLC purity). 
Yield: 297 mg (1.44 mmol, 91 %). 
m.p.: 137 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.82 (s, 3 H, C2OCH3), 3.85 (s, 3 H, C4OCH3), 6.59 (dd, 3J = 8.6 Hz, 
4J = 2.3 Hz, 1 H, C5H, (OCH3)2-Phe), 6.65 (d, 4J = 2.3 Hz, 1 H, C3H, (OCH3)2-Phe), 7.46 (d, 3J = 8.5 Hz, 
1 H, C6H, (OCH3)2-Phe), 13.42 (bs, 1 H, COOH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 55.7 (C2OCH3), 55.9 (C4OCH3), 82.9 (CCCOOH), 84.8 (CCCOOH), 
98.5 (C3H, (OCH3)2-Phe), 100.0 (C1, (OCH3)2-Phe), 106.3 (C5H, (OCH3)2-Phe), 135.8 (C6H, 
(OCH3)2-Phe), 154.7 (COOH), 162.8 (C4OCH3), 163.1 (C2OCH3) ppm. 
IR (ATR): ν̃ = 2900, 2195, 1667, 1601, 1566, 1508, 1456, 1435, 1414, 1294, 1260, 1227, 1204, 
1157, 1136, 1036, 1024, 883, 829, 810, 739 cm-1. 
HPLC (Method 2): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 207 [MH]+, 163 [MH-CO2]+ (calc. m/z = 206). 
256 | E x p e r i m e n t a l  
 
 
7.3.7 Syntheses of Series 6: Hybrid Inhibitors 
Methyl 3-amino-4,5-dihydrothiophene-2-carboxylate (271) 
 
C6H9NO2S (Mr 159.20) 
Acrylonitrile (1.30 ml, 19.6 mmol) and thioglycolic acid methyl ester (1.70 ml, 18.9 mmol) were 
added to a stirred solution of DBU (6.30 ml, 41.8 mmol) in 11 ml anhyd. methanol at 0 °C under a 
nitrogen atmosphere and stirring continued at the same temp. for 5 h and then 12 h at 80 °C. 
Afterwards, the reaction was cooled to rt, the solvent was removed under reduced pressure, sat. 
aq. NH4Cl solution was added, and the resulting suspension was extracted with ethyl acetate. 
The combined organic phases were dried over anhyd. Na2SO4 and the crude product was puri-
fied by flash chromatography (SiO2, 20-22 % ethyl acetate/petrol ether) to afford 271 as a bright 
yellow solid (100 % HPLC purity). 
Yield: 1.35 g (8.49 mmol, 45 %) (Lit.245: 70 %). 
m.p.: 103 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.89 (t, 3J = 7.9 Hz, 2 H, C4H2), 3.07 (t, 3J = 7.9 Hz, 2 H, C5H2), 3.72 
(s, 3 H, COOCH3), 5.82 (vbs, 2 H, NH2) ppm. 
13C NMR (75 MHz, CDCl3): δ = 27.8 (C5H2), 39.3 (C4H2), 51.2 (COOCH3), 90.4 (C2), 156.8 (C3), 
166.3 (COOCH3) ppm. 
IR (ATR): ν̃ = 3410, 3300, 3212, 3142, 2986, 2943, 1651, 1620, 1537, 1447, 1425, 1924, 1279, 
1265, 1188, 1134, 1076, 1036, 993, 986, 964, 912, 828, 766, 683 cm-1. 
HPLC (Method 2): tR = 3.7 min. 
LC-MS (ESI, 70 eV): m/z = 160 [MH]+ (calc. m/z = 159). 
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3-Phenyl-2-thioxo-2,3,6,7-tetrahydrothieno[3,2-d]pyrimidin-4(1H)-one (272) 
 
C12H10N2OS2 (Mr 262.35) 
271 (303 mg, 1.90 mmol) and phenyl isothiocyanate (300 µl, 2.51 mmol) were stirred in 6 ml 
anhyd. pyridine for 12 h at 100 °C under a nitrogen atmosphere. The solvent was removed under 
reduced pressure and the residue was purified by flash chromatography (SiO2, 30 % ethyl 
acetate/petrol ether, then acetone) and crystallized from methanol to afford 272 as a beige solid 
(96 % HPLC purity). 
Yield: 140 mg (534 µmol, 28 %) (Lit.210: 42 %). 
m.p.: 262 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.25 (t, 3J = 7.9 Hz, 2 H, C5H2), 3.38 (t, 3J = 7.9 Hz, 2 H, C4H2), 
7.16-7.19 (m, 2 H, C2/6H, Phe), 7.38-7.48 (m, 3 H, C3-5H, Phe), 13.23 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 29.0 (C4H2), 34.6 (C5H2), 114.4 (C5, Pyrimidine), 128.2 (C4H, 
Phe), 128.6 (C2/6H, Phe), 129.0 (C3/5H, Phe), 139.1 (C1, Phe), 149.5 (C6, Pyrimidine), 156.9 (CO), 
175.3 (CS) ppm. 
IR (ATR): ν̃ = 1653, 1622, 1595, 1508, 1454, 1418, 1350, 1223, 793, 750, 694, 660, 602 cm-1. 
HPLC (Method 2): tR = 4.2 min. 
LC-MS (ESI, 70 eV): m/z = 525 [M2H]+, 263 [MH]+ (calc. m/z = 262). 
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3-(2-Methoxyphenyl)-2-thioxo-2,3,6,7-tetrahydrothieno[3,2-d]pyrimidin-4(1H)-one 
(273) 
 
C13H12N2O2S2 (Mr 292.37) 
273 was synthesized according to the procedure for 272 from 271 (1.24 g, 7.79 mmol) and 
2-methoxyphenyl isothiocyanate (1.30 ml, 9.36 mmol) in 24 ml anhyd. pyridine. The crude 
product was purified by flash chromatography (SiO2, 30 % ethyl acetate/petrol ether, then ace-
tone) to afford 273 as a brown solid (79 % HPLC purity) that was used without further purifica-
tion in the next step. 
Yield: 315 mg (1.08 mmol, 14 %). 
1H NMR (300 MHz, DMSO-d6): δ = 3.24-3.29 (m, 2 H, C5H2), 3.36-3.39 (m, 2 H, C4H2), 3.72 (s, 3 H, 
COCH3), 7.00 (dt, 3J = 7.5 Hz, 4J = 1.2 Hz, 1 H, C5H, H3CO-Phe), 7.11 (dd, 3J = 7.7 Hz, 4J = 1.8 Hz, 1 H, 
C3H, H3CO-Phe), 7.13 (dd, 3J = 8.4 Hz, 4J = 1.1 Hz, 1 H, C6H, H3CO-Phe), 7.35-7.40 (m, 1 H, C4H, 
H3CO-Phe), 13.19 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 29.0 (C4H2), 34.6 (C5H2), 55.7 (COCH3), 112.4 (C6H, H3CO-Phe), 
114.0 (C5, Pyrimidine), 120.7 (C5H, H3CO-Phe), 127.4 (C1, H3CO-Phe), 129.7 (C3H, H3CO-Phe), 
129.9 (C4H, H3CO-Phe), 149.6 (C6, Pyrimidine), 154.2 (COCH3), 156.4 (CO), 175.2 (CS) ppm. 
HPLC (Method 2): tR = 4.2 min. 
LC-MS (ESI, 70 eV): m/z = 585 [M2H]+, 293 [MH]+ (calc. m/z = 292). 
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2-Chloro-N-(4-methylpyridin-2-yl)acetamide (276) 
 
C8H9ClN2O (Mr 184.62) 
A solution of 2-amino-4-methylpyridine (675 mg, 6.24 mmol) and Et3N (970 µl, 6.90 mmol) in 
10 ml anhyd. DCM was carefully added dropwise to chloroacetyl chloride (540 µl, 6.79 mmol) in 
3 ml anhyd. DCM over a period of 30 min under a nitrogen atmosphere. The resulting mixture 
was stirred at rt for 12 h. Afterwards, the solvent was removed under reduced pressure and the 
crude product was purified by flash chromatography (SiO2, 5-40 % ethyl acetate/petrol ether) to 
afford 276 as pink crystals (99 % HPLC purity). 
Yield: 781 mg (4.23 mmol, 68 %). 
m.p.: 73 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.40 (t, 4J = 0.5 Hz, 3 H, CH3), 4.20 (s, 2 H, CH2), 6.96 (dq, 
3J = 5.3 Hz, 4J = 0.7 Hz, 1 H, C5H, Pyr), 8.08 (bs, 1 H, C3H, Pyr), 8.15 (dd, 3J = 5.2 Hz, 5J = 0.5 Hz, 1 H, 
C6H, Pyr), 9.33 (vbs, 1 H, CONH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 21.7 (CH3), 43.0 (CH2), 115.0 (C3H, Pyr), 121.9 (C5H, Pyr), 146.3 
(C6H, Pyr), 150.2 (C2, Pyr), 151.6 (C4, Pyr), 164.9 (CO) ppm. 
IR (ATR): ν̃ = 3250, 3100, 3017, 2957, 1667, 1572, 1560, 1425, 1416, 1379, 1304, 1275, 1246, 
1200, 1167, 1146, 972, 883, 818, 785, 718, 623 cm-1. 
HPLC (Method 2): tR = 3.3 min. 
LC-MS (ESI, 70 eV): m/z = 185 [MH]+ (calc. m/z = 184). 
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2-Chloro-N-(4-(5-(4-fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-
acetamide (279) 
 
C17H14ClFN4OS (Mr 376.83) 
A solution of 120 (470 mg, 1.57 mmol) and Et3N (300 µl, 2.14 mmol) in 8 ml anhyd. DCM and 
2 ml anhyd. DMF was carefully added dropwise to chloroacetyl chloride (150 µl, 1.89 mmol) in 
2 ml anhyd. DCM over a period of 30 min under a nitrogen atmosphere. The resulting mixture 
was stirred at rt for 12 h. Afterwards, the solvent was removed under reduced pressure, the 
residue was dissolved in ethyl acetate, washed with H2O and sat. aq. NaCl solution, dried over 
anhyd. Na2SO4, and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (SiO2, 5-50 % ethyl acetate/petrol ether) to afford 279 as a yellow solid 
(96 % HPLC purity). 
Yield: 284 mg (754 µmol, 48 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (s, 3 H, SCH3), 4.31 (s, 2 H, CH2), 7.08 (dd, 3J = 5.3 Hz, 
4J = 1.6 Hz, 1 H, C5H, Pyr), 7.23-7.29 (m, 2 H, C3/5H, F-Phe), 7.46-7.51 (m, 2 H, C2/6H, F-Phe), 8.19 
(d, 3J = 5.0 Hz, 1 H, C6H, Pyr), 8.23 (bs, 1 H, C3H, Pyr), 10.72 (bs, 1 H, CONH), 12.75 (vbs, 1 H, NH) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.0 (SCH3), 43.4 (CH2), 110.5 (C3H, Pyr), 115.7 (d, 
2JCF = 22.4 Hz, C3/5H, F-Phe), 117.1 (C5H, Pyr), 130.5 (C2/6H, F-Phe), 142.7 (C2, Imdz), 148.0 (C6H, 
Pyr), 151.8 (C2, Pyr), 161.9 (d, 1JCF = 245.0 Hz, CF), 165.2 (CO) ppm. 
HPLC (Method 2): tR = 5.2 min. 
LC-MS (ESI, 70 eV): m/z = 377 [MH]+ (calc. m/z = 376). 
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N-(4-methylpyridin-2-yl)-2-(phenylamino)acetamide (277) 
 
C14H15N3O (Mr 241.29) 
Aniline (150 µl, 1.64 mmol), 276 (203 mg, 1.10 mmol), and Et3N (510 µl, 3.25 mmol) in 10 ml 
anhyd. DMF were stirred under a nitrogen atmosphere for 2 h at 80 °C. The reaction was 
quenched with H2O, extracted with ethyl acetate, and the combined organic phases were washed 
with H2O and sat. aq. NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed 
under reduced pressure and the crude product was purified by flash chromatography (SiO2, 
5-50 % ethyl acetate/petrol ether) to afford 277 as a pale yellowish solid (100 % HPLC purity). 
Yield: 55.2 mg (229 mmol, 21 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3 H, CH3), 3.91 (d, 3J = 6.3 Hz, 2 H, CH2), 6.07 (t, 
3J = 6.3 Hz, 1 H, NH), 6.56-6.62 (m, 3 H, C2/4/6H, Phe), 6.93 (dq, 3J = 5.1 Hz, 4J = 0.7 Hz, 1 H, C5H, 
Pyr), 7-07-7.12 (m, 2 H, C3/5H, Phe), 7.94 (bs, 1 H, C3H, Pyr), 8.14 (dd, 3J = 5.1 Hz, 5J = 0.5 Hz, 1 H, 
C6H, Pyr), 10.13 (s, 1 H, CONH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 47.2 (CH2), 112.3 (C2/6H, Phe), 113.6 (C3H, Pyr), 116.6 (C4H, 
Phe), 120.5 (C5H, Pyr), 129.0 (C3/5H, Phe), 147.6 (C6H, Pyr), 148.1 (C1, Phe), 149.0 (C4, Pyr), 151.6 
(C1, Pyr), 170.1 (CONH) ppm. 
HPLC (Method 2): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 242 [MH]+ (calc. m/z = 241). 
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N-(4-Methylpyridin-2-yl)-2-((4-oxo-3-phenyl-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-
yl)thio)acetamide (278) 
 
C20H18N4O4S2 (Mr 410.51) 
278 was synthesized according to the procedure for 277 from 276 (66.0 mg, 357 µmol), 272 
(80.0 mg, 305 µmol), and Et3N (150 µl, 956 µmol) in 4 ml anhyd. DMF. The crude product was 
purified by flash chromatography (SiO2, 10-80 % ethyl acetate/petrol ether) to afford 278 as a 
colorless solid (100 % HPLC purity). 
Yield: 17.6 mg (42.9 µmol, 14 %). 
m.p.: 243 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.44 (s, 3 H, CH3), 3.39-3.42 (m, 4 H, C4/5H2), 3.88 (s, 2 H, CH2CO), 
6.99 (d, 3J = 5.5 Hz, 1 H, C5H, Pyr), 7.28-7.31 (m, 2 H, C2/6H, Phe), 7.51-7.54 (m, 3 H, C3-5H, Phe), 
8.09 (d, 3J = 5.4 Hz, 1 H, C6H, Pyr), 8.17 (bs, 1 H, C3H, Pyr), 10.85 (vbs, 1 H, CONH) ppm. 
13C NMR (75 MHz, CDCl3): δ = 22.1 (CH3), 29.4 (C5H2), 37.4 (CH2CO), 37.7 (C4H2), 115.5 (C3H, 
Pyr), 121.2 (C5H, Pyr), 122.2 (C5, Pyrimidine), 128.8 (C2/6H, Phe), 130.1 (C3/5H, Phe), 130.6 (C4H, 
Phe), 135.1 (C1, Phe), 143.3 (C6H, Pyr), 150.2 (C2, Pyr), 154.1 (C4, Pyr), 157.6 (C2, Pyrimidine), 
160.5 (CO), 167.5 (CONH) ppm. 
IR (ATR): ν̃ = 3212, 3050, 2928, 2855, 1695, 1674, 1611, 1570, 1560, 1541, 1468, 1451, 1410, 
1371, 1306, 1236, 1192, 1175, 1159, 1146, 1053, 1042, 1023, 995, 858, 818, 775, 758, 750, 691, 
664 cm-1. 
HPLC (Method 2): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 411 [MH]+, 303 [M-C6H7N2]+ (calc. m/z = 410). 
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N-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-2-((3-phenyl-4-
oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)acetamide (266) 
 
C29H23FN6O2S3 (Mr 602.72) 
A solution of 272 (80.0 mg, 305 µmol), 279 (80.0 mg, 433 µmol), and Et3N (200 µl, 1.28 mmol) 
in 5 ml anhyd. DMF was stirred under a nitrogen atmosphere for 2 h at 80 °C. The reaction was 
quenched with H2O, extracted with ethyl acetate, and the combined organic phases were washed 
with H2O and sat. aq. NaCl solution, and dried over anhyd. Na2SO4. The solvent was removed 
under reduced pressure and the crude product was purified by flash chromatography (SiO2, 
10-80 % ethyl acetate/petrol ether) to afford 266 as a beige solid (100 % HPLC purity). 
Yield: 108 mg (179 µmol, 59 %). 
m.p.: 254 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.61 (s, 3 H, SCH3), 3.17 (t, 3J = 8.6 Hz, 2 H, C4H2), 3.34 (t, 
3J = 8.6 Hz, 2 H, C5H2), 4.02 (s, 2 H, CH2CO), 7.02 (dd, 3J = 5.3 Hz, 4J = 1.4 Hz, 1 H, C5H, Pyr), 
7.22-7.31 (m, 2 H, C3/5H, F-Phe), 7.39-7.42 (m, 2 H, C2/6H, Phe), 7.45-7.49 (m, 2 H, C2/6H, F-Phe), 
7.57-7.61 (m, 3 H, C3-5H, Phe), 8.14 (bs, 1 H, C6H, Pyr), 8.23 (bs, 1 H, C3H, Pyr), 10.59 (bs, 1 H, 
CONH), 12.71 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 28.5 (C5H2), 37.0 (CH2CO), 37.2 (C4H2), 110.5 (C3H, 
Pyr), 115.8 (d, 2JCF = 21.0 Hz, C3/5H, F-Phe), 166.6 (C5H, Pyr), 119.7 (C5, Pyrimidine), 122.0 (d, 
4JCF = 3.6 Hz, C1, F-Phe), 127.1 (C5, Imdz), 128.8 (C2/6H, Phe), 129.7 (C3/5H, Phe), 130.0 (C4, Imdz), 
130.1 (C4H, Phe), 130.7 (C2/6H, F-Phe), 134.3 (C4, Pyr), 135.5 (C1, Phe), 143.8 (C2, Imdz), 147.8 
(C6H, Pyr), 152.1 (C2, Pyr), 157.0 (C6, Pyrimidine), 159.0 (C2, Pyrimidine), 161.7 (d, 
1JCF = 253.4 Hz, CF), 160.7 (CO), 166.1 (CONH) ppm. 
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IR (ATR): ν̃ = 3200, 2928, 1697, 1661, 1611, 1559, 1500, 1466, 1422, 1304, 1238, 1221, 1163, 
1057, 977, 959, 839, 762, 752, 705, 692, 665 cm-1. 
HPLC (Method 2): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 603 [MH]+ (calc. m/z = 602). 
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N-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-2-((3-(2-meth-
oxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)acetamide (267) 
 
C30H25FN6O3S3 (Mr 632.75) 
267 was synthesized according to the procedure for 266 from 273 (210 mg, 718 µmol), 279 
(318 mg, 844 µmol), and Et3N (440 ml, 2.81 mmol) in 10 ml anhyd. DMF. The crude product was 
purified by flash chromatography (SiO2, 20-75 % ethyl acetate/petrol ether) to afford 267 as a 
light brown crystalline solid (100 % HPLC purity). 
Yield: 346 mg (547 µmol, 76 %). 
m.p.: 139 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.61 (s, 3 H, SCH3), 3.12-3.22 (m, 2 H, C4H2), 3.32-3.39 (m, 2 H, 
C5H2), 3.79 (s, 3 H, OCH3), 4.02 (s, 1 H, CH2CO), 7.03 (dd, 3J = 5.2 Hz, 4J = 1.6 Hz, 1 H, C5H¸ Pyr), 
7.12 (dt, 3J = 7.6 Hz, 4J = 1.0 Hz, 1 H, C5H, H3CO-Phe), 7.24-7.31 (m, 2 H, C3/5H, F-Phe), 7.26 (dd, 
3J = 8.3 Hz, 4J = 0.8 Hz, 1 H, C6H, H3CO-Phe), 7.34 (dd, 3J = 7.7 Hz, 4J = 1.7 Hz, 1 H, C3H, H3CO-Phe), 
7.44-7.50 (m, 2 H, C2/6H, F-Phe), 7.52-7.58 (m, 1 H, C5H, H3CO-Phe), 8.13 (dd, 3J = 5.3 Hz, 
5J = 0.6 Hz, 1 H, C6H, Pyr), 8.24 (bs, 1 H, C3H, Pyr), 10.56 (bs, 1 H, CONH), 12.71 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 15.1 (SCH3), 28.5 (C5H2), 36.8 (CH2CO), 37.3 (C4H2), 56.0 
(OCH3), 110.5 (C3H, Pyr), 112.9 (C6H, H3CO-Phe), 115.8 (d, 2JCF = 21.6 Hz, C3/5H, F-Phe), 116.6 
(C5H, Pyr), 119.4 (C5, Pyrimidine), 121.1 (C5H, H3CO-Phe), 123.5 (d, 4JCF = 2.6 Hz, C1, F-Phe), 125.6 
(C5, Imdz), 126.6 (C1, H3CO-Phe), 130.1 (C3H, H3CO-Phe), 130.7 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 
132.0 (C4H, H3CO-Phe), 134.3 (C4, Pyr), 138.8 (C4, Imdz), 142.3 (C2, Imdz), 147.8 (C6H, Pyr), 152.1 
(C2, Pyr), 154.7 (C2OCH3), 156.5 (C6, Pyrimidine), 159.6 (C2, Pyrimidine), 160.8 (CO), 162.0 (d, 
1JCF = 246.1 Hz, CF), 166.1 (CONH) ppm. 
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IR (ATR): ν̃ = 2930, 1680, 1661, 1603, 1549, 1499, 1474, 1416, 1371, 1283, 1263, 1221, 1159, 
1121, 1049, 1020, 837, 814, 752, 664 cm-1. 
HPLC (Method 2): tR = 5.6 min. 
LC-MS (ESI, 70 eV): m/z = 633 [MH]+ (calc. m/z = 632). 
HRMS (EI, 70 eV): m/z = 632.1134 [M]+ (calc. m/z = 632.1134). 
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4-((4-Methylpiperazin-1-yl)methyl)benzoic acid (281) 
 
C13H18N2O2 (Mr 234.30) 
N-Methylpiperazine (3.10 ml, 27.9 mmol) was added in one portion to a solution of 4-bromo-
methylbenzoic acid (2.01 g, 9.33 mmol) in 125 ml tert-butanol and the resulting mixture was 
stirred at rt for 6 h. The solvent was removed under reduced pressure and the crude product 
was crystallized from 2-propanol to afford 281 as a colorless solid (100 % HPLC purity). 
Yield: 1.09 g (4.64 mmol, 50 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.51 (s, 3 H, CH3), 2.58 (bs, 4 H, C3/5H2, Piperazine), 2.88 (bs, 
4 H, C2/6H2, Piperazine), 3.59 (s, 2 H, CH2), 7.43 (d, 3J = 8.3 Hz, 2 H, C3/5H, Phe), 7.90 (d, 3J = 8.3 Hz, 
2 H, C2/6H, Phe) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 43.2 (CH3), 50.2 (C3/5H2, Piperazine), 53.1 (C2/6H2, Piperazine), 
60.8 (CH2), 128.9 (C3/5H, Phe), 129.3 (C2/6H, Phe), 129.8 (C1, Phe), 142.8 (C4, Phe) ,167.2 (CO) 
ppm. 
HPLC (Method 3): tR = 1.3 min. 
LC-MS (ESI, 70 eV): m/z = 235 [MH]+ (calc. m/z = 234). 
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1,4-Bis(4-carboxybenzyl)-1-methylpiperazin-1-ium (283) 
 
C21H25N2O4+ (Mr 369.44) 
N-Methylpiperazine (466 µl, 4.19 mmol) was slowly added to a solution of 4-bromomethyl-
benzoic acid (600 mg, 2.79 mmol) in 23 ml tert-butanol and the resulting mixture was stirred at 
rt for 6 h. The solvent was removed under reduced pressure and the crude product was crystal-
lized from 2-propanol to afford 283 as a colorless solid (100 % HPLC purity). 
Yield: 194 mg (525 µmol, 38 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.69-2.91 (m, 4 H, C3/5H, Piperazine), 3.00 (s, 3 H, CH3), 
3.45-3.55 (m, 4 H, C2/6H, Piperazine), 3.72 (s, 2 H, CH2N), 4.76 (s, 2 H, CH2N+), 7.44 (d, 3J = 8.2 Hz, 
2 H, C3/5H, BnN), 7.70 (d, 3J = 8.3 Hz, 2 H, C3/5H, BnN+), 7.93 (d, 3J = 8.2 Hz, 2 H, C2/6H, BnN+), 8.04 
(d, 3J = 8.2 Hz, 2 H, C2/6H, BnN), 12.34 (bs, 1 H, COOH) ppm. 
HPLC (Method 3): tR = 1.4 min. 
LC-MS (ESI, 70 eV): m/z = 369 [M]+ (calc. m/z = 369). 
E x p e r i m e n t a l  | 269 
 
 
7.3.8 Sulfoxidation of Compounds: 4,5-Diaryl-2-(methylsulfinyl)-1H-
imidazoles 
General procedure for sulfoxidation of compounds (82, 84, 85, 102-104, 285-291) 
The respective sulfide (1.0 equiv) was dissolved in THF and H2O was added (approx. 3:1). The 
mixture was stirred at 0 °C for 10 min before an ice-cold aq. solution of potassium 
peroxomonosulfate (Oxone®, 0.6 equiv.) was added and stirring continued for 0.5-2 h at the 
same temp. After completion of the reaction sat. aq. NaHCO3 solution, H2O, and ethyl acetate 
were added and the phases were separated. The organic layer was washed with H2O and sat. aq. 
NaCl solution, dried over anhyd. Na2SO4, and the solvent was removed under reduced pressure. 
Purification of the crude products was achieved by crystallization from ethyl acetate or flash 
chromatography (SiO2 and RP-18, eluent and mixing ratio given for each compound) to afford 
the appropriate compound. 
Syntheses of 84 and 85 have been performed by LYDIA KUHL during her Bachelor thesis220. 
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tert-Butyl (4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-yl)-
carbamate (285) 
 
C20H21FN4O3S (Mr 416.47) 
Synthesis was performed according to the general procedure for sulfoxidation from 160 
(50.0 mg, 125 µmol) and Oxone® (42.2 mg, 68.7 µmol in 0.7 ml H2O) in 1 ml THF and 0.3 ml H2O. 
Flash chromatography (SiO2, 40-50 % ethyl acetate/petrol ether) afforded 285 as a colorless 
solid (100 % HPLC purity). 
Yield: 38.8 mg (93.2 µmol, 75 %). 
m.p.: 203 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 1.44 (s, 9 H, tBu), 3.09 (s, 3 H, SCH3), 6.97 (dd, 3J = 5.2 Hz, 
4J = 1.3 Hz, 1 H, C5H, Pyr), 7.30 (bs, 2 H, C3/5H, F-Phe), 7.50-7.55 (m, 2 H, C2/6H, F-Phe), 8.03 (s, 
1 H, C3H, Pyr), 8.13 (bs, 1 H, C6H, Pyr), 9.69 (bs, 1 H, NH), 13.88 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (300 MHz, DMSO-d6): δ = 27.9 (C(CH3)3), 39.1 (SCH3), 79.5 (C(CH3)3), 109.9 (C3H, Pyr), 
115.7 (C5H, Pyr), 116.0 (C3/5H, F-Phe), 131.1 (C2/6H, F-Phe), 135.1 (C4, Pyr), 147.8 (C6H, Pyr), 
149.1 (C2, Imdz), 152.5 (CO), 152.9 (C2, Pyr), 160.2 (C1, F-Phe), 163.6 (CF) ppm. 
IR (ATR): ν̃ = 2950, 1724, 1607, 1559, 1501, 1456, 1418, 1366, 1290, 1269, 1231, 1159, 1117, 
1057, 1017, 995, 835, 814, 766, 702 cm-1. 
HPLC (Method 1): tR = 4.6 min. 
LC-MS (ESI, 70 eV): m/z = 417 [MH]+, 361 [MH2-tBu]+ (calc. m/z = 416). 
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N-Benzyl-4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-amine 
(82) 
 
C22H19FN4OS (Mr 406.48) 
Synthesis was performed according to the general procedure for sulfoxidation from 162 
(400 mg, 1.02 mmol) and Oxone® (331 mg, 538 µmol in 6 ml H2O) in 8 ml THF and 2 ml H2O. 
Flash chromatography (SiO2, 50-100 % ethyl acetate/cyclohexane) afforded 82 as a yellowish 
solid (100 % HPLC purity). 
Yield: 197 mg (485 µmol, 47 %). 
m.p.: 180 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.07 (s, 3 H, SCH3), 4.43 (d, 4J = 6.0 Hz, 2 H, CH2, Bn), 6.50 (dd, 
3J = 5.3 Hz, 4J = 1.3 Hz, 1 H, C5H, Pyr), 6.65 (bs, 1 H, C3H, Pyr), 7.13-7.32 (m, 8 H, C3/5H, F-Phe and 
arCH, Bn and CH2NH), 7.49-7.54 (m, 2 H, C2/6H, F-Phe), 7.90 (bs, 1 H, C6H, Pyr), 13.76 (bs, 1 H, NH) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 39.2 (SCH3), 44.2 (CH2, Bn), 105.7 (C3H, Pyr), 110.4 (C5H, Pyr), 
115.6 (d, 2JCF = 21.9 Hz, C3/5H, F-Phe), 126.5 (arC4H, Bn), 127.1 (arC2/6H, Bn), 128.2 (arC3/5H, Bn), 
130.6 (C2/6H, F-Phe), 104.6 (arC1, Bn), 147.9 (C4, Pyr), 148.3 (C6H, Pyr), 159.0 (C2, Pyr) ppm. 
IR (ATR): ν̃ = 3350, 3020, 1607, 1559, 1495, 1460, 1360, 1200, 1155, 1047, 981, 864, 837, 814, 
741, 696, 682 cm-1. 
HPLC (Method 1): tR = 2.6 min. 
LC-MS (ESI, 70 eV): m/z = 407 [MH]+ (calc. m/z = 406). 
HRMS (EI, 70 eV): m/z = 406.1264 [M]+ (calc. m/z = 406.1264). 
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N-(2-Ethoxyphenyl)-4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-
2-amine (84) 
 
C23H21FN4O2S (Mr 436.51) 
Synthesis was performed according to the general procedure for sulfoxidation from 149 
(300 mg, 713 µmol) and Oxone® (219 mg, 356 µmol in 4 ml H2O) in 5 ml THF and 2 ml H2O. 
Flash chromatography (RP-18, 20-90 % methanol/H2O) afforded 84 as a voluminous yellow 
solid (100 % HPLC purity). 
Yield: 255 mg (584 µmol, 82 %). 
m.p.: 152 °C. 
1H NMR (300 MHz, CDCl3): δ = 1.42 (t, 3J = 7.0 Hz, 3 H, CH3), 3.03 (s, 3 H, SCH3), 4.07 (q, 
3J = 7.0 Hz, 2 H, CH2), 6.94-6.78 (m, 4 H, C4-6H, EtO-Phe and C5H, Pyr), 7.03 (dd, 4J = 1.4 Hz, 
5J = 0.7 Hz, 1 H, C3H, Pyr), 7.07-7.13 (m, 3 H, C3/5H, F-Phe and NH), 7.46-7.50 (m, 2 H, C2/6H, 
F-Phe), 7.62 (dd, 3J = 7.8 Hz, 4J = 1.5 Hz, 1 H, C3H, EtO-Phe), 8.14 (dd, 3J = 5.3 Hz, 5J = 0.7 Hz, 1 H, 
C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 14.9 (CH3), 40.8 (SCH3), 64.1 (CH2), 106.9 (C3H, Pyr), 111.5 (C3H, 
EtO-Phe), 113.3 (C5H, Pyr), 116.0 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 118.2 (C6H, EtO-Phe), 120.6 
(C5H, EtO-Phe), 121.9 (C4H, EtO-Phe), 129.9 (C1, EtO-Phe), 130.6 (d, 3JCF = 8.2 Hz, C2/6H, F-Phe), 
146.7 (C2, Imdz), 148.2 (C2, EtO-Phe), 148.5 (C6H, Pyr), 156.0 (C2, Pyr), 162.9 (d, 1JCF = 248.8 Hz, 
CF) ppm. 
HPLC (Method 1): tR = 3.7 min. 
LC-MS (ESI, 70 eV): m/z = 437 [MH]+ (calc. m/z = 436). 
E x p e r i m e n t a l  | 273 
 
 
N-(3,4-Dimethoxyphenethyl)-4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)-
pyridin-2-amine (85) 
 
C25H25FN4O3S (Mr 480.56) 
Synthesis was performed according to the general procedure for sulfoxidation from 150 
(500 mg, 1.08 mmol) and Oxone® (330 mg, 537 µmol in 5 ml H2O) in 9 ml THF and 3 ml H2O. 
Flash chromatography (RP-18, 20-90 % methanol/H2O) afforded 85 as a pale yellow solid (92 % 
HPLC purity). 
Yield: 208 mg (433 µmol, 39 %). 
m.p.: 183 °C. 
1H NMR (300 MHz, CDCl3): δ = 2.74 (t, 3J = 6.8 Hz, 1 H, CH2CH2NH), 2.97 (s, 3 H, SCH3), 3.36 (m, 
2 H, CH2CH2NH), 3.76 (s, 6 H, 2 OCH3), 5.00 (bs, 1 H, CH2CH2NH), 6.49 (bs, 1 H, C3H, Pyr), 6.52 (dd, 
3J = 5.4 Hz, 4J = 1.3 Hz, 1 H, C5H, Pyr), 6.60-6.63 (m, 2 H, C2/6H, (OCH3)2-Phe), 6.71 (d, 3J = 8.7 Hz, 
1 H, C5H, (OCH3)2-Phe), 6.96-7.02 (m, 2 H, C3/5H, F-Phe), 7.36-7.41 (m, 2 H, C2/6H, F-Phe), 7.80 (d, 
3J = 5.5 Hz, 1 H, C6H, Pyr) ppm. 
13C NMR (75 MHz, CDCl3): δ = 35.1 (CH2CH2NH), 40.7 (SCH3), 43.3 (CH2CH2NH), 55.9 (C3OCH3), 
55.9 (C4OCH3), 104.6 (C3H, Pyr), 111.2 (C5H, Pyr), 111.4 (C5H, (OCH3)2-Phe), 112.1 (C2H, 
(OCH3)2-Phe), 115.9 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 120.7 (C6H, (OCH3)2-Phe), 127.2 (C1, F-Phe), 
130.5 (d, 3JCF = 8.2 Hz, C2/6H, F-Phe), 131.5 (C1, (OCH3)2-Phe), 135.3 (C4/5, Imdz), 141.6 (C4, Pyr), 
146.8 (C2, Imdz), 147.4 (C6H, Pyr), 147.7 (C4OCH3), 149.0 (C3OCH3), 158.6 (C2, Pyr), 162.9 (d, 
1JCF = 249.2 Hz, CF) ppm. 
HPLC (Method 1): tR = 2.6 min. 
LC-MS (ESI, 70 eV): m/z = 481 [MH]+ (calc. m/z = 480). 
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3-(2,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorphenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (102) 
 
C26H25FN4O4S (Mr 508.57) 
Synthesis was performed according to the general procedure for sulfoxidation from 190 
(100 mg, 203 µmol) and Oxone® (64.9 mg, 106 µmol in 1 ml H2O) in 2 ml THF and 0.6 ml H2O. 
Flash chromatography (SiO2, 40-100 % ethyl acetate/petrol ether) afforded 102 as a colorless 
solid (99 % HPLC purity). 
Yield: 96.1 mg (189 µmol, 93 %). 
m.p.: 209 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.58 (t, 3J = 7.5 Hz, 2 H, CH2CH2CO), 2.75 (t, 3J = 7.4 Hz, 2 H, 
CH2CH2CO), 3.08 (s, 3 H, SCH3), 3.72 (s, 3 H, C2OCH3), 3.77 (s, 3 H, C4OCH3), 6.42 (dd, 3J = 8.3 Hz, 
4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 6.51 (d, 4J = 2.4 Hz, 1 H, C3H, (OCH3)2-Phe), 7.01-7.05 (m, 2 H, 
C5H, Pyr and C6H, (OCH3)2-Phe), 7.26-7.32 (m, 2 H, C3/5H, F-Phe), 7.51-7.55 (m, 2 H, C2/6H, F-Phe), 
8.19 (d, 3J = 5.2 Hz, 1 H, C6H, Pyr), 8.34 (bs, 1 H, C3H, Pyr), 10.40 (s, 1 H, CONH), 13.89 (bs, NH) 
ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 24.7 (CH2CH2CO), 36.3 (CH2CH2CO), 39.1 (SCH3), 55.1 (C2OCH3), 
55.3 (C4OCH3), 98.3 (C3H, (OCH3)2-Phe), 104.3 (C5H, (OCH3)2-Phe), 111.1 (C3H, Pyr), 115.8 (d, 
2JCF = 21.7 Hz, C3/5H, F-Phe), 117.0 (C5H, Pyr), 120.9 (C1, (OCH3)2-Phe), 127.3 (C1, F-Phe), 129.8 
(C6H, (OCH3)2-Phe), 130.8 (d, 3JCF = 8.2 Hz, C2/6H, F-Phe), 133.4 (C4, Imdz), 133.9 (C5, Imdz), 142.2 
(C4, Pyr), 147.9 (C6H, Pyr), 148.9 (C2, Imdz), 152.6 (C2, Pyr), 157.9 (C4OCH3), 159.0 (C2OCH3), 
162.1 (d, 1JCF = 245.5 Hz, CF), 171.54 (CO) ppm. 
E x p e r i m e n t a l  | 275 
 
 
IR (ATR): ν̃ = 2955, 1701, 1609, 1573, 1545, 1528, 1506, 1412, 1287, 1221, 1209, 1153, 1121, 
1034, 986, 831, 706 cm-1. 
HPLC (Method 1): tR = 5.0 min. 
LC-MS (ESI, 70 eV): m/z = 509 [MH]+ (calc. m/z = 508). 
HRMS (EI, 70 eV): m/z = 508.1581 [M]+ (calc. m/z = 508.1581). 
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3-(2,5-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)-
pyridin-2-yl)propanamide (103) 
 
C26H25FN4O4S (Mr 508.57) 
Synthesis was performed according to the general procedure for sulfoxidation from 191 
(100 mg, 203 µmol) and Oxone® (68.6 mg, 112 µmol in 1 ml H2O) in 2 ml THF and 0.6 ml H2O. 
Crystallization from ethyl acetate afforded 103 as a colorless solid (100 % HPLC purity). 
Yield: 26.6 mg (52.3 mmol, 26 %). 
m.p.: 204 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.62 (t, 3J = 7.7 Hz, 2 H, CH2CH2CO), 2.80 (t, 3J = 7.5 Hz, 2 H, 
CH2CH2CO), 3.09 (s, 3 H, SCH3), 3.66 (s, 3 H, C5OCH3), 3.72 (s, 3 H, C2OCH3), 6.72 (dd, 3J = 8.8 Hz, 
4J = 3.1 Hz, 1 H, C4H, (OCH3)2-Phe), 6.77 (d, 4J = 3.0 Hz, 1 H, C6H, (OCH3)2-Phe), 6.86 (d, 3J = 8.8 Hz, 
1 H, C3H, (OCH3)2-Phe), 7.02 (dd, 3J = 5.2 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.25-7.31 (m, 2 H, C3/5H, 
F-Phe), 7.51-7.55 (m, 2 H, C2/6H, F-Phe), 8.19 (d, 3J = 5.0 Hz, 1 H, C6H, Pyr), 8.33 (s, 1 H, C3H, Pyr), 
10.45 (s, 1 H, CONH), 14.00 (bs, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 25.3 (CH2CH2CO), 36.0 (CH2CH2CO), 39.0 (SCH3), 55.2 (C5OCH3), 
55.8 (C2OCH3), 111.2 (C4H, (OCH3)2-Phe), 111.3 (C3H, Pyr), 111.5 (C3H, (OCH3)2-Phe), 115.8 (d, 
2JCF = 21.3 Hz, C3/5H, F-Phe), 115.9 (C6H, (OCH3)2-Phe), 126.5 (C1, F-Phe), 130.8 (d, 3JCF = 8.3 Hz, 
C2/6H, F-Phe), 142.1 (C4, Pyr), 148.0 (C6H, Pyr), 148.8 (C2, Imdz), 151.2 (C2OCH3), 152.58 (C2, Pyr), 
153.0 (C5OCH3), 162.1 (d, 1JCF = 245.6 Hz, CF), 171.42 (CO) ppm. 
IR (ATR): ν̃ = 2960, 1705, 1609, 1557, 1497, 1454, 1437, 1416, 1296, 1283, 1236, 1219, 1184, 
1168, 1138, 1113, 1047, 1026, 876, 843, 816, 706 cm-1. 
HPLC (Method 3): tR = 5.1 min. 
LC-MS (ESI, 70 eV): m/z = 509 [MH]+ (calc. m/z = 508). 
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1-(2,4-Dimethoxyphenyl)-3-(4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)-
pyridin-2-yl)carbamide (104) 
 
C24H22FN5O4S (Mr 495.53) 
Synthesis was performed according to the general procedure for sulfoxidation from 204 
(85.0 mg, 177 µmol) and Oxone® (59.9 mg, 97.5 µmol in 1 ml H2O) in 3.4 ml THF and 1 ml H2O. 
Flash chromatography (SiO2, 35-100 % ethyl acetate/petrol ether and RP-18, 55-100 % 
methanol/H2O) afforded 104 as a colorless solid (100 % HPLC purity). 
Yield: 18.9 mg (38.1 µmol, 22 %). 
m.p.: 227 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.08 (s, 3 H, SCH3), 3.74 (s, 3 H, C4OCH3), 3.88 (s, 3 H, C2OCH3), 
6.48 (dd, 3J = 8.9 Hz, 4J = 2.7 Hz, 1 H, C5H, (OCH3)2-Phe), 6.62 (d, 4J = 2.7 Hz, 1 H, C3H, 
(OCH3)2-Phe), 6.95 (dd, 3J = 5.4 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.27-7.33 (m, 2 H, C3/5H, F-Phe), 
7.46 (bs, 1 H, C3H, Pyr), 7.51-7.56 (m, 2 H, C2/6H, F-Phe), 8.02 (d, 3J = 8.9 Hz, 1 H, C6H, 
(OCH3)2-Phe), 8.19 (d, 3J = 5.3 Hz, 1 H, C6H, Pyr), 9.70 (s, 1 H, NH), 11.07 (bs, 1 H, NH), 13.87 (bs, 
1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 39.1 (SCH3), 55.3 (C2OCH3), 56.0 (C4OCH3), 98.8 (C3H, 
(OCH3)2-Phe), 104.1 (C5H, (OCH3)2-Phe), 109.2 (C3H, Pyr), 115.1 (C5H, Pyr), 115.8 (d, 
2JCF = 21.7 Hz, C3/5H, F-Phe), 119.8 (C6H, (OCH3)2-Phe), 121.8 (C1, (OCH3)2-Phe), 127.2 (C1, F-Phe), 
130.8 (d, 3JCF = 8.4 Hz, C2/6H, F-Phe), 132.7 (C4, Imdz), 134.1 (C5, Imdz), 142.8 (C4, Pyr), 146.5 
(C6H, Pyr), 149.1 (C2, Imdz), 149.4 (C2OCH3), 152.2 (CO), 153.6 (C2, Pyr), 155.2 (C4OCH3), 162.14 
(d, 1JCF = 244.6 Hz, CF) ppm. 
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IR (ATR): ν̃ = 2950, 1657, 1603, 1564, 1547, 1508, 1454, 1360, 1298, 1281, 1215, 1179, 1155, 
1132, 1051, 1032, 978, 837, 824, 750 cm-1. 
HPLC (Method 3): tR = 4.8 min. 
LC-MS (ESI, 70 eV): m/z = 496 [MH]+ (calc. m/z = 495). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-yl)-3-(4-meth-
oxyphenyl)carbamide (286) 
 
C23H20FN5O3S (Mr 465.50) 
Synthesis was performed according to the general procedure for sulfoxidation from 206 
(100 mg, 225 µmol) and Oxone® (75.2 mg, 122 µmol in 1 ml H2O) in 2 ml THF and 0.6 ml H2O. 
Flash chromatography (RP-18, 50-70 % methanol/H2O) afforded 286 as a colorless solid (99 % 
HPLC purity). 
Yield: 62.6 mg (135 µmol, 61 %). 
m.p.: 233 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.09 (s, 3 H, SCH3), 3.73 (s, 3 H, C4OCH3), 6.89 (d, 3J = 9.1 Hz, 
2 H, C3/5H, H3CO-Phe), 6.95 (dd, 3J = 5.4 Hz, 4J = 1.5 Hz, 1 H, C5H, Pyr), 7.28-7.34 (m, 2 H, C3/5H, 
F-Phe), 7.41 (d, 3J = 9.1 Hz, 2 H, C2/6H, H3CO-Phe), 7.51-7.56 (m, 2 H, C2/6H, F-Phe), 7.65 (bs, 1 H, 
C3H, Pyr), 8.18 (d, 3J = 5.4 Hz, 1 H, C6H, Pyr), 9.43 (s, 1 H, NH), 10.47 (bs, 1 H, NH), 13.92 (bs, 1 H, 
NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 39.1 (SCH3), 55.2 (C4OCH3), 109.4 (C3H, Pyr), 114.0 (C3/5H, 
H3CO-Phe), 115.2 (C5H, Pyr), 115.9 (d, 2JCF = 21.7 Hz, C3/5H, F-Phe), 120.6 (C2/6H, H3CO-Phe), 
127.5 (C1, F-Phe), 130.9 (d, 3JCF = 8.7 Hz, C2/6H, F-Phe), 132.0 (C1, H3CO-Phe), 146.9 (C6H, Pyr), 
148.8 (C2, Imdz), 152.2 (CO), 153.5 (C2, Pyr), 154.9 (C4OCH3), 162.2 (d, 1JCF = 246.7 Hz, CF) ppm. 
IR (ATR): ν̃ = 2950, 1661, 1603, 1568, 1557, 1508, 1471, 1298, 1238, 1209, 1180, 1161, 1058, 
976, 876, 835, 818, 789, 737, 718, 681 cm-1. 
HPLC (Method 3): tR = 4.7 min. 
LC-MS (ESI, 70 eV): m/z = 466 [MH]+ (calc. m/z = 465). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-yl)-3-(m-tolyl)-
carbamide (287) 
 
C23H20FN5O2S (Mr 449.50) 
Synthesis was performed according to the general procedure for sulfoxidation from 208 
(100 mg, 231 µmol) and Oxone® (73.7 mg, 120 µmol in 1 ml H2O) in 2 ml THF and 0.6 ml H2O. 
Flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether) afforded 287 as a colorless 
solid (99 % HPLC purity). 
Yield: 74.8 mg (166 µmol, 72 %). 
m.p.: 235 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3 H, CH3), 3.09 (s, 3 H, SCH3), 6.83 (d, 3J = 7.4 Hz, 1 H, 
C4H, Tol), 6.97 (dd, 3J = 5.4 Hz, 4J = 1.4 Hz, 1 H, C5H, Pyr), 7.18 (t, 3J = 7.7 Hz, 1 H, C5H, Tol), 
7.29-7.35 (m, 4 H, C3/5H, F-Phe and C2/6H, Tol), 7.52-7.57 (m, 2 H, C2/6H, F-Phe), 7.69 (s, 1 H, C3H, 
Pyr), 8.19 (d, 3J = 5.1 Hz, 1 H, C6H, Pyr), 9.48 (s, 1 H, NH), 10.54 (bs, 1 H, NH), 13.92 (bs, 1 H, NH, 
Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 21.2 (CH3), 39.1 (SCH3), 109.3 (C3H, Pyr), 115.3 (C5H, Pyr), 
115.9 (d, 2JCF = 21.5 Hz, C3/5H, F-Phe), 116.0 (C6H, Tol), 119.3 (C2H, Tol), 123.2 (C4H, Tol), 128.7 
(C5H, Tol), 130.9 (C2/6H, F-Phe), 138.1 (C3, Tol), 138.9 (C1, Tol), 143.1 (C4, Pyr), 147.0 (C6H, Pyr), 
148.7 (C2, Imdz), 152.1 (CO), 153.4 (C2, Pyr), 162.2 (d, 1JCF = 244.0 Hz, CF) ppm. 
IR (ATR): ν̃ = 2950, 1667, 1605, 1562, 1514, 1476, 1393, 1362, 1314, 1300, 1244, 1221, 1167, 
1044, 976, 883, 842, 827, 810, 770, 745, 716, 689 cm-1. 
HPLC (Method 3): tR = 6.4 min. 
LC-MS (ESI, 70 eV): m/z = 450 [MH]+ (calc. m/z = 449). 
E x p e r i m e n t a l  | 281 
 
 
1-(3-Chloro-4-methylphenyl)-3-(4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-
yl)pyridin-2-yl)carbamide (288) 
 
C23H19ClFN5O2S (Mr 483.95) 
Synthesis was performed according to the general procedure for sulfoxidation from 209 
(100 mg, 214 µmol) and Oxone® (72.3 mg, 118 µmol in 1 ml water) in 4 ml THF and 1 ml H2O. 
Flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether and RP-18, 50-100 % 
methanol/H2O) afforded 288 as a beige solid (98 % HPLC purity). 
Yield: 78.0 mg (161 µmol, 75 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.27 (s, 3 H, CH3), 3.09 (s, 3 H, SCH3), 6.99 (dd, 3J = 5.4 Hz, 
4J = 1.3 Hz, 1 H, C5H, Pyr), 7.26 (s, 1 H, C5H, Cl-Tol), 7.26 (s, 1 H, C6H, Cl-Tol), 7.29-7.35 (m, 2 H, 
C3/5H, F-Phe), 7.52-7.56 (m, 2 H, C2/6H, F-Phe), 7.65 (bs, 1 H, C3H, Pyr), 7.76 (bs, 1 H, C2H, Cl-Tol), 
9.55 (s, 1 H, NH), 10.77 (bs, 1 H, NH), 13.93 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 18.8 (CH3), 39.1 (SCH3), 109.2 (C3H, Pyr), 115.4 (C5H, Pyr), 
115.9 (d, 2JCF = 21.5 Hz, C3/5H, F-Phe), 117.5 (C6H, Cl-Tol), 118.7 (C2H, Cl-Tol), 129.0 (C4, Cl-Tol), 
131.1 (C2/6H, F-Phe), 131.2 (C5, Imdz and C5H, Cl-Tol), 133.2 (C3, Cl-Tol), 134.6 (C4, Imdz), 138.2 
(C1, Cl-Tol), 147.0 (C6H, Pyr), 148.7 (C2, Imdz), 152.1 (CO), 153.2 (C2, Pyr), 162.3 (d, 
1JCF = 249.9 Hz, CF) ppm. 
IR (ATR): ν̃ = 3000, 1668, 1597, 1551, 1520, 1497, 1476, 1398, 1366, 1312, 1217, 1049, 835, 
808, 745 cm-1. 
HPLC (Method 3): tR = 7.4 min. 
LC-MS (ESI, 70 eV): m/z = 484 [MH]+ (calc. m/z = 483). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)pyridin-2-yl)-3-(3-
(trifluormethyl)phenyl)carbamide (289) 
 
C23H17F4N5O2S (Mr 503.48) 
Synthesis was performed according to the general procedure for sulfoxidation from 210 
(20.0 mg, 41.0 µmol) and Oxone® (13.9 mg, 22.6 µmol in 0.2 ml H2O) in 0.4 ml THF and 0.1 ml 
water. Flash chromatography (SiO2, 40-100 % ethyl acetate/petrol ether) afforded 289 as a 
colorless solid (96 % HPLC purity). 
Yield: 15.1 mg (30.0 µmol, 73 %). 
m.p.: 235 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.10 (s, 3 H, SCH3), 7.02 (dd, 3J = 5.4 Hz, 4J = 1.4 Hz, 1 H, C5H, 
Pyr), 7.30-7.37 (m, 2 H, C3/5H, F-Phe), 7.36 (d, 3J = 7.7 Hz, 1 H, C4H, F3C-Phe), 7.51-7.57 (m, 3 H, 
C2/6H, F-Phe and C5H, F3C-Phe), 7.65 (d, 3J = 8.3 Hz, 1 H, C6H, F3C-Phe), 7.71 (s, 1 H, C2H, F3C-Phe), 
8.08 (bs, 1 H, C3H, Pyr), 8.22 (bs, 1 H, C6H, Pyr), 9.59 (s, 1 H, NH), 10.90 (bs, 1 H, NH), 13.93 (bs, 
1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 39.1 (SCH3), 109.3 (C2H, F3C-Phe), 114.7 (q, 3JCF = 2.5 Hz, C3H, 
Pyr), 115.5 (C5H, Pyr), 115.9 (d, 3JCF = 21.9 Hz, C3/5H, F-Phe), 118.7 (q, 3JCF = 2.1 Hz, C4H, F3C-Phe), 
122.5 (C6H, F3C-Phe), 124.2 (q, 1JCF = 272.2 Hz, CF3), 125.9 (d, 4JCF = 3.2 Hz, C1, F-Phe), 129.6 (q, 
2JCF = 31.4 Hz, C3, F3C-Phe), 130.0 (C5H, F3C-Phe), 130.8 (C5, Imdz), 131.1 (d, 4JCF = 11.4 Hz, C2/6H, 
F-Phe), 134.5 (C4, Imdz), 139.9 (C1, F3C-Phe), 143.4 (C4, Pyr), 147.1 (C6H, Pyr), 148.7 (C2, Imdz), 
152.2 (CO), 162.4 (d, 1JCF = 242.12 Hz, CF) ppm. 
IR (ATR): ν̃ = 2900, 1680, 1607, 1576, 1516, 1495, 1476, 1265, 1240, 1229, 1163, 1121, 1099, 
1049, 997, 977, 922, 876, 835, 785, 745, 716, 694 cm-1. 
HPLC (Method 3): tR = 6.8 min. 
LC-MS (ESI, 70 eV): m/z = 504 [MH]+ (calc. m/z = 503). 
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1-(4-(5-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-4-yl)pyridin-2-yl)-3-(naphthalen-
1-yl)carbamide (290) 
 
C26H20FN5O2S (Mr 485.54) 
Synthesis was performed according to the general procedure for sulfoxidation from 212 
(51.0 mg, 109 µmol) and Oxone® (36.7 mg, 59.7 µmol in 1 ml H2O) in 5 ml THF and 1.5 ml H2O. 
Flash chromatography (SiO2, 20-100 % ethyl acetate/petrol ether) afforded 290 as a colorless 
solid (100 % HPLC purity). 
Yield: 37.0 mg (76.2 µmol, 70 %). 
m.p.: 244 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.10 (s, 3 H, SCH3), 7.04 (dd, 3J = 5.4 Hz, 4J = 1.4 Hz, 1 H, C5H, 
Pyr), 7.31-7.36 (m, 2 H, C3/5H, F-Phe), 7.49 (t, 3J = 7.9 Hz, 1 H, C3H, Naph), 7.54-7.59 (m, 4 H, C3H, 
Pyr and C2/6H, F-Phe and C6H, Naph), 7.63-7.68 (m, 2 H, C4/7H, Naph), 7.96 (dd, 3J = 8.1 Hz, 
4J = 0.8 Hz, 1 H, C5H, Naph), 8.16-8.20 (m, 2 H, C2/8H, Naph), 8.34 (d, 3J = 5.4 Hz, 1 H, C6H, Pyr), 
8.93 (s, 1 H, NH), 11.58 (bs, 1 H, NH), 13.95 (bs, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 39.1 (SCH3), 109.4 (C3H, Pyr), 115.3 (C5H, Pyr), 115.9 (d, 
2JCF = 21.8 Hz, C3/5H, F-Phe), 116.9 (C2H, Naph), 120.9 (C8H, Naph), 123.1 (C4H, Naph), 125.5 (C1, 
Naph), 126.0 (C6H, Naph), 126.0 (C3H, Naph), 126.3 (C7H, Naph), 128.6 (C5H, Naph), 130.7 (C5, 
Imdz), 130.9 (C2/6H, F-Phe), 133.7 (C4a, Naph), 134.1 (C8a, Naph), 143.5 (C4, Pyr), 146.7 (C6H, Pyr), 
148.9 (C2, Imdz), 152.6 (CO), 153.6 (C2, Pyr), 162.3 (d, 1JCF = 246.9 Hz, CF) ppm. 
IR (ATR): ν̃ = 2920, 1668, 1601, 1574, 1552, 1472, 1407, 1362, 1346, 1304, 1267, 1240, 1213, 
1157, 1053, 974, 873, 842, 792, 770, 754 cm-1. 
HPLC (Method 3): tR = 7.1 min. 
LC-MS (ESI, 70 eV): m/z = 486 [MH]+ (calc. m/z = 485). 
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4-(2,4-Dimethoxyphenyl)-N-(4-(5-(4-fluorophenyl)-2-(methylsulfinyl)-1H-imidazol-4-yl)-
pyridin-2-yl)-1-methyl-1H-pyrrol-2-carboxamide (291) 
 
C29H26FN5O4S (Mr 559.62) 
Synthesis was performed according to the general procedure for sulfoxidation from 231 
(196 mg, 368 µmol) and Oxone® (133 mg, 216 µmol in 2 ml H2O) in 4 ml THF and 1 ml H2O. 
Flash chromatography (SiO2, 40-100 % ethyl acetate/petrol ether) afforded 291 as a yellow 
solid (95 % HLC purity). 
Yield: 182 mg (325 µmol, 88 %). 
m.p.: 136 °C. 
1H NMR (300 MHz, DMSO-d6): δ = 3.11 (s, 3 H, SCH3), 3.78 (s, 3 H, C2OCH3), 3.86 (s, 3 H, C4OCH3), 
3.90 (s, 3 H, CH3), 6.57 (dd, 3J = 8.5 Hz, 4J = 2.4 Hz, 1 H, C5H, (OCH3)2-Phe), 6.61 (d, 4J = 2.3 Hz, 1 H, 
C3H, (OCH3)2-Phe), 7.07 (d, 3J = 4.8 Hz, 1 H, C5H, Pyr), 7.23-7.38 (m, 2 H, C3/5H, F-Phe), 7.42 (bs, 
1 H, C3H, Pyrrole), 7.46 (d, 3J = 8.4 Hz, 1 H, C6H, (OCH3)2-Phe), 7.54-7.59 (m, 2 H, C2/6H, F-Phe), 
7.68 (bs, 1 H, C5H, Pyrrole), 8.22 (d, 3J = 4.5 Hz, 1 H, C6H, Pyr), 8.42 (s, 1 H, C3H, Pyr), 10.17 (s, 1 H, 
CONH), 13.89 (s, 1 H, NH) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 36.6 (CH3), 39.2 (SCH3), 55.2 (C2OCH3), 55.4 (C4OCH3), 98.8 
(C3H, (OCH3)2-Phe), 105.2 (C5H, (OCH3)2-Phe), 111.8 (C3H, Pyr), 113.3 (C5H, Pyrrole), 115.9 (C1, 
(OCH3)2-Phe), 116.0 (d, 2JCF = 22.4 Hz, C3/5H, F-Phe), 116.1 (C5H, Pyr), 118.5 (C4, Pyrrole), 124.0 
(C2, Pyrrole), 125.8 (d, 4JCF = 3.3 Hz, C1, F-Phe), 127.5 (C6H, (OCH3)2-Phe), 128.6 (C3H, Pyrrole), 
131.3 (d, 3JCF = 8.3 Hz, C2/6H. F-Phe), 131.9 (C4, Imdz), 135.1 (C5, Imdz), 143.0 (C4, Pyr), 147.8 
(C6H, Pyr), 148.5 (C2, Imdz), 152.9 (C2, Pyr), 156.7 (C4OCH3), 158.6 (C2OCH3), 159.9 (CO), 162.4 
(d, 1JCF = 244.3 Hz, CF) ppm. 
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IR (ATR): ν̃ = 2960, 1685, 1609, 1520, 1506, 1480, 1412, 1395, 1300, 1285, 1254, 1230, 1206, 
1157, 1092, 1057, 1030, 941, 862, 835, 791, 702, 627 cm-1. 
HPLC (Method 2): tR = 5.9 min. 
LC-MS (ESI, 70 eV): m/z = 560 [MH]+ (calc. m/z = 559). 
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7.3.9 Irradiation of N-Benzyl-4-(5-(4-fluorophenyl)-2-(methylthio)-
1H-imidazol-4-yl)pyridin-2-amine 
N-Benzyl-9-fluoro-2-(methylthio)-1H-benzo[h]imidazo[4,5-f]isoquinolin-5-amine (292) 
 
C22H17FN4S (Mr 388.46) 
162 (100 mg, 256 µmol) was dissolved in 40 ml THF. 2 ml of the solution were transferred into a 
pointed flask and irradiated for 2 min with UV light of 365 nm and 5.4 W power. The procedure 
was repeated 20 times. All reactive approaches were combined and the solvent was removed 
under reduced pressure. The crude product was purified by flash chromatography (SiO2, 
30-100 % ethyl acetate/petrol ether) to give 292 as a yellow solid (100 % HPLC purity). 
Yield: 24.1 mg (62.1 µmol, 24 %). 
1H NMR (300 MHz, DMSO-d6): δ = 2.81 (s, 3 H, SCH3), 4.76 (d, 4J = 4.8 Hz, 2 H, CH2, Bn), 7.20-7.25 
(m, 1 H, arC4H, Bn), 7.31-7.36 (m, 2 H, arC3/5H, Bn), 7.40 (d, 3J = 5.2 Hz, 1 H, CH, Pyr), 7.46-7.49 (m, 
2 H, arC2/6H, Bn), 7.54-7.66 (m, 2 H, CH, F-Phe and NH), 8.12 (d, 3JCF = 5.3 Hz, 1 H, CH, Pyr), 
8.36-8.54 (m, 1 H, CH, F-Phe), 8.98-9.06 (m, 1 H, CH, F-Phe), 13.40-13.49 (m, 1 H, NH, Imdz) ppm. 
13C NMR (75 MHz, DMSO-d6): δ = 14.5 (SCH3), 45.2 (CH2, Bn), 105.2 (CH, Pyr), 111.3 (CH, F-Phe), 
114.5 (d, 2JCF = 22.3 Hz, CH, F-Phe), 123.7 (CH, F-Phe), 126.3 (arC4H, Bn), 127.3 (arC2/6H, Bn), 128.1 
(arC3/5H, Bn), 140.8 (arC1, Bn), 143.5 (CH, Pyr), 149.5 (C2, Imdz), 156.3 (C2, Pyr), 161.0 (CF) ppm. 
HPLC (Method 2): tR = 5.3 min. 
LC-MS (ESI, 70 eV): m/z = 389 [MH]+ (calc. m/z = 388). 
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7.4 Biological Evaluation 
7.4.1 Kinase Assays (IC50 determination) 
In vitro kinase reactions were used to determine the capacity of substrate phosphorylation by 
distinct kinases. Consequently, the decrease of enzyme activity in the presence of small molecule 
kinase inhibitors was used as a surrogate parameter for the inhibitory potency which is 
indicated by the half maximal inhibitory concentration (IC50). 
The appropriate reaction-mix contained 2 µl 10 mM inhibitor dilution in DMSO (or pure DMSO), 
3 µl kinase diluted in kinase buffer (1x) without ATP, 1.5 µl kinase buffer (10x) with ATP, 0.2 µl 
γ-32P-ATP (2 µCi per reaction), 5.3 µl H2O, and 3 µl substrate accounting for a total volume of 
15 µl 1.5 ml Eppendorf® Safe-Lock microcentrifuge tubes. After 30 min incubation at 30 °C the 
reaction was terminated by the addition of 3 µl stopping buffer and subsequent protein 
denaturation at 99 °C for 5 min. Buffers are given in detail in Table 29. Protein separation (SDS-
PAGE) and protein staining via anionic Coommassie dye were followed by de-staining in de-
staining solution and drying of the polyacrylamide gels on a vacuum gel-dryer. The amount of 
radioactive 32P was then quantified by Cherenkov counting of the excised bands of 
phosphorylated protein (Cherenkov counter LSC000IC, Beckman). 
Table 29 | Kinase assay buffers .   
 Buffer Contents 
   
 Kinase buffer (1x) without ATP 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA 
   
 Kinase buffer (10x) with ATP 1 mM ATP, 250 mM Tris-HCl (pH 7.5), 100 mM MgCl2, 1 mM EDTA 
   
 Stopping buffer 250 mM Tris-HCl (pH 6.8), 25 % (v/v) β-mercaptoethanol, 50 % (v/v) 
glycerol, 10 % (w/v) SDS, 0.5 % (w/v) bromophenol blue 
   
 
The applied kinase activities were either recombinant human GST-CK1δ TV1 (approx. 
10 ng ∙ reaction-1), recombinant rat CK1δ (FP449, approximately 15 ng ∙ reaction-1)261, or 
commercially available kinase domain of CK1δ (50 ng ∙ reaction-1, New England Biolabs, Ipswich, 
USA), and CK1ε (15 ng ∙ reaction-1, Carlsbad, USA), as well as bovine GST-CK1α, human 
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GST-CK1γ3 TV X6 and commercially available p38α (SignalChem, BIOZOL, Eching, Germany). 
α-Casein, GST-p53 fragment (aa 1-64), and GST-CK1δ fragment (aa 305-375) have been used as 
substrates. Residual kinase activity (% in relation to DMSO negative control) has been 
determined at an inhibitor concentration of 10 µM. The most promising candidates have serially 
been diluted for IC50 determination with concentrations ranging from 10 µM to 5 nM. GraphPad 
Prism 6 software (GraphPad, San Diego, USA) has been utilized for statistical analysis262. 
These kinase assays have been performed by MARC KRÜGER248 and CHIARA IANES (current work)249 
in the group of PROF. DR. UWE KNIPPSCHILD at the Department of General and Visceral Surgery, 
Ulm University Hospital, Germany. The following compounds have been tested: 
Table 30 | Test compounds  (kinase assays) . Sulfoxides are implemented in the appropriate se ries.  
 Kinase Series Compounds 
10 µM screening CK1δ, CK1ε 1 82, 84, 85, 148-155, 162, 164 
  2 102, 103, 190-194 
  3 104, 204-206, 208-210, 212, 286-290 
  4 224, 232, 291 
  6 266, 267 
 CK1α 1 84, 85, 148-155 
  2 103, 190, 191 
  3 104, 204, 206, 209, 210, 212, 286 
 CK1γ3 1 84, 85, 148-155 
 p38α 1 84, 85, 148-155 
    
IC50 determination CK1δ, CK1ε 1 150, 151, 164 
  2 102, 103, 190-194 
  3 104, 204, 205, 208-210, 287-290 
  4 224, 232, 291 
  6 266, 267 
 
In addition, CK1δ and p38α IC50 values have been determined for compounds 191 (series 2), 
204 (series 3), 223 (series 4), and 266 (series 6) using a radiometric 33PanQinase® assay263 by 
ProQinase GmbH, Freiburg, Germany. The appropriate IC50 profiles were received by testing ten 
concentrations per compound in semi-log steps and triplicate measurement with the highest 
concentration being 1 ∙ 10-4 M. Serial dilution of the compounds has been fulfilled from a 10 mM 
stock solution in DMSO. The final DMSO concentration was 1 % in each reaction-mix. 
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7.4.2 Kinase Profiling 
Kinase profiling has been performed for compound 191 (series 2) against 320 wild-type protein 
kinases plus BRAFV600E by ProQinase, Freiburg, Germany. Residual kinase activity has been de-
termined at 100 nM in singlicate using an activity-based radiometric 33PanQinase® assay263. The 
final DMSO concentration was 1 % in each reaction-mix. 
7.4.3 MTT Viability Assays 
Cytotoxic activity of compounds was analyzed using conventional MTT assays: approximately 
5 ∙ 104 cells were seeded in 96-well plates and cultivated for 24 h. The cell lines were treated 
with 10 µM, 15 µM, 20 µM, or 25 µM inhibitor and incubated for 48 h whereupon the procedure 
included untreated and DMSO-treated cells serving as control. Subsequently, 10 µl MTT solution 
(5 mg ∙ ml-1 MTT in PBS, Sigma Aldrich, Schnelldorf, Germany) were added. After incubation for 
another 4 h the medium was removed and the plates were shaken on an orbital shaker for 
30 min with 100 µl acidic isopropanol (0.04 M HCl in 2-propanol) per well. Dissolved formazan 
crystals were analyzed spectrophotometrically at 570 nm with control well mean optical density 
defined as 100 %. Half maximal effective concentration (EC50) values have been determined for 
151 and 191 utilizing GraphPad 6 Prism software (GraphPad, San Diego, USA). Cell culture 
experiments have been performed in triplicate. The used human CK1-dependent cancer cell 
lines are given in Table 31. 
MTT assays have been performed by MARC KRÜGER248 and CHIARA IANES (current work)249 in the 
group of PROF. DR. UWE KNIPPSCHILD at the Department of General and Visceral Surgery, Ulm 
University Hospital, Germany. 
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Table 31 |  Human CK1-dependent cancer cell lines used in MTT assays  with their respective 
origin .  The compounds tested on the cell lines are given  with their respective series .  
Cell line Origin Series Compounds 
    
Colo357 
Human lymph node metastasis pancreatic adeno-
carcinoma cell line264 
2 102, 103, 190-194 
3 104, 204-206, 208-210, 212, 286-290 
4 224, 232, 291 
6 266, 267 
    
HT-29 
Human colorectal adenocarcinoma epithelial cell 
line265 
1 82, 84, 85, 148-155, 162, 164 
    
MiaPaca-2 Human pancreatic carcinoma epithelial cell line266 
2 190 
4 224, 232, 291 
6 266, 267 
    
Panc-1 
Human pancreatic epithelioid carcinoma cell 
line267 
2 190 
4 224, 232, 291 
6 266, 267 
    
Panc89 Human pancreatic adenocarcinoma cell line268 
2 102, 103, 190-194 
3 104, 204-206, 208-210, 212, 286-290 
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7.5 X-ray Crystallography 
Co-crystallization of 191 with inactive, non-phosphorylated wild-type p38α MAPK was 
performed by the group of PROF. DR. DANIEL RAUH (Institute of Chemical Biology, Dortmund 
University of Technology, Germany) following established protocols for protein expression and 
purification269, and an adapted procedure for crystallization270. The protein-ligand mixture 
consisting of 20 µl 10 mg ∙ ml-1 wild-type p38α and 0.2 µl 50 mM inhibitor stock solution in 
DMSO were incubated on ice for 60 min and centrifuged at 13,000 rpm for 10 min in order to 
remove excess ligand. Crystals were cultivated using the hanging drop vapor diffusion method in 
24-well EasyXtal Tools (QIAGEN, Hilden, Germany) and by adding 0.5 µl reservoir solution 
(100 mM MES buffer pH 5.6-6.2, 20-30 % PEG4000, and 50 mM BOG) to 1.5 µl protein-ligand 
mixture. PEG400-protected crystals were flash frozen in liquid nitrogen. Diffraction data of 
protein-ligand complexes were determined at the PX II beamline of the Swiss Light Source (Paul 
Scherrer Institute, Villingen, Switzerland) using wavelengths close to 1 Å. The obtained datasets 
were integrated and scaled using XDS and XSCALE271, complex structures were interpreted by 
molecular replacement based on published p38α templates (PDB code 4LDI) utilizing 
PHASER272, and molecules in the asymmetric unit were modified manually with COOT273. 
Structures were refined by the use of REFMAC274 and validated performing RAMACHANDRAN plot 
analysis using RAMPAGE275. Ligand topology files were generated utilizing the Dundee PRODRG 
server276. Data collection, structure refinement statistics, and RAMACHANDRAN plot results for the 
obtained crystal structure of wild-type p38α MAPK in complex with 191 are given in Table 32. 
Co-crystallization of 224 and 266 with CK1δ were performed by the group of PROF. DR. ULRICH 
BAUMANN (Department for Chemistry, University of Cologne, Germany) following similar 
procedures as described above, though by utilizing the sitting drop methodology instead 
(unpublished data). The protein-ligand mixture consisted of 30 µl 10 mg ∙ ml-1 CK1δ and 1 µl 
10 µM inhibitor stock solution in DMSO. Precipitant solutions contained 0.1 M HEPES buffer pH 
7.0 M, 0.7 M sodium dihydrogen phosphate, and 0.7 M potassium dihydrogen phosphate for 224 
and 20 % PEG1000, 200 mM lithium sulfate, and 100 mM phosphate citrate buffer pH 4.2 in the 
case of 266. Cryoprotection was achieved using saturated sucrose solution (224) or PEG1000 
(266). Diffraction data of protein-ligand complexes including 224 were determined at the 
ID23-1 beamline of the European Synchrotron Radiation Facility (Grenoble, France) while 
measurement of crystals containing 266 was performed at Xo6DA (PXIII) beamline of the Swiss 
Light Source (Paul Scherrer Institute, Villingen, Switzerland). However, the structures represent 
preliminary results and require further refinement. Crystallization data is given in Table 33. 
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Table 32 | Crystallographic statistics of wild -type p38α in complex with 191 .  X-ray crystallog-
raphy has been performed by the group of PR OF .  DR .  DAN IE L R AUH .  Values in parenthesis refer to the 
highest resolution shell .  
 191/p38α  
Wavelength (Å) 1.0000  
Temperature (K) 90  
   
Data collection   
Space group P212121  
Unit cell a, b, c (Å) 66.50, 69.39, 74.14  
 α, β, γ (°) 90, 90, 90  
Resolution (Å) 50.0-1.90 (1.95-1.90)  
Rmeas (%) 9.0 (82.0)  
<I/σ(I)> 22.69 (3.38)  
Completeness (%) 100 (100)  
Redundancy 0.98 (1.05)  
    
Refinement   
Resolution (Å) 48.01-1.90 (1.949-1.900)  
No. reflections 26280 (1891)  
Rwork/Rfree 0.19/0.24  
No. atoms Total 2865  
 Protein 2667  
 Ligand/Ion 95  
B-factors Protein 27.26  
 Ligand/Ion 29.04  
 Water 26.74  
RMSD Bond length (Å) 0.019  
 Bond angles (°) 1.966  
   
RAMACHANDRAN plot   
Res. in favored regions 315  
Res. in allowed regions 6  
Res. in outlier regions 0  
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Table 33 | Crystallographic statistics of CK1δ in complex with 224 and 266 .  X-ray crystallog-
raphy has been performed by the group of P ROF .  DR .  ULRICH BAU MA N N .  Values in parenthesis refer to 
the highest resolution shell.  
 224/CK1δ 266/CK1δ 
Wavelength (Å) 0.972420 0.999990 
Space group C 1 2 1 P 61 
Unit cell a, b, c (Å) 195.485, 126.653, 152.281 176.282, 176.282, 111.25 
 α, β, γ (°) 90, 113.272, 90 90, 90, 120 
Reflections Total 192836 (30989) 1316615 (193931) 
 Unique 55965 (5445) 64064 (6304) 
Resolution (Å) 54.12-3.201 (3.315-3.201) 47.04-2.549 (2.64-2.549) 
Rmerge (%) 9.9 (70.6) - 
Rmeas (%) 11.7 (77.2) 20.7 (158.7) 
<I/σ(I)> 11.92 (1.81) 17.4 (2.29) 
Completeness (%) 99 (95) 100 (100) 
Redundancy  3.44 (3.4) 20.2 (30.7) 
CC1/2 (%) 99.7 (76.6) 99.8 (74) 
Reflections used in refinement 55952 (5445) 64048 (6304) 
Reflections used for Rfree 1995 (194) 1501 (142) 
Rwork/Rfree 0.2092 (0.3193)/0.2463 (0.3458) 0.2118 (0.2892)/0.2273 (0.2690) 
No. atoms Non-hydrogen 13878 9379 
 Macromolecules 13653 9180 
 Ligands 225 199 
 Protein Residues 1703 1133 
B-factors Average 95.52 55.84 
 Macromolecules 95.51 55.63 
 Ligands 96.15 65.64 
 Wilson 85.21 45.00 
RMSD Bond length (Å) 0.004 0.002 
 Bond angles (°) 0.66 0.55 
Clashscore  12.59 1.57 
No. of TLS groups 6 4 
RAMACHANDRAN favored (%) 92 96 
RAMACHANDRAN allowed (%) 6.5 3.9 
RAMACHANDRAN outlier (%) 1.5 0.27 
Rotamer outliers (%) 1.3 0.82 
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9 Appendix 
Supplementary Table 1 | Selectivity profiling of compound 191 .  The inhibitor has been 
screened at a concentration of 100  nM  over a panel of 320 wild -type protein kinases and B -Raf 
V600E by ProQinase GmbH. Classification of protein kinase families refers to MA N NI N G  et al5 :  
AGC = containing PKA, PKG, PKC families; CAMK = calcium/calmodulin-dependent protein kinase; 
CK1 = formerly known as casein kinase 1; CMGC  = containing Cdk,  MAPK, GSK3, CLK families;  
STE = homologs of yeast steri le 7, sterile 11,  steri le 20 kinases; TK  = tyrosine kinase;  
TKL = tyrosine kinase-like.  
# Kinase name Kinase family Residual activity (%) 
1 ABL1 TK 100 
2 ABL2 TK 91 
3 ACK1 TK 96 
4 ACV-R1 TKL 95 
5 ACV-R1B TKL 101 
6 ACV-R2A TKL 98 
7 ACV-R2B TKL 97 
8 ACV-RL1 TKL 99 
9 AKT1 aa106-480 AGC 90 
10 AKT2 aa107-481 AGC 97 
11 AKT3 aa106-479 AGC 83 
12 ALK (GST-HIS-tag) TK 114 
13 AMPK-alpha1 aa1-550 CAMK 96 
14 ARK5 CAMK 88 
15 ASK1 STE 93 
16 Aurora-A OTHER 93 
17 Aurora-B OTHER 92 
18 Aurora-C OTHER 93 
19 AXL TK 104 
20 BLK TK 77 
21 BMPR1A TKL 102 
22 BMX TK 98 
23 B-RAF V600E TKL 102 
24 B-RAF  TKL 91 
25 BRK TK 98 
26 BRSK1 CAMK 89 
27 BRSK2 CAMK 105 
28 BTK TK 105 
29 BUB1B OTHER 102 
30 CAMK1D CAMK 78 
31 CAMK2A CAMK 95 
32 CAMK2B CAMK 103 
33 CAMK2D CAMK 96 
34 CAMK2G CAMK 105 
35 CAMK4 CAMK 95 
36 CAMKK1 OTHER 99 
37 CAMKK2 OTHER 96 
38 CDC42BPA AGC 104 
39 CDC42BPB AGC 88 
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40 CDC7/ASK OTHER 97 
41 CDK1/CycA2 CMGC 91 
42 CDK1/CycB1 CMGC 95 
43 CDK1/CycE1 CMGC 97 
44 CDK19/CycC CMGC 86 
45 CDK2/CycA2 CMGC 87 
46 CDK2/CycE1 CMGC 99 
47 CDK3/CycC CMGC 95 
48 CDK3/CycE1 CMGC 98 
49 CDK4/CycD1 CMGC 98 
50 CDK4/CycD3 CMGC 88 
51 CDK5/p25NCK CMGC 117 
52 CDK5/p35NCK CMGC 85 
53 CDK6/CycD1 CMGC 105 
54 CDK6/CycD3   97 
55 CDK7/CycH/MAT1 CMGC 102 
56 CDK8/CycC CMGC 90 
57 CDK9/CycK CMGC 103 
58 CDK9/CycT1 CMGC 93 
59 CHK1 CAMK 92 
60 CHK2 CAMK 98 
61 CK1-alpha1 CK1 26 
62 CK1-delta CK1 3 
63 CK1-epsilon CK1 7 
64 CK1-gamma1 CK1 100 
65 CK1-gamma2 CK1 91 
66 CK1-gamma3 CK1 73 
67 CK2-alpha1 OTHER 97 
68 CK2-alpha2 OTHER 90 
69 CLK1 CMGC 105 
70 CLK2 CMGC 101 
71 CLK3 CMGC 98 
72 CLK4 CMGC 95 
73 COT STE 111 
74 CSF1-R TK 104 
75 CSK TK 101 
76 DAPK1 CAMK 96 
77 DAPK2 CAMK 95 
78 DAPK3 CAMK 85 
79 DCAMKL2 CAMK 94 
80 DDR2 TK 101 
81 DMPK AGC 103 
82 DNA-PK ATYP 95 
83 DYRK1A CMGC 96 
84 DYRK1B CMGC 101 
85 DYRK2 CMGC 99 
86 DYRK3 CMGC 97 
87 DYRK4 CMGC 100 
88 EEF2K ATYPICAL 84 
89 EGF-R  TK 113 
90 EIF2AK2 OTHER 91 
91 EIF2AK3 OTHER 91 
92 EPHA1 TK 104 
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93 EPHA2 TK 95 
94 EPHA3 TK 97 
95 EPHA4 TK 96 
96 EPHA5 TK 97 
97 EPHA6 TK 100 
98 EPHA7 TK 99 
99 EPHA8 TK 115 
100 EPHB1 TK 96 
101 EPHB2 TK 55 
102 EPHB3 TK 92 
103 EPHB4 TK 97 
104 ERBB2 TK 97 
105 ERBB4 TK 98 
106 ERK1 CMGC 94 
107 ERK2 CMGC 103 
108 ERK5 CMGC 95 
109 ERK7 CMGC 93 
110 FAK aa2-1052 TK 105 
111 FER TK 93 
112 FES TK 91 
113 FGF-R1  TK 113 
114 FGF-R2 TK 101 
115 FGF-R3  TK 99 
116 FGF-R4 TK 86 
117 FGR TK 103 
118 FLT3  TK 109 
119 FRK TK 93 
120 FYN TK 119 
121 GRK2 AGC 113 
122 GRK3 AGC 91 
123 GRK4 AGC 86 
124 GRK5 AGC 97 
125 GRK6 AGC 100 
126 GRK7 AGC 83 
127 GSG2 OTHER 121 
128 GSK3-alpha CMGC 107 
129 GSK3-beta CMGC 89 
130 HCK TK 58 
131 HIPK1 CMGC 102 
132 HIPK2 CMGC 92 
133 HIPK3 CMGC 94 
134 HIPK4 CMGC 94 
135 HRI OTHER 97 
136 IGF1-R TK 114 
137 IKK-alpha OTHER 98 
138 IKK-beta OTHER 92 
139 IKK-epsilon OTHER 102 
140 INS-R TK 101 
141 INSR-R TK 92 
142 IRAK1 TKL 99 
143 IRAK4 (untagged) TKL 98 
144 ITK TK 66 
145 JAK1 aa850-1154 TK 107 
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146 JAK2 TK 93 
147 JAK3 TK 88 
148 JNK1 CMGC 103 
149 JNK2 CMGC 21 
150 JNK3 CMGC 37 
151 KIT  TK 103 
152 LCK TK 26 
153 LIMK1 TKL 96 
154 LIMK2 TKL 100 
155 LRRK2  TKL 94 
156 LTK TK 101 
157 LYN TK 105 
158 MAP3K1 STE 99 
159 MAP3K10 STE 63 
160 MAP3K11 STE 87 
161 MAP3K7/MAP3K7IP1 STE 60 
162 MAP3K9 STE 97 
163 MAP4K2 STE 96 
164 MAP4K4 STE 97 
165 MAP4K5 STE 94 
166 MAPKAPK2 CAMK 90 
167 MAPKAPK3 CAMK 108 
168 MAPKAPK5 CAMK 112 
169 MARK1 CAMK 106 
170 MARK2 CAMK 94 
171 MARK3 CAMK 94 
172 MARK4 CAMK 97 
173 MATK TK 101 
174 MEK1  STE 92 
175 MEK2 STE 100 
176 MEK5 STE 93 
177 MEKK2 STE 97 
178 MEKK3 STE 101 
179 MELK CAMK 97 
180 MERTK TK 85 
181 MET  TK 105 
182 MINK1 STE 89 
183 MKK4 STE 103 
184 MKK6 S207D/T211D** STE 89 
185 MKK7 STE 96 
186 MKNK1 CAMK 99 
187 MKNK2 CAMK 101 
188 MLK4 TKL 94 
189 MST1 STE 124 
190 MST2 STE 107 
191 MST3 STE 92 
192 MST4 STE 101 
193 mTOR ATYPICAL 96 
194 MUSK TK 102 
195 MYLK CAMK 97 
196 MYLK2 CAMK 100 
197 MYLK3 CAMK 98 
198 NEK1 OTHER 101 
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199 NEK11 OTHER 77 
200 NEK2 OTHER 103 
201 NEK3 OTHER 93 
202 NEK4 OTHER 89 
203 NEK6 OTHER 99 
204 NEK7 OTHER 113 
205 NEK9 OTHER 98 
206 NIK STE 88 
207 NLK CMGC 78 
208 p38-alpha CMGC 22 
209 p38-beta CMGC 52 
210 p38-delta CMGC 99 
211 p38-gamma CMGC 99 
212 PAK1 STE 93 
213 PAK2 STE 121 
214 PAK3 STE 100 
215 PAK4 STE 101 
216 PAK6 STE 103 
217 PAK7 STE 129 
218 PASK CAMK 98 
219 PBK OTHER 121 
220 PCTAIRE1/CycY CMGC 148 
221 PDGFR-alpha  TK 102 
222 PDGFR-beta TK 99 
223 PDK1 AGC 106 
224 PHKG1 CAMK 91 
225 PHKG2 CAMK 99 
226 PIM1 CAMK 95 
227 PIM2 CAMK 99 
228 PIM3 CAMK 102 
229 PKA AGC 100 
230 PKC-alpha AGC 99 
231 PKC-beta1 AGC 99 
232 PKC-beta2 AGC 106 
233 PKC-delta AGC 88 
234 PKC-epsilon AGC 98 
235 PKC-eta AGC 80 
236 PKC-gamma AGC 93 
237 PKC-iota AGC 98 
238 PKC-mu AGC 117 
239 PKC-nu AGC 72 
240 PKC-theta AGC 87 
241 PKC-zeta AGC 95 
242 PKMYT1 OTHER 112 
243 PLK1 OTHER 106 
244 PLK3 OTHER 97 
245 PRK1 AGC 108 
246 PRK2 AGC 78 
247 PRKD2 CAMK 104 
248 PRKG1 AGC 94 
249 PRKG2 AGC 87 
250 PRKX AGC 100 
251 PYK2 TK 101 
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252 RAF1 Y340D/Y341D (untagged)** TKL 84 
253 RET  TK 113 
254 RIPK2 TKL 45 
255 RIPK5 TKL 97 
256 ROCK1 AGC 92 
257 ROCK2 AGC 99 
258 RON TK 110 
259 ROS TK 97 
260 RPS6KA1 AGC 102 
261 RPS6KA2 AGC 95 
262 RPS6KA3 AGC 94 
263 RPS6KA4 AGC 110 
264 RPS6KA5 AGC 96 
265 RPS6KA6 AGC 141 
266 S6K AGC 111 
267 S6K-beta AGC 98 
268 SAK OTHER 103 
269 SGK1 AGC 111 
270 SGK2 AGC 99 
271 SGK3 AGC 90 
272 SIK1 CAMK 101 
273 SIK2 CAMK 117 
274 SIK3 CAMK 96 
275 SLK STE 98 
276 SNARK CAMK 92 
277 SNK OTHER 94 
278 SRC (GST-HIS-tag) TK 100 
279 SRMS TK 117 
280 SRPK1 CMGC 104 
281 SRPK2 CMGC 105 
282 STK17A CAMK 98 
283 STK23 CAMK 104 
284 STK25 STE 96 
285 STK33 CAMK 90 
286 STK39 STE 109 
287 SYK aa1-635 TK 108 
288 TAOK2 STE 86 
289 TAOK3 STE 89 
290 TBK1 OTHER 96 
291 TEC TK 100 
292 TGFB-R1 TKL 100 
293 TGFB-R2 TKL 99 
294 TIE2  TK 71 
295 TLK1 AGC 107 
296 TLK2 AGC 122 
297 TNK1 TK 99 
298 TRK-A TK 101 
299 TRK-B TK 117 
300 TRK-C TK 116 
301 TSF1 OTHER 99 
302 TSK2 CAMK 93 
303 TSSK1 CAMK 97 
304 TTBK1 CK1 96 
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305 TTBK2 CK1 98 
306 TTK OTHER 94 
307 TXK TK 95 
308 TYK2 TK 84 
309 TYRO3 TK 94 
310 VEGF-R1 TK 98 
311 VEGF-R2 TK 90 
312 VEGF-R3 TK 96 
313 VRK1 CK1 100 
314 VRK2 CK1 104 
315 WEE1 OTHER 94 
316 WNK1 OTHER 96 
317 WNK2 OTHER 101 
318 WNK3 OTHER 101 
319 YES TK 100 
320 ZAK TKL 96 
321 ZAP70 TK 81 
** Constitutively active kinase. 
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Supplementary Table 2 | Register of test compounds from the current work 2 4 8 , 2 4 9 .  
# Structure IC50 (CK1δ) IC50 (CK1ε) IC50 (p38α) 
82 
 
n.d. n.d. 139 nM197 
84 
 
n.d. n.d. n.d. 
85 
 
n.d. n.d. n.d. 
102 
 
93 nM 499 nM n.d. 
103 
 
87 nM 573 nM n.d. 
104 
 
153 nM 910 nM n.d. 
148 
 
n.d. n.d. n.d. 
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149 
 
n.d. n.d. n.d. 
150 
 
644 nM 3323 nM n.d. 
151 
 
344 nM 1753 nM n.d. 
152 
 
n.d. n.d. n.d. 
153 
 
n.d. n.d. n.d. 
154 
 
n.d. n.d. n.d. 
155 
 
n.d. n.d. n.d. 
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162 
 
n.d. n.d. n.d. 
164 
 
386 nM 6731 nM n.d. 
190 
 
20 nM 129 nM n.d. 
191 
 
4 nM 
< 3 nMPQ 
25 nM 10 nMPQ 
192 
 
20 nM 233 nM n.d. 
193 
 
14 nM 91 nM n.d. 
194 
 
27 nM 204 nM n.d. 
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204 
 
19 nM 
10 nMPQ 
227 nM 28 nMPQ 
205 
 
31 nM 186 nM n.d. 
206 
 
n.d. n.d. n.d. 
208 
 
47 nM 272 nM n.d. 
209 
 
35 nM 203 nM n.d. 
210 
 
169 nM 498 nM n.d. 
212 
 
n.d. n.d. n.d. 
326 | A p p e n d i x  
 
 
224 
 
8 nM 
< 3 nMPQ 
81 nM 10 nMPQ 
232 
 
9 nM 45 nM n.d. 
266 
 
27 nM 
< 3 nMPQ 
237 nM 36 nMPQ 
267 
 
29 nM 151 nM n.d. 
286 
 
n.d. n.d. n.d. 
287 
 
160 nM 804 nM n.d. 
288 
 
115 nM 764 nM n.d. 
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289 
 
88 nM 623 nM n.d. 
290 
 
48 nM 182 nM n.d. 
291 
 
32 nM 181 nM n.d. 
PQ IC50 value has been determined by ProQinase GmbH. 
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List of Abbreviations 
#  number (of compound) 
°  degrees 
°C  degrees Celsius 
2D  two-dimensional 
3D  three-dimensional 
βAPP  amyloid-β precursor protein 
δ (NMR)  chemical shift 
µCi  microcurie 
µl  microliter(s) 
µM  micromolar 
µmol  micromole(s) 
ν̃  wavenumber 
A  alanine 
Å  Ångström 
aa  amino acid(s) 
AB  adenine-binding region 
ACN  acetonitrile 
AD  Alzheimer’s disease 
ADP  adenosine diphosphate 
AGC  containing PKA, PKG, PKC families 
AIB1  amplified in breast cancer 1 
AKAP450 A-kinase anchoring protein 450 
Akt  protein kinase B 
Ala  alanine 
ALS  amyotrophic lateral sclerosis 
AMP  adenosine monophosphate 
anhyd.  anhydrous 
APC/C  anaphase-promoting 
  complex/cyclosome 
approx.  approximately 
aq.  aqueous 
arC (NMR) aromatic carbon atom (only 
  denoted if ambiguous) 
ARF GAP1 ADP-ribosylation factor GTPase- 
  activating protein 
Arg  arginine 
Asn  asparagine 
Asp  aspartic acid 
ATP  adenosine triphosphate 
ATR  attenuated total reflection 
B-factor  Debye-Waller-/Temperature-factor 
BACE1  β-secretase 
Bcr-Abl  breakpoint cluster region- 
  Abelson tyrosine kinase 
bind.  binding 
BMAL1  brain and muscle ARNT-like protein 
Bn  benzyl 
BnBr  benzyl bromide 
Boc2O  di-tert-butyl dicarbonate 
BOG  β-octyl glucoside 
B-Raf  rapidly accelerated fibrosarcoma B 
bs (NMR) broad singlet 
Bt  benzotriazole 
BYSL  bystin 
cat  catalytic 
CAMK  calcium/calmodulin-dependent
  protein kinase 
CCK2R  cholecystokinin 2 receptor 
Cdh1  cadherin 1 
Cdk2/E  cyclin-dependent kinase 2/cyclin E 
Cdk5/p35 cyclin-dependent kinase 5/p35 
Chk1  checkpoint kinase 1 
Ci-155  full-length cubitus interruptus 
CK1  protein kinase CK1 
CK1BP  CK1-binding protein 
CK2  protein kinase CK2 
CLK1-4  CDC-like kinases 1-4 
CLS  centrosomal localization signal 
cm  centimeter(s) 
CMGC  containing Cdk, MAPK, GSK3, CLK
  families 
CML  chronic myelogenous leukemia 
CNS  central nervous system 
conc.  concentrated 
COSY  correlation spectroscopy 
cp.  compare 
CPI-17  protein kinase C-potentiated myo- 
  sin phosphatase inhibitor of 17 kDa 
CREB  cyclic AMP response element- 
  binding protein 
CRY 1/2  cryptochrome 1/2 
Cx43  connexin-43 
Cys  cysteine 
d (NMR)  doublet 
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D  asparagine 
DARPP-32 dopamine- and cAMP-regulated 
  neuronal phosphoprotein 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC  N,N'-Dicyclohexylcarbodiimide 
dCK  deoxycytidine kinase 
DCM  dichloromethane 
dd (NMR) doublet of doublets 
DDX3  DEAD-box RNA-helicase 3 
dq (NMR) doublet of quartets 
DEPT  distortionless enhancement by 
  polarization transfer 
4-DMAP  4-dimethylaminopyridine 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
Dnmt1  DNA methyltransferase 1 
Dpr1a  dapper 1a 
dt (NMR) doublet of triplets 
Dvl  dishevelled 
DYRK1A/1B dual specificity tyrosine- 
  phosphorylation-regulated 
  kinases 1A and 1B 
E  glutamic acid 
E-box  enhancer box 
e.g.  exempli gratia (for example) 
EB1  microtubule plus-end-binding
  protein 1 
EC50  half maximal effective  
  concentration 
EDCI  1-ethyl-3-(3-dimethylaminoproyl)- 
  carbodiimid 
EDTA  ethylenediaminetetraacetic acid 
EGFR  epidermal growth factor receptor 
EI  electron ionization 
eIF6  eukaryotic initiation factor 6 
Emi2  endogenous meiotic inhibitor 2 
equiv  equivalents 
ER  endoplasmic reticulum 
ERα  estrogen receptor α 
ESI  electron spray ionization 
Et3N  triethylamine 
eV  electronvolt 
F  phenylalanine 
Fam20C  family with sequence similarity 20C 
FASPS  familial advanced sleep phase
  syndrome 
Fat  Drosophila melanogaster homolog
  of human FAT 
FD  field desorption 
FDA  Food and Drug administration 
FLT1-3  Fms-like tyrosine kinases 1-3 
FoxG1  forkhead box G1 
FRQ  frequency 
g  gram(s) 
G-CK  Golgi casein kinase 
Gln  glutamine 
Glu  glutamic acid 
Gly  glycine 
GSK-3  glycogen synthase kinase 3 
h  hour(s) 
H-bond  hydrogen bond 
HATU  1-[bis(dimethylamino)methylene]-
  1H-1,2,3-triazolo[4,5-b]pyridinium-
  3-oxid hexafluorophosphate 
HEPES  2-(4-(2-hydroxyethyl)piperazin-1- 
  yl)ethanesulfonic acid 
Her2  human epidermal growth factor
  receptor 2 
Hh  Hedgehog 
HHV  human herpes virus 
HIF-1α  hypoxia-inducible factor 1α 
His  histidine 
HMBC  heteronuclear multiple bond  
  coherence 
hnRNP A1 heterogeneous nuclear  
  ribonucleoprotein A1 
HOBt  hydroxybenzotriazole 
HPI  hydrophobic pocket I 
HPLC  high performance liquid chroma-
  tography 
HRII  hydrophobic region II 
HRMS  high resolution mass spectrometry 
HSAB  hard soft acids and bases 
HSQC  heteronuclear single quantum 
  coherence spectroscopy 
Hz  Hertz 
I  isoleucine 
I/σ(I)  signal-to-noise ratio 
IC50  half maximal inhibitory 
  concentration 
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ICP0  HHV E3 ubiquitin ligase 
i.e.  id est 
Ile  isoleucine 
Imdz  imidazole 
IR  infrared spectroscopy 
J (NMR)  coupling constant 
JAK  Janus kinase 
JNK2/3  c-Jun N-terminal kinase 2/3 
K  Kelvin 
kDa  Kilodalton 
KHD  kinesin homology domain 
L  leucine 
LATS  large tumor suppressor kinase 
LC  liquid chromatography 
LCK  lymphocyte-specific protein 
  tyrosine kinase 
Leu  leucine 
Lit.  literature 
LRP5/6  low-density lipoprotein receptor-
  related proteins 5 or 6 
Lys  lysine 
m (NMR) unresolved multiplet 
M  molar 
Mr  relative molecular mass 
m.p.  melting point 
m/z  mass-to-charge ratio 
MAP1A  microtubule-associated protein 1A 
MAP4  microtubule-associated protein 4 
MAPK  mitogen-activated protein kinase 
MBP  myelin basic protein 
MCLK3  myosin light chain kinase 3 
MDM2  mouse double minute 2 homolog 
MES  2-(N-morpholino)ethanesulfonic 
  acid 
Met  methionine 
mg  milligram(s) 
MHz  Megahertz 
min  minute(s) 
ml  milliliter(s) 
mM  millimolar 
mmol  millimole(s) 
mol  mole(s) 
mRNA  messenger RNA 
MS  mass spectrometry 
mTNFα  transmembrane tumor necrosis 
  factor α 
mTOR  mammalian target of rapamycin 
MTSS1  metastasis suppressor 1 
MTT  3-(4,5-dimethyl-thiazol-2-yl)-2,5-  
  diphenyltetrazolium bromide  
N  asparagine 
n.d.  not determined 
NaHMDS  sodium bis(trimethylsilyl)amide 
Naph  naphthyl 
nBuLi  n-butyllithium 
NEDD4  neural precursor cell expressed 
  developmentally down-regulated 
  protein 4 
NFAT1  nuclear factor of activated T-cells 1 
NLS  nuclear localization signal 
nM  nanomolar 
nm23-H1 nucleoside diphosphate kinase A 
NMP  N-methyl-2-pyrrolidone 
NMR  nuclear magnetic resonance
  spectrometry 
No.  number 
Nop56  nucleolar protein 56 
NPAS2  neuronal PAS domain protein 2 
q (NMR ) quartet 
quant.  quantitative 
quint (NMR) quintet 
P  proline 
PB  phosphate-binding region 
PBS  phosphate-buffered saline 
Pd-C 10 % palladium on carbon, loading 10 % 
  w/w 
PDB  Research Collaboratory for 
  Structural Bioinformatics (RCSB)
  protein data bank 
PDGFR  platelet-derived growth factor
  receptor 
PDK1  phosphoinositide-dependent
  kinase 1 
Pd(PPh3)4 tetrakis(triphenylphosphine)- 
  palladium(0) 
PEG  polyethylene glycol 
PER 1-3  Period 1-3 
PGC-1α  peroxisome proliferator-activated
  receptor γ coactivator 1α 
pH  potentia hydrogenii 
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PHB2  prohibitin 2 
Phe (NMR) phenyl 
Phe  phenylalanine 
PIP5K2C  phosphatidylinositol 5-phosphate
  4-kinase type-2γ 
PK  protein kinases 
PKA  cAMP-dependent protein kinase 
PKCα  protein kinase C α 
PKD2  protein kinase D2 
PKI  heat stable protein kinase inhibitor 
Porcn  Porcupine 
Pro  proline 
PP1C  catalytic subunit of protein 
  phosphatase 1 
PPh3  triphenylphosphine 
ppm  parts per million 
ppUL44  human cytomegalovirus 
  phosphoprotein 
PS-2  presenilin-2 
PTFE  polytetrafluoroethylene 
PyBOP  (Benzotriazol-1-  
  yloxy)tripyrrolidinophosphonium 
  hexafluorophosphate 
Pyr  pyridine 
R-factor  reliability factor 
Rfree  free R-factor 
Rmeas  corrected R-factor 
Rmerge  internal agreement factor 
Rwork  R-factor 
RanBPM  Ran-binding protein microtubule- 
  organization center 
Rec8  Rec8 meiotic recombination 
  protein 
RhoA/B  Ras homolog family member A/B 
RIPK2  Receptor-interacting Ser/Thr- 
  protein kinase 2 
RMSD  root-mean-square deviation (for 
  atomic positions) 
RNA  ribonucleic acid 
RORα  retinoid acid receptor-related
  orphan receptor α 
RP  reversed phase 
RPL4, 8, 13 ribosomal protein L4, 8, 13 
rpm  revolutions per minute 
rt  room temperature 
s  second(s) 
s (NMR)  singlet 
S  serine 
sat.  saturated 
SCS  sulfatide and cholesterol-3-sulfate 
SEM  standard error of the mean 
Ser  serine 
siRNA  small interfering RNA 
SLS  Swiss Light Source 
smKI  small molecule kinase inhibitors 
SNARE  soluble N-ethylmaleimide-sensitive
  fusion protein attachment protein
  receptor 
SP  sugar pocket 
SPRY2  sprouty 2 
Sre1N  yeast sterol regulatory element- 
  binding protein homolog 
start.  starting material 
STE  homologs of yeast sterile 7, 
  sterile 11, sterile 20 kinases 
SV40 T-Ag simian virus 40 large T-antigen 
Swi6  chromatin-associated protein swi6 
t (NMR)  triplet 
T3P  1-propylphosphonic acid cyclic 
  anhydride 
TDP-43  TAR DNA-binding protein of 43 kDa 
tBu  tert-butyl 
tBuLi  tert-butyllithium 
TAR  trans-activation response element 
TCF/LEF  T-cell factor/lymphoid enhancer
  factor 
TDP-43  TAR DNA-binding protein of 43 kDa 
temp.  temperature 
tert  tertiary 
TGN  trans Golgi network 
Thr  threonine 
TK  tyrosine kinase 
TKL  tyrosine kinase-like 
TLC  thin layer chromatography 
Tol  tolyl 
TOP2A  topoisomerase Iiα 
tR  retention time 
Tris  2-Amino-2-hydroxymethyl- 
  propane-1,3-diol  
Trp  tryptophane 
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TTBK1/2 tau tubulin kinases 1 and 2 
TV  transcription variant 
Tyr  tyrosine 
UV  ultraviolet 
UHRF1  ubiquitin-like, with PHD and RING 
  finger domains 
v/v  volume/volume 
vbs (NMR) very broad singlet 
VEGF  vascular endothelial growth factor 
VEGFR  VEGF receptor 
VRK1-3  vaccinia-related kinases 1-3 
W  Watt(s) 
WC-1  white collar-1 
Wnt  Wingless/Int-1 
X  any amino acid 
Y  any amino acid except Ser/Thr 
YAP  Yes-associated protein 
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List of Figures 
Figure 1 | The human kinome. Human kinases are subdivided into seven distinct groups: 
AGC = containing PKA, PKG, PKC families; CAMK = calcium/calmodulin-dependent protein 
kinase; CK1 = formerly known as casein kinase 1; CMGC = containing Cdk, MAPK, GSK3, CLK 
families; STE = homologs of yeast sterile 7, sterile 11, sterile 20 kinases; TK = tyrosine kinases; 
TKL = tyrosine kinase-like. Obviously, CK1 and CK2 (black arrow) family members are non-
related. The phylogenetic tree is taken from MANNING et al.5. The dendrogram (right) is made in 
accordance to the same publication. .......................................................................................................................... 2 
Figure 2 | Sequence alignment of human CK1δ transcription variants and CK1ε. The 
conserved N-terminal domain consists of amino acids 1-8, followed by the kinase domain (286 
amino acids). Identical residues within the kinase domain are highlighted in green, different 
residues in yellow. The non-conserved C-terminal domains of CK1δ TV1/TV2 and CK1ε exhibit 
highly variable sequences. The alignment was generated by Clustal Omega16 using transcript 
sequences for CK1δ TV1 (Gene Bank AAH03558.1), CK1δ TV2 (Gene Bank ABM64211.1), and 
CK1ε (Gene Bank ABM64212.1). For abbreviations DFG, KHD, SIN, NLS cp. chapter 1.2. ................. 4 
Figure 3 | Structural presentation of the CK1δ kinase domain. The N- (red) and C-terminal 
lobe (blue) are connected by the hinge region (yellow). The nucleotide binding site (not 
occupied) lies within the cleft between the domains. Indicated by arrows are the kinesin 
homology domain (KHD) and the nuclear localization signal (NLS). The significance of the DFG 
(Asp, Phe, Gly) motif for CK1δ has not been determined yet. The nomenclature is adapted from 
XU et al.18 and LONGENECKER et al.17. The figure refers to CK1δ crystallization by HUANG et al. (PDB 
code 4HGT)22. ....................................................................................................................................................................... 6 
Figure 4 | ATP-binding mode in CK1δ. The representation is in accordance with crystallization 
results of CKi1 and magnesium-ATP complex (PDB code 1CSN) and the pharmacophore model 
by TRAXLER and FURET. For clarity, water molecules are left out17,18,23. .................................................. 7 
Figure 5 | Detailed ATP-binding mode in CKi1. Direct and water-mediated contacts between 
CKi1 and ATP adenine (A), ribose (B), and magnesium-phosphate moiety (C). Interactions were 
modeled according to XU et al. (PDP code 1CSN)18. ............................................................................................ 8 
Figure 6 | Postulated substrate-binding mode at CK1δ phosphate-binding moiety W1. An 
in silico peptide (yellow) consisting of Ser(P)-Ala-Ala-Ser is coordinated by Arg178 (T-loop, 
green in A), Gly215 (L-EF, red in A) and Lys224 (αF, blue in A). The phosphorylatable Ser 
hydroxyl group is placed in H-bonding range towards ATP (maroon) γ-phosphate. A surface 
model (B) visualizes the close fitting of Mg2+-ATP and substrate to the catalytic cleft of CK1δ. 
Modeling was performed based on MARIN et al.28 (PDB code 1CSN18, 4HGT22) utilizing 
Schrödinger software (chapter 7.1). ..................................................................................................................... 10 
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Figure 7 | Scaffold protein-mediated subcellular spatial organization. AKAP450 anchors 
CK1δ/ε to membranes and organelles, DDX3 binds CK1δ/ε and promotes Dvl phosphorylation, 
CRY-PER-CK1δ/ε complexes translocate to the nucleus, CK1BP binds and inhibits CK1δ. 
Phosphorylation is represented by yellow stars. The figure is adapted from GOOD et al.104. .......... 14 
Figure 8 | Homodimerization of CK1δ. Monomers 1 (purple) and 2 (green) form dimers via 
interaction of their dimerization domains (A). The dimerization domain (yellow) includes 
various amino acid residues of strands β1, β2, β3, and β7 as well as loops L-12 and L-78, helix 
αB, and the hinge region (B, PDB code 4HGT22). ................................................................................................ 15 
Figure 9 | Post-translational regulation of CK1δ. Mechanisms of post-translational regulation 
(A): inactivation by C-terminal autophosphorylation (1) or phosphorylation by other kinases (4) 
and subsequent activation by phosphatases (1, 4 vice versa), C-term truncation (2, 5) or 
interaction with activator molecules (3). Truncation is also imaginable without previous 
phosphorylation (6). CK1δ is marked for degradation by ubiquitination (7). Brackets indicate 
insufficient evidence. Phosphorylation sites within the CK1δ TV1 C-terminal domain (B, adapted 
from KNIPPSCHILD et al.9). Colocalization of CK1δ, PKA, and PP1C is mediated by AKAPs (C)109–117.
 ................................................................................................................................................................................................ 17 
Figure 10 | Interruption of the hydrophobic spine by type I ½ inhibitors on the example of 
dibenzosuberone derivative 1 in p38α mitogen-activated protein kinase. Binding of the 
inhibitor (green) interrupts the hydrophobic spine (red). H-bonds (black dashed lines) are 
formed towards hinge and αC-helix. Hydrophobic interaction (yellow dashed line) 
accommodates DFG Phe169. Dibenzosuberone derivative 1 refers to (S)-N-(5-((7-(2,3-
dihydroxypropoxy)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulen-2-yl)amino)-2-
fluorophenyl)benzamide (1) by FISCHER et al. The figure was modeled in accordance to the same 
publication (PDB code 3UVQ)161. .............................................................................................................................. 27 
Figure 11 | Binding mode of irreversible type V inhibitor afatinib. Afatinib (2) displays a 
type I binding mode: the quinazoline core occupies the adenine-binding region and forms an H-
bond towards a hinge residue. The halogen-substituted phenyl moiety extends into HPI. But 
unlike type I inhibition, the enone moiety reacts with a nucleophilic cysteine residue in a 
MICHAEL addition and covalently attaches the ligand to the active site of epidermal growth factor 
receptor (EGFR)7. ............................................................................................................................................................ 28 
Figure 12 | Crystal structures of inhibitors 9 and 16 in CK1δ. Comparison of teardropbinder 
9 (A, PDB code 3UZP)184 and linearbinder 16 (B, PDB code 4TWC)181 in CK1δ. .................................. 34 
Figure 13 | Postulated binding mode of lead structure 12 in CK1δ. The 2D interaction 
diagram (B) was generated in accordance to the modeling results (A, PDB code 3UZP). ................ 41 
Figure 14 | Central pharmacophore for in silico lead structure optimization. The central 
pharmacophore has been defined with X and Y being carbon, nitrogen, oxygen, or sulfur (n = 0-
3). ........................................................................................................................................................................................... 45 
L i s t  o f  F i g u r e s  | 335 
 
 
Figure 15 | Positioning of the 4-fluorophenyl moiety of 12 within the selectivity pocket of 
CK1δ. The halogenated aryl moiety penetrates deeply into the pocket forming hydrophobic 
interactions (violet) with Met80 and Met82. Met82 is rotated towards Pro66 (PDB code 
3UZP)184. ............................................................................................................................................................................. 47 
Figure 16 | Postulated binding mode of 51 in CK1δ. Hydroxyl moieties of the iminosaccharide 
(yellow) form H-bonds with residues Ser17 and Asp132. Interactions between other parts of the 
ligand and the kinase are not shown (PDB code 3UZP). ................................................................................. 51 
Figure 17 | In vitro biological evaluation of diaryl-oxazoles by SCHMIDT. Iminosaccharide-
substituted compounds 64, 65, 66 derived from unsubstituted compound 63 (left). Residual 
activity of CK1δ at 10 µM inhibitor is shown in relation to control (DMSO). Each bar shows the 
mean value of n = 3 experiments ± standard deviation (right, modified from SCHMIDT208). ............ 52 
Figure 18 | Postulated binding modes of 12, 73, and 74 in CK1δ. Smaller aromatic systems 
dictate increased angles leading to less optimal fitting of the azete scaffold 74 (violet) compared 
to imidazole 12 (green) and pyridine 73 (black) scaffolds. The indicated distances refer to the 
3D structure and thus the angle of torsion. All data refer to energetically minimized structures.
 ................................................................................................................................................................................................ 55 
Figure 19 | Replacement of a conserved water molecule in CK1δ. One conserved water 
molecule in the CK1δ active site interacts with Lys38, Asp149, and the ligand 12 (A). It might be 
replaceable by a hydroxymethyl group in 2-position of the 4-fluorophenyl moiety in 75 (B) and a 
hydroxyethyl group in 76 (C) or a chiral hydroxycyclopropyl group in 77 (D) at the imidazole 
nitrogen. The (E)-3-(2,4-dimethoxyphenyl)acrylamide side chains (cp. lead structure 12) in 2-
position of the pyridine are not displayed. Glide scores are given beyond the structures. ............. 57 
Figure 20 | Positioning of 12 in the hydrophobic region II of CK1δ, CK1ε, and p38α. The 
lipophilic groove (yellow) is restricted by acid and hydrophilic residues at the rim of the region 
(red). Modeling refers to PDB codes 3UZP, 4HNI, and 1BMK. ...................................................................... 58 
Figure 21 | Protein structure alignment of CK1δ, CK1ε, and p38α. The hinge of p38α (red) is 
displaced in relation to CK1δ (green) and CK1ε (yellow, left). Different conformation of ligands 
(12) taken from the protein structure alignment (right), though the (E)-conformation (grey box) 
is preserved. Modeling refers to PDB codes 3UZP, 4HNI, and 1BMK. ....................................................... 59 
Figure 22 | Schematic representation of series 1 to 6 deriving from 78. Residues (R) are 
defined in the following chapters. ............................................................................................................................ 60 
Figure 23 | Postulated binding modes of 79 in CK1δ. Alignment of several possible binding 
modes illustrates the high flexibility of the N-3-(2,4-dimethoxyphenyl)propyl side chain within 
the hydrophobic region II (left). In contrast, the diaryl-imidazole scaffold is highly conserved in 
all binding modes (right). Modeling refers to PDB code 3UZP. ................................................................... 61 
Figure 24 | In silico binding mode of 80 and 81 addressing Asp91. Positively charged 
dimethylamino side chains linked to the 2-aminopyridine through aliphatic (A) or cyclic (B) 
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linkers (cp. Table 15). Asp91 is positioned at the rim of CK1δ hydrophobic region II (PDB code 
3UZP).................................................................................................................................................................................... 62 
Figure 25 | Postulated binding mode of carbamide derivative 104 in CK1δ. The 2D 
interaction diagram (B) was formulated in accordance to the modeling results (A, PDB code 
3UZP).................................................................................................................................................................................... 66 
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